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Summary 
Campylobacter jejuni is one of the leading bacterial causes of human gastroenteritis world 
wide and has been linked to several severe complications including autoimmune syndromes 
characterised by paralysis.   Understanding of this human pathogen is rapidly increasing.   
However, it remains a major burden to public health in both socioeconomically developing 
and developed nations.   Since the completion of the first C. jejuni genome project, 
investigations into the molecular mechanisms involved in C. jejuni pathogenesis have gained 
momentum.   The virulence factors which contribute to the success of C. jejuni as a human 
pathogen include motility, chemotaxis, iron acquisition, adhesion, invasion, quorum sensing, 
superoxide stress defence, thermal-stress response and an ability to avoid the host immune 
system.   These factors that enable C. jejuni to survive physiological stresses like temperature 
fluctuations, variations in pH, different hosts, host immunity, oxidative stress and limited 
nutrient supply are in the process of being unravelled.   Despite recent advances, there is 
currently no vaccine available for protection against this pathogen and the mechanisms 
important for C. jejuni pathogenesis are not yet fully defined. 
 
This study has employed a range of experimental approaches to investigate the molecular 
mechanisms involved in C. jejuni pathogenesis.   The first virulence factor investigated was 
the lipooligosaccharide (LOS) produced by C. jejuni strain 81116.   LOSs are surface 
structures and known virulence factors of C. jejuni which are involved in serum resistance, 
resistance to phagocytic killing, endotoxicity and adhesion.   Mutagenesis studies targeting 
the putative LOS biosynthesis genes wlaRE, wlaRF, wlaTA, wlaTB, wlaTC and waaV were 
performed in order to characterise the proteins encoded by each of these six genes and assess 
their potential role in C. jejuni pathogenesis in vitro.   In silico analysis of the amino acid 
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sequences encoded by each of the six putative LOS biosynthesis genes of interest suggested 
that they are all involved in glycosylation. 
 
Difficulties associated with the cloning process of wlaRE prevented the construction of a 
knock-out mutant.  In addition, this investigation identified wlaTA as being essential for C. 
jejuni survival as the disruption of this gene was lethal.   Characterisation of four putative 
LOS biosynthesis gene knock-out mutants (wlaRF::KanR, wlaTB::KanR, wlaTC::KanR and 
waaV::KanR) confirmed that each gene contributed to the construction of the complete LOS 
molecule as all four mutants produced a truncated LOS moiety.   In addition, the truncation of 
LOS molecules from C. jejuni strain 81116 altered their immunoreactivity.   Further analysis 
determined that the production of complete LOSs was important for C. jejuni to invade and 
adhere to both human and chicken cells in vitro.   The phenotypic changes observed in the 
mutants lacking WlaRF and WlaTC identified a link between the putative LOS biosynthesis 
genes which encode these two proteins, motility and the correct assembly of a functional 
flagella. 
 
The second experimental approach used to study the pathogenesis of C. jejuni at a molecular 
level was an investigation of the environmental regulation of surface proteins.   Five different 
strains of C. jejuni, including two enteritis associated strains (81116 and 11168), an enteritis 
strain associated with the neurological disorder of Guillain-Barré syndrome (HB9313), a 
complication of Campylobacter enteritis, a recent chicken isolate (990922) and a recent 
human clinical isolate (MP0401) were used for this study.   Each strain was exposed to a 
range of different environmental conditions and the surface proteins were analysed.   The 
conditions of interest were modelled on environments relevant to “chicken” or “human” 
settings.    
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One of the most important sources of C. jejuni infection for humans is the consumption of 
contaminated poultry or the handling of raw poultry products.   Despite the presence of C. 
jejuni in the gastrointestinal tract of chicken at levels as high as 106-107 cfu/g of caecal 
contents, chickens do not experience symptoms.   It is generally accepted that C. jejuni exists 
as a commensal in chickens.   It is currently not known why C. jejuni is more pathogenic to 
humans than it is to chickens and the differences between these two hosts represent 
pathogenic and non-pathogenic environments respectively.   These differences were exploited 
in this study. 
 
The four conditions investigated were temperature, blood, bile and host cells.   Each condition 
lead to the detection of putative environmentally regulated surface proteins.   It was also 
established that each of the five C. jejuni strains tested responded differently when exposed to 
each condition.   Of all the potential differentially expressed proteins, six were further 
characterised and were thought to be a transthyretin-like protein, a protein involved in iron 
uptake, a hypothetical periplasmic protein, the adhesin PEB1, flagellin A and the major outer 
membrane protein.    
 
These four different modelled conditions were also used to investigate the impact of 
environmental stimuli on global gene regulation as the third experimental approach.   This 
investigation identified a number of technical issues associated with the methods of random 
arbitrarily primed differential display RT PCR and quantitative real time RT PCR using 
SYBR green chemistry.    
 
The purpose of this study was to investigate the pathogenesis of C. jejuni at a molecular level.   
The outcomes of this work include the characterisation of genes that encode proteins involved 
in the construction of a known virulence factor, LOS, the link of these genes to another 
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known virulence mechanism, that is motility and the identification of six surface proteins 
which may be important in how C. jejuni causes disease in humans.   The enhanced 
understanding with respect to the molecular mechanisms, important for the pathogenesis of C. 
jejuni, will expedite the development of successful antimicrobial therapies or vaccines to 
control or prevent infection.    
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CHAPTER 1: Literature Review 
1.1 Introduction 
Campylobacter jejuni subsp. jejuni (referred to as C. jejuni throughout this thesis) is a major 
cause of bacterial human gastroenteritis in both developed and developing nations.   The 
incidence of Campylobacter spp. enteritis (CE) in developed nations is estimated at ~ 1% of 
the population per year and the number of cases is increasing in most nations (Friedman et al., 
2000).   In developing nations CE is hyperendemic, with an incidence rate among children as 
high as ~ 40-60% of the population annually (Calva et al., 1988; Oberhelman et al., 1999; 
Taylor et al., 1988).   The financial costs associated with CE is greater than several million 
AUD per year in developed nations and incorporate medical care, treatment and loss of 
productivity (www.foodstandards.gov.au).   Despite being a serious burden to public health, it 
was not until very recently that we have begun to understand the pathogenesis of this 
organism, though there is still a way to go. 
 
C. jejuni exists as a commensal in many domestic and wild animals and is persistent in the 
environment (Butzler, 2004).   The main routes of transmission to humans is through 
consumption of or contact with contaminated food, milk or water and contact with domestic 
animals (Adak et al., 1995; Friedman et al., 2000; Skirrow, 1981b).   In addition, C. jejuni 
infection is linked to traveller’s diarrhoea (Gallardo et al., 1998; Tee & Mijch, 1998; Walz et 
al., 2001).   In temperate regions there is a peak in the number of cases in summer and to a 
lesser extent autumn and spring with the most at risk groups in both developed and 
developing countries being children, the elderly and the immunocompromised (Banmali et al., 
2006; Friedman et al., 2000; Jain et al., 2005; Tee & Mijch, 1998).  
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CE is usually an uncomplicated and self-limiting disease with the main symptoms being 
diarrhoea and abdominal pain (Skirrow, 1977a).   Rehydration of the patient is generally 
sufficient treatment although antibiotics may be required in the event that the symptoms 
persist beyond a week or if the patient is immunocompromised, pregnant or a child (Blaser, 
1997).   The risk of complications resulting from a case of CE are rare, but may include 
paralysis caused by an autoimmune response (Nachamkin et al., 2000).    
 
Antibiotic resistance amongst campylobacters is of increasing concern.   It is closely 
associated with the use of antibiotic therapy in veterinary medicine, agriculture and over 
prescription in human medicine (Allos, 2001).   Current risk reduction strategies include 
efforts to increase public awareness of proper food handling practices, a reduction in the 
spread of campylobacters through livestock and poultry, vaccination targeting food animals, 
travellers and the military in combination with improved strategies of livestock slaughter and 
processing with a view to avoid or reduce contamination (Hillers et al., 2003; Scott, 1997; 
White et al., 1997; Widders et al., 1998). 
 
Since the completion of the first C. jejuni genome project in 2000, substantial advances have 
been made in the understanding of C. jejuni pathogenesis at a molecular level.   Many 
virulence factors have been identified, including lipooligosaccharide (LOS), capsular 
polysaccharide (CPS), membrane proteins, general protein glycosylation, adhesion, invasion, 
nutrient acquisition, chemotaxis, motility and stress defence mechanisms (Baillon et al., 1999; 
Caldwell et al., 1985; de Melo & Pechere, 1990; Field et al., 1986; Field et al., 1993; Konkel 
et al., 1992a; Lee et al., 1986; McSweegan & Walker, 1986; Newell et al., 1985a; Szymanski 
et al., 1995; Szymanski et al., 2002; Wassenaar et al., 1991; Yao et al., 1994).   In addition, 
many of these virulence factors are the target of ongoing investigations and we are learning 
more about the mechanisms of action and regulation all the time, but there is more to be done.   
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With increased knowledge and understanding of C. jejuni pathogenesis at the molecular level, 
the task of developing strategies to treat, prevent and reduce the risk of exposure to this 
pathogen is made easier. 
 
1.2 History 
In 1886 Theodor Escherich described non-culturable corkscrew-shaped bacteria isolated from 
the colonic contents of infants who had died as a result of “cholera infantum”(Escherich, 
1886; Skirrow & Butzler, 2000; Vandamme, 2000).   It has been suggested that this was the 
first reported observation of the bacterium that we now know as Campylobacter (Park, 2002; 
Skirrow & Butzler, 2000).   The first success with culturing campylobacters occurred in the 
early 1900’s, when John MacFadyean and Stewart Stockman observed what they referred to 
as “vibrios” in the foetal tissue of aborted sheep (McFadyean & Stockman, 1913).   The first 
link to enteric disease was also made in the veterinary field, when Jones et al. isolated a 
“vibrio” in 1931, from calves and cows suffering from “winter dysentery” (Jones et al., 1931).    
 
It was not until the 1950’s that Elizabeth King first suggested these “vibrios” could be 
associated with human enteric disease.   King cultured them from the blood of infected 
individuals and was the first to study this human disease causing “Vibrio” spp. in depth (King, 
1957).   She observed that they grew at a distinctly higher optimum temperature than the other 
vibrios they were grouped with and referred to this subgroup as “related-vibrios” (King, 
1957).   Sebald and Véron formally separated these “related-vibrios” from the Vibrionaceae 
family and proposed the genus name Campylobacter (Greek meaning, a curved rod) in 1963 
(Sebald & Véron, 1963).   The differences which lead to this separation were their 
requirement for microaerobic growth conditions, the DNA being of a low G and C base 
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composition, their non fermentative metabolism and their elevated optimum growth 
temperature (Sebald & Véron, 1963). 
 
Certain campylobacters were recognised as potential causative agents of foodborne enteric 
disease and were successfully cultured from human faeces for the first time in 1972 (Dekeyser 
et al., 1972; Slee, 1972).   The failure to culture campylobacters from faeces up until this 
point had been attributed to the overgrowth of competing coliforms and the fastidious nature 
of campylobacters.   This problem was overcome by the use of a filtration method that 
allowed the smaller and vigorously motile campylobacters to pass through a 0.65 µM filter 
while other larger organisms were held back coupled with growth on selective media (Butzler 
et al., 1973; Dekeyser et al., 1972).   In 1977, the isolation of campylobacters on selective 
agar was improved to the point where a filtration step was no longer needed, thus enabling the 
routine examination of human faecal samples (Skirrow, 1977a).    
 
Since the introduction of routine monitoring and active reporting, the incidence of CE has 
increased annually (Park, 2002).   Today, Campylobacter spp., are commonly accepted as one 
of the major if not the leading cause of human bacterial enteritis, with Campylobacter jejuni 
recognised as the most frequently isolated species (FoodNet Working Group, 2004; Friedman 
et al., 2000; Tauxe, 1992).   In addition, C. jejuni has been associated with the development of 
complications, the most severe being the neurological disorder Guillain-Barré Syndrome 
(Nachamkin et al., 2000; Yuki, 2005). 
 
1.3 Campylobacter Biology 
The Campylobacteraceae family contains the genera of Campylobacter, the closely related 
phylogenetic neighbour Arcobacter, Sulfurospirillum and the species Bacteroides ureolyticus 
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(Figure 1.1; Vandamme, 2000).   Presently, there are 14 validly described species of 
Campylobacter, which are classified in the delta-epsilon group of the proteobacteria 
(Vandamme, 2000).   The members of this family are gram-negative, unable to ferment 
carbohydrates, microaerophilic and have a genome with a comparatively low G + C 
composition (Fouts et al., 2005; Hofreuter et al., 2006; Nachamkin & Skirrow, 1998; Parkhill 
et al., 2000).   They primarily share either a commensal or parasitic relationship with their 
human or animal hosts (Vandamme, 2000).  
 
Campylobacters are helical, curved, short or “S” shaped rods (Figure 1.2), however aged cells 
or cells exposed to atmospheric oxygen can take on a coccoid form (Bovill & Mackey, 1997; 
Rollins & Colwell, 1986).   Cells range in size from 0.5 to 5 µm long and from 0.2 to 0.8 µm 
wide and with the exception of C. gracilis, they achieve motility by way of a single polar 
unsheathed flagella at one or both ends which, together with their helical shape, generates a 
corkscrew-like motion (Ferrero & Lee, 1988).   They are fastidious, non spore-forming 
bacteria with a genome of 1.1-2.0 Mb (C. fetus subsp. fetus - C. upsaliensis, respectively), 
ranging between 29-47% G+C (Chang & Taylor, 1990; Nuijten et al., 1990; Taylor et al., 
1992). The Campylobacter genome is small in comparison to Escherichia coli which has a 
genome of 4.6 Mb with a G+C composition of approximately 50% (Blattner et al., 1997).   
The relatively small genome of campylobacters perhaps explains the inability of 
campylobacters to ferment or oxidise carbohydrates and in turn their requirement for rich 
growth media (Griffiths & Park, 1990).   Campylobacters are respiratory and 
chemoheterootrophic, with energy being generated via the metabolism of amino acids or via 
tricarboxylic acid (TCA) cycle intermediaries (Kelly et al., 2001; Myers & Kelly, 2005).  
 
Some campylobacters are pathogenic to humans and animals causing a wide range of 
conditions including: gingivitis and periodontal disease, septic abortion, infertility, abscesses 
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Figure 1.1:   Phylogenetic tree of Campylobacteraceae family and its closest genetic 
neighbours based on the percentage difference between the compared 16s RNA gene 
sequences (Vandamme, 2000). 
% Difference 
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Figure 1.2:   Electron micrograph of C. jejuni NCTC 11168, black bar ~ 1µM (Gaynor et al., 
2004). 
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and more commonly gastroenteritis (Agerholm et al., 2006; Jones et al., 1984; McFadyean & 
Stockman, 1913; Skirrow, 1977a; Tanner et al., 1981).   The most important 
humanenteropathogens of all campylobacters are C. jejuni  and C. coli.   C. jejuni is not only 
important for its role as an enteropathogen, but also for the complications associated with CE, 
which will be discussed later in this chapter. Though, it should be noted that there is some 
debate about the importance of campylobacters other than C. jejuni and C. coli as they are 
thought to be under represented due to current culturing methods failing to select for them 
over the more frequently detected C. jejuni and C. coli (Lastovica & Skirrow, 2000). 
 
C. jejuni and the closely related C. coli are thermophiles which grow at an optimum 
temperature of 42°C.   They are highly motile, require rich growth media and are 
microaerobic .   It has been suggested that the elevated optimum temperature developed as a 
result of the bacteria adapting to warm blooded animals, especially bird hosts (Ketley, 1997).   
This suggestion is supported by the fact that the temperature of the avian gut is 42°C and that 
exposure to and consumption of poultry is a dominant source of human infection (Friedman et 
al., 2000; Manning et al., 2003; Park, 2002).   It is estimated that C. jejuni is responsible for 
approximately 90% of human CE cases and C. coli responsible for most of the remaining 
cases (Dingle et al., 2005).   Generally, C. jejuni are very similar to C. coli both 
phenotypically and genotypically.   C. coli differs biologically from C. jejuni in that they are 
hippurate hydrolysis negative, although some C. jejuni strains are also negative (Vandamme, 
2000).   The two species can be further separated by growth on minimal media, by 
measurement of hydrogen sulfide production on triple-sugar-iron agar (On, 1996) or more 
reliably by molecular typing methods (Lucey et al., 2004). 
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1.4 Campylobacter jejuni Genome Project 
To date, the genomes of three different C. jejuni strains have been sequenced.   Those strains 
are NCTC11168, a human enteritis isolate (Parkhill et al., 2000), RM1221, a retail chicken 
meat isolate (Fouts et al., 2005) and 81-176, a highly virulent human enteritis isolate (Table 
1.1; Hofreuter et al., 2006).   At the time of publication, the C. jejuni genome of strain 11168 
was the densest bacterial genome with 94.3% of the genome coding for proteins (Parkhill et 
al., 2000).   In the last few years, many comparative genomics sudies have been conducted 
and have identified numerous genetic variations across different species of Campylobacter 
and strains of C. jejuni of both human and veterinary importance (Fouts et al., 2005; Gilbert 
et al., 2002; Gundogdu et al., 2007; Parker et al., 2006; Parker et al., 2007; Pearson et al., 
2003; Poly et al., 2004; Poly et al., 2005; Rivoal et al., 2005; Taboada et al., 2004).    Other 
C. jejuni genome projects, including strains 81116 and HB9313, are currently underway. 
 
Table 1.1:   Comparison of genome project data from different C. jejuni strains 
C. jejuni genome project strain 
Characteristic 
11168 RM1221 81-176 HB93-13* 
Genbank # AL111168 CP000025 CP000538 AANQ00000000 
Size (bp) 1,641,481 1,777,831 1,616,554 1,694,788 
No. of predicted 
coding regions  1643
†
 1884 1653 1710 
G + C content 
(%) 30.5 30.3 30.6 30.6 
% Coding 94.3 94 93 92 
Origin Human 
enteritis 
Skin of retail 
chicken Human enteritis 
Human Guillian-
Barré syndrome 
associated enteritis 
Presence of 
plasmids - - pVir, pTet - 
Reference (Parkhill et al., 2000) 
(Fouts et al., 
2005) 
(Hofreuter et al., 
2006) unpublished 
* Genome project incomplete (http://www.ncbi.nlm.nih.gov/genomes/static/eub.html) 
†
 Revised number of coding sequences following re-analysis of genome data (Gundogdu et al., 2007) 
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The genome sequences of the three completed C. jejuni genome project strains are syntenic.   
However, notable differences were identified.   Genomic regions which exhibited the greatest 
variablility between strains included the LOS and CPS biosynthesis clusters, flagellar 
modification genes, DNA restriction/modification loci and genes involved in respiratory 
metabolism (Parker et al., 2006; Poly et al., 2004; Poly et al., 2005).   The differences seen 
within the LOS and CPS clusters is expected due to the enormous variation seen with the 
structure of these molecules across the many C. jejuni strains investigated (Aspinall et al., 
1992; Fouts et al., 2005; Gilbert et al., 2002; Karlyshev et al., 2005a).    
 
Other differences include the presence or absence of plasmids and insertion elements.   Strain 
81-176 harbours two plasmids, pVir and pTet, which are absent from strains 11168 and 
RM1221 (Parker et al., 2006; Poly et al., 2005).   In addition, strain RM1221 contains four 
genomic islands, designated C. jejuni integrated elements (CJIE1-4), which were not detected 
in strains 11168, 81116 or 81-176 (Parker et al., 2006).   The presence of these genomic 
islands explains the larger size of the RM1221 genome when compared to strains 81-176 and 
11168 (Table 1.1).   These CJIEs are thought to encode a Mu-like phage (CJIE1), phage 
related endonucleases, methylases, or repressors (CJIE2 and CJIE4) and an integrated plasmid 
with 73% similarity to a C. coli megaplasmid (CJIE3) (Fouts et al., 2005; Morgan et al., 
2002; Parker et al., 2006).   Other C. jejuni strains have been found to contain these CJIEs 
although they exhibit a high degree of variability (Parker et al., 2006).   The genome sequence 
of strain 11168 contained only one inserted sequence element and very few repeated 
sequences (Parkhill et al., 2000; Wren et al., 2001).   The 11168 inserted sequence element, 
Cj0752, shares sequence similarity with tnpB (IS605) from Helicobacter pylori (Parkhill et 
al., 2000).    
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Minimal organisation was observed which was illustrated by the presence of only a few 
clusters, including the LOS and CPS biosynthesis clusters and the protein glycosylation 
clusters (Parkhill et al., 2000; Wren et al., 2001).   There is some arrangement of genes into 
long linked sets, however there appears to be little or no functional relationship within these 
sets (Parkhill et al., 2000).   For example, the distribution of genes involved in amino acid 
biosynthesis in strain 11168, where only the his, leu and trp genes were arranged close 
together (Parkhill et al., 2000). 
 
Another key feature of the C. jejuni genome is the presence of homopolymeric tracts of six or 
more bases which can represent hypervariable regions due to the potential for slipped strand 
miss pairing.   The variability of such regions can lead to antigenic and phase variation 
(Pearson et al., 2003).   These hypervariable sequences facilitate antigenic and/or phase 
variation where particular genes are switched on or off (Moxon et al., 1994).   This process 
could benefit the bacteria by either enabling them to adjust to specific environmental niches 
or by assisting the bacteria in host immune system avoidance (Parkhill et al., 2000; Pearson et 
al., 2003; Wren et al., 2001).   The majority of hypervariable sequences are located within 
genes involved in surface structure biosynthesis or modification which suggests that these 
sequences are important in how the bacteria interact with their environment.   This, coupled 
with the fact that C. jejuni lacks DNA repair functions that can be found in bacteria with 
larger chromosomes, e.g., E. coli, results in a potential for a dynamic and adaptable proteome.   
The number of homopolymeric tracts differs between C. jejuni strains and also between 
Campylobacter species (Pearson et al., 2003).   For example, the genomes of C. jejuni strains 
11168 and RM1221 contain 21 and 8 variable homopolymeric tracts of 6 or more bases (G/C) 
respectively (Fouts et al., 2005; Parkhill et al., 2000).    
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C. jejuni strain 81-176 is a highly pathogenic strain and its genome has been found to contain 
37 genes which are absent from both 11168 and RM1221 reference strains (Hofreuter et al., 
2006).   The additional genes present in C. jejuni 81-176 have varying functions.   Strain 81-
176 encodes several genes involved in respiration, energy metabolism and electron transport 
which are absent from or exist as pseudogenes in the two reference strains.   For example, the 
genes unique to strain 81-176 include a dimethylsulfoxide (DMSO) reductase system, 
additional cytochrome c biogenesis genes and a gene involved in the efflux of succinate, the 
end product of fumarate fermentation (Hofreuter et al., 2006; Janausch et al., 2002).   These 
genes may contribute to the ability of this strain to efficiently colonise host gastrointestinal 
tracts by facilitating greater versatility in alternative electron acceptors and respiratory 
pathways under oxygen-limited conditions (Hofreuter et al., 2006).   Other genes unique to 
strain 81-176 which may contribute to its virulence include genes thought to be involved in 
potassium uptake, kdpA, kdpB and kdpC (Altendorf et al., 1992), a γ-glutamyltranspeptidase, 
restriction-modification systems and a serine protease autotransporter.   The C. jejuni 81-176 
γ-glutamyltranspeptidase shares significant sequence similarity to a γ-glutamyltranspeptidase 
of Helicobacter pylori which has been shown to be required for H. pylori colonisation in a 
mouse model (Chevalier et al., 1999).   The diversity of restriction-modification systems 
across C. jejuni isolates is thought to contribute to their ability to take up genetic information 
horizontally (Miller et al., 2005).   The phenotypic differences seen between the three genome 
project strains, 11168, RM1221 and 81-176 could perhaps be explained, in part, by the 
differences in their DNA sequences which should be the focus of future investigations.    
 
1.5 Epidemiology  
C. jejuni is recognised as one of, if not the most common bacterial cause of human 
gastroenteritis worldwide (Allos, 2001; Coker et al., 2002; Friedman et al., 2000).   CE is 
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sporadic in as many as 99% of cases (Moore et al., 2005), though outbreaks have been 
reported (Gillespie et al., 2003; Hannu et al., 2004; Harrington et al., 1999; Maurer & 
Sturchler, 2000; Palmer et al., 1983; Van Dijk & van der Straaten, 1988).   Approximately 5-
10% of CE cases result in the hospitalisation of the patient (Skirrow & Blaser, 2000).    
Campylobacteriosis followed by salmonellosis accounted for most hospital admissions due to 
bacterial infections in Australia and the UK; in the US this order was reversed (Hall et al., 
2005).   Death as a result of CE occurs only occasionally and is usually restricted to infants, 
the elderly or the immunocompromised (Tauxe, 1992).   The true incidence of CE is unknown 
as there are many difficulties associated with the collection and recording of this information 
and many countries, especially developing nations, do not have a national surveillance 
program in place or do not routinely screen for campylobacters (Coker et al., 2002; Friedman 
et al., 2000).   An accurate understanding of the CE incidence rate is also dependent upon 
each infected person seeking medical attention that in turn results in a laboratory confirmed 
diagnosis which is reported to public health surveillance program.    
 
In the US, it was estimated that only 1 in 38 cases of CE are reported (Mead et al., 1999).   In 
the UK, ~ 50% of those suffering CE infection consult their GP and it is estimated that less 
than half of those cases are reported as laboratory confirmed (Frost, 2001).   Studies carried 
out in the Netherlands and the UK suggest that the true incidence rate is 10 –100 times greater 
than the reported incidence rate, which suggests a predicted incidence rate of as high as 1.1-
2.3% cases/population/year (Friedman et al., 2000).   The incidence rate of CE in Australia 
was ~ 117 cases/100,000 population in 2004 and is similar to other developed nations with a 
rate of 90 cases/100,000 population and is increasing each year (Tauxe, 1992; The 
OzFoodNet Working Group, 2004).   New Zealand, by comparison has a higher incidence rate 
of 300 cases /100,000/population (Nelson & Harris, 2006).   The increase observed in 
industrialised countries is possibly due to increased surveillance, improved diagnostic tools, 
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or contrastingly, the result of changes in eating habits.   A comparison of CE incidence across 
different countries is difficult as each country, and even regions within the one country have 
different approaches to gathering information.   These differences include the collection of 
data by either active or passive surveillance, the source of the data being derived from a 
hospital or laboratory, the diagnostic method used to detect the bacteria and differences in the 
cost of health care to the patient (Engberg et al., 2000; Friedman et al., 2000). 
 
Since Campylobacter spp. became notifiable organisms under active surveillance in many 
developed nations, they have been frequently reported as responsible for more infections than 
Salmonella spp., Shigella spp., E. coli O157:H7, Yersinia spp., Listeria spp. or Vibrio spp. 
(Friedman et al., 2000; Slutsker et al., 1997).   In many developed nations, campylobacters 
often cause more GE cases than Salmonella spp. and Shigella spp. combined (Table 1.2; 
Friedman et al., 2000; Mead et al., 1999; Slutsker et al., 1997). 
 
Table 1.2:   Rates of selected enteric bacterial infections detected by FoodNet, CDC (U.S.A) 
Causative organism No. of infections per 100,000 population/year 
 1996 1997 1998 1999 
Campylobacter spp. 23.5 25.2 21.4 17.3 
Salmonella spp. 14.5 13.6 12.3 14.8 
Shigella spp. 8.9 7.9 8.5 5.0 
E. coli O157:H7 2.7 2.3 2.8 2.1 
Yersinia spp. 1.0 0.9 1.0 0.8 
(Allos, 2001; Mead et al., 1999) 
 
In recent years, the number of CE cases reported by FoodNet in the USA is declining.   This 
change is thought to be in part due to the implementation of regulations focussing on 
pathogen reduction in the meat and poultry industries at the point of slaughter (FoodNet 
Working Group, 2004).   This decline has not been seen in countries such as Australia, New 
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Zealand, Norway and the UK (Friedman et al., 2000; Frost, 2001; The OzFoodNet Working 
Group, 2004). 
 
1.5.1 Transmission 
Campylobacters are ubiquitous in the environment and human food chain, though the specific 
paths of infection are largely unclear. The majority of sporadic cases are thought to be 
foodborne in origin while outbreaks, though uncommon, are more likely the result of 
ingesting unpasteurised or bird-pecked milk or contaminated water (Frost, 2001; Skirrow, 
1991).   In the case of sporadic infections, campylobacters are usually transmitted to the 
patient via ingestion of or contact with contaminated water, milk or food products, with 
poultry arguably being the most important foodborne reservoir (Osano & Arimi, 1999; 
Pearson et al., 2000; Sopwith et al., 2003; Workman et al., 2005).   In many areas of the U.S., 
Europe and Australia, studies have attributed 50-70% of CE cases to the consumption of or 
contact with contaminated chicken meat (Adak et al., 1995; Allos, 2001; Deming et al., 1987; 
Harris et al., 1986).   Live thermophilic campylobacters were found on the skin of 80% of 
commercially available chicken carcasses in the UK (Corry & Atabay, 2001).   Other known 
risk factors include environmental water sources, e.g., rivers, lakes and water sports; wild 
birds, domestic animals (especially young animals, or animals with diarrhoea), farm animals, 
contact with raw meat or consumption of undercooked meat or cross-contaminated food 
(Alter et al., 2005; Friedman et al., 2000; Hillers et al., 2003; Kusumaningrum et al., 2003; 
Miettinen et al., 2001; Stanley et al., 1998a; Stanley & Jones, 2003; Takahashi et al., 2006; 
Workman et al., 2005).   Campylobacters have a low infective dose which can be as few as 
500-800 cells as determined by human volunteer studies (Black et al., 1988).   In contrast the 
carriage rate of campylobacters in the intestines of ceca of chickens is ~ 105 to >109 CFU/g 
(Berndtson et al., 1992; Jacobs-Reitsma, 2000; Mead et al., 1995). 
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Many studies have investigated the transmission routes of C. jejuni infections (Broman et al., 
2004; Ekdahl et al., 2005; FoodNet Working Group, 2004; Louis et al., 2005; Palmer et al., 
1983; Sopwith et al., 2003; Wieland et al., 2006) and the one clear outcome is that the sources 
and vehicles of human C. jejuni infection are numerous and complicated.   No single risk 
factor could be responsible for all reported cases of CE therefore it would seem that there is 
more than one factor involved at any one time.   It follows then that any single risk reduction 
strategy would not yield a significant reduction in the number of cases recorded.   Therefore 
any public health policy targeting C. jejuni infection would need to be comprehensive and 
multifaceted in design. 
 
1.5.2 Trends 
In developed countries, those most at risk of infection are young children, the 
immunocompromised and to a lesser extent, young adults (Friedman et al., 2000).   In 
developing countries, children and the immunocompromised are most at risk, however CE 
does not seem to be of much importance amongst adults (Coker et al., 2002).   In contrast, the 
child mortality rates in developing countries are far greater than of developed countries for 
many economic associated reasons (O'Ryan et al., 2005).   CE is of particular concern for 
children at weaning age in developing countries as they are no longer receiving antibodies 
against campylobacters present in breast milk and are immunologically immature (Coker et 
al., 2002; Nachamkin et al., 1994).   In addition, children in economically developing 
countries are often malnourished, experience poor hygiene and sanitation, live in close contact 
with farm animals, have access to only untreated drinking water, do not have adequate 
medical care and are more likely to be uneducated (Coker et al., 2002; O'Ryan et al., 2005).   
In developing countries, the incidence rate of CE for children under the age of 5 is thought to 
be as high as 40,000 to 60,000 cases per 100,000 population based on studies performed in 
Thailand, Mexico and Peru (Calva et al., 1988; Oberhelman et al., 1999; Taylor et al., 1988).   
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Comparatively, the estimated incidence rate in developed nations is less than 300/100,000 in 
children of the same age (Skirrow, 1987).   The high incidence rate in children in developing 
countries tends to decrease with increased age, with most cases seen in children younger that 
2 years (Calva et al., 1988; Oberhelman & Taylor, 2000; Taylor et al., 1991).   Children are 
more likely to be asymptomatic carriers of campylobacters in developing countries than 
developed countries with an incidence of 14.9% and 0.5% respectively (Coker et al., 2002).   
Another notable difference observed with C. jejuni infections in children in developing 
nations is the incidence of co-infections or the presence of multiple enteric pathogen species 
within the one patient, which is infrequent in developed countries (Biswas et al., 1996; Taylor 
et al., 1988).  
 
A possible explanation for young adults being a higher risk group in developed countries is 
that this group is more likely to travel internationally and are more adventurous in their eating 
habits and thus, increase their chance of contracting “traveller’s diarrhoea” by ingesting 
contaminated water or food while abroad, (Ekdahl & Andersson, 2004).   Immunodeficient 
patients, such as those living with AIDS, are more susceptible to infection due to their low 
CD4-positive T-lymphocyte counts and usually experience a more severe and prolonged bout 
of CE than do immunocompetent patients (Morpeth & Thielman, 2006).   
 
Males present with CE 1.2 –1.5 times more often than do females, this difference is most 
apparent in the young adult age group, though it is not known why this is so (Friedman et al., 
2000; Kapperud & Aasen, 1992; Skirrow, 1987).   In 2004, the CDC reported the sex-specific 
incidence of CE in the USA as 14.15 and 11.4 cases/100,000 population, for males and 
females respectively (FoodNet Working Group, 2004).   A study conducted in the US found 
that more males suffer from CE than do females in all age groups tested (Samuel et al., 2004).   
It has been suggested that males in the US are more at risk of C. jejuni infection due to 
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behavioural differences associated with food handling and consumption practices (Ekdahl & 
Andersson, 2004; Samuel et al., 2004).  
 
A seasonal trend is observed in the number of CE cases reported in temperate zones with a 
peak observed in the warmer summer months, though it is not known why this occurs (Louis 
et al., 2005; Meldrum et al., 2005; Miller et al., 2004; Nylen et al., 2002).   Several 
explanations for this trend have been postulated; 1) ingesting undercooked barbecue meat, 
which is more commonly eaten in the warmer months 2) ingesting cross-contaminated food 3) 
simply the increase in temperature 4) seasonally associated agricultural activities and/or an 
increase in the C. jejuni carriage rates of farm animals, in turn increasing the numbers of 
campylobacters in environmental water or 5) flies acting as mechanical vectors contaminating 
food by direct contact between animal faeces and human food (Ekdahl et al., 2005; Kemp et 
al., 2005; Louis et al., 2005; Stanley et al., 1998b).   This trend is not well understood. 
Interestingly, a similar seasonal peak in carriage rates of campylobacters in the UK and 
Northern Europe has been observed in important animal reservoirs such as poultry and cattle 
(Stanley et al., 1998b).   The seasonality of CE in developing nations is not obvious and is 
still debated (Coker et al., 2002) .    
 
1.5.3 Economic Impact 
As it is difficult to obtain accurate incidence rates of CE in any population due to only a 
fraction of cases being reported, it follows then that determining the economical burden 
would be equally difficult.   The impact of CE on the public health system, loss of 
productivity and the cost of treatment is largely unknown, however attempts to estimate the 
costs have been made.   However, the cost in terms of pain, suffering and loss of life is 
recognised, but immeasurable.  
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In Australia, it is estimated that the economic burden of foodborne diarrhoeal illness is $2.6 
billion AUD per year (www.foodstandards.gov.au).   The same website reports that 51.3% of 
total bacterial foodborne notifiable diseases were caused by campylobacters, therefore the 
cost of campylobacteriosis is ~ $1.3 billion AUD in Australia per year.   This Figure takes 
into account the cost of lost salary, loss in productivity, medical care, medication, pathology, 
hospitalisation, epidemiological surveillance, potential litigation, product recall, loss of 
consumer confidence and impact on export.    
 
A study conducted in England put the cost of CE at £9 million in 1989 (Skirrow, 1991).   A 
comprehensive study conducted in 1994 in England, taking into account the cost of and to 
patients and carers whether the patient visit the GP or not, puts the estimated cost much 
higher, at £ 69.6 million (Roberts et al., 2003).In 1995, a study conducted in New Zealand 
estimated a cost of $4.48 NZD billion for that year (Withington & Chambers, 1997).   In the 
US, campylobacteriosis was reported to cost $1.3-$6.2 US billion per annum, if the cost of 
associated complications was added, there was a combined loss of $1.5-$8 US billion per 
annum (Buzby et al., 1997).    
 
1.6 Clinical Aspects of C. jejuni Infection 
Different symptoms are observed in patients with CE in developing countries as compared to 
developed nations.   Generally, immunocompetent adults and children over the age of 5 years 
carrying campylobacters in developing countries are asymptomatic, due to acquired immunity 
(Oberhelman & Taylor, 2000).   Children in developing nations will generally present with 
watery non-inflammatory diarrhoea (O'Ryan et al., 2005; Tauxe, 1992).   Travellers returning 
from recent travel in developing nations or patients in developed countries present with more 
severe symptoms, including inflammatory diarrhoea which can contain blood and/or mucus 
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accompanied by severe cramping in young adults (Butzler & Skirrow, 1979a; Butzler, 1982; 
Butzler & Skirrow, 1979b; Skirrow & Blaser, 2000; Skirrow, 1977b).   A case of CE is rarely 
fatal and fatalities will generally be restricted to the elderly, infants or immunocompromised 
patients (Skirrow & Blaser, 2000; Smith & Blaser, 1985).   Of the total number of patients 
admitted into hospital due to enteritis type disease in the US, CE and Salmonella spp. enteritis 
account for ~17% and 26% of hospital identified cases respectively (Mead et al., 1999).    
 
For C. jejuni to cause disease, the immunological susceptibility of the host and the virulence 
of the infecting strain are both important factors.   An infection of C. jejuni is usually self-
limiting and is accompanied by a prodrome of fever, headache, dizziness, myalgia and general 
malaise in ~ 30% of cases (Amin, 1984; Skirrow & Blaser, 2000).   Only ~15% of patients 
will vomit or have stools containing occult blood (Skirrow & Blaser, 2000).   In severe cases, 
children can experience convulsions and adults, delirium and those patients who do 
experience prodromal symptoms tend to experience more severe diarrhoea (Skirrow & Blaser, 
2000).   On average, the incubation period is ~3.2 d which is longer than most other intestinal 
infections, but can range from 18 h to 8 d (Skirrow & Blaser, 2000).   The length of the 
incubation period coupled with the prodrome of typically flu-like symptoms can make the 
initial diagnosis a difficult one.   The disease usually progresses to acute abdominal pain and 
diarrhoea within 1-7 d of infection, where the pain can be so severe as to mimic appendicitis 
and is the most common reason for hospitalisation (Skirrow & Blaser, 2000).   Although, 
occasionally a C. jejuni infection can actually result in a case of acute appendicitis and 
campylobacters can be isolated from the infected appendix (Campbell et al., 2006).   The 
profuse, sudden-onset diarrhoea usually lasts ~ 3-5 d, though can persist for longer 
(Wassenaar & Blaser, 1999).   Shedding of the bacteria continues for several weeks after the 
symptoms have ceased unless the patient was treated with antibiotics (Kapperud et al., 1992).    
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CE in infants progresses differently than in older children and adults.   There is rarely fever 
and the symptoms are generally less severe (Skirrow & Blaser, 2000).   Though, there is 
greater chance of vomiting and bloody stools to the extent where 92% of children <1 year 
passed occult blood stools when observed in a hospital based study (Karmali & Fleming, 
1979).   Neonatal infection is usually caused by contact with the infected mother during the 
process of birth, which can occur without the mother experiencing diarrhoea (Anders et al., 
1981).   There are also reports of nosocomial spread within neonatal nurseries sufficient to 
result in an outbreak due to inadequately disinfected communal equipment (Van Dijk & van 
der Straaten, 1988). 
 
1.6.1 Complications of C. jejuni Infection 
The number of complications associated with C. jejuni infection are many and varied in 
nature, although they rarely occur.   CE can cause skin irritations such as urticaria, or hives, 
and erythema nodosum, the presence of tender red nodules usually found on the shins due to 
exudation of blood and serum associated with inflammation (Bretag et al., 1984; Lambert et 
al., 1982; Lopez-Brea et al., 1984).   Other intestinal complications include intestinal 
hemorrhage, perforation, ulceration, abscesses and toxic megacolon (Gould, 1985; Krajden et 
al., 1986; Meuwissen et al., 1981; Michalak et al., 1980; Skirrow, 1981a).    
 
C. jejuni infection can also lead to complications in other areas of the body.   Bacteraemia is 
found in < 1% of CE cases where the patient experienced diarrhoea and is mostly restricted to 
immunocompromised or elderly patients (Ladron de Guevara et al., 1994; Manfredi et al., 
1999 .; Spelman et al., 1986.).   The incidence of bacteraemia is thought to be under reported 
potentially due to a lack of routine blood culturing early in the disease progression and/or 
inappropriate culture conditions (Monselise et al., 2004; Skirrow et al., 1993).   Other 
extraintestinal complications include meningitis, endocarditis, hepatitis, cholecystitis, 
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osteomyelitis, pancreatitis, splenic rupture and septic abortion (Butzler, 1982; Ezpeleta et al., 
1992; Kita et al., 1990; Korman et al., 1997; Monselise et al., 2004; Pines et al.).   Conditions 
such as arthritis, Reiter's Syndrome, Guillain-Barré syndrome (GBS) and Miller Fisher 
Syndrome (MFS) are late onset complications associated with CE (Keat, 1983; Kuroki et al., 
1993; Rees et al., 1995b; Rhodes & Tattersfield).   Of all the CE associated complications, 
bacteraemia, the neurological disorders of GBS and MFS and reactive arthritis are the most 
serious and severe (Havelaar et al., 2000; Salloway et al., 1996; Smith, 2002).   When 
considering the morbidity and socioeconomic impact of CE, these associated complications 
amplify the cost again.    
 
Reiter’s Syndrome is often referred to as reactive arthritis, and is a disorder which causes 
uveitis (redness and inflammation of the iris and surrounding part of the eye) or conjunctivitis 
and urinary tract inflammation in addition to arthritis, affecting mostly the ankles, knees and 
wrists (Edmonds, 1984; Keat, 1983).   The symptoms usually last for a couple of weeks, but 
can linger for up to a year, though patients can expect to make a full recovery (Skirrow & 
Blaser, 2000).   Little is known about the pathogenesis of this condition and the molecular 
mechanisms involved in how C. jejuni is associated with the development of these symptoms 
(Nachamkin, 2002).   A study conducted in Finland reported an incidence of 2.6 % of CE 
cases leading to reactive arthritis (Hannu et al., 2004). 
 
GBS is an autoimmune-mediated disorder of the peripheral nervous system characterised by 
acute ascending flaccid paralysis (Guillain et al., 1916; Nachamkin et al., 2000).   The onset 
of GBS symptoms usually occurs 1-3 weeks after the CE diarrhoeal stage (Nachamkin et al., 
2000; Rhodes & Tattersfield, 1982).   Since the virtual eradication of poliomyelitis, GBS has 
become the leading cause of neuromuscular paralysis worldwide (Willison, 2005).   C. jejuni 
is widely reported as being the most prominent antecedent infectious agent associated with 
 27 
GBS (Hughes et al., 1999; Toyka, 1999; Yuki, 2001).   It is estimated that an average of 30-
40% of GBS cases are linked to C. jejuni infection (Gruenwald et al., 1991; Kuroki et al., 
1993; Nachamkin et al., 2000).   In 1995 in the US, the chance of developing GBS after CE 
was 1 in 1,058 cases (Nachamkin et al., 2000).   Over the last decade, advances in the 
knowledge of Campylobacter-associated GBS have been rapid.   The symptoms of GBS 
appear to be more severe when preceded by a case of CE (Rees et al., 1995a; Vriesendorp et 
al., 1993).   The serotype of the C. jejuni strain is also important when considering the 
probability of CE leading to GBS.   The C. jejuni strains of Penner serotype HS:19 and HS:41 
are commonly associated with GBS though are less common in cases of uncomplicated CE in 
South Africa and Japan (Goddard et al., 1997; Lastovica et al., 1997; Prendergast & Moran, 
2000; Takahashi et al., 2005; Willison & O'Hanlon, 2000).   However, a study conducted in 
The Netherlands found that serotypes HS:35 and HS:13/65 were associated with GBS and 
MFS and HS:41 was not (Endtz et al., 2000).   This study also found that HS:19 was present 
in only 2 of the 18 cases investigated (Endtz et al., 2000). 
 
There are several different patterns of GBS, those are Acute Inflammatory Demyelinating 
Polyneuropathy (AIDP), Acute Motor Axonal Neuropathy (AMAN) and MFS (Griffin et al., 
1996; Ho et al., 1998).   AIDP is characterised by the symptoms of flaccid paralysis, areflexia 
(an absence of reflexes) and usually some sensory loss (Griffin et al., 1995; Yuki et al., 
1999).   AIDP is not strongly associated with C. jejuni infection.   AMAN is characterised by 
weakness or paralysis without sensory loss and is found in China and other Asian countries 
more frequently than in Northern America and Europe (Griffin et al., 1995).   The AMAN 
form is most often linked with self antibodies to the ganglioside (human nerve cell epitope), 
GM1, though a stronger link is seen with the GD1a ganglioside (Gong et al., 2002).   MFS, 
also called Fisher’s Syndrome, is characterised by ataxia (loss of ability to coordinate muscle 
movement), ophthalmoparesis (paralysis of the eye), areflexia and an accumulation of 
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antibodies that recognise the human GQ1b ganglioside (Ang et al., 2002).   A recent study has 
postulated that the AMAN form of GBS is linked with Campylobacter infection, while the 
demyelinating forms of GBS are not (Kuwabara et al., 2004).   However, this is the only 
study to suggest this distinction and it is not clear if this is actually the case. 
 
Several factors that play a role in the development of GBS after Campylobacter infection 
include molecular mimicry, additional bacterial factors that are not yet understood and host 
factors involved in the regulation of the immune response (Hadden & Gregson, 2001; 
Nachamkin, 2002; Yuki, 2005).   Molecular mimicry is at this stage the most well understood.   
Specifically, certain classes of LOS molecules produced by particular C. jejuni strains are 
structurally similar to human gangliosides present on the surface of human nerve cells, though 
are derived from dissimilar genes (Figure 1.3; Aspinall et al., 1994; Gilbert et al., 2002; 
Godschalk et al., 2004; Moran et al., 1996; Moran & Penner, 1999; Yuki, 2005).   C. jejuni is 
involved in inducing an autoimmune response as a result of molecular mimicry, thus priming 
the human host to attack its own nerve cells and eventually causing paralysis.   There is also 
an epidemiological association between C. jejuni infection and GBS (Rees et al., 1995a; 
Takahashi et al., 2005).   Antibodies directed against “self” target molecules can be isolated 
from GBS patients and the disease can be reproduced in animal models (Yuki et al., 2001; 
Yuki, 2005).   These criteria together confirm that molecular mimicry is at play within the 
relationship between C. jejuni infection and GBS (Gregson et al., 1997; Hadden & Gregson, 
2001).   Though it should be noted that not every CE associated case of GBS is explained by 
molecular mimicry, e.g., a case where C. jejuni expressing GM1-like epitopes was isolated 
from a GBS patient in whom GM1 antibodies could not be detected (Sheikh et al., 1998).   
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Figure 1.3: Ganglioside mimicry by C. jejuni LOS (Yuki, 2005).   Those C. jejuni which 
express CstII (Thr 51) produce GM1 or GD1a-like LOS structures that can induce the 
production of anti-GM1 or anti-GD1a IgG antibodies in some patients.   GM1 and GD1a 
gangliosides are found on the motor nerves of all four limbs, therefore the binding of these 
antibodies to GM1 and GD1a would induce GBS.   Whereas, should the infecting C. jejuni 
strain express CstII (Asn 51), the LOS structures would be GT1a or GD1c-like.   Antibodies 
to these LOS structures can induce the production of anti-GQ1b IgG in some patients.   GQ1b 
is a ganglioside present on the oculomotor nerves and primary sensory neurons, hence the 
binding of these antibodies to GQ1b would induce the development of MFS (Yuki, 2005). 
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To view this interaction between C. jejuni and GBS as one of molecular mimicry alone is 
perhaps too simplistic.    However, the molecular complexities of this interaction are not the 
focus of this study and will not be discussed further. 
 
1.6.2 Treatment and Prevention 
Based upon symptoms alone, campylobacteriosis, salmonellosis and shigellosis cannot be 
distinguished one from another (Skirrow & Blaser, 2000).   A diagnosis of CE can only be 
confirmed by detecting campylobacters in the patient’s faeces (Skirrow & Blaser, 2000; 
Vaneechoutte & Van Eldere, 1997).   Laboratory confirmed diagnosis requires ~ 72-96 h for 
the bacteria to grow from stool samples (Allos, 2001), is expensive and requires specialised 
media and conditions making it difficult for scientists in developing countries and 
remote/rural areas (Misawa & Blaser, 2000).   A cost effective, rapid detection method that 
could identify campylobacters to the species level and detect their antibiotic sensitivities at the 
point of care, would not only directly benefit the patient, but would allow a more accurate 
epidemiological picture to be obtained about the incidence of campylobacteriosis worldwide.   
More research and development in this area is needed. 
 
The majority of patients do not seek medical attention before 4-6 days of being ill on average, 
by this time a laboratory confirmed diagnosis of C. jejuni is too late for the administration of 
antibiotics to be effective (Tabibian et al., 1987).   The usual treatment is therefore 
rehydration to replace the electrolytes and fluid lost as a result of diarrhoea and/or vomiting 
(Faruque et al., 1993; Mackenzie & Barnes, 1988; Skirrow & Blaser, 2000).   In the event that 
antibiotic treatment is required, that is if the patient is immunocompromised, the diarrhoea 
lasts longer than ~ 1 week, the patient is pregnant or the case is particularly severe (Allos, 
2001; Faruque et al., 2004), macrolides (especially erythromycin) are the antibiotics of choice 
(Mamelli et al., 2003).   Fluoroquinolones used to be the antimicrobial drugs of choice as 
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other enteric pathogens, e.g., Salmonella or Shigella species were generally susceptible to 
them, therefore the patient could be treated without the need to wait for laboratory 
confirmation or susceptibility testing (Allos, 2001).   However, over the last decade, antibiotic 
resistance among campylobacters has increased and fluoroquinolones now appear to be of 
little use in certain geographical areas where fluoroquinolone resistance is a problem (Hoge et 
al., 1998; Talsma et al., 1999).   Erythromycin resistance amongst campylobacters is 
comparatively low and tetracylines have been suggested as an alternative in cases of 
suspected macrolide resistance, however they are rarely used in practise (Funke et al., 1994; 
Moore et al., 2005).   The newer macrolides, such as azithromycin and clarithromycin are 
effective against C. jejuni infection however they are more costly than erythromycin and 
provide no added therapeutic advantage (Allos, 2001).   The increase in antibiotic resistance 
amongst campylobacters is closely related to over prescription in human medicine and to their 
use in veterinary medicine as well as in the meat industry for livestock growth promotion, 
prophylaxis or feed supplements (Allos, 2001; Endtz et al., 1991; Luangtongkum et al., 2006; 
Teuber, 2001; Witte, 2000).   Antibiotic resistance among C. jejuni has become a serious 
problem world wide (Moore et al., 2006).    
 
Current thinking on the topic of campylobacteriosis prevention is an approach of reducing the 
risk of exposure.   Reducing the infection level among food animals for human consumption 
seems an obvious target, though in practice may be difficult if not impossible to achieve due 
to the rapid spread and colonisation of poultry flocks and the high bacterial loads (Pattison, 
2001).   Improved strategies to reduce the cross-contamination of carcasses during slaughter 
would also reduce risk.   The treatment of meat for retail sale to reduce the number of live 
campylobacters present on the carcass by irradiation is still met with enormous public 
scrutiny, despite the obvious benefit (Crushell et al., 2004; Farkas, 1998).   As contaminated 
environmental water, e.g., lakes and rivers, are implicated as important sources of C. jejuni 
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infection, the treatment of agricultural waste water run off would also be a risk reduction 
target (Jones, 2001).    
 
Another approach to risk reduction is public education of the dangers of unpasteurised milk, 
the necessity of proper food handling practices, an awareness of the potential for cross-
contamination in the kitchen (Humphrey et al., 2001), the importance of thoroughly cooking 
meat and vigilant attention to personal hygiene with particular regard to hand washing before 
eating, after contact with pets and after using the toilet (Allos, 2001; Crushell et al., 2004).   
Certain risk reduction strategies would potentially be more difficult to implement in 
developing areas where access to a clean water source may not be possible, close contact with 
farm animals may be difficult to avoid and infrastructure required for sufficient waste 
treatment may not be economically possible.    
 
Development of a vaccine to protect against C. jejuni infection is under way by several 
different research groups, though the process has been hindered by a lack of understanding of 
the molecular pathogenesis of this organism, the need to validate an appropriate animal model 
for trials and concern about the theoretical risk of triggering GBS (Baqar et al., 1995; Burr et 
al., 2005; Crushell et al., 2004; Islam et al., 2006; Lee et al., 1999; Prokhorova et al., 2006; 
Walker, 2005).   The risk of triggering GBS could be avoided by careful selection of a non-
GBS associated C. jejuni strain or an LOS mutant with the ganglioside mimicking structure 
removed.   Recently, a formalin-killed whole vaccine has been shown to provide protection 
against subsequent challenge in ferrets (Burr et al., 2005).   E.coli expressing immunogenic 
antigens of C. jejuni origin have also been evaluated as vaccine candidates in mice with some 
success (Prokhorova et al., 2006).   An inactivated whole-cell prototype vaccine trial was 
conducted in mice at the Navy Medical Research Institute, (Bethesda, USA) with promising 
outcomes (Baqar et al., 1995; Scott, 1997) and is now undergoing trials in non-human 
 33 
primates (Islam et al., 2006).   Another approach is being investigated, also at the Navy 
Medical Research Institute (Bethesda, USA), in the form of a truncated recombinant flagellin 
subunit vaccine shown to provide a level of protection to mice (Lee et al., 1999).   The 
application of vaccines against Campylobacter spp. would either be to reduce the bacterial 
load in food animals or to inhibit their initial colonisation, especially in chickens (Barrow & 
Page, 2000; Pawelec et al., 2000), or to immunise humans, particularly travellers, infants in 
developing countries and/or the military (Girard et al., 2006). 
 
1.7 Pathogenesis 
Since the completion of the first C. jejuni genome project (Parkhill et al., 2000), the 
mechanisms behind C. jejuni pathogenesis are in the process of being unravelled.   Molecular 
investigations into these mechanisms have gained momentum and the virulence determinants 
employed by C. jejuni to persist in the environment, survive the acidity of the stomach and 
colonise the intestinal epithelium are becoming clearer (Snelling et al., 2005).   For C. jejuni 
to establish an infection sufficient to cause disease, the bacterium is required to survive the 
physiological stresses associated with external and internal environments such as; temperature 
fluctuations, variations of pH, different hosts, host immunity, oxidative stress and limited 
nutrient supply (Park, 2002; Snelling et al., 2005).   The virulence factors important in 
enabling C. jejuni to be a human pathogen include motility, chemotaxis, iron acquisition, 
adhesion and invasion, quorum sensing, superoxide stress defence, thermal-stress response 
and an ability to avoid the host immune system (Bereswill & Kist, 2003; Ketley, 1997).   
Other potential virulence factors include toxin production (Pickett, 2000) and a virulence 
plasmid, pVir,  found in some C. jejuni strains (Bacon et al., 2000; Schmidt-Ott et al., 2005).   
The virulence plasmid is not the focus of this study and will therefore not be discussed in this 
review. 
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1.7.1 Lipopolysaccharides, Lipooligosaccharides & Capsule  
LPSs are a major surface component of gram-negative bacteria and are known virulence 
factors (Ketley, 1997).   Investigations into the biochemistry of C. jejuni surface 
polysaccharides (PSs) were undertaken for several reasons.   First, the basis of the Penner 
serotyping system involves a heat-stable antigen, originally thought to be the O-antigen (O-
Ag) component of the LPS molecule (Mills et al., 1985; Moran et al., 2000; Penner & 
Hennessy, 1980; Penner et al., 1983).   Second, the realisation that these sialylated surface 
PSs could potentially be connected to the development of C. jejuni-associated GBS through 
molecular mimicry (Aspinall et al., 1994; Kuroki et al., 1993).   Third, the importance of LPS 
as a virulence factor was established (Rietschel et al., 1994), however the molecular 
mechanisms involved were not well understood.    
 
Historically, there has been some confusion surrounding the structural nature of 
polysaccharides on the C. jejuni cell surface.   Initially, due to an absence of conflicting 
evidence, it was thought that C. jejuni expressed LPS of two different sizes.   Early reports 
stated that all strains possessed low molecular weight (LMW) LPS, also termed LOS 
indicating that the carbohydrate chain consisted of 3 – 10 sugar residues, where the O-Ag 
repeats that are typical of high molecular weight (HMW) LPS were absent (Logan & Trust, 
1984; Rietschel et al., 1994).   These HMW LPS molecules were detected in less than half of 
the C. jejuni serotypes analysed and were thought to be similar to the LPS of Salmonella 
enterica serovar Typhimurium (referred to as S. typhimurium throughout this thesis) and E. 
coli complete with a chain of O-Ag repeats, or “O-chain” (Aspinall et al., 1992; Moran & 
Penner, 1999). 
 
LPS and LOS consist of an endotoxic lipid A moiety that is anchored into the outer leaflet of 
the outer membrane.   The Lipid A consists of a glucosamine backbone and variations in the 
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phosphorylation of lipid A or length of the fatty acid chain may potentially effect the host 
immune response (Szymanski et al., 2003b).   Attached to the lipid A component via a 3-
deoxy-α-D-manno-oct-2-ulopyranosonic acid (Kdo) residue is the core region (Karlyshev et 
al., 2005b).   The core consists of a branched- chain oligosaccharide which is divided into an 
inner more conserved region and an outer more variable region (Figure 1.4; Moran et al., 
2000).   The variability seen in among the surface PSs of C. jejuni is far greater than that of E. 
coli for example, as reflected in the number of serotypes.   There are over 60 C. jejuni Penner 
serotypes while E.coli has as few as five core types (Moran et al., 2000).   The O-Ag, thought 
to be present in the C. jejuni HMW LPS, was presumed to be attached to the outer core, 
though it was not known how.   In addition to being structurally important components of the 
cell membrane, LPS and LOS contribute to pathogenesis in several ways.    
 
They are involved in serum resistance, resistance to phagocytic killing, endotoxicity and 
adhesion (McSweegan & Walker, 1986; Moran et al., 2000; van Vliet & Ketley, 2001).   
While not common amongst prokaryotes, some surface PSs in C. jejuni and other bacterial 
pathogens (Neisseria and Haemophilus spp.) contain sialic acid residues, which have been 
observed to enhance serum resistance in C. jejuni (Guerry et al., 2000b).   The presence of 
sialic acid residues can interfere with enzyme C3 of the alternate complement pathway which 
disrupts the host’s complement cascade.   Sialic acid residues are also found on human 
gangliosides, therefore their presence on the external surface of C. jejuni suggested, what we 
now know, that molecular mimicry is involved in C. jejuni-associated GBS and MFS (Yuki & 
Odaka, 2005).   This theory was supported by a study of a knockout mutant lacking WaaF, a 
heptosyltransferase which attaches the second heptose of the LOS inner core.   The WaaF 
mutant produced a truncated core oligosaccharide that was no longer reactive with anti-
ganglioside antibodies (Oldfield et al., 2002).  
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Figure 1.4: The core oligosaccharide structure of LOS from C. jejuni NCTC11168 based on 
previously published data (Oldfield et al., 2002; St Michael et al., 2002; Szymanski et al., 
2003b) featured in (Karlyshev et al., 2005b).   The brackets indicate structures analogous to 
gangliosides of types GM1a and GM2 which have been implicated in molecular mimicry.   
Sugar abbreviations: Kdo, 3-deoxy-α-D-manno-oct-2-ulopyranosonic acid; Hep, L-glycero-
D-mannoheptose; Glc, glucose; Gal, galactose; Neu5Ac, N-acetylneuraminic acid or sialic 
acid; GalNAc, N-acetyl-D-galactosamine; P, phosphate; PEtn, 2-amino ethyl phosphate 
(Karlyshev et al., 2005b; St Michael et al., 2002). 
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In the late 1990s, putative LPS biosynthesis genes from a 16 kb cluster referred to as the wla 
cluster based on the nomenclature proposed by Reeves and others (Reeves et al., 1996), were 
expressed in E. coli and shown to react with antisera that recognised C. jejuni surface PSs, 
confirming their involvement in glycosylation (Fry et al., 1998; Korolik et al., 1997; Wood et 
al., 1999).   However, the C. jejuni lipid A-core complex expressed in E.coli resulted in a 
structure larger than that of Campylobacter spp., though the size of the O-Ag like structure 
was not increased.   This suggested that the molecule reacting to the C. jejuni specific antisera 
was actually the E.coli lipid A-core structure to which a Campylobacter spp. specific PS was 
attached, interestingly the O-Ag-like structure was unaffected (Fry et al., 1998).   The O-Ag-
like ladder was visualised by immunoblotting, though not by silver staining, unlike the LOS 
that it was thought to be attached to (Fry et al., 1998; Wood et al., 1999).   Similar findings 
were reported for other PS biosynthesis genes and questions were raised about whether the O-
Ag-like structure actually was a true O-Ag and if it was linked to the LPS at all (Fry et al., 
1998; Fry et al., 2000; Wood et al., 1999).   Suspicion of this O-Ag-like molecule actually 
being a CPS or an enterobacterial common antigen instead of an LPS O-Ag was first 
mentioned in 1996 as a result of an investigation into the heat-stable antigen used in the 
Penner serotyping system (Chart et al., 1996b).   A few years later, it was postulated that 
these putative LPS biosynthesis genes were actually involved in general protein glycosylation 
(Szymanski et al., 1999).   There were also reports about the existence of a second PS 
biosynthesis locus as well as the identification of genes involved in CPS biosynthesis 
(Karlyshev et al., 2000; Wood et al., 1999).   On completion of the C. jejuni NCTC 11168 
genome project and together with further investigation and characterisation of C. jejuni PSs 
and their respective biosynthesis genes, it was confirmed that C. jejuni does not possess LPS 
containing the O-chain like E. coli or Salmonella spp., but LOS and CPS instead (Karlyshev 
et al., 2000; Karlyshev et al., 2001).   Further, it was determined that the CPS is the basis of 
the Penner serotyping method (Karlyshev et al., 2000).    
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It is now accepted that this O-chain is actually the CPS and that C. jejuni possess both LOS 
and CPS molecules, with CPS being the outermost structure (Karlyshev et al., 2005b; 
Szymanski et al., 2003b).   CPS consists of an oligosaccharide repeating unit that is 
polymerised into a chain as previously published for the structure of the “O-Ag” (Karlyshev 
et al., 2005b).   The CPS is attached to the phospholipid component of the outer leaflet of the 
outer membrane, specifically to a dipalmitoyl-glycerophosphate lipid anchor (Corcoran et al., 
2006; St Michael et al., 2002).   CPS is primarily comprised of ribose, galactose and glucose 
residues and some strains include a phosphoramide glycan modification (Szymanski et al., 
2003b).   The biochemical structure of various side chains have been described, one example 
is the 6-O-Me-D-α-L-gluco-heptopyranose (Figure 1.5; St Michael et al., 2002).  
 
LOS structures produced by a range of different C. jejuni strains have been organised into 8 
classes, A – H (Gilbert et al., 2002; Parker et al., 2005).   Initially, three classes (A – C) were 
proposed by Gilbert and colleagues based on the organisation of the LOS biosynthesis genes 
from 11 C. jejuni strains (Gilbert et al., 2002).   Where class B appears to be the evolutionary 
link between classes A and C (Gilbert et al., 2002).   All three classes, A – C, produce 
sialylated LOS molecules which can mimic a range of human gangliosides (Gilbert et al., 
2002).   A later study conducted by Parker and colleagues expanded the number of C. jejuni  
strains to 123, including 39 Penner serotypes, and proposed the addition of classes D – H and 
added the subclasses A1, A2, B1 and B2 (Parker et al., 2005).   Over 60% of the strains 
investigated were classified into classes A, B or C (Parker et al., 2005).   C. jejuni strains 
11168, 81116, 81-176 and RM1221 produce class C, E, B1 and F LOS respectively (Parker et 
al., 2005).   However, not all strains included in the study by Parker and co-workers could be 
classified (Parker et al., 2005).    
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Figure 1.5:   Structure of high Mr capsule polysaccharide from C. jejuni 11168 (St Michael et 
al., 2002).   Sugar  residue abbreviations: Rib, ribose; GalƒNAc, N-acetyl-D-galactosamine; 
Glc, glucose; Me, methyl; glcHepp, glycero-α-L-gluco-heptopyranose; -α-D-GlcpA6(NGro), 
uronic acid amidated with 2-amino-2-deoxyglycerol at C-6 (St Michael et al., 2002). 
→2)-β-D-Ribƒ-(1-5)-β-D-GalƒNAc-(1-4)-α-D-GlcpA6(NGro)-(1→ 
6-O-Me-D-α-L-glcHepp 
1 
↓ 
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This study conducted by Gilbert and colleagues also found that there are at least five distinct 
mechanisms which enable C. jejuni to vary the structure of the LOS molecule that it produces 
(Gilbert et al., 2002).   These mechanisms include 1) different genes present within the LOS 
biosynthesis locus, 2) phase variation due to slipped-strand mispairing in regions containing 
homopolymeric nucleotide runs, 3) a single base deletion or insertion leading to gene 
inactivation, 4) a point mutation leading to gene inactivation and 5) mutations which alter the 
acceptor specificity of glycosyltransferases (Gilbert et al., 2002). 
 
Both the LOS and CPS molecules have the potential for structural variation as a result of 
phase variation (Guerry et al., 2002; Prendergast et al., 2004; Wren et al., 2001).   A variation 
of CPS containing a HMW glycan was detected in strain 81-176 and observed to be phase 
variable (Bacon et al., 2001).   An 81-176 mutant lacking CPS experienced increased 
susceptibility to human serum, increased hydrophobicity, a reduced capacity to invade and 
adhere to INT407 human epithelial cells and showed reduced virulence in the ferret model 
(Bacon et al., 2001).   Further investigation of this CPS variant reveals that it is a 4-linked α-
glycan with an average length of 25 residues that occurs in addition to the serodeterminant 
CPS in C. jejuni 81-176 (Papp-Szabo et al., 2005).   It is not yet established whether this α-
glycan is located within the CPS or not.   Importantly, recent evidence suggests that some 
strains of C. jejuni produce polysaccharides in addition to LOS and CPS and were called 
polysaccharide-related compounds (PRCs; Corcoran & Moran, 2007). 
 
Developments providing more information about the nature of C. jejuni carbohydrates are 
occurring, allowing a clearer understanding.   However, despite these advances, the molecular 
details of the activated sugar intermediaries which play are role in carbohydrate and metabolic 
pathways are still not known (Karlyshev et al., 2005b).   The complexity of Campylobacter 
carbohydrates between strains and within the one strain due to phase variation (Szymanski et 
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al., 2003b), coupled with the bifunctionality of certain enzymes involved in their construction 
(Kanipes et al., 2006), makes the task of unravelling this story an intriguing but difficult one.   
We do know that the extraordinary variability is likely to play an important role in host 
immune system avoidance and is perhaps involved in increasing the host range of 
campylobacters (Karlyshev et al., 2005b).   Carbohydrate biosynthesis is obviously 
enormously important to the C. jejuni strain NCTC 11168 as it invests > 8% of its genome in 
the process (Figure 1.6; Karlyshev et al., 2005b).   Protein glycosylation will be discussed 
later in this chapter. 
 
1.7.2 Surface Proteins 
According to the sequence data, there are over 150 predicted membrane proteins and 
lipoproteins present in C. jejuni NCTC 11168 (Parkhill et al., 2000).   Surface proteins; 
including outer membrane proteins, integral membrane proteins, lipoproteins and 
glycoproteins, play a role in how the bacterium interacts with its environment.   These 
proteins can be involved in pathogenesis in many ways including adhesion to the host, 
avoidance of the host immune system, nutrient acquisition, motility, adaptation to low pH 
environments or antibiotic resistance.    
 
1.7.2.1 Porins 
Porins, or pore-forming proteins are situated in the membrane of many gram-negative bacteria 
and enable the cell to change the permeability of its membrane in response to changes in its 
environment (Dedieu et al., 2002).   The membrane surface of C. jejuni is organised into a 
hexagonal lattice and contains the most highly expressed outer membrane protein (OMP), the 
major OMP or MOMP (Bolla et al., 2004; Penn, 2001).   MOMP is a pore forming trimer 
with cationic selectivity and is thought to belong to the maltoporin super-family (Labesse et 
al., 2001).   In strain 11168, MOMP is composed of 424 aa and is 45.688 kDa in size.   
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Figure 1.6:   Known glycosylated structures on the surface of C. jejuni (Karlyshev et al., 
2005b). 
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MOMP is the most well characterised OMP of C. jejuni and is widely distributed amongst C. 
jejuni strains (Pumbwe et al., 2004) and between these strains it displays structural variation 
and ranges in size from 41-46 kDa (Newell et al., 1984).   Variation of the aa sequence among 
different strains is clustered and appears to be present in the surface exposed regions (Labesse 
et al., 2001).   It also plays an important role in the structural integrity of the cell membrane 
(Dé et al., 2000; Dedieu et al., 2002).   Crystallographic data supports the role of MOMP as a 
porin (Bolla et al., 2004).   Interestingly, both the trimer and monomer forms are capable of 
forming a pore in vitro (Labesse et al., 2001).   The MOMP is encoded by porA, though this 
gene has been termed cmp by other researchers who have used it as the target of a PFGE 
typing system (Huang et al., 2005; Zhang et al., 2000).   The porA promoter controls the 
regulation of porA and responds to changes in pH and temperature (Dedieu et al., 2002). 
 
MOMP has been observed to be immunogenic in western blots using antisera derived from 
human patients suffering CE in both the acute disease phase and during convalescence (Dunn 
et al., 1987; Nachamkin & Hart, 1985).   In contrast, the immunogenicity of MOMP has also 
been reported as weak and infrequently detected in the saliva and serum of convalescing 
patients (Cawthraw et al., 2002).   The antigenicity of MOMP during infection is still debated.   
MOMP has been observed as playing a role in adhesion of C. jejuni to INT407 human 
epithelial cells in vitro (Moser et al., 1997; Schroder & Moser, 1997).   A complex of MOMP 
and LOS has been found to exhibit toxic properties (Bacon et al., 1999), though this 
presumably is due to the properties of the lipid A endotoxin component of the LOS and not 
MOMP.   In addition, there is a report stating that MOMP is not a cytotoxin mediating 
inflammatory diarrhoea (Khan et al., 2005).   Furthermore, an investigation of multiple 
antibiotic resistance in C. jejuni has provided no evidence that MOMP is involved in this 
process (Pumbwe et al., 2004). 
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Another C. jejuni pore forming protein is Omp50 and is encoded by the Cj1170c gene which 
is present in strains of C. coli and C. lari and in C. jejuni 11168 (Bolla et al., 2000).   
Interestingly, the Omp50 protein was detected in C. jejuni and not C. coli, despite the 
presence of the gene (Bolla et al., 2000).   It is a novel protein as there is no significant 
sequence similarity with other known bacterial porins.   Omp50 consists of 453 aa, has a pI = 
5.81 and is 51.1692 kDa in C. jejuni 11168 (Bolla et al., 2000).   There is only weak sequence 
similarity present between MOMP and Omp50 and no antibody cross reactivity was observed 
between the two porins (Bolla et al., 2000).    
 
1.7.2.2 Adhesins 
The ability of C. jejuni to colonise the gastrointestinal tract of humans is an essential phase in 
pathogenesis (Wassenaar & Blaser, 1999).   Surface proteins that play a role in anchoring the 
bacteria to the host cell are called adhesins.   They are either assembled into pili/fimbriae or 
directly associated with the cell surface (Soto & Hultgren, 1999).   The three described 
adhesins from C. jejuni, JlpA, PEB1 and CadF, are OMPs and therefore directly associated 
with the cell surface.   Putative adhesins identified by detection of C. jejuni surface 
components that had adhered to HEp-2 cells include proteins of the following molecular 
masses: 28, 32, 36 and 42 kDa (de Melo & Pechere, 1990).   More recent investigations have 
identified the 28 kDa protein known as PEB1 (28 kDa; Pei & Blaser, 1993), the 36 kDa 
protein CadF (37 kDa; Konkel et al., 1997) and the 42 kDa protein called JlpA (42 kDa; Jin et 
al., 2001). 
 
Adhesins of interest in pathogenesis are the PEB1-4 antigenic surface proteins as they are 
conserved periplasmic virulence determinants involved in adhesion (Pei et al., 1998; Pei et 
al., 1991).   In strain 81-176, the size of each of the PEB proteins (1-4) is 28 kDa, 29 kDa, 30 
kDa and 31 kDa respectively and are all basic with a pI of > 8.5 (Pei et al., 1991).   However 
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the size of the proteins can vary depending on the strain of origin (Meinersmann et al., 1997; 
Pei et al., 1991).   Cell binding factors, CBF1 and 2, were identified independently and found 
to be identical to PEB1 and PEB4 respectively (Kervella et al., 1993).   In addition, a C. jejuni 
OMP, termed OmpH1, was postulated as being a modified form of PEB1 which the bacteria 
has adapted specifically for colonising chicken intestines, while the PEB1 form is specific for 
human colonisation (Meinersmann et al., 1997).   In C. jejuni strains A74/O and A74/C 
OmpH1 and PEB1 proteins have a molecular weight of 32 and 34 kDa respectively and in the 
two strains tested, only one copy of the gene was detected thus suggesting that post 
translational modification is responsible for the antigenic differences (Meinersmann et al., 
1997).    
 
All four PEB proteins are strongly cationic, lack cysteine and undergo post translational 
cleavage of the N-termini (Bolla et al., 2004).   This cation charge may aid the protein in 
anchoring into the membrane via electrostatic interactions with negatively charged LOS as 
well as interactions with eukaryotic cells (Pei et al., 1991).   All four PEB proteins differ in 
their N-terminal sequences and their ability to stimulate the host immune system, with PEB1 
being the most immunogenic (Pei et al., 1991).   Based on sequence similarity, PEB1 is a 
putative periplasmic binding protein of an ABC-type aa transporter (Parkhill et al., 2000; Pei 
& Blaser, 1993).   Investigations into the role of peb1A, which encodes PEB1,  via knock-out 
mutagenesis revealed that this gene is important in but not solely responsible for both 
colonisation and invasion (Pei et al., 1998).   This peb1A mutant was observed to provide 
protection from disease and intestinal colonisation in a mouse model (Pei et al., 1998).   
Human sera taken from convalescing patients recovering from CE caused by either C. jejuni 
or C. coli has been observed to react with both PEB1 and 3 (Pei et al., 1991).   PEB1 is found 
in all C. jejuni and C. coli strains and given its strong immunogenic nature it is potentially an 
ideal vaccine candidate.   These characteristics have been exploited by Sizemore and others in 
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the form of a live attenuated S. Typhimurium strain containing one of three types of 
expression vectors into which PEB1, minus the signal sequence, had been cloned (Sizemore 
et al., 2006).   At this stage no protection was observed post oral challenge with C. jejuni 
despite anti-PEB serum IgG being present in significant levels (Sizemore et al., 2006). 
 
Another OMP of interest in the pathogenesis of C. jejuni is the 37 kDa (Campylobacter 
adhesion to Fibronectin, CadF) protein which, as the name suggests, is involved in adhesion 
through binding to fibronectin (Fn; Konkel et al., 1997).   CadF is conserved among C. jejuni 
and C. coli strains which has allowed cadF to be used as the target of a diagnostic PCR test 
for food products (Konkel et al., 1999).   Fn is a high molecular weight adhesive glycoprotein 
(~ 440 kDa) present in its insoluble form in the extracellular matrix of human epithelial cells 
in association with microfilaments where it is involved in cell to cell interactions (Joh et al., 
1999).   Microfilaments, or fine thread-like protein fibres (~3-6 nm diameter), are one of the 
three primary fibre types that make up the cytoskeleton and are primarily composed of actin.   
These microfilaments extend into the villi of the intestinal epithelial cell giving shape to the 
cell surface. 
 
The ability of CadF to bind fibronectin allows C. jejuni to adhere to the extracellular surface 
of the host’s intestinal epithelium (Konkel et al., 1997) thus allowing the bacteria to anchor 
itself in the intestine and avoid being flushed through the gastrointestinal tract as a result of 
peristalsis.   Specifically, the likely binding site of Fn to CadF has been identified as AA134-
137, a four aa sequence consisting of phenylalanine-arginine-leucine-serine (Konkel et al., 
2005).   Other bacterial pathogens also employ a Fn-binding strategy, including 
Staphylococcus aureus (Kuusela, 1978), Streptococcus pyogenes (Myhre & Kuusela, 1983), 
Salmonella enteritidis (Baloda et al., 1985), E. coli (Fröman et al., 1984), Neisseria 
gonorrhoeae (van Putten et al., 1998), Mycobacterium avium (Schorey et al., 1996) and 
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Treponema spp (Dawson & Ellen, 1990).   CadF is important for the adherence of C. jejuni to 
INT407 human epithelial cells in vitro, as a cadF knock-out mutant demonstrated a reduction 
in adherence of 50-90% (depending on the inoculum) when compared with the parent strain 
(Monteville et al., 2003).   The presence of microfilament inhibitors also reduced the 
percentage of invaded bacteria (Monteville et al., 2003).   The necessity of CadF in vivo was 
demonstrated via experimentation with a C. jejuni CadF knock-out mutant that was observed 
as being unable to colonise chickens (Ziprin et al., 1999).   Further investigation into the role 
of CadF suggests that it is the first step in the pathway of bacterial internalisation.   Infections 
of INT407 cells with C. jejuni have lead to the observation of an increase in the levels of 
tyrosine phosphorylated paxillin, a multi-domain cytoskeleton protein found mostly at sites of 
cell adhesion called focal adhesion sites (Giancotti & Ruoslahti, 1999).   Activated paxillin is 
linked to a signal transduction pathway which involves the interaction of Fn with integrins to 
eventually result in the organisation of the intracellular actin cytoskeleton (Giancotti & 
Ruoslahti, 1999; Miyamoto et al., 1998; Monteville et al., 2003).   It would seem that C. 
jejuni internalisation is dependent upon its ability to manipulate the host cell’s signal 
transduction pathways.    
 
JlpA is also a surface exposed C. jejuni adhesin and is encoded by the 1116 bp jlpA gene.   
JlpA is a 372aa lipoprotein (~ 42.3 kDa) that is specific to C. jejuni (Jin et al., 2001).   An 
investigation involving a JlpA mutant provided data to the effect that JlpA is an important 
adhesin as the mutant showed a reduced capacity to adhere to and invade HEp-2 cells when 
compared to the parent strain (Jin et al., 2001).   The mechanisms of interaction between JlpA 
and HEp-2 cells has been further characterised and this adhesin appears to trigger host cell 
signalling pathways which eventually lead to inflammatory/immune responses in host cells 
following C. jejuni infection (Jin et al., 2003).   Specifically, JlpA interacts directly with a 
host cell surface heat shock protein 90 α (Hsp90), a eukaryotic molecular chaperone which 
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can stimulate two signalling pathways.   Firstly, the interaction of JlpA with Hsp90 eventually 
activates NF-κB, a transcription factor which is known to be essential for the regulation of 
genes involved in inflammatory and immune responses (Jin et al., 2003).   The function of 
this transcription factor is exploited by other enteric pathogens including Salmonella 
Typhimurium (Hobbie et al., 1997), Shigella flexneri (Dyer et al., 1993), enteroinvasive E. 
coli (Savkovic et al., 1997), enterohaemorrhagic E. coli (Berin et al., 2002), Yersinia 
enterocolitica (Schulte et al., 2000) and Listeria monocytogenes (Tang et al., 1998).   
Secondly, Hsp90 and JlpA trigger an enzyme that plays a role in signal transduction, p38 
MAP kinase, again involved in the inflammatory/immune responses of host cells (Dong et al., 
2002). 
 
1.7.2.3 General Surface Proteins 
Other surface proteins of interest include an 18 kDa OMP of C. jejuni that shows significant 
sequence similarity to peptidoglycan-associated lipoproteins (PALs) of other gram-negative 
bacteria, was given the name Omp18 and is encoded by pal (Burnens et al., 1995; Konkel et 
al., 1996).   PALs are involved in maintaining the structural integrity of the membrane by 
anchoring the outer membrane to the peptidoglycan layer and are important in cell envelope 
organisation (Bouveret et al., 1999).   C. jejuni Omp18 is immunogenic, which is consistent 
with PALs from other bacteria being implicated in playing a role in the induction of an 
immune response in the host.   A signal peptide sequence was detected in Omp18 suggesting 
that the protein undergoes cleavage resulting in a mature protein of 16 kDa (Konkel et al., 
1996).   PALs have been described as highly immunogenic and conserved in certain gram-
negative bacteria and could therefore be useful antigens as targets for diagnostic detection 
systems (Konkel et al., 1996).    
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Initially, a 19 kDa protein termed p19 was thought to be a major component of the C. jejuni 
outer membrane when isolated by the acid/glycine outer membrane method (Janvier et al., 
1998).   However, it is actually a periplasmic protein that is not surface exposed and there is 
no definitive evidence that it is immunogenic in natural C. jejuni infections in humans 
(Janvier et al., 1998).   Interestingly, p19 did have immunogenic properties when investigated 
in a mouse model where the same mouse antibody detected it in both C. jejuni and C. coli 
(Janvier et al., 1998).   Recent gene expression analysis investigating the response of C. jejuni 
to iron limited conditions detected a significant upregulation of p19 (Holmes et al., 2005).   
The p19 gene is reported as potentially being involved in iron-transport, the product of which 
is involved in a putative iron uptake system (van Vliet et al., 2002), similar to the 
ferroxidase/ferric uptake system of Saccharomyces cerevisiae (Askwith et al., 1996).   The 
p19 protein is encoded by Cj1659 which is regulated by iron and the iron-responsive ferric 
uptake regulator (Fur) protein (van Vliet et al., 2000).   Iron and its acquisition from the host 
environment is essential for the survival of the infecting bacteria (Holmes et al., 2005).    
 
Another type of surface protein is the efflux pump which contributes to bacterial resistance 
against a broad range of antimicrobials.   The two multi drug resistant (MDR) efflux systems 
described in C. jejuni are CmeABC (Lin et al., 2002) and CmeDEF (Pumbwe et al., 2004).   
In addition to antibiotic resistance, these efflux systems provide protection for the bacteria 
against the damaging effects of detergents and bile salts.   Without this protection, C. jejuni 
was unable to colonise the chicken intestine as determined by observing the effects of 
CmeABC inactivation (Lin et al., 2003).   CmeABC is also essential for bile resistance in 
vitro as detected by growth assays of several C. jejuni strains performed in MH broth 
supplemented with crude ox bile extract (Lin et al., 2003).   Increased bile susceptibility 
achieved by the therapeutic use of efflux pump inhibitors, could be exploited to prevent C. 
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jejuni colonisation of the chicken intestine that, in turn, could reduce the risk of exposure to 
humans up the food chain.  
 
Other OMPs, ranging in size from 20 kDa – 180 kDa have been detected in C. jejuni however 
have yet to be characterised in detail (Chart et al., 1996a; Panigrahi et al., 1992).   Those 
OMPs identified by Panigrahi and co-workers (1992) were expressed when grown in rabbit 
intestinal loops though not in vitro.   Similarly, Chart and others observed three OMPs that 
could not be detected in vitro, but were expressed only when the bacteria were maintained in 
chickens (Penn, 2001).   A 59 kDa OMP which displayed some N-terminal sequence 
similarity to CadF and the ability to bind INT407 membranes and Fn has been observed 
(Moser et al., 1997).   In addition, a 32-34 kDa OMP termed OmpH1 was described and 
found to show similarity to the sequence of PEB1 and shared 56.3% similarity to the Bacillus 
stearothermophilus glutamine-binding protein GlnH (Meinersmann et al., 1997).    
 
1.7.3 Protein glycosylation 
During the last decade, another factor has been identified as being involved in C. jejuni 
virulence, which is general protein glycosylation (Karlyshev et al., 2004; Szymanski et al., 
1999; Szymanski et al., 2002).   The C. jejuni flagella and various surface and periplasmic 
proteins including PEB3 are glycosylated (Constantinidou et al., 1997; Kowarik et al., 2006; 
Szymanski et al., 1999; Young et al., 2002).   C. jejuni is unusual for a bacteria in that it 
contains two protein glycosylation systems, an O-linked and an N-linked system (Figure 1.6; 
Kowarik et al., 2006; Szymanski et al., 2003a).   The O-linked system is responsible for the 
glycosylation of flagellin A and B found on the flagellar filament and there are potentially 
other protein targets that are as yet unknown.   The range of glycan structures and 
modifications on the heavily glycosylated flagella is linked to antigenic variation (Chou et al., 
2005; Guerry et al., 2006).   The O-linked glycan consists of monosaccharides or 
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disaccharides and the modifications can be of a acetamidino, dihydroxypropionyl and 
deoxypentose nature (Szymanski et al., 2003a).   The flagella will be discussed later in this 
chapter. 
 
N-linked glycosylation is essential in eukaryotic organisms, it occurs in the endoplasmic 
reticulum and is important in certain cellular processes such as protein folding, sorting and 
transporting secretory and membrane proteins (Helenius & Aebi, 2004).   The N-linked 
protein glycosylation system is conserved in C. jejuni and C. coli (Szymanski et al., 2003b).   
The 12 genes in C. jejuni that encode the enzymes involved in the N-linked glycosylation 
pathway are located in the pgl locus (Linton et al., 2005; Szymanski et al., 1999).   The Pgl 
enzymes act to synthesise the common heptasaccharide, GalNAc-α 1,4- GalNAc-α 1,4-(Glc-
β 1,3)- GalNAc-α 1,4- GalNAc-α 1,4- GalNAc-α 1,3-bacillosamine (bacillosamine is 2,4-
diacetamido-2,4,6-trideoxy-D-Glc) onto a lipid donor (Kowarik et al., 2006; Young et al., 
2002).   The heptasaccharide is transferred by the oligosaccharyltransferase, PglB, from the 
lipid donor to a protein acceptor at the consensus sequence of Asp-X-Ser/Thr, where X can be 
any aa except Pro (Kowarik et al., 2006).   The enzymes, PglF, PglE and PglD are thought to 
be involved in the synthesis of bacillosamine (Larsen et al., 2004).   In certain strains of C. 
jejuni, N-glycosylation is important in the immunogenicity of several glycoproteins, natural 
competence, adherence to and invasion of host cells in vivo as well as the colonisation of 
murine and avian animal models (Hendrixson & DiRita, 2004; Karlyshev et al., 2004; Larsen 
et al., 2004; Szymanski et al., 2002).    
 
1.7.4 Flagella 
The single polar unsheathed flagella was the first well characterised external structure of C. 
jejuni.   Our understanding of the flagella extends from the organisation and regulation of the 
flagella biosynthesis genes through the molecular composition and morphological structure to 
 52 
the mode of action and function.   Flagella are one of the most important virulence factors 
involved in C. jejuni pathogenesis.   The flagella of campylobacters impart motility, are 
strongly immunogenic and act as adhesins which aid in adherence and invasion (Guerry et al., 
2000a; Newell et al., 1985a).   The flagellum is subject to phase (Caldwell et al., 1985) and 
antigenic (Harris et al., 1987) variation.   Antibodies recognising flagella have been detected 
in the sera of convalescing human patients after suffering from a natural case of CE (Winsor 
et al., 1986).   An intact and functional flagella is essential for C. jejuni to achieve optimal 
motility which enables the bacteria to colonise the host intestine and is therefore critical in the 
process of causing disease (Guerry et al., 2000a).   Aflagellate campylobacters are incapable 
of colonisation in vivo (Caldwell et al., 1985; Morooka et al., 1985) and some flagellar 
mutants show a reduced capacity to invade in vitro (Wassenaar et al., 1994).    
 
Campylobacters have been observed to employ different patterns of motility depending on the 
viscosity of the solution that they are in and show a surprisingly enhanced rate of movement, 
up to 75 µm/s (Szymanski et al., 1995), in highly viscose environments, such as mucus 
(Guerry et al., 2000a).   It is thought that both the flagella and the corkscrew shape of 
campylobacters contribute to their ability to remain motile in viscous environments where 
other flagellated bacteria can not (Ferrero & Lee, 1988).   In certain C. jejuni serogroups of 
the Lior serotyping scheme (Lior et al., 1982), the flagella has been described as the heat-
labile serodeterminant (Alm et al., 1991) though it is not solely responsible as previously 
thought (Wenman et al., 1985). 
 
Structurally the flagellum consists of the basal motor and switch structures which are 
anchored in the cytoplasmic membrane, the rod which spans and lies perpendicular to the cell 
membrane, the hook and the filament (Penn, 2001).   The main components of flagella are the 
flagellin proteins, FlaA and FlaB.   There is a significantly greater quantity of FlaA in the 
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filament than FlaB, though both subunits appear to be essential for intact flagella and optimal 
motility.   The two flagellin subunits share > 93% aa sequence similarity primarily at the N 
and C termini, with variation existing between strains around the middle of the protein 
sequence of FlaA (Guerry et al., 2000a).   This antigenic variability between C. jejuni strains 
supports the notion of flagellin involvement in the Lior typing scheme.   Variability is also 
seen in the sequence of the flagellar hook protein, FlgE, which is perhaps also involved in 
antigenic variation (Luneberg et al., 1998).   FlaA and FlaB are ~ 60 kDa in size and are post-
translationally modified by O-linked glycosylation, which contributes to antigenic variation 
(Constantinidou et al., 1997; Guerry, 1997; Szymanski et al., 1999).    The major 
modification of either flagellin is the 9 carbon sugar, pseudaminic acid which is similar to a 
sialic acid (Goon et al., 2003).   Glycosylation of the flagellum is implicated in the ability of 
C. jejuni to adhere to host cells (Karlyshev et al., 2004; Newell et al., 1985a).    
 
The two flagellins are encoded by the two adjacently located flagellin structural genes, flaA 
and flaB respectively.   Interestingly, some of the flagella biosynthesis gene regulatory 
elements common to the Enterobacteriaceae are absent in C. jejuni (Parkhill et al., 2000).   
The flaA and flaB genes are regulated by different promoters, σ28 and σ54 respectively (Penn, 
2001).   The σ54 promoter is growth phase dependent and subject to environmental regulation, 
which suggests that C. jejuni is capable of altering the expression of a flagellin in response to 
specific environmental conditions (Alm et al., 1993).   The flagella is also indirectly involved 
in pathogenesis as a result of its function as an export apparatus for certain proteins, some of 
which are virulent, e.g., the Campylobacter spp. invasion antigen (Cia;Konkel et al., 2004).    
 
1.7.5 Chemotaxis 
Chemotaxis is the ability to detect and respond to chemical gradients via a complex signal 
transduction pathway which effects flagella rotation allowing the cell to move toward or away 
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from an environmental stimulus (Eisenbach, 1996).   Chemotactic motility is a prerequisite 
for C. jejuni pathogenesis and survival.   The importance of chemotaxis in pathogenesis has 
been demonstrated via the investigation of phenotypic changes in non-chemotactic mutants in 
vivo (Hendrixson & DiRita, 2004; Takata et al., 1992) and in vitro (de Melo & Pechere, 
1990).   In the mouse model, chemotactic mutants failed to colonise the intestines (Takata et 
al., 1992).    
 
A mutant lacking a functional chemotaxis regulatory gene, cheY, resulted in increased 
adherence to and invasion of INT407 human epithelial cells in vitro, though was unable to 
colonise or cause disease in the ferret model (Yao et al., 1997).   CheY has also been 
demonstrated as playing a role in C. jejuni flagellar motor switching (Marchant et al., 2002).   
The phosphorylation signal transduction cascade at the centre of C. jejuni chemotaxis 
involves recognition of the chemical stimulus via a transmembrane methyl-accepting 
chemotaxis protein (MCP) or “chemoreceptor”.   The stimulation of the chemoreceptor leads 
to phosphorylation of a histidine protein kinase (CheA) from ATP, which eventually causes 
the phosphorylation of a response regulator (CheY) which interacts with the flagellar motor to 
make it change rotational direction or stop (Armitage, 1999; Baker et al., 2006).   Usually this 
pathway is terminated by a phosphatase termed CheZ which increases the rate of CheY 
dephosphorylation (Marchant et al., 2002).   However, the genome projects of C. jejuni 
strains 11168, RM1221 and 81-176 did not identify any homologues of CheZ (Fouts et al., 
2005; Hofreuter et al., 2006; Parkhill et al., 2000)   Once the pathway has run to completion, 
the chemoreceptors are “reset” to their non-signalling conformation which involves the 
methyltransferase (CheR) and the methylesterase (Baker et al., 2006).    
 
Chemical stimuli to which C. jejuni is attracted include salts of organic acids (such as 
pyruvate, succinate and fumarate), bile extract, mucin and its components, L-serine and L-
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fucose, and is repelled from individual bile acids (Hugdahl et al., 1988).   L-fucose, a 
carbohydrate present in both bile and mucin, may play a primary role in the affinity of C. 
jejuni to the gallbladder and the intestinal tract as bile and mucin are the main secretions of 
these organs (Hugdahl et al., 1988).   This reaction to these environmental stimuli cause the 
bacterium to move toward the mucous layer which coats the intestinal epithelium of the host 
and is an important part of colonisation.   C. jejuni has also been observed to colonise the 
mucous layer itself with high numbers of bacteria detected in the mucus-rich caecal crypts of 
mice (Lee et al., 1986).   The mechanism of chemotaxis contributes to C. jejuni’s ability to 
survive environmental temperatures as it is still active at as low as 4°C allowing the bacteria 
to move to more favourable locations even when it is too cold to grow (Hazeleger et al., 
1998). 
 
1.7.6 Iron Acquisition 
Iron is an essential nutrient for bacterial growth and survival as it plays a major role in the 
catalysis of many biochemical reactions that are necessary to almost all living organisms 
(Andrews et al., 2003).   It is an important cofactor in DNA synthesis and electron transfer 
reactions, however its acquisition from the host environment presents a problem as free iron is 
almost nonexistent (Payne & Finkelstein, 1978).   The concentration of bioavailable iron in a 
mammalian host under aerobic conditions at neutral pH has been measured to span the range 
of 10-18 M – 10-24 M (Braun & Hantke, 2002).   This is far too low to support the iron 
requirements of bacteria which are at least 10-7 M (Braun & Hantke, 2002).   The lack of free 
iron in the host can be described as a non-specific host defence (van Vliet et al., 1998).   As a 
result, bacteria have had to develop ways of sequestering iron from their environment, 
however too much iron can also be a problem.   In the presence of oxygen, iron homeostasis is 
important as iron can cause the generation of oxygen radicals which can cause damage to 
DNA, protein and membranes (Andrews et al., 2003).   For this reason, iron storage systems 
 56 
and strategies to combat the effects of oxidative stress are also important for bacterial survival 
in vivo.   Therefore successful colonisation of the host intestine requires C. jejuni to 
effectively compete with normal flora for iron, maintain sufficient quantities of iron from the 
host to support bacterial growth and to avoid the accumulation of excess iron which is 
potentially toxic.    
 
Pathogenic bacteria acquire iron during the process of infection via iron scavenging and 
uptake systems (Ketley, 1997).   Within the mammalian host, bacteria can access iron that is 
present in body fluids.   This iron can be complexed with high affinity iron-binding proteins 
(Payne & Finkelstein, 1978; van Vliet et al., 1998).   The serum contains iron in the form of 
haemoglobin or transferrin while iron exists as lactoferrin in secretions on mucosal surfaces 
(Payne & Finkelstein, 1978).   C. jejuni is not known to utilise either transferrin or lactoferrin 
as an iron source despite having homologous genes to those of other bacteria known to be 
involved in this process (Tom-Yew et al., 2005).   Iron can be obtained from the environment 
via the use of iron scavenging molecules termed siderophores, which are highly specific iron 
chelators (Park & Richardson, 1995).   Only certain strains of C. jejuni synthesise their own 
siderophores, however all strains tested can utilise siderophores from other bacteria including 
the indigenous microflora of the host gastrointestinal tract (Field et al., 1986).   Iron sources 
which can be utilised by C. jejuni include the siderophores ferrichrome and enterochelin 
(Field et al., 1986), the haem compounds haemin, haemoglobin, haemin-haemopexin and 
haemoglobin-haptoglobin (Pickett et al., 1992), as well as the almost completely insoluble at 
pH > 7 Fe3+ and the soluble Fe2+ (van Vliet et al., 2002).   Ferric iron-siderophore complexes, 
which are recognised by specific cell surface receptors, are transported across the outer 
membrane of the bacteria with energy provided by the proton motive force and are transduced 
by a TonB/ExbB/ExbD complex (van Vliet et al., 2002).   These complexes are too large to 
enter the cell via a porin, therefore they reach the cytoplasm by way of a periplasmic-binding 
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protein which is energised by an inner membrane ABC transporter consisting of a permease 
and an ATP-binding protein (van Vliet et al., 2002).   A mutant lacking TonB was observed to 
be unable to utilise the heamin, ferrichrome or enterochelin siderophores as iron sources 
(Guerry et al., 1997).    
 
Ferrous iron uptake usually involves a single inner membrane protein such as the iron specific 
transporter protein FeoB (Naikare et al., 2006) and this process is energised via ATP or GTP 
hydrolysis (van Vliet et al., 2002).   A C. jejuni FeoB- mutant accumulated 50% less iron than 
the parent strain and its ability to colonise and survive within the rabbit ileal loop was 
significantly compromised (Naikare et al., 2006). 
 
The response of C. jejuni to changes in environmental iron concentrations is regulated by the 
Fur (ferric uptake regulator) and the PerR (Peroxide stress Regulator) proteins (van Vliet et 
al., 1998; van Vliet et al., 1999).   Fur responds to increases in intracellular iron concentration 
that are sufficiently high enough to cause the formation of a complex consisting of a Fur 
dimer bound to a Fe(II) molecule, this complex binds to the consensus sequence or “Fur box” 
and will eventually result in repressed transcription of iron-regulated promoters (van Vliet et 
al., 1998).   Transcriptome profiling by microarray has identified 53 genes as being Fur 
regulated (Palyada et al., 2004).   However, similar microarray analysis combining a Fur- 
mutant and the parent strain question the reliability of the presence of a Fur box as a way to 
identify Fur regulated genes (Holmes et al., 2005).   Despite some variation, these two 
transcriptome profiling studies did identify many of the same genes and they were reported as 
being Fur regulated (Holmes et al., 2005; Palyada et al., 2004).    
 
Interestingly, a Fur- mutant was still capable of iron repression thus suggesting the existance 
of another iron regulation system (van Vliet et al., 1998).   This system was later identified as 
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the PerR regulation system (van Vliet et al., 1999), which shared sequence similarity to the 
PerR of Bacillus subtilis (Chen et al., 1995).   Genes involved in iron uptake are regulated by 
the Fur regulator and genes involved in oxidative stress defence are regulated by the PerR 
regulator.   Interestingly, the oxidative stress defence proteins catalase (KatA) and alkyl 
hydroperoxide reductase (AhpC) are iron repressed via PerR (Baillon et al., 1999; van Vliet et 
al., 2002).   Iron limited conditions have also been linked to increases in protein glycosylation 
which in turn may increase the virulence of C. jejuni (Palyada et al., 2004).   It has been 
demonstrated that virulence factors have been iron regulated and that iron can act as a signal 
to inform the bacteria that it has gained entry to a host (Palyada et al., 2004; Ratledge & 
Dover, 2000).  
 
Several iron acquisition systems have been described in C. jejuni and include a 
haemin/haemoglobulin uptake system (chuABCDZ; Ridley et al., 2006), an enterochelin 
transport system (ceuBCDE; Richardson & Park, 1995) and a ferrichrome uptake system 
(cfhuABD; Galindo et al., 2001).   Other individual genes with demonstrated involvement in 
iron acquisition or that are iron regulated are cfrA, feoB, Cj1658, p19 (van Vliet et al., 2002), 
Cj1613c (chuZ; Ridley et al., 2006) and a ferric binding protein (cFbpA; Tom-Yew et al., 
2005).   CrfA is found in all C. coli strains tested, though it was not detected in all C. jejuni 
strains (van Vliet et al., 2002) and has been identified as a receptor of the E. coli siderophore, 
enterobactin (Palyada et al., 2004).   Mutants without cfrA did not synthesise an iron-
repressible OMP suggesting that it functions as a siderophore receptor which is supported by 
some sequence identity to siderophore receptors of other bacteria (Guerry et al., 1997).   
Several other genes of C. jejuni which show similarity to genes known to be involved in iron 
uptake in other bacteria have been identified, though their specific role is yet to be determined 
(van Vliet et al., 2002). 
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Storage of excess iron in a non-reactive state allows the bacteria to protect itself from possible 
damage by hydroxyl radicals and to have a ready supply in the event that environmental iron 
is scarce.   Two types of proteins involved in bacterial iron storage are the ferritins, which do 
not contain haem and the bacterioferritins that do contain haem (Andrews, 1998).   Genes 
encoding both types were detected within the genome sequence of C. jejuni 11168, the ferritin 
protein Cft (Cj0612c) and the putative bacterioferritin Cj1534c (Andrews, 1998; Wai et al., 
1996).   A C. jejuni Cft- mutant grew less well under iron limited conditions and was more 
sensitive to oxidative stress (Wai et al., 1996).   Other iron-binding proteins have been 
identified but are yet to be fully characterised. 
 
1.7.7 Adhesion & Invasion 
The ability of C. jejuni to both adhere to and invade human and experimental animal model 
intestinal epithelial cells in vivo and in vitro is well documented, although the molecular 
mechanisms involved in this process are not well characterised as yet (Biswas et al., 2000; de 
Melo & Pechere, 1990; Everest et al., 1992; Hickey et al., 1999; Hu & Kopecko, 1999; Hu et 
al., 2006; Konkel & Joens, 1989; Kopecko et al., 2001; McSweegan et al., 1987; Monteville 
& Konkel, 2002; Prasad et al., 1996; Wassenaar et al., 1991; Wooldridge & Ketley, 1997; 
Yao et al., 1994; Zheng et al., 2006).   The act of adhesion between C. jejuni and host cells is 
an essential first step in how this pathogen initiates infection (Wassenaar & Blaser, 1999).    
 
The contact made by C. jejuni to the host epithelium causes damage to the host’s intestinal 
epithelial cells in turn disrupting the intestines normal absorptive function (Wooldridge & 
Ketley, 1997).   The mechanism of damage can lead to different symptoms as evidenced by 
the distinct differences seen with the pathological consequences of CE cases in patients from 
developed as opposed to developing countries (Hu & Kopecko, 2000).   However, it should be 
noted that variation of symptoms can be attributed to many host and pathogen specific factors 
 60 
including the characteristics of the infecting strain, dosage and the prior immune status of the 
host. 
 
Based on the different symptoms observed with patients suffering from Campylobacter 
infection, three strategies of infection have been postulated.   Firstly, direct adherence of C. 
jejuni to host intestinal cells coupled with the production of cytotoxins which results in watery 
non-inflammatory diarrhoea such as that usually experienced in developing nations (Hu & 
Kopecko, 2000; Wooldridge & Ketley, 1997).   Second, the invasion and proliferation of the 
bacteria in the intestinal mucosa leading to cell damage that induces an inflammatory 
response (Hu & Kopecko, 2000; Wooldridge & Ketley, 1997).   The inflammatory response is 
in keeping with the symptoms most often observed in CE patients in developed countries, 
which includes inflammatory diarrhoea with leukocytes present in the patients faeces (Hu & 
Kopecko, 2000).   Invasion is also thought to trigger inflammation, as markers indicative of 
inflammation were only detected when invasion took place (Everest et al., 1993; Hickey et 
al., 1999).   Finally, should the patient experience symptoms beyond those usual for enteritis, 
then the C. jejuni cells have most likely translocated the intestinal epithelium and migrated via 
the lymphatic system to other areas of the body causing diseases such as meningitis, 
mesenteric adenitis or bacteraemia (Hu & Kopecko, 2000).   The ability of C. jejuni to 
translocate across monolayers of intestinal cells in vitro has been observed (Bras & Ketley, 
1999; Everest et al., 1992; Konkel et al., 1992c).    
 
Factors which are important in adhesion and invasion are the virulence of the infecting strain, 
motility, bacterial and host surface structures and the susceptibility of the host (van Vliet & 
Ketley, 2001).   Several surface structures have been implicated as playing a role in C. jejuni 
adhesion to host targets, including LOS, CPS, flagella, specific adhesin proteins and 
glycoproteins (Bacon et al., 2001; Hu & Kopecko, 2000; Karlyshev et al., 2004).   The 
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flagella has a three pronged approach to colonisation and adhesion in that it imparts motility, 
is a glycosylated adhesin and serves as the export apparatus for some virulence proteins, 
including the Cia (Konkel et al., 2004) and FlaC (Song et al., 2004) which are both involved 
in invasion.   Surface proteins involved in host cell attachment include CadF, Peb1 and JlpA 
and have been discussed earlier in this chapter (see Section 1.7.2.2).    Pilus-like appendages, 
which have been implicated as important for adhesion in other enteric pathogens, were 
thought to exist on the surface of C. jejuni cells as a result of environmental stimuli (Doig et 
al., 1996).    However, it was later discovered that these structures were an artifact of the 
culture medium and not derived from the bacteria at all (Gaynor et al., 2001). 
 
Mechanisms important in the internalisation of enteric pathogens include the polymerisation 
or rearrangement of components of the host’s cytoskeleton, such as microfilaments (MFs) 
and/or microtubules (MTs) as well as the manipulation of host cell signal transduction 
pathways (Biswas et al., 2000; Biswas et al., 2003).   Some common enteric pathogens, e.g., 
Salmonella spp., Shigella spp., Listeria spp. and Yersinia spp. mostly utilise a MF-dependent 
uptake system (Hu & Kopecko, 1999).   The role of MFs and MTs have been investigated in 
C. jejuni and both have been shown to be involved in internalisation, with MTs playing the 
major role (Konkel & Joens, 1989; Konkel et al., 1992b; Kopecko et al., 2001; Oelschlaeger 
et al., 1993).   On the basis of studies involving MT biochemical inhibitors (Oelschlaeger et 
al., 1993) and immunofluorescence (Hu & Kopecko, 1999), it has been observed that C. 
jejuni’s method of internalisation is both novel and MT-dependent (Hu et al., 2006).   The C. 
jejuni MT-dependent uptake system observed in strain 81-176 also involves the MT motor 
dynein, an ATPase which facilitates movement of cellular organelles and structures along 
MTs (Hu & Kopecko, 1999), and the release of Ca2+ from host intracellular stores (Hu et al., 
2006).   Divalent calcium is known to be important to several cellular processes including 
calmodulin-activated enzymes, nuclear transcriptional upregulation and cytoskeletal 
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rearrangements (Hu et al., 2005).   In C. jejuni the role of free Ca2+ is thought to be in the 
activation of enzymes that may be involved in host cytoskeletal rearrangements that further 
facilitate bacterial uptake (Hu et al., 2005).   At this stage the exact molecular mechanisms 
involved in C. jejuni infection are not completely understood, Kopecko and others have 
proposed the current working model (Figure 1.7; Kopecko et al., 2001).  
 
1.7.8 Toxins 
The two types of toxins associated with C. jejuni are enterotoxins and cytotoxins (Pickett, 
2000).   Enterotoxins are secreted proteins that can bind to a host cell receptor, enter the cell 
and cause an increase in intracellular cAMP (Wassenaar, 1997).   A study conducted by 
Pancorbo and colleagues compared an enterotoxigenic and a non-enterotoxigenic strain of C. 
jejuni in a murine model (Pancorbo, et al., 2001).   The strain which produced the enterotoxin 
suppressed both immunoglobulin M and immunoglobulin G synthesis and increased the 
production of interleukin-2 (Pancorbo et al., 2001).   However, it was unclear if the different 
immune responses were caused be the presence or absence of the enterotoxin or other 
differences between the two strains tested.  
 
Cytotoxins are defined as proteins that cause the death of target cells.   Cytotoxins can act in 
several ways, by inhibiting essential cellular processes, e.g., protein synthesis, actin filament 
formation or by forming pores in the membranes of target cells resulting in cell death by lysis.   
A pore forming cytotoxin designed to specifically target an erythrocyte, is referred to as a 
haemolysin (Wassenaar, 1997).   The most well characterised C. jejuni toxin is the cytotoxic 
cytolethal distending toxin (CDT) first described in 1988 (Johnson & Lior, 1988) and is at this 
stage the only confirmed C. jejuni toxin (AbuOun et al., 2005).   The CDT protein is encoded 
by three highly conserved genes, cdtA, cdtB and cdtC (AbuOun et al., 2005).   CdtB is
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Figure 1.7:   The proposed model of C. jejuni internalisation mechanisms (Kopecko et al., 
2001).   MT, microtubule; PI-3, phophoinositol 3-kinase; PMN, polymorphonuclear 
leukocyte; CDT, cytolethal distending toxin; IL-8, interleukin 8. 
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thought to be the toxic component while CdtA and CdtC are involved in binding and 
internalisation of the toxin into host cells (Lara-Tejero & Galan, 2001).   CDT is not present 
in all C. jejuni strains and those naturally CDT negative have been found to contain a 
mutation in the form of a deletion across both cdtA and cdtB (AbuOun et al., 2005).   When 
observed in vitro it causes the tissue culture cells to distend after ~ 3-4 days, then die 
(Wassenaar, 1997).   CDT is also produced by other Campylobacter spp. as well as some E. 
coli and Shigella spp. (Whitehouse et al., 1998).    
 
The toxin has been observed to permanently block cell division in HeLa and Caco-2 cells at 
either the G2 phase or early M phase (Pickett, 2000; Whitehouse et al., 1998).   This was 
confirmed by an enzyme essential for mitosis, CDC2, not being activated in CDT-treated 
HeLa cells (Whitehouse et al., 1998).   The inability of the affected cells to divide eventually 
results in cell death (Pickett, 2000).   The role of C. jejuni toxins in pathogenesis is still 
unclear and yet to be confirmed.   It has been suggested that they are involved in causing the 
symptom of watery diarrhoea as opposed to inflammatory, however the epidemiological 
evidence of toxin positive versus toxin negative strains does not correlate with the observed 
patient symptoms in all cases (Wassenaar, 1997).   A postulated mechanism of toxin 
pathogenesis is that the cell damage caused by eg CDT to the intestinal epithelium could lead 
to a decrease in normal absorptive function and, in turn, watery diarrhoea (Pickett, 2000).   It 
is important to note that the watery diarrhoea cases of CE are consistent with the symptoms 
that one would expect with the presence of a toxin.   Interestingly, a recent study 
demonstrated a lack of antigenicity of CDT in a young chicken model (AbuOun et al., 2005).   
In contrast, CDT is immunogenic in humans (AbuOun et al., 2005).    
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1.8 Gene Regulation and Environmental Stimuli 
C. jejuni is successfully adaptable to and able to survive a wide range of environmental 
conditions and stresses making it ubiquitous and persistent, despite having a relatively small 
genome, an elevated optimal temperature, sensitivity to atmospheric oxygen levels and a 
requirement for rich growth media (Park, 2000).   Therefore it is essential for C. jejuni to have 
the capacity to respond rapidly to changes in environmental conditions through a range of 
regulatory systems.   These systems function to recognise specific stimuli indicative of 
environmental change and facilitate a response which translates into physical modification.   
C. jejuni possess a number of different gene regulation systems which allow a rapid response 
to changes in environment through adjustment of the transcriptome.   Some expression 
regulation mechanisms employed by C. jejuni include slippage synthesis, alternative sigma 
factors, gene organisation into operons and regulons, activator/repressor proteins, two-
component regulation systems and possibly global regulatory proteins (Finlay & Falkow, 
1997; Helmann, 2002; Nuijten et al., 1995; Park, 2000; Parkhill et al., 2000).    
 
Slippage of the position of the RNA polymerase enzyme at the initiation of transcription due 
to the presence of homopolymeric nucleotides is thought to be used by C. jejuni to regulate 
contingency genes, or genes containing hypervariable sequences.   Contingency genes can 
therefore be switched “on” or “off” as a result of slipped-strand mispairing, resulting in a 
frame shift to achieve a rapid change in translation of the corresponding gene product and 
account for phase variation (Newell et al., 2000).   The frequency of slipped-strand mispairing 
is comparatively high in C. jejuni, being more frequent than in other pathogenic bacteria, e.g. 
Neisseria meningitidis (Wassenaar et al., 2002).   This is largely due to C. jejuni lacking in 
DNA repair function which is potentially supported by the fact that many genes associated 
with DNA repair in E. coli were not detected in C. jejuni (Allos, 2001; Lastovica & Skirrow, 
2000).   It is possible that the rapid nature of the genetic variation could be a reaction to the 
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dynamic environment of the intestines (Frost, 2001).   The use of phase variation can be seen 
for example in the regulation of C. jejuni LOS biosynthesis genes (Linton et al., 2000a) and 
flagella genes (Karlyshev et al., 2002).    
 
A common mechanism for the regulation of bacterial gene expression is the use of alternative 
sigma factors (Helmann, 1991).   The sigma (σ) factor being the detachable protein subunit 
that binds to the RNA polymerase core enzyme (E) to form the holoenzyme (Eσ), where the σ 
factor is responsible for providing binding specificity for a particular promoter to allow 
transcription to begin (Helmann, 2002).   The substitution of one σ factor for another is 
therefore an important mechanism in changing the specificity of the RNA polymerase which 
activates the transcription of new genes (Helmann, 2002).   From the genome sequence 
(Parkhill et al., 2000), it is predicted that C. jejuni possess 3 sigma factors; σ28, σ54 and σ70 
encoded by fliA, rpoN and rpoD respectively (Jagannathan et al., 2001).   Both σ28 and σ54 are 
implicated in the regulation of flagellar genes of C. jejuni and other bacteria, e.g., H. pylori 
(Jagannathan et al., 2001; Niehus et al., 2004).   With σ54 being involved in the regulation of 
flaB, the hook protein gene flgE as well as genes responsible for the construction of the 
flagella secretory apparatus and nitrogen metabolism (Guerry et al., 1991; Hendrixson & 
DiRita, 2003; Luneberg et al., 1998; Park, 2000).   The regulation of the σ54 promoter is 
affected by environmental stimuli such as changes in pH, temperature and the presence of 
particular inorganic salts and divalent cations (Alm et al., 1993).   While the σ28 promoter 
regulates the expression of flaA and is up-regulated by a range of chemotactically relevant 
intestinal stimuli including pH, bovine bile, deoxycholate and L-fucose and down-regulated 
by viscosity (Allen & Griffiths, 2001).   As in E. coli, σ70,or the primary σ factor, is important 
in the regulation of housekeeping genes in C. jejuni though the consensus sequence is 
different than in many other enteric bacteria (Helmann, 2002; Park, 2000).   However, the 
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extent of the involvement of each σ factor in environmental regulation and virulence in C. 
jejuni is not known. 
 
Another bacterial regulation mechanism referred to as the Operon model involves the 
organisation of genes, usually of related function, into clusters allowing coordinated 
expression (Helmann, 2002).   Many of the C. jejuni genes encoding proteins involved in LOS 
biosynthesis, protein glycosylation and CPS biosynthesis are organised into operons (Parkhill 
et al., 2000; Wren et al., 2001).   The regulation of an operon is often controlled by a 
regulatory protein which interacts at specific binding sites within or near to the promoter 
sequence (Helmann, 2002).   These regulatory proteins can act negatively to repress or 
positively to activate expression and are referred to as repressors or activators respectively 
(Helmann, 2002).   Repressors bind to specific sites called operators while activators bind to 
activator binding sites (Helmann, 2002).   The expression of several operons and isolated 
proteins can be mediated by the same regulatory protein to form a regulon (Helmann, 2002), 
e.g., the Fur protein is a repressor that is involved in the negative regulation of many iron 
uptake related genes (Holmes et al., 2005; Palyada et al., 2004) as previously discussed in 
Section 1.8.6.   Gene expression can be organised further in the form of a stimulon, which 
consists of numerous genes whose regulation is dependent upon the same signal or stimulus, 
e.g., the heat shock stimulon (Helmann, 2002).    
 
In addition, bacteria can employ more than one protein in the regulation of genes in the form 
of a two-component system (TCR) where one protein is responsible for detecting the stimulus 
and the other responds to control expression of the appropriate gene or genes (Helmann, 
2002).   A TCR system generally takes the form of a sensor protein which spans the cell 
membrane with the external domain sensing the environmental stimulus and the cytoplasmic 
domain is a histidine kinase (Finlay & Falkow, 1997).   The regulator protein is a cytoplasmic 
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protein which can behave as a transcriptional activator and/or repressor (Finlay & Falkow, 
1997).   Several TCR systems have been identified in C. jejuni, e.g., the FlgS/FlgR system 
which regulates flagella motility by activating the fla regulon and appears to be growth phase 
dependent (Wösten et al., 2004).   Though, it is important to note that multiple regulatory 
mechanisms can be involved to coordinate the expression of target genes, e.g., the FlgR 
protein, which is the regulator protein in the TCR system described above, contains a 
homopolymeric nucleotide tract and is phase variable (Hendrixson, 2006).   Another TCR 
identified in C. jejuni is the RacR/RacS system that appears to be temperature-dependent and 
affects the ability of the bacteria to colonise chickens (Brás et al., 1999).   Recently another 
TCR system, referred to as the PhosS/PhosR system, has been identified and observed to be 
regulated by phosphate limitation (Wösten et al., 2006).   Several potential TCR systems have 
been identified in C. jejuni however, the extent and target of their regulatory control is largely 
unknown. 
 
Global regulatory proteins have been characterised in other bacteria, e.g., E. coli, and some 
show a level of similarity to C. jejuni proteins, i.e. LysR (Cj1000) and AraC (Cj1042c), 
though experimental confirmation of this has not yet been reported (Park, 2000).   Prior to the 
completion of the C. jejuni NCTC11168 genome project little was known about 
environmental regulatory systems of campylobacters.   Early work focused on C. jejuni’s 
response to heat shock (Konkel et al., 1998), oxidative stress (Wai et al., 1996) and iron 
limitation (Field et al., 1986) though more recent studies have incorporated bile (Doig et al., 
1996), quorum sensing (Elvers & Park, 2002), nitrosative stress (Elvers et al., 2004) and 
biofilm formation (Dykes et al., 2003) as factors important to environmental regulation.   Iron 
limitation in conjunction with oxidative stress and their effect on gene regulation was 
discussed earlier in this chapter (see Section 1.7.6).   Though it is important to note that 
oxidative stress can be caused by situations other than high iron levels, e.g., as a result of 
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respiratory burst, also known as oxidative burst.   Respiratory burst refers to the rapid release 
of reactive oxygen species (ROS), e.g., H2O2 of peroxynitrite, by host immune cells, e.g., 
macrophages, upon contact with pathogenic bacteria (Day et al., 2000; Santos et al., 1999).   
Oxidative stress defence is recognised as important for C. jejuni survival, however it is 
beyond the scope of this study and will not be discussed further.    
 
C. jejuni’s response to changes in temperature is perhaps the most thoroughly investigated 
environmental stress.   Campylobacters can encounter a wide range of environmental 
temperatures from refrigerated food (4°C) to the avian GI tract (42°C) and live C. jejuni can 
be isolated from both of those extremes.   It is therefore reasonable to assume that C. jejuni 
possess both cold and heat shock defence mechanisms.   Many C. jejuni heat shock proteins 
have been identified, though interestingly genes similar to cold shock proteins of other 
bacteria, e.g., CspA from E. coli (Rath & Jawali, 2006), have not been found in C. jejuni 
(Hazeleger et al., 1998).   Presumably C. jejuni has a novel approach to cold shock defence 
that we do not yet understand. 
 
Heat stress can affect bacteria by causing proteins to not be folded correctly which can 
interfere with their function.   It is common for bacteria to respond to heat shock by over 
expressing a group of ATP-dependent proteases which are involved in the degradation of 
deformed or denatured proteins and are referred to as heat shock proteins (HSPs; Thies et al., 
1998).   Temperature is potentially a key environmental factor in the difference between C. 
jejuni as a commensal organism or C. jejuni as a pathogen, given that we know it is not 
pathogenic in chickens (body temperature = 42°C) but is in humans (Stintzi, 2003).   Some 
chaperones and heat shock proteins have been identified in C. jejuni, i.e. GroEL, GroES, 
DnaJ, DnaK, GrpE, HrcA and Lon (Park, 2000).   Both GroEL and GroES have been 
observed as immunogenic in rabbits (Wu et al., 1994).   In addition, the HSP DnaJ is 
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important in chicken colonisation and growth at > 46°C as determined by analysis of a DnaJ- 
mutant (Konkel et al., 1998).   HrcA is thought to act as a repressor protein which controls the 
regulation of other HSPs in the same operon, those being grpE, dnaK and dnaJ based on 
studies conducted with Bacillus subtilis (Park, 2000; Schulz & Schumann, 1996).   In C. 
jejuni the organisation of a similar operon is slightly different in as far as dnaJ (Cj1260c) is 
located elsewhere on the chromosome, while homologues of hrcA (Cj0757), grpE (Cj0758) 
and dnaK (CJ0759) are located together (Park, 2000). 
 
Bile is also an important environmental stimulus for C. jejuni as, like temperature, it indicates 
entry to a host intestines.   Bile consists of detergent-like amphiapathic molecules, cholesterol 
phospholipids and bilirubin and possesses potent antimicrobial activity (Lin et al., 2003).   
Bile is produced in the liver, stored in the gall bladder and secreted into the small intestine 
where it has a digestive, excretory and protective role (Hofmann, 1999).   Bacteria that inhabit 
the enteric environment develop strategies to avoid the antimicrobial activity of bile.   Some 
mechanisms of bile resistance include porins, transport proteins, efflux pumps and LPS/LOS 
(Prouty et al., 2004b).   Many bacteria, including C. jejuni, also use bile as a stimulus for gene 
regulation (Allen & Griffiths, 2001; Lin et al., 2005; Prouty et al., 2004a).   Bile has been 
reported as being involved in the regulation of the C. jejuni efflux pump, CmeABC (Lin et al., 
2005) which was discussed earlier in Section 1.8.2.3.   Further, the flaA σ28 promoter was 
observed to undergo a change in regulation due to the presence of bovine bile extract as well 
as a purified bile salt, sodium deoxycholate, which is a major component of bile (Allen & 
Griffiths, 2001).   This is not surprising given that chemotactic motility is important for C. 
jejuni colonisation of the host intestine, where bile is found in abundance. 
 
Another form of environmental signal is one that reflects bacterial cell density and is referred 
to as quorum sensing.   This population-dependent signalling mechanism is based on the 
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bacteria being able to produce and detect secretory signalling molecules (Elvers & Park, 
2002).   Quorum sensing is a capacity for bacteria to, in a sense, communicate with each other 
and receive information in a bacterial biochemical language.   This ability of cell-to-cell 
signalling has been observed in several gram-negative bacteria including Vibrio harveyi, V. 
fischeri (in which quorum sensing was first detected), E.coli, S. typhimurium, Helicobacter 
pylori and C. jejuni (Cloak et al., 2002; Nealson & Hastings, 1970; Surette et al., 1999).    
 
There are two types of signalling systems, referred to as system 1 and system 2, each are 
composed of a sensor and a molecule that is detected, called the autoinducer (AI).   System 1 
consisting of sensor 1 and AI-1, which is a highly species specific family of homoserine 
lactones and system 2, which is less species specific and is composed of sensor 2 and AI-2 
(Cloak et al., 2002).   Gene expression is triggered by the accumulation of extracellular AIs 
which is clearly population-dependent (Jeon et al., 2005).   C. jejuni possesses the type 2 
quorum sensing system and the LuxS protein is the AI-2 synthase (Cloak et al., 2002).   In C. 
jejuni there is a link between AI-2, LuxS and regulation of the cytolethal distending toxin 
genes cdtA, B and C (Jeon et al., 2005) and flaA (Jeon et al., 2003).   Therefore quorum 
sensing is important in virulence. 
 
C. jejuni is one of if not the leading bacterial cause of gastroenteritis world wide.   Our 
understanding of this human pathogen is rapidly increasing, however it remains a serious 
health burden in both socioeconomically developing and developed nations.   Further 
investigation of this organism, with particular emphasis on the molecular mechanisms 
important for pathogenesis, will enable the development of treatment and preventative 
strategies to combat C. jejuni infection and associated complications. 
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1.9 Research Aims 
This project was designed to investigate the pathogenesis of C. jejuni at a molecular level, 
with several approaches: 
1) To investigate the function and potential role in virulence of the putative LOS biosynthesis 
genes, wlaRE, wlaRF, wlaTA, wlaTB, wlaTC and waaV, of Campylobacter jejuni strain 
81116, serotype HS:6. 
 
2) To investigate C. jejuni virulence genes other than those involved in LOS biosynthesis at 
the transcriptome and proteome level with a view to detecting genes that undergo a change in 
regulation in a “chicken” modelled environment compared to a “human” modelled 
environment. 
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CHAPTER 2: Materials and General Methods 
2.1 General Procedures 
Sterilisation of glassware, pipette tips, PCR tubes, centrifuge tubes, toothpicks, media and 
appropriate solutions was achieved by autoclaving at 121°C for 20 min unless stated 
otherwise.   All glassware was washed in pyroneg detergent and rinsed twice in distilled 
water.   Deionised distilled water was obtained by filtration through a Millipore Milli-Q 
system (Liquipure) and was used to prepare all solutions unless otherwise stated.   All 
solutions were prepared using analytical or molecular grade chemicals and stored at room 
temperature unless otherwise stated.   Solutions that were sterilised by filtration were passed 
through a sterile 0.2µM syringe filter disc (PALL Life Sciences).   Finnpipettes (Path Tech) 
were used to dispense solutions ranging from 0.5 µL to 10 mL.   General chemical suppliers 
and the make and model of general equipment used during this study is listed in Appendix 
XX. 
2.2 Bacteriological Methods 
2.2.1 Media and Antibiotics 
 
2.2.1.1 Alsever’s Solution 
This solution was used as an anticoagulant and preservative for both chicken and human 
blood and prepared as described previously (Alsever & Ainslie, 1941).   Briefly, 2.05% of 
Dextrose, 0.8% Sodium Citrate, 0.055% Citric Acid and 0.42% Sodium Chloride in sterile 
deionised H2O.   The solution was adjusted to pH 6, filter sterilised, combined 1:1 with blood 
and stored at 4˚C. 
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2.2.1.2 Antibiotic Stock Solutions 
Ampicillin and Kanamycin were dissolved in deionised water to give a final concentration of 
100 mg/mL, filter sterilised and stored at -20°C.   Ampicillin and Kanamycin were used in 
agar or broth media as appropriate at final concentrations of 100 µg/mL and 50 µg/mL 
respectively. 
 
2.2.1.3 Brucella Broth (BB) 
Brucella broth powder (2.8% w/v) was dissolved in distilled water and sterilised by 
autoclaving under standard conditions.   BB was stored at room temperature. 
 
2.2.1.4 Enriched Brucella Broth (BB+) 
Brucella broth prepared as described above, supplemented with 12.5 mM MgCl2, 12.5 mM 
MgSo4 and 0.4% glucose.   The supplements were added to the broth, which was then filter 
sterilised and stored at room temperature. 
 
2.2.1.5 Mueller-Hinton (MH) Agar 
MH Agar powder (3.8% w/v) was dissolved in distilled water and sterilised by autoclaving 
under standard conditions.   The sterile media was cooled to approximately 50°C and 
dispensed  into sterile Petri dishes.   Agar plates were stored at 4°C.  
 
2.2.1.6 MH Agar with Antibiotics (Ampicillin, Kanamycin) 
MH agar was prepared as described above.   The antibiotics were added to the cooled agar, 
mixed thoroughly just prior to pouring into Petri dishes and stored at 4°C.  
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2.2.1.7 MH Broth 
Mueller-Hinton broth powder (2.1% w/v) was dissolved in distilled water, sterilised by 
autoclaving under standard conditions and stored at room temperature. 
2.2.1.8 Horse Blood Agar with Skirrow Supplement (HBA-Sk) 
Columbia agar base powder (3.9% w/v) was dissolved in distilled water and sterilised by 
autoclaving under standard conditions.   The sterile media was cooled to approximately 50°C 
before adding defibrinated horse blood (5% v/v) and 1 vial of Skirrow’s selective supplement 
(Oxoid).   Each vial of Skirrow’s selective supplement contained 5 mg of vancomycin, 1250 
i.u. of polymixin B and 2.5 mg of trimethoprim lactate.   The media was mixed thoroughly 
and dispensed into Petri dishes.  
 
All wild type C. jejuni strains were grown on this media under microaerobic conditions.   
Microaerobic conditions were achieved by the use of an anaerobic jar and either a Campygen 
gas pack (Oxoid), or by the addition of a microaerobic gas mixture (CO2 9.9%, O2 5%, N2 
84.1%).   All campylobacters were grown at 42˚C unless otherwise stated.   All C. jejuni 
Kanamycin resistant knock-out mutants were grown on HBA-Sk supplemented with 
Kanamycin (50 µg/µL) under microaerobic conditions. 
 
2.2.1.9 Human and Chicken Blood Agar with Skirrow’s Supplement 
Chicken blood was kindly supplied as a gift by The University of Melbourne, School of 
Veterinary Science, or purchased from the Institute of Medical and Veterinary Science, 
Adelaide, SA. Human blood was supplied by the Australian Red Cross, Melbourne.   The 
whole blood was resuspended 1:1 with Alsever’s Solution (see Section 2.2.1.1) to preserve 
and prevent the blood from clotting.   Chicken and human blood agar were prepared in the 
same way as horse blood agar, however the agar was supplemented with 10% (v/v) blood due 
to the presence of 50% Alsever’s Solution. 
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2.2.1.10 Thioglycolate Agar 
Bacteriological agar powder (0.35% w/v) and Thioglycolate broth powder (2.9% w/v) was 
dissolved in distilled water and autoclaved under standard conditions.   The agar was cooled 
to 42°C prior to pouring. 
 
2.2.1.11 Blue White Screening Agar 
This screening method was adapted from Sambrook and Russell (Sambrook & Russell, 2001). 
Using MH agar supplemented with the appropriate antibiotics, 50 µL of 24 mg/mL IPTG and 
30 µL of 20 mg/mL X-gal were spread plated onto the agar surface just prior to inoculation.   
These plates were incubated wrapped in foil as X-gal is light sensitive.  
 
2.2.2 Motility Assay  
Based on the method of Grant and co-workers (1993), each C. jejuni LOS knock-out mutant 
and the parent strain (81116) was grown at 42°C for 16 h from an inoculum of 100 µL of a 
OD600nm = 2 culture under microaerobic conditions on horse blood agar supplemented with 50 
µg/mL of kanamycin where appropriate.   The cells were harvested in 1.5 mL of sterile PBS 
and pelleted by centrifugation at 16000 xg for 2 min.   Serial dilutions of each culture were 
performed and 100 µL of the diluted cultures were transferred to a Petri dish.   Autoclaved 
thioglycolate broth containing 0.35% agar was cooled to 42˚C, then poured over the bacterial 
suspension and mixed by gentle swirling before incubating at 37°C for 24h in microaerobic 
conditions then examined for motility (Grant et al., 1993).  
 
2.2.3 Modelling Environmental Test Conditions 
Each C. jejuni strain was resuscitated from a –70˚C stock on horse blood agar containing 
Skirrow’s supplement and grown for 48 h under microaerobic conditions at 42°C.   The 
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cultures were passaged no more than twice prior to the commencement of each experiment.   
The different environmental conditions modelled were separated into 4 trials, which were 1) 
Temperature, 2) Blood, 3) Bile and 4) Host Cell.   Each trial was used to model human versus 
chicken environments and was run in duplicate, simultaneously.   The following C. jejuni 
stains were used for each trial; 81116, 11168, HB93-13, 990922, MP0401 (Table 2.1) 
 
All OMP extractions were carried out on ice to slow the growth of the bacteria and preserve 
the OMP profile.   Cultures used for OMP analysis were grown for 16 h as previous studies 
have identified that C. jejuni strain 11168 reaches late log phase at this point (Sampathkumar 
et al., 2006).    All RNA was stabilised immediately upon removal of the bacteria from the 
test environment using RNA Protect (Qiagen) as described by the manufacturer.  
 
2.2.3.1 Temperature Trial 
The 5 C. jejuni isolates were exposed to either 37°C or 42°C to model the temperature of the 
human or avian body respectively.   A 24 h culture of each C. jejuni strain was adjusted to 
OD600nm = 2 and 100 µL was subcultured to 8 fresh horse blood agar plates, 2 incubated at 
37°C and 6 at 42°C for a further 16 h.   Two plates, each grown at 37°C and 42°C, were used 
for OMP expression analysis and the remaining 4 grown at 42°C were resuspended in pre-
warmed Brucella broth (either 37°C or 42°C) and exposed to either temperature for 15 min 
then processed to extract mRNA based on the method of Stinzi and others (Stintzi, 2003).  
 
The cultures used for OMP analysis were harvested in chilled PBS and pelleted by 
centrifugation at 5445 x g for 10 min.   On ice, the cells were again resuspended in 10 mL of 
chilled PBS as a wash step and pelleted as described above.   The OMPs were then extracted 
as per Section 2.6.2.1.  
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For the purpose of extracting RNA, the cultures from the 4 plates grown at 42°C were 
harvested in 10 mL of Brucella broth and pelleted by centrifugation at 5445 x g for 10 min.   
The pellet was resuspended in 4 mL of Brucella broth (1 mL/plate) and half the culture was 
transferred to a new tube.   The cells were re-pelleted and resuspended in 2 mL of Brucella 
broth pre-warmed at either 37˚C or 42˚C as described previously (Stintzi, 2003) then 
dispensed into a 24-well tissue culture plate at 1 mL/well.   The cultures were incubated for 
15 min under microaerobic conditions at the temperature of the broth they were resuspended 
in.   RNA protect (Qiagen) was immediately added directly to each 1 mL of bacterial 
suspension, incubated at room temperature for 10 min to stabilise the mRNA profile and then 
the RNA was extracted as described in Section 2.4.2.1. 
 
2.2.3.2 Blood Trial 
Each of the 5 C. jejuni isolates  were grown in the presence of chicken, human and horse 
blood agar as well as MH agar without blood added as a negative control.   A 24 h culture 
grown on horse blood agar under microaerobic conditions at 42˚C was adjusted to OD600nm = 
2 and 100 µL was subcultured to the appropriate agar (with or without blood).   Cultures 
grown for RNA extraction were incubated for 1 h, while those grown for OMP extraction 
were incubated for 16 h.   All C. jejuni cultures were incubated at 42°C under microaerobic 
conditions. 
 
Cells grown for RNA extraction were harvested in PBS and immediately stabilised in an 
equal volume of RNA protect (Qiagen) to stabilise the expression profile.   RNA was then 
extracted as described in Section 2.4.2.1.   Cells grown for protein expression analysis were 
harvested in chilled PBS, pelleted at 5445 x g and the OMPs were extracted as described in 
Section 2.6.2.1. 
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2.2.3.3 Bile Trial 
To model a human intestinal environment, porcine bile extract was used in place of human 
bile as it was not possible to obtain human bile.   Porcine bile was generously supplied by 
Steve Driesen (Department of Primary Industries, Bendigo) and chicken bile, which was 
pooled from several 1-2 week old chickens, was kindly supplied by Xenia Cardassis (CRC for 
Poultry, RMIT).   The bile extracts were stored on ice immediately after collection and during 
transport.   The extracts were then diluted in sterile PBS to a final concentration of 5% (v/v) 
as a 10 x stock, filter sterilised and stored at –20˚C.    
 
A 24 h culture was used to inoculate 12 horse blood agar plates which were grown for a 
further 16 h at 42°C under microaerobic conditions.   The bacteria from all 12 plates were 
harvested in 30 mL of Brucella broth and dispensed into 3 sterile 10 mL tubes.   The cells 
were pelleted by centrifugation and resuspended in 9 mL of Brucella broth per tube and 
supplemented with 1 mL of a 10 x stock of either chicken bile extract or porcine bile extract 
for the test samples or 1 mL of PBS for the negative control.   A volume of 2.5 mL from each 
10 mL tube was dispensed into 4 wells of a 24-well tissue culture plate.   The cultures were 
incubated in the presence or absence of bile extract (at a final concentration of 0.5% v/v) at 
42°C in microaerobic conditions for 1 h or 16 h for the purpose of RNA or OMP extraction 
respectively.    The cultures to be used for RNA extraction were stabilised immediately in 
RNA Protect (Qiagen). 
 
2.2.3.4 In vitro Host Cell Trial 
A human epithelial cell line (INT407) and a chicken embryo fibroblast cell line (CEF-DF1) 
were used to model human and chicken environments in vitro respectively.   Each C. jejuni 
strain was subcultured onto HBA-Sk and grown at 42˚C for 16 h prior to being exposed to the 
tissue culture cell environment. A culture of ~ 108 cfu/mL of each strain was used to inoculate 
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each tissue culture or control condition in 25 cm2 flasks.   Each cell line was grown without C. 
jejuni strains added as a negative control.   The positive control consisted of the C. jejuni 
strains grown in tissue culture media in the absence of either tissue culture cell line.  
 
The bacterial cells used to inoculate the tissue culture flasks with or without tissue culture 
cells present were harvested from the horse blood agar containing Skirrow’s supplement in 5 
mL of PBS and pelleted by centrifugation at 5445 x g for 15 min.   The pellet was washed 
once in 10 mL of PBS and the OD600nm was measured and a serial dilution was performed to 
enumerate the cfu/mL.   The bacteria were then resuspended in DMEM-C and transferred to a 
tissue culture flask containing an 85-95% confluent monolayer of the appropriate continuous 
cell line.  
 
For the purpose of extracting RNA, the cells were exposed to the tissue culture environment 
for 1 h at 42˚C under microaerobic conditions.   The cells were immediately transferred from 
the flasks to a 10 mL tube containing an equal volume of RNA protect (Qiagen) via a 5 µm 
sterile filter to separate any eukaryotic cells from the bacterial cells.   Alternatively, if it was 
estimated that > 30% of the eukaryotic cells had dissociated from the surface of the flask as 
determined by observations under inverted light microscopy, the eukaryotic cells were first 
pelleted at 1000 x g for 2 min leaving the bacteria in the supernatant.   The centrifugation step 
was added to avoid clogging the filter and reducing the percentage recovery of bacterial cells.   
The supernatant was then passed through the 5 µm filter directly into a tube containing RNA 
Protect (Qiagen) and incubated at room temperature for 10 min.   The bacteria were then 
pelleted by centrifugation at 5445 x g for 15 min at 4˚C and the RNA was extracted as 
described in Section 2.4.2.1. 
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For the purpose of extracting OMPs, the bacteria were exposed to the tissue culture 
environment for 16 h at 42˚C under microaerobic conditions.   The cells were transferred from 
the 25 cm2 tissue culture flasks to sterile 10 mL tubes on ice and washed once in chilled PBS.   
The bacterial cells were separated from the eukaryotic cells via filtration using a sterile 5 µm 
syringe filter.   The cells were again pelleted by centrifugation at 5445 x g for 15 min, the 
pellet was resuspended in acid-glycine solutions and the OMPs were extracted as described in 
Section 2.6.2.1. 
 
2.3 DNA Methods 
2.3.1 Reagents 
 
2.3.1.1 DNA Elution Buffer 
The DNA elution buffer was used to extract DNA from silver stained polyacrylamide gels as 
described previously (Sanguinetti et al., 1994).   The buffer contained 50 mM KCl, 1.5 mM 
MgCl2, 0.1% (v/v) Triton X-100 and 10 mM Tris.HCl at pH 9 in molecular grade water and 
stored at 4°C.  
 
2.3.1.2 Formamide DNA Loading Buffer 
DNA samples were loaded onto denaturing polyacrylamide gels in 1 x formamide DNA 
loading buffer, which was made as a 5 x stock.   The stock contained 10 mM NaOH, 95% 
(v/v) formamide, 0.05% (w/v) bromophenol blue and 0.05% (w/v) xylene cyanol in deionised 
distilled water. 
 
 82 
2.3.1.3 Frozen Storage Buffer (FSB) 
MnCl2.4H2O (45 mM), CaCl2.2H2O (10 mM), KCl (100 mM), Hexamminecobalt Chloride (3 
mM), potassium acetate (10 mM, pH 7.5), glycerol (10% v/v) dissolved in H2O, pH adjusted 
to 6.4, filter sterilised and stored at 4˚C. 
 
2.3.1.4 IPTG Solution 
Isopropylthio-β-D-galactosidase (IPTG; 24 mg/mL) was dissolved in water, filter sterilised 
and stored at 4ºC. 
 
2.3.1.5 Lambda PstI DNA Molecular Weight Marker 
Lambda DNA digested with restriction enzyme PstI was used as a molecular weight marker at 
a final concentration of 50 ng/µL (Appendix XIX).  
 
2.3.1.6 Orange G DNA Loading Buffer  
DNA samples were loaded onto agarose gels in 1 x Orange G loading buffer, which was 
prepared as a 11 x stock.   The stock contained 10% (v/v) ficol-400, 50% (v/v) glycerol, 0.5% 
(w/v) Orange G, 1% (w/v) SDS, 10 mM EDTA and 50 mM Tris.HCl pH 8.0 in deionised 
distilled water and stored at room temperature.  
 
2.3.1.7 Potassium Acetate Solution 
Potassium acetate (3 M) was combined with glacial acetic acid (2 M) in deionised distilled 
water then sterilised by autoclaving under standard conditions.   The solution was stored at 
4˚C.  
2.3.1.8 Proteinase K 
Proteinase K solution was prepared by dissolving 20 mg of lyophilised Proteinase K powder 
in 1 mL of sterile water and was stored at -20ºC.  
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2.3.1.9 RNase Solution (DNase free) 
Bovine pancreatic ribonuclease was dissolved in water (10 mg/mL) then boiled for 5 min to 
denature any contaminating DNases if required.   The stock solution was stored at -20ºC and 
diluted with water to 1 mg/mL before use.  
 
2.3.1.10 TAE 50x 
Tris-base (24.2% w/v), EDTA (1.86% w/v) and glacial acetic acid (5.17% v/v) were dissolved 
in water.   This solution was used at a 1 x concentration.  
 
2.3.1.11 TBE 10x 
Tris-base (10.8%), boric acid (5.5%) and EDTA (0.37%) were dissolved in water and the pH 
was adjusted to 8.3 with HCl.   This buffer was diluted to 1 x before use.  
 
2.3.1.12 TE Buffer 
Tris-base (10 mM) and EDTA (1 mM) were dissolved in water.   The solution was then 
adjusted to pH 8.0 with HCl and sterilised by autoclaving under standard conditions.  
 
2.3.1.13 TEG Buffer 
Tris-base (25 mM), EDTA (10 mM) and glucose (50 mM) were dissolved in water and the pH 
was adjusted to pH 8.0 with HCl prior to autoclaving under standard conditions.  
2.3.1.14 X-gal Stock Solution  
The 5-Bromo-4-chloro-3-indolyl-β-galactose (X-gal) powder was dissolved in dimethyl 
formamide at a concentration of 20 mg/mL and stored at 4ºC in the dark.  
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2.3.2 Methodology 
 
2.3.2.1 DNA Extraction and Purification 
 
2.3.2.1.1 Chromosomal DNA isolation from C. jejuni 
Chromosomal DNA was isolated from a full plate of C. jejuni cells grown at 42°C for 24-48 
h.   The cells were harvested in 1.5 mL of PBS, transferred to a sterile microfuge tube and 
pelleted at 16,000 x g for 5 min.   A Wizard Genomic DNA Purification Kit (Promega) was 
used from this point on as described by the manufacturer for Gram negative bacteria.    
 
2.3.2.1.2 Plasmid DNA extraction – Mini Prep 
The alkaline lysis method was used to isolate plasmid DNA based on the method of Birnboim 
and Doly (Birnboim & Doly, 1979).   A single colony of bacteria was used to inoculate a 10 
mL Mueller-Hinton broth (MH broth) and was grown overnight at 37ºC shaking.   Cells were 
harvested from 1.5 mL of culture in a sterile microfuge tube by centrifugation at 16,000 x g 
for 5 min.   The pellet was resuspended in 100 µL of TEG Buffer containing 4 mg/mL of 
lysozyme and incubated at room temperature for 5 min.   The cells were lysed by adding 200 
µL of 0.2 M NaOH/1% SDS solution.  
 
Protein and chromosomal DNA were precipitated with 150 µL of chilled Potassium Acetate 
Solution, mixed thoroughly, then incubated on ice for 5 min.   Precipitated proteins, 
chromosomal DNA and cell wall debris were pelleted by centrifugation at 16,000 x g for 20 
min at 4ºC.   The supernatant was transferred to a new tube and an equal volume of 
phenol/chloroform/isoamyl alcohol (PCI) was added to remove any remaining proteins or 
chromosomal DNA.   The sample was mixed, then the phases separated via centrifugation at 
16,000 x g for 5 min.   The aqueous phase was transferred to a new tube containing 50 µL of 
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chloroform/isoamyl alcohol (CI) to remove residual phenol.   Again the phases were separated 
by centrifugation and the aqueous phase transferred to a new tube.  
 
The plasmid DNA was precipitated with 900 µL of 100% ethanol and pelleted by 
centrifugation at 16,000 x g for 10 min.   The DNA pellet was washed in 1 mL of 70% 
ethanol and air-dried for 5-10 min.   The dry DNA pellet was resuspended in 50 µL of sterile 
molecular grade water and stored at -20ºC.  
 
2.3.2.1.3 Plasmid DNA extraction - Midi Prep 
This scaled-up version of the alkaline lysis method described above was used to isolate larger 
amounts of DNA from larger volumes of culture.   One millilitre of a 5 mL overnight bacterial 
culture, grown in MH broth at 37ºC shaking, was used to inoculate a 50 mL MH broth.   The 
50 mL culture was grown at 37ºC shaking overnight.   The cells were harvested by 
centrifugation at 5,445 x g for 15 min.   The cells were resuspended in 10 mL of TEG buffer 
containing 2 mg/mL of lysozyme and left at room temperature for 5 min.   To ensure thorough 
lysis of the cell walls, 20 mL of 0.2 M NaOH/1% SDS solution was added, mixed by 
inversion several times and incubated on ice for 10 min.  
 
To neutralise the pH, 15 mL of potassium acetate solution was added and mixed via inversion 
before incubating on ice for 10 min.   The precipitate, containing chromosomal DNA and 
protein, was pelleted by centrifugation at 5,445 x g for 20 min.   Residual precipitate was 
removed after incubation with 5 mL of PCI.   The phases were separated by centrifugation at 
5,445 x g for 10 min.   The phenol extraction was repeated twice, followed by a CI wash step 
to remove residual phenol.   An equal volume of isopropanol was added, the DNA was 
precipitated at –20˚C for 10 min then pelleted by centrifugation at 5,445 x g for 15 min.   The 
DNA pellet was washed twice in 1.5 mL of 70% ethanol, transferred to a sterile microfuge 
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tube and again pelleted by centrifugation at 16,000 x g for 5 min.   The DNA pellet was air-
dried for up to 5 min at 56ºC, then resuspended in 50 - 100 µL of RNase solution (1 mg/mL 
RNase in sterile molecular grade water) and stored at -20ºC. 
 
2.3.2.1.4 Purification of DNA from Agarose Gels and Solutions 
DNA was extracted from agarose gels using the Geneclean Kit (Q-Biogene, USA) for DNA 
purification according the manufacturers instructions and stored at –20°C. 
 
2.3.2.1.5 Purification of DNA from Polyacrylamide Gels 
A range of methods were attempted for the recovery of silver stained DNA from 
polyacrylamide gels.   All DNA bands of interest were sliced from the gel under sterile 
conditions using a sterile razor blade. 
 
2.3.2.1.5.1 Recovery of DNA by passive diffusion  
The polyacrylamide gel slice containing the silver-stained DNA band of interest was 
transferred to a PCR tube and submerged in 50 µL of sterile ddH2O and incubated at room 
temperature overnight (Caetano-Anolles & Trigiano, 1997). Volumes ranging from 1 µL to 10 
µL were used as template in subsequent PCR cycles to optimise recovery.   To further 
optimise recovery, the 50 µL water was concentrated using the Geneclean Kit (Q-Biogene, 
USA; see Section 2.3.2.1.4) to 10µl and the entire volume was used as template. 
 
2.3.2.1.5.2 Recovery of DNA by boiling in elution buffer 
Based on the method of Sanguinetti and others (1994) the silver-stained DNA band of interest 
was submerged in 100 µL of elution buffer (50 mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100 
and 10 mM Ttris.HCl) and incubated at 95°C for 20 min.   Volumes ranging from 1 µL to 10 
µL were used as template in subsequent PCR cycles to optimise recovery.   To further 
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optimise recovery, the 100 µL elution buffer was concentrated using the Geneclean Kit (Q-
Biogene, USA; see Section 2.3.2.1.4) to 10 µl and the entire volume was used as template. 
 
2.3.2.1.5.3 Recovery of DNA by PCR  
Based on the method of Cho and co-workers (1996), differentially expressed fragments of 
DNA were excised from a silver stained polyacrylamide gel and the gel slice was placed 
directly into the PCR mix and used as the template.   The PCR was rerun at the conditions that 
produced the band initially and attempts were made at optimising the procedure by modifying 
the annealing temperature between 40°C - 60°C at increments of 5°C (Cho et al., 1996).   
This method was further optimised by Weaver and co-workers to incorporate additional PCR 
rounds to increase sensitivity (Weaver et al., 1994).   Usually no more than 3-5 PCR rounds 
were required to obtain substantial amounts of PCR product.   The cycling conditions were 
performed at the same specifications as the original PCR, except when the annealing 
temperature was increased between 40°C - 60°C at increments of 5°C in an attempt to avoid 
non-specific product. 
 
2.3.2.2 PCR  
 
2.3.2.2.1 Primer Design 
Primers were designed according to the guidelines of the Sci Ed Central Primer Designer 4 V 
4.2 program. Due to the low G+C content of C. jejuni, a G+C of 35- 50% was considered 
acceptable.   To facilitate the cloning of amplicons into vectors, restriction enzyme (RE) sites 
were included in the design of primers where appropriate.   When RE sites were incorporated, 
an additional 4 bp were added to the 5’-end of the primer sequence to allow the binding of the 
RE.   A RE site was incorporated at a position in the sequence where the native sequence 
displayed 50% or greater identity.  
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2.3.2.2.2 General PCR procedure 
PCR was performed using the following general protocol: 
10 x Buffer 2.5 µL 
MgCl2 (50 mM) 1 µL  
dNTP Mix (10 mM each base) 0.5 µL 
Forward Primer (50 ng/µL) 1-2 µl 
Reverse Primer (50 ng/µL) 1-2 µl 
Template DNA 50-100 ng  
Taq polymerase  1 U 
dH2O X µL 
Total Volume 25 µL 
The details of the PCR cycling conditions are stated in the Results section for each PCR 
performed. 
 
2.3.2.2.3 Expand Long Template PCR 
Expand Long Template PCR System (Roche) was performed according to the following 
protocol: 
10 x Buffer #3 5 µL 
dNTP Mix (10 mM) 1 µL 
Forward Primer (50 ng/µL) 2-3 µL 
Reverse Primer (50 ng/µL) 2-3 µL 
Template DNA  10-100 ng 
Taq polymerase 0.2 U 
dH2O X µL 
Total Volume 50 µL 
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The details of the PCR cycling conditions are stated in the Results section for each PCR 
performed. 
 
2.3.2.2.4 Pfu PCR 
Pfu polymerase PCR (Promega) was performed according to the following protocol: 
10 x Buffer 5 µL 
dNTP Mix (10 mM) 1 µL 
Forward Primer (50 ng/µL) 2 µL 
Reverse Primer (50 ng/µL) 2 µL 
Template DNA (100-200 ng) 1 µL 
Pfu polymerase 0.5 µL 
dH2O 38.5 µL 
Total Volume 50 µL 
The details of the PCR cycling conditions are stated in the Result section for each PCR 
performed. 
 
2.3.2.2.5 DNA Sequence Characterisation 
DNA template was purified using the DNA clean-up kit (Qiagen) according to the 
manufacturer’s instructions and the DNA was then eluted with molecular grade water.  
 
PCR was performed using the Micromon Dye Terminator 3.1 system according to the 
following protocol: 
Dye Terminator Mix 2 µL 
5 x Buffer 3 µL 
Primer (50 ng/µL) 1 µl 
Template DNA 200-500 ng 
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dH2O X µL 
Total Volume 20 µL 
 
The DNA was amplified under the following PCR cycling conditions: 96˚C x 1 min, 30 x 
(96˚C x 10 s, 50˚C x 5 s, 60˚C x 4 min).   The PCR product was cleaned via a sodium 
acetate/ethanol precipitation.   Briefly, the entire PCR product (20 µL) was transferred to a 
sterile microfuge tube and combined with 2 µl of 3 M sodium acetate (ph 4.6) and 50 µL of 
95% ethanol then mixed via vortex and incubated for 10 min at room temperature.   The 
precipitated DNA was pelleted via centrifugation at full speed for 20 min.   The pellet was 
washed twice with 250 µL of 70% ethanol and again pelleted at full speed for 5 min.   The 
pellet was air dried and sent to the Micromon facility at Monash University, Melbourne, 
Australia, for DNA sequence characterisation analysis. 
 
2.3.2.3 Gel Electrophoresis 
 
2.3.2.3.1 Agarose Gel Electrophoresis 
DNA agarose gels were prepared using 0.8-3.0% agarose powder in 1 x TAE buffer and 
dissolved by boiling.   The DNA fragments were separated according to size by applying a 
current of 40 – 100 V for 1 – 4 h.   The DNA was stained with ethidium bromide and 
visualised under UV light using a Biorad Gel Doc system.  
 
2.3.2.3.2 Denaturing Polyacrylamide Gel Electrophoresis 
Continuous denaturing polyacrylamide gels were prepared in 1 x TBE buffer and contained a 
final concentration of 6% acrylamide:bisacrylamide and 7 M urea.   The gels were set with 
APS and TEMED at final concentrations of 0.035% and 0.1% respectively.   Prior to loading 
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the DNA samples, unset gel solution was displaced from the wells of a set gel using a syringe 
loaded with 1 x TBE and the gel was equilibrated by pre running at 70 V for 30 min.  
 
Mini gels were run using a Biorad Protean 3 gel apparatus at 70 V for ~ 1.5 h or until the dye 
front had neared the bottom of the gel.   Maxi gels were run using a DNA sequencing 
apparatus. To improve the resolution and separation of the expression profiles, the samples 
were resolved electrophoretically on a DNA sequencing apparatus when required.   Due to the 
fragility and size of the gels, maxi gels were prepared differently to the mini gels to reduce the 
risk of breakage during the staining procedure.   Firstly, the glass plates were treated with 5% 
potassium hydroxide in methanol to remove any residual glass surface treatments, then 
meticulously cleaned using pyroneg detergent.   The glass plates were rinsed in deionised 
water and dried using 70% ethanol soaked Kim Wipes.   The larger glass plate was treated 
with Acrylease as per the manufacturer’s instructions to allow the gel to slide easily away 
from the surface upon separating the plates.   The smaller plate was treated in Bind Silane as 
per the manufacturer’s instructions to allow the gel to stick to the glass surface, as it was too 
fragile to be handled during staining.  
 
DNA bands were visualised by staining with Plus One DNA Silver Staining Kit (Amersham 
Pharmacia) and used as instructed by the manufacturer.   Briefly, the gel was fixed in 1 x 
Fixing Solution diluted in 24% ethanol and incubated gently shaking at room temperature for 
at least 1 h.   The Fixing Solution was replaced with 1 x Staining Solution and incubated 
gently shaking for 30 min.   The Silver Staining Solution was replaced with deionised water 
and the gel was rinsed for 1.5 min.   The gel was then submerged in 1 x Developing Solution 
and incubated a room temperature, gently shaking for 5-10 min or until the DNA was stained 
at an appropriate intensity.   The developing reaction was stopped by adding 1 x Stop 
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solution.   The gel was scanned within 1-2 h of being developed to reduce fading of faint 
bands.  
 
2.3.2.4 Recombinant DNA Methods 
 
2.3.2.4.1 Restriction Enzyme Digestion 
All restriction enzyme (RE) digests were carried out with the following reagents: 
DNA X µL 
RE 0.5 µL (10 U/µL) 
10 x buffer 2 µL 
Water X µL 
Total volume 20 µL 
All reactions were carried out at 37°C for 2 - 16 h and then stored at –20°C. 
 
2.3.2.4.2 DNA Ligation 
Sticky-end ligation reactions were performed at 16°C for 16 h, while blunt end ligations were 
performed at room temperature as per the manufacturer’s instructions (pPCRScript Amp SK+ 
vector, Stratagene).   The protocol used for ligation reactions is outlined below: 
Plasmid DNA X µL* 
Insert DNA X µL* 
Ligase (T4) 1 µL (1 U/µL) 
10 x Ligation buffer 2 µL 
Water X µL 
Total volume 20 µL 
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* The amount of plasmid DNA and insert DNA added to the ligation reaction was determined 
by the following equation:  
 
Vector DNA (ng) x size of insert (kb) 
Insert DNA (ng) = 
Size of vector (kb) 
      x  molar ratio of 3/1 
 
2.3.2.4.3 Electro-Competent Transformation of E.coli 
A single colony was used to inoculate a 10 mL MH broth culture of E. coli DH5α which was 
grown overnight at 37°C shaking.   Two millilitres of inoculum was subcultured from the 
overnight culture to 200 mL of pre-warmed MH broth and grown to mid log phase.   The 
optical density was tested at 600 nm (OD600nm) and used at an OD600nm of approximately 0.6.   
The culture was incubated on ice for 30 min to slow the cell growth.   The cells were 
harvested by centrifugation at 5,445 x g for 20 min at 4°C.   The pellet was resuspended in 
100 mL chilled sterile water and harvested again as above.   This wash step was repeated in 
50 mL of chilled sterile water, then in 4 mL of 10 % glycerol in chilled sterile water in 
microfuge tubes.   The cells were pelleted at 16,000 x g for 5 min, resuspended in 200 µL of 
10% glycerol and aliquoted out in 40 µL volumes and stored immediately at –70°C.  
 
Frozen electro-competent cells were thawed on ice and mixed with up to 2 µL of ligation 
product and transferred to a chilled electroporation cuvette with a 0.2 cm gap.   The pulse 
settings used to deliver DNA into the competent cells were 2.5 kV, 25 µF and 200 Ω.   
Electroporation with a time constant of greater than 4.5 were immediately resuspended in 1 
mL of Brucella broth plus (BB+) and then incubated at 37°C for 1 h to allow the cells to 
recover.   The entire electro-transformed culture was plated at neat, 10-1 and 10x 
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concentrations onto either MH agar or Blue-White Screening Agar (see Section 2.2.1.11) 
containing the appropriate antibiotic.  
 
2.3.2.4.4 Chemically-Competent Transformation of E. coli 
Based on a method described previously (Sambrook & Russell, 2001), a 200 mL MH broth 
was inoculated with 1% of an overnight culture of E.coli DH5α and grown to mid-log phase 
at 37˚C shaking until the culture achieved an OD600nm of approximately 0.6.   The culture was 
incubated on ice for 1 h, before the cells were harvested by centrifugation at 5445 x g for 20 
min at 4˚C.   Cells were washed in 40 mL of ice-cold FSB Solution.   After centrifugation at 
5445 x g for 20 min at 4˚C, cells were resuspended in 2 mL of FSB, dispensed in volumes of 
200 µL in sterile microfuge tubes and immediately stored at –70˚C.  
 
Aliquots of chemically competent cells were thawed on ice and 10 µL of ligation reaction was 
added to 200 µL of competent cells.   The cells were mixed by pipetting and incubated on ice 
for 30 min.   To perform the transformation, competent cells were “heat shocked” at 42˚C for 
90 s.   Transformations were incubated on ice for 2 min, then 1 mL of BB+ broth was added.   
Transformants were allowed to recover at 37˚C for 1 h before 100 µl of each dilution, neat, 
10-1 and 10 x, were plated onto either MH Agar or Blue-White Screening Agar (see Section 
2.2.1.11) containing the appropriate antibiotic. 
 
2.3.2.4.5 Natural Transformation of C. jejuni 
Two to three full plates of C. jejuni cells were grown at 42˚C for 16 h, then harvested in 5 mL 
of PBS.   The cells were then washed in 5 mL of BB and up to 30 µg of DNA was added and 
mixed with the cells by inversion.   The DNA/bacterial suspension was transferred to a non-
selective HBA-Sk agar plate and incubated at 42˚C for 3 h.   The potentially transformed cells 
were transferred to a sterile tube and pelleted by centrifugation at 5445 x g for 15 min.   The 
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pellet was resuspended in PBS, inoculated on to selective HBA-Sk media supplemented with 
kanamycin and incubated for 24-48 h at 42˚C.   Positive transformants were confirmed by 
PCR and DNA sequence characterisation.  
 
2.4 RNA Methods  
All RNA related work was performed in a biohazard class II cabinet to reduce exposure to 
ubiquitous environmental RNases.   All solutions were made with RNase-free water, and 
stored in Diethylpyrocarbonate (DEPC) treated sterile glassware or sterile RNase-free plastic 
ware and only sterile barrier pipette tips were used. 
 
2.4.1 Reagents 
 
2.4.1.1 RNase-free water 
For volumes less than 100 mL, molecular grade RNase-free water (Sigma-Aldrich) was used, 
for larger volumes, e.g. formaldehyde gel running buffer, DEPC-treated water was used.   
Deionised water was treated by adding DEPC at a final concentration of 0.1%.   The solution 
was incubated at 37°C overnight, then sterilised by autoclaving under standard conditions, 
which also removed residual DEPC. 
 
2.4.1.2 RNase-free 75% Ethanol 
An unopened bottle of analytical grade absolute ethanol was opened in a biohazard class II 
cabinet and decanted into a DEPC treated bottle.   Ethanol was diluted in DEPC treated water 
(75%) and stored at –20°C.  
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2.4.1.3 Formaldehyde Gel Running Buffer (10 x) 
A 10x stock solution of formaldehyde gel running buffer was prepared with 0.2 M 3-[N-
morpholino] propanesulfonic acid (MOPS), 0.05 M sodium acetate and 0.01 M EDTA.   The 
buffer was then adjusted to pH 7 with sodium hydroxide.   The buffer was diluted to a 1 x 
solution with RNase-free water to which formaldehyde was added to a final concentration of 
0.74% before use.  
 
2.4.1.4 RNA Loading Buffer (5 x) 
The RNA Loading Buffer contained 16 µL  saturated Orange G, 80 µL of 500 mM EDTA (pH 
8), 720 µL of 37% formaldehyde, 2 mL of 100% glycerol, 3.038 mL of formamide and 4 mL 
of 10 x Formaldehyde Gel Running Buffer.   The Loading Buffer was stored at 4˚C.  
 
2.4.2 Methodology 
 
2.4.2.1 RNA Isolation 
C. jejuni RNA was isolated using the RNAgents Total RNA Isolation Kit (Promega) as 
described by the manufacturer with the following modifications.   C. jejuni cell suspensions 
were immediately mixed with 50% (v/v) RNA protect solution (Qiagen) and incubated for 10 
min at room temperature to stabilise the mRNA expression profile and then pelleted by 
centrifugation at 16 000 x g for 5 min.  
 
The stabilised cell pellet was resuspended in 600 µL of chilled RNAgents Denaturing 
Solution and passed through a 25-gauge needle to break up any cell clumps.   A volume of 60 
µL of sodium acetate solution was added and mixed via inversion.   Then 600 µL of room 
temperature P:C:I was added, mixed via inversion and then shaken vigorously for 10 s.   After 
incubating on ice for 15 min, the two phases were separated by centrifugation at 16,000 x g 
 97 
for 20 min.   The upper aqueous phase was transferred to a new sterile RNase-free microfuge 
tube, to which an equal volume of isopropanol was added.   The sample was then incubated at 
–20˚C for at least 30 min to facilitate the precipitation of the RNA in the presence of 
isopropanol.   The precipitated RNA was collected by centrifugation at 10,000 x g for 5 min, 
washed once with 1 mL of 75% ice cold RNase-free ethanol and the previous centrifugation 
step was repeated.   The air-dried pellet was resuspended in 50 µL of molecular grade RNase-
free water and stored at –70˚C.  
 
2.4.2.2 Determination of RNA Concentration 
The RNA sample was diluted to 0.5% in water.   The diluted sample was measured in a dual 
beam spectrophotometer in quartz cuvettes at both 260 nm and 280 nm wavelengths.   
Quantitation of total RNA was determined based on an absorbance of 1 at 260 nm 
corresponding to 40 µg of RNA per mL when measured in water.   Therefore the RNA 
concentration of the original sample was determined using the following equation, [RNA] = 
40 x A260 x dilution factor. 
Sample calculation: 
RNA sample diluted 1/200 in water to a total volume of 1 mL.  
A260 = 0.37 
[RNA] = 40 x 0.37 x 200 µg/mL 
[RNA] = 2960 µg/mL 
[RNA] = 2.96 µg/µL 
Total yield of RNA = concentration x volume of original sample 
2960 µg/mL x 0.05 mL = 148 µg. 
 
Stocks of each RNA sample were prepared at a final concentration of 100 ng/µL in molecular 
grade RNase-free water and stored at –70˚C. 
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2.4.2.3 Formaldehyde Gel Electrophoresis 
All RNA samples were visualised to determine the quality and purity of the isolation by 
formaldehyde gel electrophoresis to ensure the RNA was in linear form and to reduce the 
effect of potential contaminating RNases. 
 
To remove contaminating RNases from the gel tank, tray and comb, the apparatus was 
cleaned with 0.5% SDS, rinsed with water and then dried with 70% ethanol.   The entire 
apparatus was then incubated in 3% H2O2 for 10 min at room temperature, then rinsed 
thoroughly in DEPC-treated water.  
 
The RNA samples were mixed with 5 x RNA loading buffer, which contained formamide and 
formaldehyde to denature the RNA.   The samples were loaded with barrier tips into a pre 
equilibrated 1.2% agarose gel prepared in 1 x formaldehyde running buffer containing 1 µL of 
10 mg/mL ethidium bromide.   The current was applied at 70-90 V and run continuously until 
the dye front reached the bottom of the gel.   The ethidium bromide stained RNA was 
visualised under UV light using a Biorad Gel Doc System.  
 
2.4.2.4 DNase Treatment of RNA 
RNA [100 ng/µL] stocks were treated with RQ1 RNase-Free DNase (Promega) as per the 
manufacturer’s instructions to remove any contaminating genomic DNA.   The protocol used 
for DNase reactions is outlined below: 
RNA sample [100 ng/µL] 43 µL 
RQI 10 x buffer 5 µL 
RQI DNase 2 µL 
Total volume 50 µL 
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The reaction was set up on ice and then incubated at 37°C for 30 min to allow DNA digestion.   
The reaction was stopped by adding 1 µL of RQI stop solution to each sample, on ice. The 
DNase was inactivated at 65°C for 10 min. The DNase treated RNA samples [78 ng/µL] were 
stored at -70°C.  
 
2.4.2.5 RT PCR 
 
2.4.2.5.1 Reverse Transcription 
The RNA was converted to cDNA via reverse transcription (RT) using Improm-II   Reverse 
Transcription System (Promega) according to the manufacturer’s instructions.   The RT 
reaction was performed in three stages.   A) RNA and primer denaturation, B) Preparation of 
RT reaction reagents, C) Production of cDNA. 
 
A) Briefly, 100-200 ng of RNA was mixed with 100 ng of primer in an RNase-free microfuge 
tube in a total volume of 11 µL.   The mixture was then denatured at 70˚C for 5 min. The 
denaturation reaction was prepared in an ice water bath. 
 
B) The RT reaction was prepared in a sterile microfuge tube on ice in the following order: 
5 x Buffer 4 µL 
MgCl2 (25 mM) 2.5 µL 
dNTPs (10 mM) 1 µL 
RNasin (40 U/µL, Promega) 0.5 µL 
Reverse Transcriptase (RTase) 1 µL 
Total volume 9 µL 
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C) The production of cDNA was achieved by combining the solutions from both parts A and 
B and incubating them at 25˚C for 5 min, 42˚C for 1 h and then 70˚C for 15 min to inactivate 
the RTase.   All cDNA products were stored at –20˚C and were used as the template for the 
PCR step in which cDNA was converted to dsDNA.    
 
2.4.2.5.2 Random Arbitrarily Primed Differential Display (RAP DD) RT PCR 
The PCR step for RAP DD RT PCR was performed as outlined below: 
10 x Buffer 5 µL 
MgCl2 [25 mM] 2 µL 
dNTP Mix [10 mM each base] 1 µL 
Random 11-mer [100 ng/µL] 5 µl 
Random 10-mer [100 ng/µL] 5 µl 
Template cDNA 10 µL 
Taq polymerase  1 U 
dH2O X µL 
Total Volume 50 µL 
 
The PCR program used was 1 x (94°C x 5 min, 40°C x 5 min, 72°C x 5 min) then 40 x (94°C 
x 1 min, 50°C x 1 min, 72°C x 2 min) followed by a final elongation of 72°C for 5 min.   The 
initial cycle containing a non stringent annealing temperature of 40°C, was used to encourage 
the production of a high number of random amplicons essentially as described previously 
(Liang & Pardee, 1992; Welsh & McClelland, 1990).    
 
2.4.2.5.3 Gene Specific RT PCR 
The gene specific PCR step was performed using the following protocol: 
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10 x Buffer 2.5 µL 
MgCl2 [50 mM] 3.5 µL  
dNTP Mix [10 mM each base] 0.5 µL 
Forward Primer [50 ng/µL] 1.5 µl 
Reverse Primer [50 ng/µL] 1.5 µl 
Template cDNA 2 µL  
Platinum Taq polymerase (Invitrogen) 1 U 
dH2O X µL 
Formamide 0.3 µL 
Total Volume 25 µL 
 
The cycling conditions used for all gene specific RT PCR samples were 1x 94°C for 3 min, 35 
x (94°C x 45 s, 60°C x 30 s, 72°C x 5 s) followed by a final elongation step of 1x 72°C for 5 
s.   Formamide was added to the PCR reaction at a final concentration of 1.25% to avoid non-
specific bands as previously described (Sarkar et al., 1990). 
 
2.4.2.6 Real Time RT PCR  
Real time (rt) RT PCR was performed using the iQ SYBR Green I Supermix (Biorad).   
Primer sets for each gene of interest were designed to amplify a fragment of 300-400 bp with 
comparable melting temperatures to allow all reactions to be run under the same cycling 
conditions.  
 
The rt RT PCR step was performed using the following protocol: 
iQ SYBR ® Green Supermix 12.5 µL 
Forward Primer [50 ng/µL] 1.5 µl 
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Reverse Primer [50 ng/µL] 1.5 µl 
Formamide 0.3 µL 
dH2O 5.2 µL 
Template cDNA  2-4 µL  
Total Volume 25 µL 
 
The experimental plate was used to generate dynamic well factors.   The melt curve 
descended from 95°C to 40°C at decrements of 0.5°C with a dwell time of 10 s at each 
temperature.   The standard curve was generated from a dilution series of a plasmid (prpoA) 
of known concentration containing the reference gene rpoA at 10-2, 10-4, 10-6 and 10-8.  
 
The cycling conditions used for all gene specific rt RT PCR samples was 1x 5°C for 3 min, 40 
x (94°C x 45 s, 60°C x 30 s, 72°C x 5 s) followed by a final elongation step of 1x 72°C for 5 
s.   Formamide was added to all PCR samples at a final concentration of 1.25% to avoid non-
specific bands as previously described (Sarkar et al., 1990). 
 
2.5 Lipooligosaccharide and Capsule Methods 
 
2.5.1 Reagents 
 
2.5.1.1 Alcian Blue Stain 
Alcian Blue Stain was prepared at a final concentration of 0.1% (w/v) in LOS/CPS Fixing 
Solution (see Section 2.5.1.6).  
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2.5.1.2 Anode Buffer 
The Tricine SDS-PAGE Anode Buffer was prepared as a 10 x stock which consisted of 2 M 
Tris.HCl (pH 8.9) in dH2O.   The buffer was diluted to 1 x with dH2O prior to use.  
 
2.5.1.3 Cathode Buffer 
The Tricine SDS-PAGE Anode Buffer was prepared as a 10 x stock which consisted of 1 M 
Tris, 1 M Tricine and 1% SDS in dH2O (pH 8.25).   The buffer was diluted to 1 x with dH2O 
prior to use. 
 
2.5.1.4 DNase I Solution 
DNase I enzyme was resuspended to a final volume of 50 U/µL in TMG Buffer and stored at 
–20˚C.  
 
2.5.1.5 Laemmli Sample Mix  
In a total volume of 15 mL, Laemmli sample mix contained  2.5 mL of 0.5 M Tris.HCl, 4 mL 
of 10% SDS, 2 mL of 100% glycerol, 1 mL β-mercaptoethanol, 2 mL of 0.02% bromophenol 
blue in deionised water, as described previously (Laemmli, 1970). 
 
2.5.1.6 LOS/CPS Fixing Solution 
LOS and CPS were fixed in 5% (v/v) glacial acetic acid and 40% (v/v) ethanol in deionised 
water. 
 
2.5.1.7 LOS/CPS Lysis Buffer 
The lysis buffer contained 31.25 mM Tris.HCl (pH 8), 4% (w/v) SDS, 0.025% (w/v) 
bromophenol blue and 20% (v/v) glycerol in deionised water and was filter sterilised before 
use.  
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2.5.1.8 Tricine SDS-PAGE Gel Buffer 
A 10 x stock containing 3 M Tris.HCl and 0.3% SDS (pH 8.45) in dH2O was diluted to a 1 x 
solution with dH2O prior to use. 
 
2.5.1.9 Tris Buffered Saline (TBS) 
TBS was prepared as a 10 x stock of 8% (w/v) NaCl, 0.2% (w/v) KCl and 3% (w/v) Tris, 
adjusted to pH 7.4 with HCl and used at a working concentration of 1 x. 
 
2.5.1.10 TMG Buffer 
TMG Buffer was used to resuspend DNase I and was prepared with 20 mM Tris.HCl (pH 
7.4), 1 mM MgCl2, 50% (v/v) glycerol in deionised water.   The buffer was filter sterilised 
and stored at 4˚C.  
 
2.5.1.11 Solution I 
Solution I was used during isolation of LOS samples and contained 50 mM Tris.HCl and 2 
mM EDTA (pH 8.5).   The solution was sterilised by autoclaving under standard conditions.  
 
2.5.1.12 Solution II 
Solution II consisted of 2 mM Tris.HCl (pH 7.8) and was sterilised by autoclaving under 
standard conditions.  
 
2.5.2 Methodology 
 
2.5.2.1 LOS Extraction 
C. jejuni cells were grown at 42˚C for 48 h under microaerobic conditions.   The cells were 
harvested in sterile PBS and pelleted by centrifugation at 5445 x g for 15 min.   The cell 
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envelopes were isolated as described previously (Lugtenberg et al., 1975), with some 
modification.   Briefly, the cells were washed once in PBS then resuspended in 3 mL of 
Solution 1 for lysis by sonication.   The sonication step was performed on ice at 60 W for 5 
cycles of 30 s pulses with 30 s rest between each pulse.    
 
The cell wall debris was pelleted at 700 x g in a microfuge for 20 min at 4˚C and the 
supernatant containing the LOS was transferred to a new tube.   The LOS was pelleted at 
9,300 x g in a microfuge for 1 h at 4˚C and resuspended in 100 µL of Solution 2 and 300 µL 
of Laemmli Sample Mix.   The LOS samples were boiled for 15 min and any contaminating 
protein was digested with 20 µL of 20 mg/mL Proteinase K at 56˚C for 1 h.   The LOS sample 
was stored at 4˚C.   The LOS was visualised by Alcian Blue Stained Tricine SDS-PAGE 
analysis, see Section 2.5.2.4.  
 
2.5.2.2 LOS and CPS Co-Extraction 
The LOS and CPS was isolated as described previously by Karlyshev and Wren (2001).   
Briefly, the cells were grown at 42˚C for 48 h under microaerobic conditions and harvested in 
PBS.   The cells were pelleted by centrifugation in a microfuge at full speed for 5 min.   The 
pellet was resuspended in 100 µL of LOS/CPS Lysis Buffer, 70 µL DNase Solution and 30 
µL of RNase Solution.   RNA and DNA were digested at 37˚C for 2.5 h then boiled for 5 min.   
The sample was pelleted at 9,300 x g for 10 min at room temperature in a microfuge then the 
supernatant was transferred to a new tube.   The sample was then incubated at 50˚C for 1 h 
with 10 µL of 20 mg/mL Proteinase K.   The sample was stored at 4˚C and analysed by 
Alcian Blue Stained Tricine SDS-PAGE as described in Section 2.5.2.4. 
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2.5.2.3 Lipooligosaccharide Purification for GCMS Analysis 
High purity LOS was obtained as described previously (Westphal & Jann, 1965).   The 
samples were subjected to hot phenol extraction to remove all proteins.   Both the samples 
and saturated phenol were heated to 65˚C.   Heated phenol was added to each sample at a ratio 
of 1:1 (v/v).   The sample/phenol suspension was mixed thoroughly by vortex and incubated 
for 15 min at 65˚C.   The sample/phenol suspension was then cooled to room temperature and 
pelleted by centrifugation at 5445 x g for 45 min.   The upper aqueous phase was transferred 
to a new tube.   Preheated water was then added to the original phenol phase, incubated again 
at 65˚C and pelleted again, as in the previous step.   This extraction procedure was repeated 
three times to collect any LOS remaining in the phenol phase.   To ensure LOS sample purity, 
the samples were dialysed for 24 h at 4˚C against deionised water changed at 8 h intervals 
using dialysis tubing with a 3.5 kDa cut off.   The dialysed samples were lyophilised and the 
dried LOS was resuspended in sterile deionised distilled water at a final concentration of 1 
mg/mL and stored at –20˚C.   Purified LOS samples were analysed using GCMS by Prof. 
Malcolm McConville at The University of Melbourne, Biochemistry Department.   The peak 
areas for each glycan residue was determined and normalised by dividing the total peak area 
for each sugar by the total peak area of Kdo.   The data was normalised against Kdo, which 
occurs in LOS and not CPS, as there was some CPS contamination of the LOS preparations. 
 
2.5.2.4 Tricine SDS-PAGE  
Polysaccharides were separated by SDS-PAGE using a tricine buffering system as previously 
described (Bollag & Edelstein, 1991; Lesse et al., 1990), with some modification.   LOS and 
LOS/CPS samples were separated by tricine SDS-PAGE with a separate anode and cathode 
buffer using either a maxi gel or mini gel apparatus (Biorad).   The maxi gel samples were 
stacked at 100 V for 1 h, and resolved at 200 V for 10 h while the mini gel samples were 
stacked at 60 V for 30 min and resolved at 200 V for 40 min or until the dye front had reached 
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the bottom of the gel.   The samples from either gel size were visualised with alcian blue 
stain.   The LOS was stained with Alcian Blue as described previously by Karlyshev and 
Wren (2001).   Breifly, the gel was washed in LOS/CPS Fixing Solution for 15-20 min gently 
shaking.   The gel was stained with Alcian Blue Stain, shaking gently for 30 min and 
destained in 3-4 changes of LOS/CPS Fixing Solution.  
 
2.5.2.5 Western Blot  
The Western Blot or Immuno Blot was performed as previously described (Bollag & 
Edelstein, 1991), with some modification.   LOS samples separated by tricine SDS-PAGE 
were transferred to a nitrocellulose membrane using a transblot apparatus (Biorad) to 
determine their immunogenicity.   The samples were transferred at 70 V for 1 h and the 
membrane was incubated in a blocking solution of 5% skim milk in TBS at room temperature 
for 1 h gently shaking.   The blocked membrane was then washed 4 times in TBS to remove 
unbound skim milk proteins.   The membrane was incubated with mouse anti 81116 LOS 
antisera at 4°C overnight gently shaking.   The membrane was washed again in TBS for 10-15 
min, then incubated in 1% skim milk in TBS containing 0.033% of goat anti-mouse IgG HRP 
conjugant.   The membrane was developed in 0.6 mg/mL chloronapthol, 20% methanol and 
0.018% H2O2 in TBS in darkness for ~ 30 min.   The developed membrane was washed in 
deionised distilled water, air dried and stored at room temperature. 
 
2.6 Protein Methods 
2.6.1 Reagents 
2.6.1.1 Acid/Glycine Extraction Solution 
The OMPs were extracted in 0.2 M glycine adjusted to pH 2.2 with HCl which was sterilised 
by autoclave under standard conditions.  
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2.6.1.2 Protein Loading Buffer (5 x) 
Protein samples were loaded on to polyacrylamide gels in 1 x protein loading buffer.   The 
buffer contained 25% (v/v) glycerol, 2% (w/v) SDS, 14.4 mM β-mercaptoethanol, 0.1% 
bromophenol blue and 60 mM Tris.HCl pH 6.8 in deionised distilled water and stored at 4°C.  
 
2.6.1.3 Resolving Gel 
Tris.HCl pH 8.8 (375 mM), SDS (0.1% w/v), bis acrylamide (12.5% v/v) was prepared in 
deionised distilled water.   The setting agents ammonium persulfate (0.06% w/v) and TEMED 
(0.03% v/v) were added to the gel and mixed via inversion just prior to pouring. 
 
2.6.1.4 Stacking Gel 
The 4.5% stacking gel contained 125 mM Tris.HCl pH 6.8, 0.1% (w/v) SDS and 4.5% bis 
acrylamide in deionised distilled water.   Just prior to pouring, 0.06% (w/v) ammonium 
persulfate and 0.03% (v/v) TEMED was added to the gel solution and mixed via inversion.   
The gel was then poured to overlay the set resolving gel. 
 
2.6.1.5 Lowry Solution A 
Sodium carbonate (2% w/v), sodium hydroxide (0.4% w/v), sodium potassium tartrate (0.16% 
w/v), SDS (1% w/v) was prepared in deionised distilled water and sterilised by autoclave 
under standard conditions.  
 
2.6.1.6 Lowry Solution B 
Cupric sulfate pentahydrate (4% w/v) was dissolved in deionised distilled water. 
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2.6.1.7 Lowry Solution C 
This solution was prepared fresh from Lowry reagents A and B at a ratio of 100:1 
respectively. 
 
2.6.1.8 Folin Reagent 
Folin-Ciocalteau phenol reagent was mixed with an equal volume of deionised distilled water.   
The solution was stored at 4°C and covered in foil as it is light sensitive.  
 
2.6.1.9 Coomassie Blue Stain 
Coomassie brilliant blue (R) powder (0.1% w/v) was dissolved in methanol (50% v/v) and 
glacial acetic acid (10% v/v) in deionised distilled water. 
 
2.6.1.10 Destaining Solution 
Ethanol (10% v/v) and glacial acetic acid (10% v/v) was prepared in deionised distilled water.  
 
2.6.2 Methodology 
 
2.6.2.1 OMP Extraction 
C. jejuni OMPs were extracted as described previously (Logan & Trust, 1983), with some 
modification.   Briefly, the cells were exposed to each environmental condition, harvested in 
chilled PBS and kept on ice.   The cells were washed once in PBS, then resuspended in 2 mL 
of 0.2 M glycine/HCl solution at pH 2.2.   The OMPs were extracted in the acidic glycine 
buffer by gently shaking at room temperature for 3 h.   Whole cells were pelleted at 12,000 x 
g for 15 min and the supernatant containing the OMPs were transferred to a new tube.    
 
 110 
The OMP samples were concentrated using either a Centricon YM-3 (Millipore) 3 kDa cut off 
concentration device or an Ultra 4 (Millipore) 5 kDa cut off double membrane concentration 
device.   Both devices were used as instructed by the manufacturer.   Briefly, the membranes 
were pre-rinsed with 2 mL of 0.1 M NaOH by centrifugation at 4000 x g for 15-30 min.   The 
membranes were then rinsed 3 x in deionised distilled water.   The sample was then added to 
the device and concentrated at 4000 x g at 4°C until there was ~ 500 µL remaining.   The pH 
of the OMP sample was then neutralised to pH 7 by adding the necessary volume of 
neutralisation buffer (0.2 M glycine, 2 mM Tris.HCl, adjusted to pH 9 with NaOH) and 
confirmed with a pH test strip.   Once the OMP were concentrated down to less than 150 µL, 
the sample was collected at 900 x g for 2 min at 4°C and mixed with ~ 20% glycerol as a 
cryoprotectant and stored at -20°C.   The protein concentration was determined by Lowry 
Assay and analysed by glycine SDS-PAGE and visualised with Coomassie blue stain.  
 
2.6.2.2 Modified Lowry Assay 
The protein concentration was measured using the Lowry Assay (Lowry et al., 1951) 
modified as described previously (Cadman et al., 1979).   Briefly, 20 µL of OMP sample was 
combined with 180 µL of molecular grade water and 600 µL of Lowry reagent C and 
incubated at room temperature for 20 min.   The colour was developed by adding 60 µL of 
Folin reagent, mixed thoroughly and incubated at room temperature for 30 min.   The colour 
intensity was measured at 600 nm by ELISA reader and the protein concentration was 
determined as compared to a standard curve of a range of known bovine serum albumin 
(BSA) concentrations.  
 
2.6.2.3 Glycine SDS-PAGE with Coomassie Blue Stain 
The neutralised and concentrated OMP samples were separated via SDS-PAGE and visualised 
using Coomassie blue stain as described previously (Bollag & Edelstein, 1991), using a mini 
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gel protean 3 apparatus (Biorad).   The OMPs were denatured by adding 1 x protein loading 
buffer and boiling for 5-10 min.   A volume of OMP sample containing 10-15 µg was loaded 
per well, stacked at 60 V for 30 min and resolved at 180 V for 50 min or until the dye front 
had just run off the bottom of the gel.   The proteins were stained in Coomassie blue stain 
while gently shaking at room temperature and the background dye was removed with several 
changes of destaining solution.   Destained gels were scanned using a CannonScan LiDE 20 
scanner in conjunction with Microsoft PhotoEd software. 
 
2.7 Tissue Culture Methods 
 
2.7.1 Media and Reagents 
INT407 cells were cultured in standard DMEM media, while CEF-DF1 cells were grown in 
modified DMEM (DMEM-C).   Standard PBS was used when working with INT407 cells 
while Dulbecco’s PBS without CaCl2 and MgCl2 (Gibco) was used for the CEF-DF1 cells.  
 
2.7.1.1 Dulbecco’s Modified Eagle’s Media (DMEM) 
To 372 mL of sterile deionised distilled water, 100 mL of 5 x DMEM, 13.5 mL of 7.5% 
Sodium bicarbonate, 10 mL of HEPES buffer and 4.5 mL of L-glutamine were added by 
direct filter sterilisation and stored at 4˚C.   Fresh aliquots of DMEM supplemented with 10% 
v/v newborn calf serum (NCS) were used in culture. 
 
2.7.1.2 Dulbecco’s Modified Eagle’s Media for CEF-DF1 cells (DMEM-C) 
To 320 mL of sterile deionised distilled water, 100 mL of 5 x DMEM, 10 mL of 7.5% 
Sodium bicarbonate, 10 mL of HEPES buffer, 10 mL of L-glutamine and 50 mL of 45 g/L 
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glucose were added by direct filter sterilisation and stored at 4˚C.   Fresh aliquots of DMEM-
C supplemented with 10% v/v newborn calf serum (NCS) were used in culture. 
 
2.7.1.3 Trypsin Solution 
Trypsin/EDTA was mixed 1:1 with PBS and used to dissociate INT407 cells and stored at -
20˚C. 
 
2.7.1.4 Trypsin/Versene Solution 
Trypsin/versene solution contained 0.1% v/v versene (0.53 mM; Gibco), 4% Trypsin (2.5%; 
Gibco) in Dulbecco’s PBS (Gibco) without CaCl2 and MgCl2 was used to dissociate CEF-
DF1 cells.    
 
2.7.1.5 Gentamycin Solution 
Gentamycin sulphate (400 µg/mL) in DMEM or DMEM-C. 
 
2.7.2 Methodology 
 
2.7.2.1 Culturing Method 
Tissue culture cell lines, INT407 and CEF-DF1, were resuscitated from liquid nitrogen stocks 
and grown in DMEM or DMEM-C respectively.   Cultures were grown to exponential phase (~ 
80 - 90% confluent) before they were split, transferred to a larger flask or used experimentally.   
The cells were passaged no more than 15 - 20 times before a fresh stock of cells were 
resuscitated.  
Cultures were split by first removing the media and washing twice in PBS.   An appropriate 
volume of trypsin solution was added and the flask was incubated at 37°C for 5-10 min in 5% 
CO2.   The dissociated cells were removed from the flask and the action of the trypsin was 
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countered by the addition of DMEM or DMEM-C containing 10% v/v serum.   The cells were 
washed twice in media and an appropriate volume of cells were used to seed a new flask or 
flasks.  
 
Cells were stored in liquid nitrogen by dissociating them and washing them as described 
above, then resuspending them in media supplemented with 10% DMSO as a cryoprotectant.   
A 75 cm2 flask of ~80 – 90% confluent cells was used to bank down 2 cryovials each 
containing 1 mL of cell suspension.   The cells were first incubated at -70°C for 2-3 days 
before transferring them to liquid nitrogen. 
 
2.7.2.2 Invasion/Adhesion Assay 
The ability for C. jejuni strains to invade and adhere to eukaryotic cell lines in vitro was 
determined based on the previously described method of Elsinghorst (Elsinghorst, 1994) and 
modified by Jason Chang, RMIT University (Chang, 2002).   Briefly, cells were cultured to a 
pre-confluent monolayer, harvested and the viability was determined via trypan blue staining.   
Only cultures of > 95% viability were used for invasion or adhesion studies.   Eukaryotic cells 
were seeded at 3 x 105 cells/well in 1 mL of fresh media in a 24 well plate and incubated 10-
16 h.   The cells in each well were washed with PBS 3 x to remove residual media, 
particularly if antibiotics had been present.   The assay was simultaneously performed in 
triplicate and was repeated twice.   To each well of washed eukaryotic cells, 100 µL of ~ 109 
bacterial culture and 400 µL of DMEM was added.   The inoculated 24 well plate was then 
incubated at 37°C in 5% CO2 for either 1 h or 3 h to allow the bacteria to adhere to or invade 
the host cells respectively.   A serial dilution of the bacterial inoculum was performed to 
accurately enumerate the bacteria to facilitate the calculation of % adhesion and invasion.    
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To investigate adhesion, after 1 h the non-adherent bacteria was washed away from the 
designated adhesion assay wells by washing twice with PBS.   Intracellular bacteria were 
released by adding 200 µL of the detergent triton-X-114 at a concentration of 0.25%.   The 
plates were then incubated at 37°C for a further 15 min to lyse the eukaryotic cells.   Eight 
hundred microlitres of PBS was added to each well and then 100 µL of this lysate was taken 
and passed through a serial 10-fold dilution before 100 µL samples were taken and plated out 
onto HBA-Sk plates supplemented with kanamycin where appropriate for enumeration of 
viable adherent bacteria via the following calculation: 
 
No. invasive and adherent bacteria – No. of invasive bacteria 
                                Original inoculum 
 
To enumerate the number of invaded bacteria each designated invasion assay well was 
washed twice with PBS to remove any bacteria that had not adhered to or invaded the host 
cells.   The extracellular bacteria were killed by the addition of 400 µg/mL gentamicin in 
DMEM during an incubation of 1 h at 37°C in 5% CO2.   Intracellular bacteria were released 
by adding 200 µL of 0.25% triton-X-114 detergent and incubating for 15 min at 37°C in 5% 
CO2.   The lysate was made up to a total volume of 1 mL with PBS and 100µL from each 
plate was serially diluted and 100 µL of the appropriate dilution was plated in triplicate on 
HBA-Sk supplemented with antibiotics where appropriate and incubated for 48 h at 42°C for 
enumeration of viable invasive bacteria.   Whenever invasion was expressed as a percentage, 
the value was derived from the equation:  
 
 
 
No. of invaded bacteria 
No. of adherent bacteria 
    x 100 = % Invasion 
x 100 = % Adherence 
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2.8 Electron Microscopy 
C. jejuni cells were resuscitated from -70°C stocks and grown at 42°C for 48 h under 
microaerobic conditions on horse blood agar plates.   A loop of resuscitated cells was used to 
inoculate 2 mL of brucella broth, containing kanamycin where appropriate, in a 6-well tissue 
culture plate.   The cells were incubated at 42°C under microaerobic conditions gently 
shaking overnight.   The cells were then pelleted by centrifugation and resuspended in PBS 
supplemented with 0.2 mg/mL BSA.  
 
A range of dilutions of bacterial suspension were incubated with copper grids coated with 
0.75% w/v formvar in chloroform at room temperature for 15 min.   The bacteria were fixed 
in place and stained with 2% phosphotungstic acid pH 7, at room temperature for 30 s.   The 
excess stain was removed with the torn edge of Whatmann filter paper.   The grids were 
allowed to dry at least overnight before being viewed under a JEOL EM100SX-1 
transmission electron microscope.    
 
2.9 MALDI-TOF Analysis 
A potentially differentially expressed protein band was excised from a Coomassie blue 
stained SDS-PAGE gel from each trial (temperature, blood, bile and host cell) under sterile 
conditions and analysed at the Australian Proteome Analysis Facility Ltd (APAF), Macquarie 
University, Sydney.   Each excised protein of interest was cleaved with trypsin (cleaves at R-
X and K-X except when X is a proline residue) at 37°C for 16 h and the resulting profile, or 
peptide mass fingerprint (PMF), was analysed by matrix-assisted laser desoption/ionisation 
(MALDI) time of flight (TOF) mass spectrometry.   The data generated was subjected to a 
search using the program “Mascot” at www.matrixscience.com with a view to identify or find 
the most similar known protein to the protein of interest.   The search parameters used were as 
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follows; database MSDB; Taxonomy, Campylobacter; enzyme, trypsin; variable 
modifications, oxidation (M) and propionamide (C); mass values, monoisotopic; protein 
mass, unrestricted; peptide mass tolerance, ± 50 ppm; fragment mass tolerance ± 0.8 Da; 
maximum missed cleavages, 1 and instrument type, MALDI-TOF-TOF. 
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Table 2.1:   Bacterial strains used in this study 
Bacterial 
strain 
Description Source 
Penner 
Serotype 
Reference 
C. jejuni     
81116 Enteritis isolate Human HS:6 (Palmer et al., 1983) 
NCTC11168 Enteritis isolate, genome strain Human HS:2 (Parkhill et al., 2000) 
HB-9313 GBS-associated enteritis 
isolate 
Human HS:19 (Nachamkin et al., 2002) 
990922 Recent chicken isolate Chicken 
Farm, 
Victoria 
HS:31* RMIT University Culture 
Collection. Collected by 
Thamara Peduru-Hewa. 
MP0401 Recent human clinical isolate Melbourne 
Pathology 
HS:33 or 
HS:44* 
This Study, 2004 
* Typed by RFLP as previously described (Shi et al., 2002) 
E. coli Genotype Reference 
DH5α ∆lacU169 (Φ80 lacZ∆M15) hsdR17 recA1 endA1 gyrA96 
thi-1 relA1 
(Hanahan, 1983) 
Top 10 F’ F’[lacIqTn10(TetR)]mcrA∆(mrr-hsdRMS-mcrBCΦ80lacZ 
∆ M15 ∆lacX74 recA1araD139 ∆(ara-leu) 7697 galK 
rpsL (StrR) endA1 nupG 
Invitrogen TA Cloning 
Manual, Invitrogen. 
XL10-Gold TetR ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr) 173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac The [F’ proAB 
lacIqZ∆M15 Tn10 (TetR) Tn5 (KanR) Amy] 
PCR-Script Amp 
Cloning Kit Instruction 
Manual, Stratagene. 
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Table 2.2:   Primers used in this study 
Primer Sequence (5’→ 3’) Application Reference 
grpE F1 gtgcaaaacgctgaatttgaa C. jejuni 11168, RT PCR This Study 
grpE R1 tttgaagcacttgaaccact C. jejuni 11168, RT PCR This Study 
Cj0715 F1 atactagcaagcgtgccaat C. jejuni 11168, RT PCR This Study 
Cj0715 R1 accaaaaggagaaagggtta C. jejuni 11168, RT PCR This Study 
fur F1 aagacaaggcggacttaaat C. jejuni 11168, RT PCR This Study 
fur R1 caatcaccacaaacaccata C. jejuni 11168, RT PCR This Study 
p19 F1 agctgcggttattagtacaa C. jejuni 11168, RT PCR This Study 
p19 R1 cccacacctgtttcttcatc C. jejuni 11168, RT PCR This Study 
Cj0998c F1 gttagcttcggctttaagtg C. jejuni 11168, RT PCR This Study 
Cj0998c R1 gcaacatcgcttaatgcttt C. jejuni 11168, RT PCR This Study 
peb1A F1 tgctaatgcagcagaaggta C. jejuni 11168, RT PCR This Study 
peb1B R1 ttgcacctttcatatcagcta C. jejuni 11168, RT PCR This Study 
flaA F1 gggatggcgatagcagatag C. jejuni 11168, RT PCR This Study 
flaA R1 gtttcaaagcgtgttaaacc C. jejuni 11168, RT PCR This Study 
cadF F1 tttagcaggtggaggatatg C. jejuni 11168, RT PCR This Study 
cadF R1 aacaaagcaccttctcttgg C. jejuni 11168, RT PCR This Study 
porA F1 tgctgctgatggtggttatg C. jejuni 11168, RT PCR This Study 
porA R1 gcagcaccgtaaagatttcc C. jejuni 11168, RT PCR This Study 
rpoA F1 gagatcggctatggaatcac C. jejuni 11168, RT PCR This Study 
rpoA R1 ttcagcatcttcgttgattg C. jejuni 11168, RT PCR This Study 
Ea1 ttttatccagc RAP DD RT PCR (Fislage et al., 1997) 
Ea2 actttacgcag RAP DD RT PCR (Fislage et al., 1997) 
Ea3 tttatccagcg RAP DD RT PCR (Fislage et al., 1997) 
Ea6 ttttttcagca RAP DD RT PCR (Fislage et al., 1997) 
Ea8 atcatccagca RAP DD RT PCR (Fislage et al., 1997) 
Es3 gaagtgctgg RAP DD RT PCR (Fislage et al., 1997) 
Es7 atgcgctggc RAP DD RT PCR (Fislage et al., 1997) 
Es8 tgccgatgaa RAP DD RT PCR (Fislage et al., 1997) 
Es13 atggcgatga RAP DD RT PCR (Fislage et al., 1997) 
orf12.1f cctaggatccctctttgtatagccggaagta C. jejuni 81116 Cloning wlaTA, 
wlaTB 
(Lodge, 2000) 
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cipA gaatgtcgacatataaaagagcatagacc C. jejuni 81116 Cloning wlaRE 
and detection of  +ve wlaRF 
transformants 
B. Fry (unpublished) 
orf2.1 atggggatccatatagtttccgaga Detection of +ve wlaRF 
transformants 
T. Ying (unpublished) 
rmlB5 taaaggatccttgcgtggctatagaaagt C. jejuni 81116 Cloning wlaRE B. Fry (unpublished) 
galE1 gcggtggtgcaggttatatagg C. jejuni Typing  (Fry et al., 2000) 
wlaH3 tcagttcttgccattaaatttctc C. jejuni Typing (Shi et al., 2002) 
waaF2 atgcgtcgactttcgatcataatcccgcttt C. jejuni 81116 Cloning wlaTA 
and wlaTB 
(Lodge, 2000) 
inv13f caccagatctcaccaagacttaagttctacc Inverse wlaTA PCR (Lodge, 2000) 
inv13r gatgagatctttggagcccaaacttatgtgc Inverse wlaTA PCR (Lodge, 2000) 
orf15.1f tggtgtgctagaaattatcg Detection of +ve waaV 
transformants  
This Study 
orf17.1r ccctaaaaagtgctgtggaa Detection of +ve waaV 
transformants  
This Study 
inv9F gtgtagatctttgggatacttgga Inverse wlaRE PCR This Study 
inv9R tgtaagatctgttgatccatcatc Inverse wlaRE PCR This Study 
orf8.3f cacaacaactcgagaagatctagaa C. jejuni 81116 Cloning wlaRE This Study 
orf13.1f atcatacaagctgttgatgg Detection of +ve wlaTA 
transformants  
This Study 
orf13.1r gcaaggtgcattatcaatac Detection of +ve wlaTA 
transformants  
This Study 
wlaSB.1f ctcttcgcttccatcattgc Confirmation of wlaTA lethal 
mutation 
This Study 
KanaR2 ggagacattccttccgtatc Confirmation of wlaTA lethal 
mutation 
This Study 
pCRScript F tgccgatttcggcctattgg DNA sequence analysis This Study 
M13  ggaaacagctatgaccatg DNA sequence analysis Stratagene 
M13 (-20) gtaaaacgacggccagt DNA sequence analysis Stratagene 
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CHAPTER 3: Mutagenesis of putative LOS 
biosynthesis genes from C. jejuni 81116 
 
3.1 Introduction 
C. jejuni LOS is a known virulence determinant and is implicated in enabling the bacteria to 
adhere to host cells, avoid the host immune response and cause serious complications like the 
Guillain-Barré syndrome (McSweegan & Walker, 1986; van Vliet & Ketley, 2001; Yuki et 
al., 2004).   Some confusion has surrounded the genetics behind C. jejuni PS biosynthesis due 
to the presence of different PS moieties (i.e. LPS, LOS, CPS and glycosylated surface 
proteins) as well as some PS biosynthesis enzymes having a dual function (Karlyshev et al., 
2005b; Szymanski et al., 1999).   As a result, the nomenclature used for PS biosynthesis genes 
is somewhat disorganised. Initially, C. jejuni was reported as containing two LOS 
biosynthesis gene clusters, wlaI and wlaII, though at the time they were thought to be LPS 
biosynthesis gene clusters.   The DNA sequence analysis of wlaII from C. jejuni 81116 was 
performed and published by Oldfield and others in 2002 (Accession number AF343914).    
 
As greater understanding about the nature of C. jejuni surface PSs was obtained, the 
associated nomenclature also developed to incorporate the increasing information available 
about the function of the PS biosynthesis genes.   The first wla cluster, wlaI, we now know 
mostly consists of genes which encode proteins involved in N-linked protein glycosylation 
and as a result this cluster is also referred to as the pgl cluster, (Szymanski et al., 1999).   
Similarly, the wlaII cluster is also referred to as the LOS cluster (Karlyshev et al., 2005b).   
The pgl and LOS clusters are separated by galE (Cj1131 in C. jejuni NCTC11168), also 
called gne (Karlyshev et al., 2005b).   The enzyme encoded by galE is a UDP-galactose 4-
epimerase, which catalyzes the interconversion of UDP-galactose and UDP-glucose (Fry et 
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al., 2000) and is important in the biosynthesis of LOS, CPS and N-linked glycosylated 
proteins (Fry et al., 2000; Karlyshev et al., 2005b).   For the purpose of this study the wla 
nomenclature (Reeves et al., 1996) will be used for individual genes located within the LOS 
biosynthesis gene cluster, except where the function of a specific gene has been determined 
and the name has been changed to reflect that function. 
 
The DNA sequence of the C. jejuni 81116 (also known as NCTC11828) LOS cluster was 
found to be ~ 19 kb and consists of 19 potential open reading frames (ORFs) which are 
thought to be involved in LOS core biosynthesis (Figure 3.1; Oldfield et al., 2002).   The 
contents of this cluster vary between strains, which is not surprising given that the LOS 
structure also varies between strains.   This variation accounts for why some strains of C. 
jejuni can induce autoimmune complications and others can not, as evidenced by the over 
representation of Penner serotypes HS:19 and HS:41 among GBS-associated isolates in South 
Africa and Japan (Prendergast & Moran, 2000).   The key difference is the presence or 
absence of sialic acid residues.  This is key because human gangliosides are decorated with 
sialic acid residues.    Not all strains of C. jejuni produce LOS containing sialic acid residues.   
Only those strains that do are associated with GBS.   Moreover, variation of LOS has been 
observed between strains of the same Penner serotype (Nakari et al., 2005).     
 
Prior to the completion of the C. jejuni NCTC11168 genome project little was known about 
the genetics behind the construction of surface PSs.   The function of several LOS 
biosynthesis genes from particular strains have been experimentally determined, they include 
neuA/cgtA, neuB and neuC (Linton et al., 2000b), waaF (Oldfield et al., 2002), wlaN (Linton 
et al., 2000a) and cgtB (Linton et al., 2000a).   The neuA/cgtA, neuB and neuC genes encode 
proteins required for sialic acid (N-acetyl neuraminic acid) biosynthesis and attachment to the 
LOS outer core (Karlyshev et al., 2005b).   WaaC and waaF were confirmed as being 
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heptosyltransferases responsible for the attachment of the first and second heptoses 
respectively, to the Kdo molecule of the inner LOS core (Oldfield et al., 2002).   WlaN 
displays β-1,3 galactosyltransferase activity and is responsible for attaching the terminal LOS 
β-1,3 Gal residue in strain NCTC11168 (Gilbert et al., 2000; Karlyshev et al., 2005b).    
 
Investigation of the function of individual genes can be achieved by insertional inactivation or 
“knock-out” mutagenesis to prevent the transcription of the gene of interest.   A phenotypic 
comparison of the mutant and the parent strain from which the mutant was derived can 
provide information as to the function of the inactivated gene.   The aim of the work 
undertaken for this chapter was to create knock-out mutants of wlaRE and wlaTA (9th and 13th 
ORFs in the LOS cluster respectively) in C. jejuni 81116 with a view to investigate their 
possible role in LOS biosynthesis and their potential contribution to pathogenesis. 
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Figure 3.1: Genetic map of the LOS gene cluster from C. jejuni 81116 (Oldfield et al., 2002). 
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3.2 Methods and Results 
The proteins encoded by wlaRE (369aa, 44.04 kDa, pI 9.87) and wlaTA (257 aa, 30.5 kDa, pI 
9.33) were analysed using the WebAngis Biomanager Blastp search to identify other proteins 
with which they share sequence similarity with a view to investigate the putative function of 
each gene (Appendices VIII and IX).   Significant Blastp matches to wlaRE and wlaTA are 
summarised in Table 3.1.   The proteins most similar to wlaRE were glycosyltransferases 
involved in CPS biosynthesis and the proteins most similar to wlaTA were also 
glycosyltransferases.   However, they were involved in LOS/LPS biosynthesis. 
 
3.2.2 Cloning and mutagenesis of wlaTA from C. jejuni 81116 
As a part of an investigation undertaken previously in our laboratory, a fragment of the C. 
jejuni 81116 LOS cluster containing wlaTA had been cloned into the phagemid pBluescript® 
II SK - (Appendix I; 2.961 kb), to create the construct pKL1314 (5.088 kb; Appendix IV; 
Lodge, 2000).   To facilitate downstream cloning, the two naturally occurring BglII restriction 
sites located within wlaTB from pKL1314 were removed by digesting the plasmid with BglII 
and HincII (Ying, 2001).   The resulting incompatible overhangs generated were filled in with 
Klenow Enzyme (Roche Diagnostics) as per the manufacturer’s instructions, and the two 
blunt ends were self-ligated (Ying, 2001).   This modification of pKL1314 created the 
construct of pTY9 (4.207 kb; Appendix V; Ying, 2001).    
 
Inverse PCR was used to amplify a region of pTY9 with primers inv13F and inv13R which 
resulted in a deletion of 418 bp within wlaTA (Figure 3.2).   The PCR conditions used to 
generate the inverse PCR amplicon of 3.789 kb in length, were as follows, 93°C x 2 min, 10 x 
(93°C x 10 s, 60°C x 1 min, 68°C x 5 min), 20 x (93°C x 10 s, 60°C x 1 min, 68°C x 5 min [+ 
20 s per cycle, accumulating]), 68°C x 7 min.   The restriction enzyme DpnI, which 
specifically digests methylated DNA, was used to selectively digest residual pTY9 template 
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DNA from the inverse PCR product.   The inverse PCR product was self ligated to generate 
the construct pKL13 and transformed into E.coli DH5α.   The construct pKL13 was extracted 
from an overnight culture and digested with BglII (data not shown).   Both primers, inv13F 
and inv13R were designed to incorporate BglII sites to facilitate the insertion of a selective 
marker, a Kanamycin resistance gene (KanR), to inactivate wlaTA. KanR was excised from 
pMW2 with BamHI (Appendix VI; Wösten, 1997), as the sticky ends generated are 
compatible to those created by BglII.   Ligation of the inverse PCR product and the fragment 
containing the KanR generated the plasmid pKLko13 (5.263 kb; Figure 3.3).   The plasmid 
was confirmed with RFLP ethidium bromide agarose gel electrophoresis (Figure 3.4) and 
DNA sequence analysis (data not shown).   This plasmid (clone #2) was transformed into the 
parent strain, C. jejuni 81116 in an attempt to inactivate wlaTA on the chromosome and 
generate a WlaTA- knock-out mutant.   Despite multiple repeats and optimisation of the 
transformation methodology, including increasing the amount of DNA transformed, 
increasing the number of C. jejuni 81116 parent cells and scaling up from an agar slant in a 
1.5 mL tube to an agar plate, no wlaTA mutants were detected. 
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Table 3.1:   Summary of Blastp results for WebANGIS Biomanager searches targeting the C. jejuni 81116 proteins WlaRE and WlaTA 
Protein Organism  Description E values 
WlaRE Streptococcus agalactiae CPS biosynthesis proteins 1e-23, 1e-20, 4e-20, 
2e-18, 9e-18, 3e-17 
 Streptococcus suis CPS biosynthesis proteins 3e-21, 7e-20, 1e-18 
 Streptococcus pneumoniae glycosyltransferases of the group 2 family 1e-19 
 Geobacter sulfurreducens glycosyltransferases of the group 2 family 2e-19 
 Bacillus cereus glycosyltransferases of the group 2 family 1e-17 
 Photorhabdus luminescens hypothetical glycosyltransferases 2e-22, 4e-20 
 Bacteroides thetaiotaomicron hypothetical glycosyltransferases 9e-20 
 Leptospira interrogans hypothetical glycosyltransferases 3e-18 
WlaTA Brucella suis  glycosyltransferases of the group 25 family 5e-12 
 Humans glycosyltransferases of the group 25 family 7e-12 
 Mice glycosyltransferases of the group 25 family 1e-11 
 Photorhabdus luminescens  putative LOS and LPS biosynthesis genes 8e-17 
 Erwinia carotovora putative LOS and LPS biosynthesis genes 8e-17 
 Brucella melitens putative LOS and LPS biosynthesis genes 6e-13 
 Haemophilus ducreyi putative LOS and LPS biosynthesis genes 2e-12 
 127 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2:   A) Inverse PCR product of construct pTY9 containing wlaTA with a 418 bp 
deletion.   Lane 1, λ DNA marker digested with PstI; Lane 2, inverse PCR product derived 
from pTY9 diluted 1/1000.   B) A schematic diagram depicting the genetic map of the area 
amplified constructed using SECentral Clone Manager version 6.   Red arrows indicate the 
position of genes and the blue boxes indicate the location of the inverse PCR primers. 
1        2         
2.8 kb 
11.5 kb 
5.1, 4.7, 4.5 kb 
3.8 kb 
InvPCR13 (3789 bps)
1000 2000 3000
BglII
XhoI
KpnI DdeI DdeI DdeI DdeI
XbaI
BamHI
HindIII
DdeI
BglII
'wlaTA
inv13F
wlaTB'
'''LacZ Amp LacZ' wlaTA''
inv13R
A 
B 
 128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3:   Ligation product of pKL13 digested with BglII together with KanR digested with 
BamHI to generate the clone pKLko13.   A) Lane 1, λ DNA marker digested with PstI; Lanes 
2-5, potential positive transformants of pKLko13 linearised with ClaI, designated clones #1-
#4 respectively.   B) Schematic diagrams representing the genetic maps of plasmid pKLko13 
containing the insert in both possible orientations constructed using SECentral Clone 
Manager version 6. Red arrows indicate the position of genes and the blue boxes indicate the 
location of the primers orf9.2 and orf9.3. 
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Figure 3.4:   RFLP analysis of the clone pKLko13 by ethidium bromide agarose gel 
electrophoresis to determine the orientation of KanR in relation to wlaTA.   Lane 1, λ DNA 
marker digested with PstI; Lanes 2-4, pKLko13 digested with HindIII clones #2, #3 and #4 
respectively.   Clones #2 and #3 contained KanR in the same orientation as wlaTA, clone #4 
contained KanR in the opposite orientation.  
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3.2.3 Detection of a lethal mutation in wlaTA 
Due to the absence of a wlaTA mutant, the possibility of wlaTA being essential for growth 
was investigated by PCR following previously described methodology (Burns et al., 2000).   
Primers wlaSBF1 and KanaR2 were designed to amplify a successful cross over event that 
incorporated KanR into the chromosome within wlaTA.   Primer wlaSBF1 was positioned 
within the gene upstream of wlaTA though in an area that was not incorporated into any of the 
cloning constructs used in the wlaTA mutagenesis studies.   The other primer, KanaR2, was 
situated within the KanR DNA sequence.   A product could therefore only result from a 
successful recombination of the flanking regions within pKLko13 that led to the insertion of 
the KanR into wlaTA on the chromosome (Figure 3.5).   Template DNA was derived from 
cells harvested post transformation incubation where pKLko13 was incubated with the C. 
jejuni 81116 parent strain.   The Taq polymerase PCR was performed under the following 
conditions, 94°C x 5 min, 35 x (94°C x 30 s, 57°C x 1 min, 72°C x 3 min), 72°C x 7 min.  
The disruption to wlaTA on the chromosome of C. jejuni 81116 was confirmed by DNA 
sequence analysis (Figure 3.6). 
 
3.2.4 Cloning of wlaRE from C. jejuni 81116 
Genomic DNA was isolated from C. jejuni 81116 (Figure 3.7a) and used as a template to 
amplify a fragment containing the gene of interest, wlaRE, by PCR (Figure 3.7b). The PCR 
was performed using the Expand Long Template PCR system under the following conditions; 
93°C x 2 min, 10 x (93°C x 10 s, 55°C x 1 min, 68°C x 4 min), 20 x (93°C x 10 s, 55°C x 1 
min, 68°C x 4 min [+ 20 s per cycle, accumulating]), 68°C x 7 min.   The amplicon containing 
wlaRE was digested with XhoI/SalI  to generate a smaller fragment to insert into the cloning 
vector, pBluescript (Figure 3.8).   PBluescript, was also digested with XhoI/SalI to generate 
compatible sticky ends facilitating its ligation to the wlaRE digested amplicon.   The C. jejuni 
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Figure 3.5:   PCR to confirm lethal mutation of wlaTA.   A) Lane 1, λ DNA marker digested 
with PstI; Lane 2, pKLko13a vector as a negative control; Lane 3, C. jejuni 81116 parent 
strain as a negative control; Lane 4, Chromosomal DNA from a previously constructed C. 
jejuni 81116 mutant of wlaTB as a positive control (Lodge, 2000); Lane 5, Chromosomal 
DNA from post transformation culture of C. jejuni 81116 that was transformed with 
pKLko13a.   B) Schematic diagram depicting the genetic map surrounding the area amplified 
constructed using SECentral Clone Manager version 6.   The genes shown in orange indicate 
the region present within pKLko13.   The blue boxes designate primers. 
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Figure 3.6:   Sequence analysis to confirm the integration of KanR within wlaTA on the 
chromosome of C. jejuni 81116.   The blue block represents an alignment of 100% similarity 
analysed using Align Plus 4, version 4.10 software (Sci Ed Central version 6).   A)   DNA 
sequence alignment of the genome sequence generated in silico representing the expected 
integration of KanR into wlaTA (Sequence 1) and the sequence of the region excised from 
pMW2 containing KanR (Sequence 2).   B)   DNA sequence alignment of Sequence 1 and the 
DNA sequence experimentally derived from the transformation of pKLko13 into C. jejuni 
81116 using primer wlaSBF1 (Sequence 3).   C)   DNA sequence alignment of Sequence 2 
and Sequence 3.   The red dotted box highlights the region of the KanR insert which disrupted 
the sequence of wlaTA.   See Appendix VII for data represented as an alignment showing 
individual base pairs. 
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Figure 3.7:   A) Genomic DNA isolated from C. jejuni 81116. Lane 1, λ DNA marker 
digested with PstI; Lane 2, C. jejuni 81116 genomic DNA   B) PCR product amplified from 
C. jejuni 81116 genomic DNA with primers rmlB5 and cipA. Lane 1, λ DNA marker digested 
with PstI; Lane 2, Amplicon containing wlaRE.   C) Schematic diagram depicting the genetic 
map of the area amplified constructed using SECentral Clone Manager version 6. Red arrows 
indicate the position of genes and the blue boxes indicate the location of primers. 
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Figure 3.8:   Restriction enzyme digestion of the rmlB5/cipA amplicon containing wlaRE.   
Lane 1, λ DNA marker digested with PstI; Lane 2, rmlB5/cipA amplicon digested with XhoI 
and BamHI; Lane 3, rmlB5/cipA amplicon digested with XhoI and SalI, where the box 
indicates the DNA fragment containing wlaRE. 
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wlaRE amplicon was excised from an agarose gel and purified using Geneclean (Q-Biogene) 
according to the manufacturer’s instructions and ligated to pBluescript.   The ligation product 
was transformed into either chemically competent or electrocompetent E. coli DH5α.   
Potential positive transformants were detected by blue/white screening in the form of white 
colonies on selective agar and single colonies were subcultured to LB broth.   RFLP ethidium 
bromide agarose gel electrophoresis analysis was performed on plasmids isolated from 
overnight cultures of potential transformants (data not shown).   No positive clone was 
identified by RFLP.   Several plasmid samples were unable to be digested and therefore the 
insert was analysed by PCR instead,  using the However, no positive clone was detected.   
Repeated attempts and optimisation failed to yield a positive clone.   Therefore, the strategy of 
cloning directly into pBluescript was discontinued. 
 
The second cloning strategy involved the use of the pCR2.1 TA cloning kit (Invitrogen; 
Appendix II), according to the manufacturer’s instructions.   All attempts to clone the 5.766 
kb amplicon containing genes wlaRA to wlaRF into pCR2.1 were unsuccessful, data not 
shown.   The strategy was modified to reduce the size of the insert by designing a new 
forward primer primer (orf8.3) to be used together with the original primer (cipA) to amplify 
wlaRE on a smaller amplicon.   The PCR conditions used were; 5 min at 94°C, 35 x (30 s at 
94°C, 1 min at 55°C, 3.5 min at 72°C), 7 min at 72°C.   The resulting amplicon (Figure 3.9), 
was ligated with the TA cloning vector pCR2.1 to generate the cloning construct pCR2.19 
(Figure 3.10) and transformed into E. coli Top10 F’ (Invitrogen).   Positive clones were 
confirmed by RFLP (Figure 3.11) and DNA sequence analysis, data not shown. 
 
Due to the presence of a Kanamycin resistance marker within the pCR2.1 cloning vector, it 
was necessary to subclone the inserts before proceeding with the insertional inactivation step. 
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Figure 3.9:   A) Lane 1, Amplicon generated with primers orf8.3/cipA containing wlaRE 
using Taq polymerase ; Lane 2, λ DNA marker digested with PstI.   B) Genetic map 
representing the orf8.3/cipA amplicon using SECentral Clone Manager version 6. Red arrows 
indicate the position of genes and the blue boxes indicate the location of primers. 
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Figure 3.10:   A) pCR2.19b: an amplicon containing wlaRE amplified with primers orf8.3 
and cipA (designated by the blue boxes) from C. jejuni 81116 genomic DNA was cloned into 
the pCR2.1 TA cloning vector (Invitrogen) and transformed into E. coli DH5α.   Plasmids 
were isolated from an overnight culture of transformed E. coli cells and screened for potential 
positive transformants.   Lane 1, λ DNA marker digested with PstI; Lanes 2 - 5, Undigested 
pCR2.1 empty vector 3.9 kb, (negative transformants); Lane 6, Undigested pCR2.19b (6.576 
kb), pCR2.1 ligated together with the PCR product containing wlaRE, (positive transformant).   
B) a schematic diagram representing the genetic map of the plasmid using SECentral Clone 
Manager version 6.   Red arrows indicate the position of genes and the blue boxes indicate the 
location of primers.  
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Figure 3.11:   RFLP analysis of the pCR2.19b clone by ethidium bromide agarose gel 
electrophoresis.   PCR2.19b digested with different restriction enzymes.   Lane 1, λ DNA 
marker digested with PstI; Lane 2, BglII; Lane 3, EcoRV ; Lane 4, XbaI; Lane 5, XhoI. 
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Subcloning the confirmed insert containing wlaRE into pBluescript was attempted multiple 
times, though was unsuccessful (data not shown).    
 
The pCR2.1 subcloning strategy was abandoned in favour of another cloning vector, PCR-
Script AmpR SK+ (Stratagene; Appendix III).   Primers orf8.3 and cipA were used to 
amplify wlaRE with Expand Long Template PCR and polished with Pfu to generate blunt 
ends according to the manufacturer’s instructions.   The wlaRE gene was amplified under the 
following conditions, 93°C x 2 min, 10 x (93°C x 10 s, 58°C x 1 min, 68°C x 2 min), 20 x 
(93°C x 10 s, 58°C x 1 min, 68°C x 2 min [+ 20 s per cycle, accumulating]), 68°C x 7 min 
(Figure 3.12).   The PCR product was ligated into PCR-Script, transformed into E. coli 
XL10-Gold and the resulting cloning construct which incorporated wlaRE was named PCR-
Script9 (5.6 kb; Figure 3.13).   Plasmid PCR-Script9 was isolated from an overnight culture 
and analysed by RFLP ethidium bromide agarose gel electrophoresis (Figure 3.14). 
 
The BglII site present in orf8.3 was removed from the PCR-Script9 DNA sequence by 
digesting the plasmid with both BglII and BamHI.   The modified PCR-Script9 was self-
ligated and transformed into E. coli DH5α (data not shown).   PCR-Script9 was used as the 
template for inverse PCR to introduce a BglII site into wlaRE to facilitate the insertion of a 
KanR using primers, inv9F and inv9R which both contain BglII sites.   The Expand Long 
Template PCR system was used under the following cycling conditions: 93°C x 2 min, 10 x 
(93°C x 10 s, 50°C x 1 min, 68°C x 8 min), 20 x (93°C x 10 s, 50°C x 1 min, 68°C x 8 min 
[+20 s per cycle, accumulating]), 68°C x 7 min (Figure 3.15).   The PCR product was digested 
with DpnI, to degrade any template carried over, and BglII.   The digested inverse PCR 
product generated from the PCRScript9 template was self-ligated and transformed into E. coli 
DH5α to create the plasmid pInv9 (Figure 3.16a).   The pInv9 plasmid was analysed by RFLP 
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Figure 3.12:   A PCR product containing wlaRE, which was cloned into the PCR-Script 
cloning vector.   Lane 1, λ DNA marker digested with PstI; Lane 2, Amplicon containing 
wlaRE amplified with primers orf8.3/cipA using the Expand Long Template system. 
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Figure 3.13:   PCR-Script clone containing the wlaRE amplicon insert.   A) Potential positive 
transformants of PCR-Script9 (5.608 kb) plasmid, uncut and analysed by ethidium bromide 
agarose gel electrophoresis. Lanes 1, 20, λ DNA marker digested with PstI; Lanes 2-7, 9, 11-
16, 18 undigested PCRScript empty vector (2.961 kb), (negative transformants); Lanes 8, 10, 
17, 19 potential PCRScript9 clones indicated by white boxes (positive transformants) 
representing clones #1, 2, 3 and 4 respectively.   B) Schematic diagram representing the 
genetic map of PCR-Script9 in one of the two possible orientations. Red arrows indicate the 
position of genes and the blue boxes indicate the location of primers cipA and orf8.3. 
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Figure 3.14:   RFLP confirmation of PCR-Script9a by ethidium bromide agarose gel 
electrophoresis.   PCR-Script9a digested with different restriction enzymes, clones #1, 2, 3 
and 4 respectively.   Lanes 1-4, DdeI; Lanes 5-6 and 11, λ DNA marker digested with PstI; 
Lanes 7-10, XbaI; Lanes 12-15, EcoRV; Lanes 16-19, BglI. 
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Figure 3.15:   DNA sequence analysis to confirm clone PCR-Script9a using primers M13 and 
M13(-20).   The blue blocks represent a region of 99% identity, analysed using Align Plus 4, 
version 4.10 software (Sci Ed Central version 6). 
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Figure 3.16:   A) Inverse PCR product from PCR-Script9a template using primers inv9F and 
inv9R containing wlaRE.   Lane 1, λ DNA marker digested with PstI; Lane 2, Inverse PCR 
product, Inv9PCR.   B)   RFLP ethidium bromide agarose gel electrophoresis analysis of the 
wlaRE inverse PCR product.   Each lane shows Inv9PCR digested with a different restriction 
enzyme.   Lane1, λ DNA marker digested with PstI; Lane 2, BglII; Lane 3, DpnI; Lane 4, 
SalI; Lane 5, HindIII; Lane 6, PCRScript9a template digested with BglII and DpnI.   The 
white boxes highlight the fragment generated when digested with BglII.  
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 ethidium bromide agarose gel electrophoresis (Figure 3.16b).   Mutagenesis of wlaRE was 
abandoned due to unexpected discrepancies with restriction enzyme digest patterns generated 
by pInv9 when digested with BglII and BamHI (Figure 3.16b).   Digestion profile 
discrepancies were also evident with the original vector, PCR-Script Amp SK+, without an 
insert (Figure 3.17).    
 
Different strategies to remove the BglII site from the PCR-Script9 inverse PCR template were 
applied.   Those strategies included digestion of PCR-Script9 with BglII, followed by Klenow 
Enzyme (Roche Diagnostics) fill in of the subsequent overhang and blunt end self-ligation 
prior to being used as the template for inverse PCR.   Alternatively, the inverse PCR product 
was not digested with BglII, instead it was polished with Pfu to generate blunt ends and 
ligated to the KanR fragment after the BamHI overhangs had been filled in with Klenow 
Enzyme (Roche Diagnostics).   Despite repeated attempts, optimisation and the application of 
multiple strategies to remove the BglII site, no positive cloning constructs were generated. 
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Figure 3.17:   RFLP analysis of vector PCR-Script Amp SK+.   Lanes 1 and 8, λ DNA 
marker digested with PstI; Lanes 2-4, PCRScript isolate #1 digested with BamHI, BglII and 
BamHI/BglII respectively; Lanes 5-7, PCRScript isolate #2 digested with BamHI, BglII and 
BamHI/BglII respectively; Lanes 9-13, PCRScript isolate #1 (digestion repeated with new 
restriction enzymes), digested with BamHI, BglII, BamHI/BglII, undigested, HindIII 
respectively.   The white box is highlighting the double digestion (BamHI/BglII) product. 
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3.3 Discussion 
Both wlaRE and wlaTA are putative glycosyltransferases located within the LOS gene cluster 
of C. jejuni 81116.   Glycosyltransferases are responsible for catalysing the synthesis of 
carbohydrates, or glycans, and glycoconjugates which appear as the most structurally diverse 
and abundant biopolymers in nature (Lowe & Marth, 2003).   Specifically, 
glycosyltransferases catalyse the transfer of mono- or oligosaccharide residues from activated 
donor molecules to specific acceptor molecules, forming glycosidic bonds (Campbell et al., 
1997).   Glycosyltransferases are found in both prokaryotes and eukaryotes and they function 
to transfer glycan residues to an acceptor molecule in order to initiate or elongate a 
carbohydrate chain (Kikuchi et al., 2003).   Glycans and glycoconjugates are important in 
both prokaryotic and eukaryotic systems as they play a major role in providing structural 
integrity to the cell wall, impart specificity to the molecule to which they are covalently 
linked, are the first line of defence against the host immune response, e.g., complement, act as 
antigenic determinants and have been associated with virulence (Varki et al., 1999). 
 
Recently, glycosyltransferases have been categorised into families, GT-1 to GT-60, based on 
sequence similarities observed by Blastp analysis (Kikuchi et al., 2003).   Blastp analysis was 
carried out on the amino acid sequence of both WlaRE and WlaTA and putative conserved 
domains (CDs) were detected in the sequence of each protein.   The CDs detected within each 
gene suggest that wlaRE is of the glycosyltransferase family 2 (GT-2) and wlaTA belongs to 
the glycosyltransferase family 25 (GT-25).   Enzymes of the GT-2 family (pfam 00535) are 
diverse and involved in transferring either UDP-glucose, UDP-N-acetyl galactosamine, GDP-
mannose or CDP-abequose to numerous substrates including cellulose, dolichol phosphate 
and teichoic acids (www.sanger.ac.uk).   The GT-25 family (pfam 01755) consist of enzymes 
involved in LPS/LOS biosynthesis by catalysing the transfer of sugars onto the growing 
LPS/LOS chain (www.sanger.ac.uk).   The translated wlaRE and wlaTA DNA sequences 
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displayed similarity to glycosyltransferases of both gram negative and gram positive bacteria 
(Appendices VIII and IX).   In addition, wlaTA was similar to glycosyltransferases of 
eukaryotes including humans and mice (Appendix IX). 
 
The cloning and transformation of suicide vector pKLko13 into C. jejuni 81116 (Figures 3.2-
3.4) gave rise to kanamycin resistant colonies.   However, a wlaTA mutant was not detected.   
The insertional inactivation of wlaTA was confirmed as lethal to the C. jejuni 81116 parent 
strain by PCR (Figures 3.5-3.6).   Why the putative glycosyltransferase product of wlaTA 
could potentially be essential for survival was beyond the scope of this investigation and 
requires further research.   Characterisation of the structure of WlaTA could potentially shed 
more light on its likely function, in turn providing more information about how it could 
contribute to the survival and perhaps pathogenesis of C. jejuni 81116.    
 
Based on the Blastp results, it is reasonable to speculate that wlaTA encodes a 
glycosyltransferase involved in the transfer of sugar residues to the growing LOS core region.   
However, a mutant expressing a truncated LOS molecule that consists of at least the lipid A 
and Kdo component of LOS is capable of survival and growth which has been experimentally 
confirmed in numerous strains of C. jejuni (Fry et al., 2000; Kanipes et al., 2006; Oldfield et 
al., 2002; Wood et al., 1999) and other bacteria, including S. typhimurium, E. coli, Neisseria 
meningitidis (Belunis et al., 1995; Tzeng et al., 2002) and Moraxella catarrhalis (Luke et al., 
2003).   This suggests then that perhaps the product of wlaTA is possibly a multiple function 
enzyme involved in the glycosylation of a molecule other than LOS.   Further, this other 
unknown molecule appears to be essential for, or is involved in a process which is essential 
for the growth and survival of C. jejuni 81116. 
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A GT-25 protein which exhibited similarity to WlaTA was LbgA, a 25.8 kDa protein from 
Haemophilus ducreyi, also referred to as LosA.   LbgA has been confirmed as a β-(1-4)-
galactosyltransferase (Tullius et al., 2002), though it recognises different acceptor molecules 
in different strains, e.g., a terminal DD-heptose or a terminal glucose (Post et al., 2007).   
However, no single strain tested was able to recognise both types of acceptor (Post et al., 
2007).   The specificity of WlaTA is not known and requires further investigation.   Defining 
the specificity of this putative glycosyltransferase may provide clues as to its other potential 
functions, e.g., protein glycosylation.    
 
A region containing wlaRE from C. jejuni 81116 was successfully amplified (Figure 3.7).   
However, all attempts to insert the digested amplicon (Figure 3.8) directly into the suicide 
cloning vector pBluescript were unsuccessful (data not shown).   Cloning directly into 
pBluescript was hampered by difficulties with the restriction enzyme digestion of the vector 
despite repeated attempts.   The plasmid was isolated via the alkaline lysis method and an 
extra purification step using either Geneclean or Qiagen DNA purification kits that was added 
to remove any residual phenol did not improve the digestibility of the plasmid.   The amplicon 
and other plasmids were digesting as expected.   Therefore, the problem was specific to the 
current stock of pBluescript.   Investigation and resolution of this problem with pBluescript 
was not the focus of this study and in the interest of time, cloning was continued with another 
vector, pCR2.1 (Invitrogen). 
 
A smaller amplicon containing wlaRE was successfully inserted into pCR2.1 (Figures 3.9 – 
3.11).   As pCR2.1 contains both an ampicillin and kanamycin antibiotic resistance selective 
marker as well as a BglII site, it was necessary to subclone the insert of interest into a vector 
which was kanamycin sensitive and lacking a BglII restriction site for the downstream 
insertional inactivation of wlaRE.   All attempts to subclone the DNA fragment containing 
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wlaRE into pBluescript were unsuccessful (data not shown).   Cloning strategies incorporating 
pBluescript were abandoned in favour of a different vector, PCR-Script Amp SK+ 
(Stratagene) as it lacked a kanamycin resistance marker, did not contain a BglII site and 
digested correctly with different restriction enzymes.    
 
A fragment containing wlaRE was amplified with the existing primers orf8.3 and cipA and 
successfully inserted into PCR-Script generating the cloning construct pCR-Script9 (Figures 
3.12 – 3.15).   Unfortunately, orf8.3 contained a BglII site and needed to be removed prior to 
using pCR-Script9 as a template for inverse PCR.   Inverse PCR facilitated the deletion of 
part of wlaRE in preparation for the insertion of the kanamycin resistance gene to disrupt its 
transcription.   PCR-Script9 was digested at BglII and BamHI sites to generate compatible 
sticky ends, self-ligated and transformed back into E. coli DH5α to remove the BglII site 
(data not shown).   An inverse PCR product was successfully generated (Figure 3.16).   
However, upon RFLP analysis it became apparent that there was a size discrepancy 
suggesting that the vector still contained an intact BglII site in addition to the one introduced 
by primers inv9F and inv9R.   The digestion of the inverse PCR product with BglII resulted in 
two bands of approximately 4.5 kb and 0.5 kb.   These sizes are consistent with the expected 
digestion profile of BglII if the BglII site introduced with primer orf8.3 had not been removed.    
 
Another attempt to remove the BglII site introduced by orf8.3 involved digesting the inverse 
PCR template, PCR-Script9, with BglII using Klenow enzyme to fill in the over hangs 
generated and the modified template was then self-ligated and transformed into E. coli DH5α.   
Inverse PCR using this modified PCR-Script9 as template was successful.   However, RFLP 
analysis generated unexpected digestion profiles which again suggested that the BglII site was 
still present (data not shown).   Facing the inability to successfully remove the BglII site, 
another strategy was employed to continue mutagenesis without removing it.   The inverse 
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PCR product was polished with Pfu polymerase to generate blunt ends and was ligated to the 
kanamycin resistance gene fragment excised from pMW2 with BamHI with the overhangs 
filled in with Klenow enzyme.   This blunt end ligation did not generate any positive clones 
(data not shown).    
 
The persistence of the BglII site and the difficulties experienced when trying to remove it 
were unexpected and to explain the cause of these difficulties requires further investigation.   
The problem could lie with the cloning vector itself as the RFLP analysis of the empty vector, 
PCR-Script, resulted in an unexpected digestion profile when digested with BglII and BamHI 
(Figure 3.17).   Preliminary DNA sequence analysis data of PCR-Script did not identify a 
BglII site (data not shown).   Future work to resolve this problem would include the 
redesigning of the orf8.3 primer to avoid incorporating a BglII site and repeating the cloning 
steps outlined above. 
 
The DNA sequence of wlaRE was translated into the protein sequence and analysis of the 
putative function of WlaRE was conducted in silico by Blastp performed using WebANGIS 
Biomanager.   As previously mentioned, the sequence of WlaRE showed significant similarity 
to the sequences of other glycosyltransferases, specifically those of the GT-2 family.   
Interestingly, WlaRE displayed sequence similarity to gram positive capsular polysaccharide 
biosynthesis proteins as well as gram negative LOS, LPS and O-antigen biosynthesis proteins. 
CPS biosynthesis proteins from Streptococcus species represented 40% of the top 50 
similarities resulting from the Blastp search.   WlaRE was most frequently compared to 
Streptococcus agalactiae CPS biosynthesis genes.   Moreover, other Streptococcal species 
which showed similarity to WlaRE included S. suis Cps1I, Cps2K,Cps1J, S. pneumoniae GT-
2, and S. thermophilus exopolysaccharide biosynthesis protein. 
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The two different types of polysaccharide antigens on the surface of S. agalactiae are the 
group antigen which consists of a number of rhamnose units and is common to all strains, and 
the type-specific CPSs that separate S. agalactiae into 9 different serotypes (1a, 1b, II-VIII; 
Wessels, 1997).   The cps biosynthesis genes are arranged in a cluster and the individual 
genes contained within the cluster vary slightly between serotypes (Kong et al., 2002).   The 
CPS biosynthesis proteins, specifically CpsI, CpsJ and CpsK, showed similarity to WlaRE.   
The sequences of CpsI, CpsJ and CpsK in S. agalactiae serotype 1a, showed similarity to the 
respective genes in S. pneumoniae serotype 14 where CpsI has been confirmed as a β-(1-3)-N-
acetylglucosaminyltransferase, CpsJ is a β-(1-4)-galactosyltransferase and the function of 
CpsK is unknown (Yamamoto et al., 1999).   Investigation of these proteins in S. agalactiae 
serotype 1a suggested that CpsI displayed N-acetylglucosaminyltransferase activity and CpsJ 
was a β-(1-4)-galactosyltransferase (Yamamoto et al., 1999).   Further investigation of CpsK 
in type III S. agalactiae has identified it as a sialyltransferase (Chaffin et al., 2005; Kolkman 
et al., 1997).    
 
Other proteins from gram negative bacteria that were significantly similar to WlaRE included 
the Clostridium perfringens spore coat polysaccharide biosynthesis protein (1e-20), two 
putative glycosyltransferases from Photorhabdus luminescens subsp. laumondii (2e-22, 4e-
20) and a glycosyltransferase involved in O-antigen biosynthesis in Shigella boydii.   In 
addition, 11 of the top 50 hits were hypothetical proteins and putative glycosyltransferases 
from Leptospira species (8e-19 – 3e-17). 
 
The majority of proteins from gram negative bacteria which were significantly similar to 
WlaRE were putative or hypothetical.   Therefore, the information available regarding their 
function was minimal.   The structure of the polysaccharide present on the surface of the C. 
perfringens spore coat is not well defined, nor are the proteins involved in its biosynthesis 
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(Shimizu et al., 2002).   The genome project of P. luminescens was published in 2003 and the 
existence of glycosyltransferases is hypothetical at this stage (Duchaud et al., 2003).   The J22 
protein from L. interrogans serovar copenhageni (de la Pena-Moctezuma et al., 1999) and 
H22 from L. borgpetersenii serovar hardjobovis (Kalambaheti et al., 1999) both displayed 
similarity to WlaRE.   An investigation of structure by hydrophobic cluster analysis revealed 
that H22 contains a domain A which is similar to other β-glycosyltransferases (Kalambaheti 
et al., 1999).   Further, a conserved aspartate residue present at the C-terminal of the predicted 
β-sheet structures was postulated as being involved in the enzyme’s active site (Kalambaheti 
et al., 1999; Saxena et al., 1995).   However, despite this information, the specificity of the 
glycosyltransferase is not yet known.  
 
Given the mix of similarities with both gram positive capsule related biosynthesis genes and 
gram negative LOS/LPS biosynthesis genes and that C. jejuni contains both CPS and LOS it 
is reasonable to postulate that wlaRE is possibly pleiotropic in nature.   Interestingly, a  
monosaccharide residue common to both CPS and LPS is GalNAc (Muldoon et al., 2002; St 
Michael et al., 2002).   Other genes from C. jejuni 81116 have been found to have mutliple 
functions, including galE which encodes a UDP-galactose 4-epimerase involved in LOS, CPS 
and N-linked protein glycosylation (Fry et al., 2000; Karlyshev et al., 2005b). 
 
Two putative glycosyltransferase genes were investigated, wlaRE and wlaTA.   All attempts to 
construct an insertionally inactivated mutant of wlaRE failed.   By contrast, the inactivation of 
wlaTA was confirmed as a lethal mutation by PCR.   Further experimental analysis is required 
to confirm and characterise the function of each gene product. 
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CHAPTER 4:   Characterisation of four genes from 
the LOS biosynthesis gene cluster of C. jejuni 81116  
 
4.1 Introduction 
Surface polysaccharides (PSs) are known virulence factors important to the pathogenesis of C. 
jejuni and many other human bacterial pathogens, including Legionella pneumophila, Group 
B Streptococcus spp, Haemophilus influenzae and Neisseria meningitidis (Chaffin et al., 
2005; Lewis et al., 2006; Tzeng et al., 2002).   Key factors of mucosal pathogens which 
possess lipooligosaccharides (LOS), e.g., N. meningitidis and H. influenzae, include antigenic 
mimicry, the presence of sialic acid residues and phase variation which has been associated 
with the presence of intragenic homopolymeric tracts (Linton et al., 2000a; Preston et al., 
1996).   Variation in the PS structures on the surface of mucosal pathogens has been shown to 
be important in virulence (Moxon & Kroll, 1990).   Variation can be achieved by the presence 
of different sugar moieties within the PS or glycoconjugates, varied linkages between sugars, 
the substrate to which the glycan chain is attached and possibly the length and sequence of the 
repeating units which make up the glycan chain (Gilbert et al., 2002).    
 
C. jejuni possess LOS, capsular polysaccharides (CPS) and glycosylated surface proteins 
(Karlyshev et al., 2005b).   The genes involved in the biosynthesis of each type of PS are 
mostly organised into clusters, wlaII (Oldfield et al., 2002), kps (Karlyshev et al., 2000) and 
pgl (Szymanski et al., 1999) clusters respectively (Linton et al., 2001).   This clustered 
genetic arrangement is also seen in the closely related Helicobacter pylori (Schoenhofen et 
al., 2006b).   The genes responsible for the biosynthesis of the LOS core oligosaccharide were 
identified as a single locus in all C. jejuni strains investigated, although the content of genes 
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varied between strains (Parker et al., 2005).   This observation was to be expected as the LOS 
core structures also vary between strains as discussed earlier in Section 1.7.1.    
 
C. jejuni strains 11168 and 81116 possess LOS gene clusters that vary greatly from each 
other, however, the LOS gene clusters of strains 81116 and ATCC 43431 are very similar 
(Figure 4.1; Oldfield et al., 2002; Parker et al., 2005; Parkhill et al., 2000).   Each of the three 
LOS biosynthesis gene cluster shown below contain the highly conserved waaC, waaV and 
waaF.   However, wlaN and the neuA, neuB and neuC genes are not present within the LOS 
gene cluster of C. jejuni 81116.   This is not surprising given that the neuABC operon is 
responsible for the production of sialic acid residues which are not present on the core region 
of C. jejuni 81116 LOS (Muldoon et al., 2002), unlike the LOS core region of C. jejuni 11168 
(St Michael et al., 2002).  
 
C. jejuni LOS can undergo phase variation allowing the bacteria to express multiple surface 
antigen structures which may suggest a role in host defence avoidance, adaptation to different 
host environments and to survive within different hosts.   In C. jejuni the variation of the outer 
LOS core structure has been attributed to one or more of the following mechanisms: 1) 
different biosynthesis genes present between strains, 2) phase variation via homopolymeric 
tracts, 3) a single base pair deletion or insertion which leads to gene inactivation independent 
of phase variation, 4) a single mutation which causes the inactivation of a glycosyltransferase 
and 5) one or more mutations which lead to a change in glycosyltransferase specificity 
(Gilbert et al., 2002).   In addition to antigenic variation, the LOS of C. jejuni imparts 
structural integrity to the bacterium, is involved in avoidance of the host immune system, 
plays a part in adherence and invasion and can mimic host carbohydrate structures (Karlyshev 
et al., 2005b).   The presence of sialic acid residues are of major importance in serum 
resistance (Guerry et al., 2002) and the ability of the bacterium to mimic the structure
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Figure 4.1:   Comparison of LOS gene clusters from C. jejuni strains 11168, 81116 and 
ATCC 43431 with GenBank Accession numbers AL111168, AF343914 and AY800272 
respectively (Oldfield et al., 2002; Parker et al., 2005; Parkhill et al., 2000; Phongsisay, 
2006).   The strain name is written to the right of each LOS gene cluster and the 
corresponding Penner serotype is in brackets.   Genes which are conserved across the different 
strains are represented in the same colour.   Genes are named as per the references in which 
the sequences were published.   Homopolymeric tracts of > 7 G residues are represented by a 
black and white striped triangle.    
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of host carbohydrates, e.g., human gangliosides, which is directly linked to the development 
of the severe neurological disorder Guillain-Barré syndrome (GBS; Yuki et al., 2004).   This 
observation is supported by strains lacking sialic acid residues, e.g., C. jejuni 81116, not being 
associated with the development of GBS. 
 
This chapter will focus on individual putative LOS biosynthesis genes from the LOS gene 
cluster of C. jejuni 81116.   Understanding the function of the individual gene products 
involved in the construction and variation of LOS can provide valuable insights into the 
virulence mechanisms of bacterial pathogens.   The specific aim of this chapter was to 
investigate the function of four putative LOS biosynthesis genes of C. jejuni strain 81116; 
wlaRF, wlaTB, wlaTC and waaV (Figure 4.2).   Previously in our laboratory, knock-out 
mutants were constructed targeting these and other genes from the LOS genes cluster of C. 
jejuni 81116 (Figure 4.2; Chen, 2002; Lodge, 2000; Vos, 2001; White, 2001; Ying, 2001).   
The aim of this study was to analyse potential changes in phenotype brought about by the 
mutation of these specific genes.   Each mutant was insertionally inactivated by the addition 
of a kanamycin resistance gene.    
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Figure 4.2:   Schematic diagram representing the LOS gene cluster of C. jejuni 81116.   The 
Yellow arrows represent the two genes investigated in Chapter 3.   The Blue arrows (both 
solid and striped) represent genes of which insertionally inactivated knock-out mutants have 
already been generated in our laboratory, wlaNA::kanr – rmlB::kanr (Chen, 2002), wlaRF::kanr 
(Ying, 2001), wlaSA::kanr (Andrada, 2003), wlaTB::kanr (Lodge, 2000), wlaTC::kanr (Vos, 
2001) and waaV::kanr (White, 2001).   The Striped blue arrows represent the genes which will 
be investigated in this chapter.   The red arrows denote genes that are yet to be investigated. 
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4.2 Methods and Results 
Previously in our laboratory, mutants of four putative LOS biosynthesis genes, wlaRF, wlaTB, 
wlaTC and waaV, were generated by insertional inactivation using the kanamycin resistance 
gene (KanR) from pMW2 (Appendix VI; Wösten, 1997).   The presence and location of the 
inserted KanR gene in the chromosome of each mutant and the deletion of some of each gene 
of interest was detected by analysing amplicon size and visualised by ethidium bromide gel 
electrophoresis (Figure 4.3).   The presence of the KanR in the chromosome of each mutant 
was confirmed previously by DNA sequence analysis RFLP and/or southern blotting (Lodge, 
2000; Vos, 2001; White, 2001; Ying, 2001).   The orientation of the KanR in the genome of 
each mutant was previously determined by RFLP confirming that both wlaRF and wlaTC 
contained kanR in the reverse orientation to the interrupted gene and wlaTB and waaV both 
contained kanR in the same orientation (Lodge, 2000; Vos, 2001; White, 2001; Ying, 2001).    
 
The protein sequence encoded by each predicted gene of interest was analysed by a Blastp 
search using WebAngis Biomanager to identify other proteins with which they share sequence 
similarity with a view to identify the putative function of each gene (Appendices X and XIII 
and summarised in Table 4.1).      The most similar proteins of known function to WlaRF 
include aminotransferases from Aneurinibacillus thermoaerophilus (FdtB), Photorhabdus 
luminescens subsp. laumondii (WblQ), Clostridium thermosaccharalyticum (QdtB) and E. 
coli (WbtC).   A conserved domain detected within the predicted protein sequence of WlaRF 
suggested that it belonged to the DegT/DnrJ/EryC1/StrS aminotransferase family (pfam 
01041.12, e value = 1e-96). The predicted protein encoded by wlaTB showed sequence 
similarity to other C. jejuni proteins involved in glycosylation, including Cj1137c from strain 
11168 (Table 4.1).   WlaTB also shared a degree of similarity to other bacterial glycosylation 
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Figure 4.3:   PCR products of the region of each of the inactivated LOS biosynthesis genes to 
detect the insertion of the KanR within each gene of interest by ethidium bromide agarose gel 
electrophoresis.   The PCR product containing wlaRF was amplified with primers cipA and 
orf2.1, primer set A.   The PCR product containing wlaTB, wlaTC and waaV was amplified 
using the primers waaF2 and orf12.1F, primer set B.   Lane 1, λ DNA marker digested with 
PstI; Lane 2, C. jejuni 81116 wild type DNA amplified with primer set A; Lane 3, 
wlaRF::KanR mutant amplified with primer set A; Lane 4 C. jejuni 81116 wild type DNA 
amplified with primer set B; Lane 5, wlaTB::KanR mutant amplified with primer set B; Lane 
6, wlaTC::KanR mutant amplified with primer set B; Lane 7 waaV::KanR mutant amplified 
with primer set B. 
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Protein 
name 
Length 
(aa) 
Size 
(kDa) 
Organism Protein with 
highest similarity 
Proposed Function GenBank 
Accession no. 
Identity 
(%) 
E 
value 
WlaRF 360 41.5 C. jejuni strain ATCC 43431 - Hypothetical protein AY800272 96 0.0 
   Helicobacter hepaticus - Hypothetical protein AE017125 63 1e-129 
   Aneurinibacillus thermoaerophilus FdtB Transamination AY442352 62 1e-128 
   Photorhabdus luminescens subsp. laumondii WblQ Transamination BX571875 54 1e-114 
   Clostridium thermosaccharalyticum QdtB Transamination AY422724 53 1e-110 
   E. coli WbtC Transamination AY532664 53 1e-110 
WlaTB 318 38.7 C. jejuni strain ATCC 43431 - Hypothetical protein AY800272 97 0.0 
   C. jejuni strain NCTC 11168 Cj1137c Glycosylation AL111168 42 7e-71 
   Bacteroides thetaiotaomicron BT2872 CPS biosynthesis AE015928 34 1e-41 
   Lactobacillus delbrueckii (subsp. bulgaricus) EpsI EPS biosynthesis AF267127 28 3e-26 
   Streptococcus pneumoniae WciW Glycosylation AF316642 25 4e-22 
   S. pneumoniae Cps14K CPS biosynthesis X85787 28 1e-21 
WlaTC 319 38.7 C. jejuni strain ATCC 43431 - Hypothetical protein AY501976 92 1e-109 
   E. coli K12 HtrL LPS biosynthesis M94888 28 1e-19 
   Shigella flexneri HtrL LPS biosynthesis AE005674 29 2e-19 
   E. coli O157:H7 HtrL LPS biosynthesis AE005174 28 8e-19 
WaaV 272 32.6 C. jejuni strain ATCC 43431 WaaV Glycosylation AY800272 90 1e-143 
   C. jejuni strain ATCC 43438 - Glycosylation AF400048 89 1e-139 
   C. jejuni strain ATCC 43446 WaaV Glycosylation AF167344 88 1e-137 
   C. jejuni strain ATCC 43460 WaaV Glycosylation AY044868 88 1e-135 
   C. jejuni strain 81-176 WaaV Glycosylation AY423899 88 1e-134 
   C. jejuni strain ATCC 43456 WaaV Glycosylation AF401528 88 1e-134 
Table 4.1:   Summary of Blastp data for each of the predicted LOS biosynthesis proteins of interest from C. jejuni strain 81116   
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proteins, including CPS biosynthesis proteins from Bacteroides thetaiotaomicron and 
Streptococcus pneumoniae as well as an EPS biosynthesis protein from Lactobacillus 
delbrueckii subsp. Bulgaricus.   Two conserved domains were detected within the sequence 
of WlaTB, those being the Caps_synth (pfam 05704.4) and the Gly_transf_sug (pfam 
04488.6) with the related functions of a CPS biosynthesis protein and a glycosyltransferase 
containing a sugar-binding region DXD motif respectively.    
 
A Blastp search of the predicted protein encoded by wlaTC identified only few proteins that 
shared significant sequence similarity and no conserved domain matches were detected 
(Table 4.1).   The most similar sequences were hypothetical proteins from various C. jejuni 
spp.   WlaTC did show some similarity to the HtrL protein, also called YibB, of E. coli K12 
and O157:H7, and Shigella flexneri.    
 
Based on Blastp sequence analysis, WaaV is possibly a LOS biosynthesis 
glycosyltransferase which showed a match to the conserved domain of Glycos_transf_2 or 
glycosyltransferase 2 family (GT-2; Table 4.1).   WlaRE (Chapter 3) was also classified into 
the GT-2 family.   WaaV shared sequence similarity with C. jejuni β-1,3-
galactosylatranferases and appears to be conserved among many different strains (Table 4.1).    
 
Each mutant created from the parent strain, C. jejuni 81116, was analysed for possible 
changes in LOS molecule size, LOS immunogenicity, motility, morphology, invasion and 
adhesion abilities and LOS biochemical composition.   LOS molecules were extracted by 
sonication and separated from cell wall debris by centrifugation and treated with proteinase 
K (see Section 2.5.2.1).   The purified LOS molecules were analysed by Alcian blue stained 
tricine SDS-PAGE which showed that the LOS from each mutant migrated 
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more rapidly than the LOS of the parent strain (Figure 4.4a).   The estimated sizes of each 
truncated LOS molecule produced by each mutant, wlaRF, wlaTB, wlaTC and waaV was 9 
kDa, 7 kDa, 8 kDa and 10 kDa respectively.   The parent strain of C. jejuni 81116 produces 
an LOS molecule of ~ 11 kDa.   The possibility of each inactivated gene being involved in 
both CPS and LOS biosynthesis was also investigated.   The LOS and CPS molecules were 
co-isolated based on the method of Karlyshev and others which involved lysis of C. jejuni 
cells with SDS and treatment with DNase, RNase and proteinase K (see Section 2.5.2.2; 
Figure 4.4b; Karlyshev & Wren, 2001).   The co-isolated LOS and CPS were analysed by 
Alcian blue stained tricine SDS-PAGE.    
 
The immunogenicity of each mutant was analysed by western blotting and compared to the 
parent strain using antisera raised in mice against purified C. jejuni 81116 LOS molecules 
(Figure 4.5).   The antisera were prepared as described previously (Chang, 2002) and was 
kindly provided by Dr Jason Chang (RMIT).   Each of the mutants that produced the smallest 
LOS molecules, wlaRF, wlaTB and wlaTC displayed a very weak antibody binding capacity 
when compared to the parent strain.   Mutant waaV produced LOS molecules which 
exhibited an antibody binding capacity as strong as if not stronger than the parent strain.    
 
The possibility of WlaRF, WlaTB, WlaTC and WaaV being multifunctional was also 
investigated by analysing any potential change in motility as compared to the motility of the 
parent strain (Figure 4.6).   The motility assay was performed in semi-solid thioglycolate 
agar as described in Section 2.2.2.   Mutants wlaTB::KanR and waaV::KanR exhibited the 
same degree of motility as the C. jejuni 81116 parent strain.   In contrast, mutants 
wlaRF::KanR and wlaTC::KanR appeared non-motile. 
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Figure 4.4:   Alcian blue stained tricine SDS-PAGE analysis of A) LOS molecules purified 
without CPS (see Section 2.5.2.1) and B) LOS and CPS molecules co-isolated (see Section 
2.5.2.2) from each mutant and the parent strain.   Lane M, See Blue prestained protein 
marker (Invitrogen); Lane 1, C. jejuni 81116 parent strain; Lane 2, wlaRF::KanR mutant; 
Lane 3, wlaTB::KanR mutant; Lane 4, wlaTC::KanR mutant; Lane 5, waaV::KanR mutant. 
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Figure 4.5:   Western blot analysis of each mutant LOS compared to the parent strain C. 
jejuni 81116.   Antiserum was raised in mice using purified LOS molecules extracted from 
C. jejuni 81116.   Lane 1, C. jejuni 81116 parent strain LOS; Lane 2, wlaRF::KanR mutant 
LOS; Lane 3, wlaTB::KanR mutant LOS; Lane 4, wlaTC::KanR mutant LOS; Lane 5, 
waaV::KanR mutant LOS. 
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Figure 4.6:   Motility analysis using semi-solid thioglycolate agar of each mutant and the 
parent strain, C. jejuni 81116.   A) C. jejuni 81116.   B) wlaRF::Kanr mutant.   C) 
wlaTB::Kanr mutant.   D) wlaTC::Kanr mutant.   E) waaV::Kanr mutant. 
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In addition the morphology of each mutant was compared to the parent strain by staining the 
bacteria with phosphotungstic acid and visualising the stained cells using transmission 
electron microscopy (TEM) as described in Chapter 2, Section 2.8 (Figure 4.7).   The parent 
strain and the two motile mutants (wlaTB::KanR and waaV::KanR) produced flagella visible 
under TEM.   However, no flagella was visible on either of the non-motile mutants 
(wlaRF::KanR and wlaTC::KanR).    
 
The effect that each mutation had on the ability of C. jejuni 81116 to adhere to and invade 
cell lines from both humans (INT407) and chickens (CEF-DF1) was investigated (Figure 
4.8).   The adhesion and invasion assays were performed twice and in triplicate, see Section 
2.7.2.2.   The adhesive ability of each bacterial sample was expressed as a percentage of the 
number of adhered bacteria over the inoculum (cfu/mL).   The invasive ability was expressed 
as a percentage of the number of invasive bacteria over the total number of adherent bacteria 
(cfu/mL).   The statistical analysis of the data was performed using the Microsoft Excel 
student’s t-test.   All statistically significant results have a p value of less than p=0.05.   The 
mutants wlaRF::KanR, wlaTB::KanR and wlaTC::KanR were significantly less adhesive to 
CEF-DF1 cells than the parent strain and mutant waaV::KanR, with p values of 0.0019, 
0.0011 and 0.0016 respectively.   The parent strain was significantly less adhesive to CEF-
DF1 cells than INT407 cells, p value = 0.0023.   Interestingly, the waaV::KanR mutant was 
the most adherent to the chicken or the human cell lines in comparison to the other mutants 
and parent strains tested. 
 
The invasion assay data points generated from the chicken cell line which were statistically 
significant included the wlaTB::KanR mutant which was significantly less invasive than the 
parent strain, p value = 0.0431.   The parent strain was significantly more invasive in the 
human cell line than all four mutants, with the following p values wlaRF::KanR (0.0075),
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Figure 4.7:   Analysis of C. jejuni mutants and the 
parent strain, C. jejuni 81116, by transmission electron 
microscopy (TEM).   1a and 1b) parent strain; 2a and 
2b) wlaRF::KanR mutant; 3a and 3b) wlaTB::KanR 
mutant; 4a and 4b) wlaTC::KanR mutant; 5a and 5b) 
waaV::KanR mutant.   The white arrows indicate the 
presence of flagella. 
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Figure 4.8:   Analysis of the adherent A) and invasive B) abilities of each mutant and the 
parent strain C. jejuni 81116 from which each mutant was derived with human (INT407) and 
chicken (CEF-DF1) cell lines.    
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wlaTB::KanR (0.0071), wlaTC::KanR (0.0075) and waaV::KanR (0.0151).   The parent strain 
was significantly more invasive in the INT407 cell line than the CEF-DF1 cell line, p value 
0.0079. 
 
Gas chromatography mass spectrometry (GCMS) analysis of the glycan biochemistry of 
each mutant and parent strain LOS molecule was undertaken to investigate the potential 
absence of certain glycan residues (Figure 4.9).   However, due to the presence of differing 
amounts of contaminating CPS across each of the samples, this data can only be viewed as 
preliminary.   The data was analysed as follows, the sum of each peak area derived from the 
GCMS raw data was determined for each sugar residue and represented as a ratio to the peak 
area of Kdo in graph format using Microsoft Excel.   Kdo was used to normalise the data in 
an attempt to account for potential non-LOS glycan contamination as there is no evidence to 
suggest that Kdo is present in any glycoconjugates other than LOS in C. jejuni. 
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Figure 4.9:   GCMS data of purified LOS molecules from each mutant and the parent strain 
C. jejuni 81116.   The data is represented as a ratio of GCMS peak area for each sugar 
divided by the GCMS peak area of Kdo.   C14.0 Me = methylated carbon. 
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4.3 Discussion 
The four open reading frames of interest, wlaRF, wlaTB, wlaTC and waaV are putative LOS 
biosynthesis genes located within the LOS gene cluster of C. jejuni 81116.   Mutants were 
constructed by insertional inactivation for each gene and potential phenotypic changes 
caused by such mutations were investigated.    
 
The protein sequence encoded by each gene was subjected to a Blastp search in an attempt to 
identify a potential function based on sequence similarity to other proteins (Table 4.1).   
Based on sequence similarities, WlaRF is a putative aminotransferase.   Sugar 
aminotransferases, also referred to as sugar transaminases, are a class of enzymes that 
catalyse the removal and transfer of an α-amino group from an α-amino acid donor to a 
recipient α-keto acid, thus converting it into an amino acid (Stryer, 1995).   Amino sugars 
are unusual and can generally be found as components of macrolide antibiotics, in antibiotic 
producing microbes of the Actinomycetales order or in the O-antigens and LPS of 
pathogenic gram negative bacteria (Awram & Smit, 2001; Bastin & Reeves, 1995; Dhillon et 
al., 1989).   In C. jejuni amino sugars are present in the CPS, LOS and some glycosylated 
proteins (Aspinall et al., 1994; St Michael et al., 2002; Vijayakumar et al., 2006).   There is 
recent evidence of C. jejuni aminotransferases being involved in the glycosylation of the 
flagella and general protein glycosylation (Schoenhofen et al., 2006b).   In C. jejuni 11168, 
the proteins encoded by the genes Cj1294 and Cj1121c are involved in the pseudaminic acid 
(O-linked flagella glycoconjugate) and bacillosamine biosynthetic pathways (N-linked 
protein glycoconjugate) respectively (Schoenhofen et al., 2006b).   The glycosylation of each 
of these structures is important to C. jejuni virulence (Obhi & Creuzenet, 2005; Vijayakumar 
et al., 2006).    
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A defence mechanism requiring the activity of an aminotransferase which is employed by 
some gram negative bacteria, is the ability to modify the Lipid A component of the LPS/LOS 
causing a reduction in charge (Field & Naismith, 2003).   This, in turn, decreases its potential 
to interact with the host cationic antimicrobial peptides (Field & Naismith, 2003).   WlaRF 
contains a conserved domain which categorises it within the DegT/DnrJ/EryC1/StrS 
aminotransferase family.   This family is probably entirely composed of pyridoxal-phosphate 
(PLP) -dependent aminotransferases.   PLP is a prosthetic group of all aminotransferases 
which functions as a cofactor and is transiently converted into pyridoxamine phosphate 
(PMP) during transamination (Field & Naismith, 2003; Stryer, 1995).   WecE, a sugar 
aminotransferase produced by E. coli K12 which is also a member of the 
DegT/DnrJ/EryC1/StrS aminotransferase family displays specificity for TDP-4-keto-6-
deoxy-D-glucose and L-glutamate as acceptor and donor respectively (Hwang et al., 2004).   
The activity of WecE results in the production of TDP-4-amino-4,6-dideoxy-D-galactose.   
Little is known about the specificity of sugar aminotransferases as the first enzymatic assay 
analysis was conducted only recently (Hwang et al., 2004) and is therefore a relatively new 
area of experimentation.    
 
The predicted protein encoded by wlaTB appears to be a glycosyltransferase.   However, the 
specificity of the enzyme is not known.   WlaTB showed significant sequence similarity to 
CPS biosynthesis proteins produced by other bacteria, including Bacteroides 
thetaiotaomicron and Streptococcus pneumoniae (Table 4.1).   The conserved domains 
detected within the amino acid sequence of WlaTB also support the notion that this protein is 
involved in glycosylation, specifically CPS biosynthesis.   As C. jejuni possesses both CPS 
and LOS and as both structures contain some of the same glycan residues, it is possible that 
the same enzyme could be involved in the synthesis of both structures.   Other C. jejuni 
proteins, like GalE in strain 11168, have been implicated as being multifunctional, playing a 
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role in the biosynthesis of CPS, LOS and N-linked protein glycosylation (Bernatchez et al., 
2005). 
 
The amino acid sequence of WlaTC showed the greatest similarity to the HtrL protein of E. 
coli K12, E. coli O157:H7 and Shigella flexneri.   The HtrL protein of E. coli  is thought to 
be involved in LPS biosynthesis (expasy.org), though its exact function at a molecular level 
is yet to be determined.   The Htr proteins of E. coli are involved in enabling the bacteria to 
survive and grow at high temperatures (Delaney et al., 1992).   The HtrD gene of E. coli is 
thought to be pleiotropic in nature as it has been linked to playing a role in resistance to high 
temperatures as well as resistance to H2O2 (Delaney et al., 1992).   E. coli mutants lacking 
functional HtrB and HtrC were observed to lyse at temperatures above 42°C (Karow et al., 
1991).   An E. coli temperature sensitive HtrM mutant was also seen to be sensitive to bile 
salts (Karow et al., 1991).    
 
WaaV is highly conserved among C. jejuni strains and is a putative β-1,3-
galactosyltransferase thought to be involved in LOS biosynthesis (Table 4.1; Appendix 
XIII).   However, the exact role of WaaV is yet to be experimentally defined.   Also within 
the LOS gene cluster of many C. jejuni strains are the highly conserved waaC and waaF 
genes and the products of which have both been experimentally determined to encode for 
heptosyltransferases responsible for the attachment of the first and second heptose of the 
LOS core to the Kdo molecule respectively (Klena et al., 1998; Oldfield et al., 2002).   
However, WaaV does not appear to share significant sequence similarity with either WaaC 
or WaaF. 
 
The mutation of each gene resulted in the production of a truncated LOS molecule by C. 
jejuni strain 81116 (Figure 4.4).   The truncated LOS molecules from each mutant varied in 
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size and arranged in order of smallest to largest are wlaTB::KanR, wlaRF::KanR, 
wlaTC::KanR and waaV::KanR.   The variation in size suggests that each gene is involved in 
a different task required for the synthesis of the core oligosaccharide of C. jejuni strain 
81116.    
 
One of the four inactivated genes, wlaTB, shared sequence similarity with CPS biosynthesis 
proteins.   However, it is unlikely that WlaTB is involved in the biosynthesis of CPS 
molecules as the size of the CPS produced by the wlaTB::KanR mutant appeared to be the 
same size as the CPS produced by the parent strain and therefore seems to be unaffected by 
the mutation (Figure 4.4b).   The mutant lacking WaaV also produces CPS that appears to be 
the same size as the parent strain CPS and therefore, also appears to be unaffected by the 
mutation.   Mutants wlaRF::kanr and wlaTC::kanr may produce slightly smaller CPS, though 
the results are a qualitative guide only and are not conclusive.   Structural changes to the CPS 
molecule caused by the mutation of each gene of interest need to be investigated further and 
in biochemical detail to confirm any potential structural alteration, which was beyond the 
scope of the present study. 
 
The immunogenicity of each of the truncated LOS molecules from each mutant was 
investigated and compared to the parent strain (Figure 4.5).   Interestingly, waaV::KanR 
appeared to be more reactive than the parent strain.   Given that the truncated LOS molecule 
produced by waaV::KanR is only slightly smaller than that of the parent strain, it is possible 
that the increase in immunogenicity is due to the absence of perhaps only a single glycan 
making the antibody binding site more accessible.   As expected, the other three mutants 
which produced comparatively small LOS truncates were clearly less immunogenic than the 
parent and waaV::KanR.   Presumably, the absence of certain carbohydrate residues from the 
LOS molecules of each mutant has caused the antibodies that were raised against the intact 
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LOS of the parent strain to no longer recognise these truncated forms as compatible antigens.   
LOS molecules produced by other C. jejuni LOS biosynthesis gene mutants have been 
observed to undergo a change in immunoreactivity (Guerry et al., 2000b).   Guerry and 
others reported that the inactivation of an LOS biosynthesis gene, neuC1, in C. jejuni strain 
MSC57360 led to enhanced immunoreactivity (Guerry et al., 2000b).   NeuC1 is responsible 
for transferring sialic acid (NeuNAc) onto the growing C. jejuni LOS molecule (Guerry et 
al., 2000b).   They concluded that the presence of NeuNAc on the LOS molecule resulted in 
decreased immunogenicity.   It would appear as though the sugar residue transferred onto the 
LOS molecule by WaaV has a similar effect.   Further investigation of the specificity of 
WaaV is needed.    
 
In recognition of the fact that putative LOS biosynthesis genes may also be involved in the 
glycosylation of other glycoconjugate structures, the impact of each mutation on C. jejuni 
motility was investigated (Figure 4.6).   The inactivation of wlaTB and waaV did not 
interfere with the motility of C. jejuni 81116, as both mutants appeared as motile as the 
parent strain.   By contrast, both mutants wlaRF::KanR and wlaTC::KanR lost the capacity for 
motility.   Further investigation by transmission electron microscopy (TEM) revealed that 
both the nonmotile mutants appeared to be lacking flagella, while flagella were clearly 
visible on both the motile mutants and the parent strain (Figure 4.7).    
 
It is widely accepted that intact functional flagella and therefore motility are essential for C. 
jejuni colonisation and invasion of intestinal cells in vitro (Goon et al., 2003; Grant et al., 
1993; Guerry et al., 2000a; Guerry et al., 2006; Wassenaar et al., 1994).   It has also been 
determined that the flagella of C. jejuni undergo post translational modification in the form 
of O-linked glycosylation which appears to be important to its pathogenesis as it imparts 
structural diversity which may play a part in immune evasion (Harris et al., 1987; Szymanski 
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et al., 2003a).   Flagella glycosylation is also thought to be involved in host/pathogen 
interactions and flagella function and assembly (Goon et al., 2003; Logan et al., 2002; 
Schirm et al., 2003; Schoenhofen et al., 2006a).   Whether the nonmotile mutants actually 
lack flagella or possess fragile non functional flagella that were sheared off during the 
sample preparation for TEM is not known and requires confirmation.   Nevertheless, it is 
more likely that the glycosylation of protein components which make up flagella is essential 
for successful assembly of a complete flagellum.   The results obtained in this study support 
previously published work (Goon et al., 2003), which indicated that glycosylation is 
necessary for correct flagella function and assembly.   In addition to their role in the 
formation of functional flagella, WlaRF and WlaTC are required to generate an intact LOS 
molecule.   It appears that both WlaRF and WlaTC are responsible for more than one 
function.   As WlaRF shows sequence similarity to aminotransferases it is possible that it is 
involved in the transamination of flagellar glycan residues as carbohydrate modifications on 
C. jejuni flagella containing amino groups have been identified (Schoenhofen et al., 2006a).   
However, the specific molecular function of WlaTC remains a mystery.  
 
A major factor of C. jejuni pathogenesis is its ability to colonise and invade a range of host 
cells both in vitro and in vivo (Black et al., 1988; Hu et al., 2006; Kanipes et al., 2004; 
Wooldridge et al., 1996).   The range of host symptoms that manifest as a result of natural C. 
jejuni infection range markedly from the acute gastroenteritis experienced by humans to the 
absence of any detectable pathological intestinal change in poultry (Byrne et al., 2007; 
Meinersmann et al., 1991).   The ability for the parent strain and each mutant to adhere to 
and invade both human epithelial (INT407) and chicken embryo fibroblast (CEF-DF1) cell 
lines was determined.   Any potential changes to this phenotype brought about by the 
mutation of each of the four genes of interest was investigated by in vitro adhesion and 
invasion assays (Figure 4.8).   The parent strain was significantly more adherent to the 
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chicken cell line than it was to the human cell line (p<0.05).   The mutants, wlaRF::KanR, 
wlaTB::KanR and wlaTC::KanR which represent both motile and non motile phenotypes, 
were significantly less adherent to the chicken cells than the parent strain (p<0.05).   This 
suggests that in addition to motility, a truncated LOS molecule and perhaps other undetected 
phenotypes affected by each mutation, play an important part in adherence to chicken host 
cells in vitro.   The waaV::KanR mutant was generally more adherent to the human cell line 
than the parent strain was, however the difference was not significant (p = 0.10288).   This 
trend was unexpected and the reason for it is not clear. 
 
The parent strain was significantly more invasive to human cells than chicken cells (p<0.05), 
which is expected given that C. jejuni 81116 is a pathogen to humans, but exists as a 
commensal within the avian host.   Interestingly, the parent strain does appear to be capable 
of invading chicken cells, though at very low numbers.   This observation is supported by 
recent data investigating the adherence and internalisation capacity of a range of C. jejuni 
strains to both human and chicken cells directly biopsied from intestinal tissue (Byrne et al., 
2007).   There was no significant difference observed with the internalisation of the parent 
strain into CEF-DF1 cells when compared to each of the four mutants.   In contrast, all 
mutants were significantly less invasive to the human cell line than the parent strain 
(p<0.05).   Again, this data suggests that both intact and functional flagella and LOS are 
important to C. jejuni colonisation and pathogenesis.   It should be noted that the change in 
LOS structure and motility that has resulted from these mutations may not be the extent of 
the changes caused by the inactivation of each gene and other glycoconjugates may be 
involved.   This requires further characterisation.    
 
Preliminary GCMS data provides initial information about which individual glycans may be 
absent from each of the putative LOS biosynthesis knock-out mutants (Figure 4.9).   The 
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LOS of mutant wlaRF::KanR appears to contain a lower ration of Glc to Kdo than the parent 
strain and therefore may be lacking a Glc residue(s).   Similarly, the purified LOS of the 
wlaTB::KanR mutant may be lacking in GlcNAc.   Mutant waaV::KanR appeared to have a 
ratio of Glc to Kdo only slightly lower than the parent strain.   In contrast, the wlaTC::KanR 
mutant did not show any obvious reduction in the ratio of any of the sugars detected when 
compared to the parent strain LOS.   The difficulty with interpreting this data is that there 
appears to be some non-LOS glycan contamination which is present in different amounts in 
each sample.   As a result, this data can only serve as an initial qualitative view of the 
truncated LOS molecules produced by each mutant.   Further biochemical analysis is 
required to characterise the nature of the change in the LOS structure of each mutant. 
 
The function and role in pathogenesis of four putative LOS biosynthesis genes were 
investigated by phenotypic analysis of four insertionally inactivated mutants.   All of the 
resulting mutants produced truncated LOS molecules and therefore, WlaRF, WlaTB, WlaTC 
and WaaV are all involved in the process of LOS biosynthesis.   The change in LOS 
structure impacted on the immunogenicity of the LOS in addition to the motility, adhesion 
and invasion ability of the bacteria.   The three mutants with the smallest truncated LOS 
molecules were the least immunogenic, while the largest truncate produced by waaV::KanR 
surprisingly appeared to be more reactive than the parent strain LOS to antisera raised in 
mice exposed to purified C. jejuni 81116 LOS.   These mutations seemed to have little if any 
effect on the CPS molecule.   Two of the four mutants, wlaRF::KanR and wlaTC::KanR were 
non motile and their flagella could not be detected by TEM.   Each mutation impacted on the 
virulence of C. jejuni 81116, specifically in their ability to invade human intestinal cells in 
vitro, and therefore the product of each gene is important to pathogenesis in as far as it can 
be assessed in vitro.   The next experimental step would include in vivo analysis of each 
mutant to confirm the involvement of each WlaRF, WlaTB, WlaTC and WaaV in 
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pathogenesis.   At this stage the specific function of the protein encoded by each gene of 
interest is not defined and remains to be fully characterised. 
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CHAPTER 5: Investigation of environmentally 
regulated surface proteins from C. jejuni  
 
5.1 Introduction  
C. jejuni is one of the leading bacterial causes of gastroenteritis in humans world wide 
(Allos, 2001).   One of the most important sources of C. jejuni infection for humans is the 
consumption of contaminated poultry or the handling of raw poultry products (Allos, 2001; 
Butzler, 2004; Corry & Atabay, 2001).   Despite the presence of this known human pathogen 
in the GI tract of chickens at levels as high as 106-107 cfu/g of caecal contents (Corry & 
Atabay, 2001), the birds appear to be asymptomatic and no evidence of cell damage has been 
found (Byrne et al., 2007).   There is some in vitro evidence of C. jejuni achieving immune 
avoidance in chickens by causing apoptosis of lymphocytes (Zhu et al., 1999) and inducing a 
cytokine response in avian macrophages (Smith et al., 2005).   Several reports in the early 
1980s documented enteritis-like symptoms in chickens of < 2 weeks of age and a death rate 
of 32 % when orally dosed with ~ 9 x 107 cfu of human C. jejuni isolates (Corry & Atabay, 
2001; Ruiz-Palacios et al., 1981; Sanyal et al., 1984).   However, this oral dosage does not 
reflect a natural infection and it is generally accepted that C. jejuni exists as a commensal in 
chickens (Hendrixson & DiRita, 2004; Ziprin et al., 2001).   It is currently not known why C. 
jejuni is more pathogenic to humans than it is to chickens.    
 
Upon entry of a host, C. jejuni needs to adapt to the associated changes in the environment if 
it is going to be able to colonise the host and establish infection.   The ability of C. jejuni to 
colonise the gastrointestinal tract of humans is an essential phase in pathogenesis (Wassenaar 
& Blaser, 1999).   Many changes take place within the bacteria to combat the physiological 
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stresses encountered both internal and external to the host environment.  Such stressors 
include temperature fluctuations, variations of pH, different hosts, host immunity, oxidative 
stress, limited nutrient supply and being physically flushed from the host system by 
peristalsis (Park, 2002; Snelling et al., 2005).   Some virulence factors involved in such 
bacterial-host interactions are surface proteins including outer membrane proteins, integral 
membrane proteins, lipoproteins and glycoproteins.   According to the sequence data, there 
are over 150 predicted membrane proteins and lipoproteins present in C. jejuni NCTC 11168 
(Parkhill et al., 2000).   These proteins can be involved in pathogenesis in many ways 
including adhesion to the host, avoidance of the host immune system, nutrient acquisition, 
motility, adaptation to low pH environments or antibiotic resistance.    
 
Motility is essential for C. jejuni to colonise the host intestine and is therefore critical in the 
process of causing disease (Guerry et al., 2000a).   Motility is achieved by functional 
flagella, the major component of which are the flagellin proteins FlaA and FlaB (Penn, 
2001).   Both of these proteins are post translationally modified by O-linked glycosylation 
which contributes to antigenic variation which facilitates avoidance of the host immune 
response (Constantinidou et al., 1997; Guerry, 1997; Szymanski et al., 1999).    
 
The ability of the bacteria to sense and respond by moving to a favourable direction or away 
from an unfavourable one requires both motility and chemotaxis.   Chemotaxis is the ability 
to detect and respond to chemical gradients via a complex signal transduction pathway which 
effects flagella rotation allowing the cell to move toward or away from an environmental 
stimulus (Eisenbach, 1996).   The importance of chemotaxis in pathogenesis has been 
demonstrated via the investigation of phenotypic changes in non-chemotactic mutants in vivo 
(Hendrixson & DiRita, 2004; Takata et al., 1992) and in vitro (de Melo & Pechere, 1990).   
C. jejuni chemotactic mutants failed to colonise the intestines in the mouse model (Takata et 
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al., 1992).   A mutant lacking a functional chemotaxis regulatory gene, cheY, was more 
adherent to and invasive of INT407 human epithelial cells in vitro, though was unable to 
colonise or cause disease in the ferret model (Yao et al., 1997).   CheY has also been 
demonstrated as playing a role in C. jejuni flagellar motor switching (Marchant et al., 2002).   
The phosphorylation signal transduction cascade at the centre of C. jejuni chemotactic 
motility relies on the recognition of chemical stimulus via a membrane anchored methyl-
accepting chemotaxis protein (Marchant et al., 2002).  
 
Porins, or pore-forming proteins allow the bacteria to adjust the permeability of their 
membranes in response to environmental stimuli (Dedieu et al., 2002).   The most highly 
expressed outer membrane protein (OMP) of C. jejuni is a porin called the major OMP 
(MMP; Bolla et al., 2004; Penn, 2001), though it also expresses a minor porin which is 
unique to Campylobacter sp., called Omp50 (Bolla et al., 2000).    
 
Adhesins are surface proteins that play a role in anchoring the bacteria to the host cell and 
can initiate internalisation.   Three adhesins which have been characterised in C. jejuni are 
the 28 kDa protein known as PEB1 (Pei & Blaser, 1993), the 36 kDa protein CadF (Konkel 
et al., 1997) and the 42 kDa protein called JlpA (Jin et al., 2001).   (Kervella et al., 1993).   
The antigenic adhesin PEB1 is thought to undergo post translational modification resulting in 
antigenic variation.   One form, termed ompH1, was postulated as being a modified form of 
PEB1 which the bacteria has adapted specifically for colonising chicken intestines, while the 
PEB1 form is specific for human colonisation (Meinersmann et al., 1997).   The ompH1 and 
PEB1 variants were observed at 32 and 34 kDa respectively and in the two strains tested, 
only one copy of the gene was detected (Meinersmann et al., 1997).   The adhesins, CadF 
and JlpA, are important to C. jejuni adhesion and are able to induce a biochemical cross-talk 
between bacteria and host cell, manipulating the host cell’s signal transduction pathways 
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initiating rearrangement of components of the cytoskeleton facilitating bacterial invasion (Jin 
et al., 2003; Monteville et al., 2003).    
 
C. jejuni is able to adapt to and survive a wide range of environmental conditions and 
stresses making it ubiquitous and persistent, despite having a relatively small genome, an 
elevated optimal temperature, sensitivity to atmospheric oxygen levels and a requirement for 
rich growth media (Park, 2000).   Therefore it is essential for C. jejuni to have the capacity to 
respond rapidly to changes in environmental conditions through a range of regulatory 
systems.   Environmental stimuli that enable bacteria to “know” that they have entered a host 
include temperature, a scarcity of essential nutrients such as iron, the presence of particular 
chemotactic stimuli such as bile and its constituents as well as the presence of host cells with 
which the bacteria can interact directly.    
 
In this study, bacteria were exposed to a range of environments which were modelled on 
“human” and “chicken” gastrointestinal conditions.   The four environmental stimuli 
investigated were temperature (humans 37°C and birds 42°C), whole blood (human and 
chicken), bile extracts (pig and chicken) and host cells (human, INT407 and chicken, CEF-
DF1).   Given the differences in body temperature of the two hosts this is an obvious 
parameter to investigate and has been a target of previous investigations using microarray 
technology (Moen et al., 2005; Stintzi, 2003).   Changes in environmental temperature can 
provide the bacteria with information about whether it is inside or outside of a host and 
perhaps which host, based on different body temperatures.   In addition, temperature is a 
known regulatory stimulus.  
 
Whole blood is important to host-pathogen interactions as it carries many components of the 
host immune system and the lack of free iron constitutes a non-specific host defence 
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(Holmes et al., 2005; van Vliet et al., 1998).   Iron limited conditions have also been linked 
to increases in protein glycosylation which in turn may increase the virulence of C. jejuni 
(Palyada et al., 2004).   It has been demonstrated that some virulence factors are iron 
regulated and that iron can act as a signal to inform bacteria that they have entered a host 
(Palyada et al., 2004; Ratledge & Dover, 2000).    
 
Enteric bacteria are inevitably exposed to a range of toxic factors, including bile salts.   Bile 
is produced in the liver, concentrated and stored in the gall bladder and eventually released 
into the intestines (Okoli et al., 2007).   It contains bile salts, lipids such as cholesterol, 
phospholipids, fatty acids and triglycerides, proteins including immunoglobulin, ions 
including Na+, K+, Ca2+, Cl-, HCO3-, cyclic alcohol derivatives, bilirubin, biliverdin and 
metabolites such as creatinine (Hofmann, 1999; Okoli et al., 2007).   Bile acids are surface-
active amphiapathic molecules which can disrupt cell membranes like detergents and are 
considered to be potent antimicrobials (Fox et al., 2007; Okoli et al., 2007).   C. jejuni have 
developed a level of bile tolerance which is demonstrated by their ability to grow at 
concentrations of > 0.3% bovine bile (Fox et al., 2007), which is the accepted threshold of 
bile salt resistance (Andrews, 1998).   Studies have shown that bile influences C. jejuni 
expression (Allen & Griffiths, 2001; Fox et al., 2007; Lin et al., 2005). 
 
The chemical composition of bile varies from animal to animal (Liu et al., 2002; Oomen et 
al., 2004).   It appears that chicken bile imparts unique qualities.   In a study investigating the 
bioaccessibility of soil contaminants in a risk assessment setting via an in vitro digestion 
model, chicken bile was the only bile type tested which increased the bioaccessibility of lead 
by 3 – 5.5 times and cadmium by 1.5 times when compared to ox or pig bile (Oomen et al., 
2004).   This variation suggests that the chemical composition of bile is species specific.   
Furthermore, bile extracted from different origins varies in colour, e.g., chicken bile is darker 
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and greenish in appearance when compared to the pig bile which is lighter and a more 
yellowish green.   This colour difference suggests a difference in chemical characteristics 
and was also observed by Oomen and colleagues (2004).   The chemical composition of bile 
from pig, chicken and human sources has been analysed previously (Alvaro et al., 1986).   
The main difference is that chicken bile contains 100 % tauro-conjugated bile salts, while pig 
and human contain 7 and 23% respectively (Alvaro et al., 1986; Hay et al., 1993; Oomen et 
al., 2004; Wildgrube et al., 1986).   The tauro-conjugated bile salts are taurohydeoxycholic 
acid (THDCA), taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA) and 
taurodeoxycholic acid (TDCA) (Alvaro et al., 1986).   Chicken bile contains only TCA and 
TCDCA, pig bile contains THDCA and TCDCA and human bile contains TCA, TCDCA and 
TDCA (Alvaro et al., 1986).    
 
C. jejuni are capable of adhering to and invading both human and chicken cells (Byrne et al., 
2007; Wassenaar et al., 1991).   For this process to take place the bacteria need to move 
toward the host epithelium, anchor themselves to the intestinal wall, bind to the epithelial 
cell surface to initiate the biochemical cross-talk required to influence signal pathways which 
cause rearrangement of the host cytoskeleton and eventually leads to the internalisation of 
the bacteria (Hu & Kopecko, 1999; Kopecko et al., 2001).   This series of events is essential 
for C. jejuni pathogenesis and requires the involvement of many surface structures. 
The aim of this study was to investigate the environmental regulation of surface proteins of 5 
different C. jejuni strains.   Those strains included two enteritis associated strains (C. jejuni 
11168 and 81116), an enteritis strain associated with GBS (C. jejuni HB9313), a recent 
chicken isolate (C. jejuni 990922) and a recent human clinical isolate (C. jejuni MP0401).    
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5.2 Methods and Results 
A recent human clinical isolate cultured from a faecal specimen of a patient suffering from 
gastroenteritis (MP0401), kindly provided by Melbourne Pathology, and a recent chicken 
isolate (990922) taken from a chicken farm in Victoria, Australia (RMIT University Culture 
Collection) were subjected to genotyping as previously described (Figure 5.1; Shi et al., 
2002).   Both isolates were collected with minimal passaging steps and stored at -80°C.   The 
RFLP profiles resulting from the digestion of a 9.6 kb section of the wlaI gene cluster with 
HhaI and DdeI categorise the C. jejuni strains MP0401 and 990922 as Hh10/Dd10 and 
Hh3/Dd16 respectively.   The corresponding Penner serotypes to Hh10/Dd10 are HS:15, 
HS:33 and HS:44 (Shi et al., 2002).   The corresponding Penner serotype to Hh3/Dd16 is 
HS:31 (Shi et al., 2002).    
 
Each of the 5 C. jejuni strains 81116, 11168, HB9313, 990922, MP0401 were subjected to a 
range of environmental conditions which were designed to model the internal environments 
of the human and chicken host.   Four environmental conditions were investigated: 
temperature, blood, bile and host cells in vitro (see Section 2.2.3).   The temperature trial 
exposed each C. jejuni strain to either 37°C or 42°C to model the temperature of the human 
and avian body, respectively (see Section 2.2.3.1).   Due to the different growth 
temperatures, growth studies were performed with strains 81116 and 11168 to compare 
cfu/mL after 16 h.   The C. jejuni 81116 culture reached 1.8 x 109 and 6 x 109 cfu/mL at 
37°C and 42°C, respectively.   The C. jejuni 11168 culture reached 3.6 x 109 and 6.5 x 109 
cfu/mL at 37°C and 42°C, respectively. 
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Figure 5.1:   Molecular typing of recent C. jejuni chicken isolate, 990922 and recent human 
clinical isolate, MP0401 by amplification of the wlaI cluster (using primers wlaH3 and 
GalE1) and RFLP analysis of the pattern created by digestion with HhaI as previously 
described (Shi et al., 2002).   A) Lane M, λ DNA marker digested with PstI; Lane 1, C. 
jejuni 990922 digested with DdeI; Lane 2, C. jejuni 990922 digested with HhaI.   B) Lane 
M, λ DNA marker digested with PstI; Lane 1, C. jejuni MP0401 digested with DdeI; Lane 2, 
C. jejuni MP0401 digested with HhaI.    
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The C. jejuni strains were exposed to each temperature for 16 h to late log phase and the 
surface proteins were isolated by acid/glycine extraction (see Section 2.6.2.1).   The protein 
concentration was determined by a Lowry assay and 10 µg of protein was loaded per lane.   
The surface protein profile of strain 81116 contained 6 potential differentially expressed and 
temperature regulated proteins of ~ 45, 33, 30, 19, 12 and 6 kDa (Figure 5.2a).   All 6 
proteins were up-regulated at 37°C or down-regulated at 42°C.   The genome sequence strain 
appeared to have 4 temperature regulated surface proteins at ~ 49, 43, 20 and 12 kDa (Figure 
5.2b).   The peptide mass fingerprint (PMF) generated by tryptic digestion of the 43 kDa 
protein, OMP43, was analysed by MALDI-TOF mass spectrometry at the Australian 
proteome analysis facility (APAF; Figure 5.4).   No significant PMF matches were found.   
The GBS-associated strain expressed 2 proteins, ~ 49 and 19 kDa, which seemed to be 
subject to temperature regulation (Figure 5.2c).   As seen with both 11168 and 81116, both 
these proteins were either up-regulated at 37°C or down-regulated at 42°C.    
 
The recent chicken isolate, 990922, also displayed 2 differentially expressed proteins, one of 
~ 17 kDa and the other ~15 kDa (Figure 5.3a).   In contrast to the laboratory strains, 990922 
had a 17 kDa protein that was up-regulated at 37°C or down-regulated at 42°C, while the 
other protein (15 kDa) was down-regulated at 37°C or up-regulated at 42°C.   The human 
clinical isolate, MP0401, displayed 4 differentially expressed proteins of ~ 30, 19, 12 and 6 
kDa respectively (Figure 5.3b).   As seen in strains 81116, 11168 and HB9313, a ~ 19 kDa 
protein of MP0401 also appeared to be up-regulated at 37°C or down-regulated at 42°C.   
The second smallest of the differentially expressed proteins, OMP12, was analysed by 
MALDI-TOF at APAF as previously described (Figure 5.5).   OMP 12 was down-regulated 
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Figure 5.2:   SDS-PAGE analysis of acid/glycine extractions from C. jejuni GBS and non-
GBS causing strains A) 81116, B) 11168 and C) HB9313 exposed to human and avian body 
temperatures, 37°C and 42°C respectively.   Each sample was run in duplicate from 
experiments performed as simultaneous repeats.   Lane M, SeeBlue® Plus2 Pre-Stained 
Standard protein marker (Invitrogen); Lanes 1-2, protein fractions from strains grown at 
37°C; Lanes 3-4, protein fraction from strains grown at 42°C.   The red arrows indicate a 
potential differentially expressed protein.   The red box indicates the band, designated 
OMP43, which was excised and sent to APAF for MALDI-TOF analysis.  
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Figure 5.3:   SDS-PAGE analysis of acid/glycine extractions from C. jejuni recent isolates 
of A) chicken (990922) and B) human clinical (MP0401) origin, exposed to human and 
avian body temperatures, 37°C and 42°C respectively.   Lane M, SeeBlue® Plus2 Pre-
Stained Standard protein marker (Invitrogen); Lanes 1-2, C. jejuni strains grown at 37°C, 
duplicate samples run as simultaneous repeats; Lanes 3-4, C. jejuni strains grown at 42°C, 
duplicate samples run as simultaneous repeats.   The red arrows indicate a potential 
differentially expressed protein.   The red box indicates the band, designated OMP12, which 
was excised and sent to APAF for MALDI-TOF analysis. 
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Figure 5.4:   A) MALDI-TOF analysis of OMP43 isolated from C. jejuni strain 11168 by 
acid/glycine extraction which was differentially expressed when exposed to 42°C and 37°C.   
B) Graph representing the range of hits generated by the MALDI-TOF search results using 
the Mascot Search at www.matrixscience.com.   A score of > 49 is a significant match 
(p<0.05), the green shaded area denotes matches that are not significant. 
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Figure 5.5:   A) MALDI-TOF analysis of OMP12 isolated from C. jejuni strain MP0401 by 
acid/glycine extraction which appeared to be differentially expressed when grown at 37°C or 
42°C.   B) Graph representing the range of hits generated by the MALDI-TOF search results 
using the Mascot Search at www.matrixscience.com.   A score of > 49 is a significant match 
(p<0.05), the green shaded area denotes matches that are not significant. 
Significant match: 
Accession no. F81342, mass 
15.9 kDa, Score 69, expect 
0.00057, transthyretin-like 
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at 37°C or up-regulated at 42°C.   The significant match displaying the greatest PMF 
similarity to OMP12 was Cj0715 from C. jejuni 11168 (p<0.05) which is thought to encode a 
transthyretin-like protein (TLP) located in the periplasm (accession number F81342).    
 
The effect of the presence and absence of blood and a range of blood types on the expression 
of C. jejuni surface proteins was also investigated.   Each C. jejuni strain was grown in the 
presence of either chicken, human or horse whole blood in the form of blood agar plates at 
42°C for 16 h.   A negative control of Mueller-Hinton agar without blood was also tested.   
The blood agar was prepared as described in Sections 2.2.1.9 and 2.2.1.8.   The surface 
proteins from each strain exposed to either the test or control conditions were isolated by 
acid/glycine extraction (see Section 2.6.2.1) and analysed electrophoretically for differential 
expression.   The protein concentration was determined by a Lowry assay and 10 µg of 
protein was loaded per lane.    
 
Differentially expressed surface proteins were detected in all strains tested (Figures 5.6 – 
5.7).   The strains 81116 and 11168 each exhibited 2 potentially differentially expressed 
proteins.   A 64 kDa protein which was down-regulated in strain 81116 in the presence of 
blood from any origin tested or was up-regulated when grown on Mueller-Hinton agar 
(MHA) in the absence of blood (Figure 5.6a).   Also in strain 81116 a 58 kDa protein was 
detected when C. jejuni was grown in the presence of blood and was absent when grown 
without blood.   A potential differentially expressed 58 kDa protein was also detected for 
11168 (Figure 5.6b).   In contrast to 81116, it was present when grown on chicken blood agar 
(CBA) or human blood agar (HuBA) or MHA and was absent when grown on horse blood 
agar (HBA).   An 11 kDa protein was detected when strain 11168 was grown in the presence 
of blood and was absent when grown on MHA without blood (Figure 5.6b).    
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Figure 5.6:   SDS-PAGE analysis of acid/glycine extractions from C. jejuni strains A) 
81116, B) 11168 and C) HB9313 grown on a range of blood agar.   Each sample was run in 
duplicate from experiments performed as simultaneous repeats.   Lane M, SeeBlue® protein 
marker (Invitrogen); Lanes 1-2, protein fractions from strains grown on CBA; Lanes 3-4, 
protein fractions from strains grown on HuBA; Lanes 5-6, protein fractions from strains 
grown on HBA; Lanes 7-8, protein fractions from strains grown on MHA without blood 
added.   The red arrows indicate a potential differentially expressed protein.   The red box 
indicates the band, designated OMP19a, which was excised and sent to APAF for MALDI-
TOF analysis. 
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The GBS-associated strain, HB9313, differentially expressed 4 proteins of ~ 21, 19, 11 and 
10 kDa respectively (Figure 5.6c).   The 21 kDa protein was up-regulated when grown on 
either CBA, HuBA or MHA or down-regulated when grown on HBA.   The 19 kDa protein 
was up-regulated on CBA and HBA or down-regulated when grown on HuBA and MHA.   
This protein, designated OMP19a, was selected for further analysis by MALDI-TOF at 
APAF.   The PMF obtained by MALDI-TOF analysis for OMP19a was most similar to 
Cj0998c (20.5 kDa) followed closely by Cj1659 (19.642 kDa, which encodes p19 a known 
periplasmic protein) from C. jejuni 11168 (Figure 5.8).   When using the wider taxonomy 
search parameter of Proteobacteria, the two matches were placed in the reverse order, with 
p19 registering a significant score of 77 and Cj0998c with a score of 61 which was not 
significant in the larger database.   The 11 kDa protein was up-regulated in the presence of 
any blood type or down-regulated in the absence of blood.   The 10 kDa protein was present 
in CBA or MHA and absent on HuBA and HBA. 
 
The four differentially expressed proteins observed for the chicken isolate 990922 were 65, 
9, 7 and 6 kDa respectively (Figure 5.7a).   The 65 kDa protein was up-regulated on HuBA 
and HBA or was down-regulated on CBA or MHA.   The 9 and 6 kDa proteins were down-
regulated when grown on HBA or up-regulated on CBA, HuBA and MHA.   The 7 kDa 
protein behaved in the exact opposite way as it was up-regulated when grown on CBA, 
HuBA and MHA or it was down-regulated in the presence of horse blood.   In addition to 
OMP19 and a 10 kDa protein observed within the surface protein profiles isolated from 
HB9313, the 65 kDa protein of 990922 was the only other protein which exhibited a 
difference between CBA and HuBA.   This would also be another candidate for further 
analysis, however the restrictions caused by limited funding prevented further investigation.    
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Figure 5.7:   SDS-PAGE analysis of acid/glycine extractions from C. jejuni recent isolates 
of A) chicken (990922) and B) human clinical (MP0401) origin, grown in the presence of 
whole blood from different sources.   Each sample was run in duplicate from experiments 
performed as simultaneous repeats.   Lane M, SeeBlue® protein marker (Invitrogen); Lanes 
1-2, protein fractions from strains grown on chicken blood agar; Lanes 3-4, protein fractions 
from strains grown on human blood agar; Lanes 5-6, protein fractions from strains grown on 
horse blood agar; Lanes 7-8, protein fractions from strains grown on Mueller-Hinton agar 
without blood added.   The red arrows indicate a potential differentially expressed protein.    
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Figure 5.8:   A) MALDI-TOF analysis of OMP19a isolated from C. jejuni strain HB9313 by 
acid/glycine extraction which was differentially expressed when grown in the presence of 
human and chicken blood.   B) Graph representing the range of hits generated by the 
MALDI-TOF search results using the Mascot Search at www.matrixscience.com.   A score 
of > 49 is a significant match (p<0.05), the green shaded area denotes matches that are not 
significant. 
Significant matches: 
1. Accession no. C81375, mass 20.5 kDa, Score 69, expect 
0.0006, probable periplasmic protein Cj0998c, C. jejuni 11168 
2. Accession no. 007089 CAMJE, mass 17 kDa, Score 60, 
expect 0.0047, p19 periplasmic protein C. jejuni  
3. Mixture of components with combined total score = 127 
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The recent human isolate, MP0401, exhibited six differentially expressed surface proteins 
ranging in size from 64 kDa to 9 kDa (Figure 5.7b).   The 64 kDa protein was up-regulated 
on HBA or down-regulated on CBA, HuBA and MHA.   The 32 kDa protein was down 
regulated  in the presence of all blood types tested or was up-regulated on MHA.   Both of 
the 28 and 20 kDa proteins were up-regulated on CBA, HuBA and MHA or down-regulated 
on HBA.   Both of the 19 kDa and 9 kDa proteins were up-regulated in the presence of all 
blood types tested or down-regulated in the absence of blood.    
 
Bile from different sources was used as a stimulus to investigate environmental regulation of 
C. jejuni surface proteins.   As it was not possible to obtain human bile, porcine bile extract 
was used instead which is similar to human bile (Alvaro et al., 1986).   In addition, piglets 
have been used successfully as a model for human campylobacteriosis where 
histopathological examination of infected piglets revealed the presence of oedema and 
lesions similar to those observed in humans infected with C. jejuni (Babakhani et al., 1993).   
The bile extracts were used at a concentration of 0.5%, determined by a range finding 
experiment (Figure 5.9) and in accordance with concentrations used previously (Allen & 
Griffiths, 2001).    
 
A concentration of 0.5% was the highest concentration tested that did affect growth but 
within acceptable levels to provide sufficient biomass from which to extract sufficient 
quantities of protein for analysis.   The C. jejuni strains were exposed to either chicken bile 
extract, human bile extract or PBS (as a negative control; see Section 2.2.3.3).   The surface 
proteins were isolated by acid/glycine extraction, see Section 2.6.2.1, and analysed 
electrophoretically using SDS-PAGE.   The protein concentration was determined by a 
Lowry assay and 10 µg of protein was loaded per lane.    
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Figure 5.9:   Bile extract range finding experiment for each of the 5 C. jejuni strains of 
interest grown in the presence of porcine bile diluted with PBS at concentrations ranging 
from 0.05 – 1.0%.   The absorbance of the bacterial culture was measured OD600 at t = 0 min 
(t0) and t = 16 h (t16).   The data was represented as a ratio of the absorbance of each strain 
at OD600, t16 /t0 for each concentration of bile tested and graphed using Microsoft Excel. 
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Figure 5.10:   SDS-PAGE analysis of acid/glycine extractions from C. jejuni GBS and non-
GBS causing strains a) 81116, B) 11168 and C) HB9313 grown in the presence of pig and 
chicken bile extracts.   Each sample was run in duplicate from experiments performed as 
simultaneous repeats.   Lane M, SeeBlue® protein marker (Invitrogen); Lanes 1-2, protein 
fractions from strains grown in the presence of PBS; Lanes 3-4, protein fractions from strains 
grown in the presence of chicken bile extract; Lanes 5-6, protein fractions from strains 
grown in the presence of pig bile extract.   The red arrows indicate a potential differentially 
expressed protein.   The red boxes indicate the bands, designated OMP19b, 28 and 64, that 
were excised and sent to APAF for MALDI-TOF analysis. 
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Figure 5.11:   SDS-PAGE analysis of acid/glycine extractions from C. jejuni recent isolates 
of A) chicken (990922) and B) human clinical (MP0401) origin, grown in the presence of 
pig and chicken bile extracts.   Each sample was run in duplicate from experiments 
performed as simultaneous repeats.   Lane M, SeeBlue® protein marker (Invitrogen); Lanes 
1-2, protein fractions from strains grown in the presence of PBS; Lanes 3-4, protein fractions 
from strains grown in the presence of chicken bile extract; Lanes 5-6, protein fractions from 
strains grown in the presence of pig bile extract.   The red arrows indicate a potential 
differentially expressed protein.  
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C. jejuni 81116 expressed a ~64 kDa protein at higher levels in the presence of chicken bile 
or lower levels when grown with porcine bile or without bile (Figure 5.10a).   A protein of 
approximately the same size (64 kDa) with the same expression behaviour was also observed 
with strains 11168, HB9313 and MP0401 (Figures 5.10 - 5.11).   Strain 11168 exhibited the 
most differentially expressed proteins, of sizes ~ 28, 19 and 10 kDa in addition to the ~ 64 
kDa protein already mentioned (Figure 5.10b).   The ~28 kDa protein was down-regulated in 
the presence of chicken bile or up-regulated in the presence of porcine or no bile.   The ~19 
kDa protein behaved in the opposite way by being up-regulated in the presence of chicken 
bile or down-regulated in the presence of porcine or no bile.   The ~ 10 kDa protein was 
down-regulated in the presence of chicken bile or up-regulated in the absence of bile and 
expressed at higher levels in the presence of porcine bile.    
 
The ~ 64, 28 and 19 kDa proteins that appeared to be differentially expressed by 11168, 
designated OMP64, OMP28 and OMP19b respectively, were excised from the gel and 
analysed by MALDI-TOF at APAF, see Section 2.9 (Figures 5.12 – 5.14).   The PMF data 
obtained from the analysis of OMP19b was similar to that of the 19 kDa protein identified in 
the blood trial (OMP19a) in that Cj0998c was among the highest scoring matches.   In this 
case, Cj0998c was the only significant match generated (Figure 5.12).   The Cj0998c protein 
sequence did not reveal any conserved domains (www.ncbi.nlm.nih.gov).   A Blastp search 
returned significant matches to only other hypothetical proteins, whose functions were also 
unknown.   However, the Blastp search did reveal that this protein seems to be highly 
conserved across many C. jejuni strains and some C. jejuni subsp doylei (95% identity, 
accession ZP 01378575.1) and C. coli (accession ZP 00367994.1) strains.   The identity 
between Cj0998c of 11168 and HB9313 (accession ZP 01071041) was measured at 98% 
with and e value of 2e-90.   It also shared 98% identity with a hypothetical protein of strains 
RM1221 (accession YP 179071.1) and 81-176 (accession YP 01000677.1). 
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98% with an e value of 2e-90.   It also shared 98% identity with a hypothetical protein from 
strains RM1221 (accession YP 179071.1) and 81-176 (accession YP 001000677.1).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12:   A) MALDI-TOF analysis of OMP19b protein isolated from C. jejuni strain 
11168 by acid/glycine extraction which was differentially expressed when grown in the 
presence of human and chicken bile extracts.   B) Graph representing the range of hits 
generated by the MALDI-TOF search results using the Mascot Search at 
www.matrixscience.com.   A score of > 49 is a significant match (p<0.05), the green shaded 
area denotes matches that are not significant.  
Significant match: 
Accession no. C81375, mass 20.5 kDa, 
Score 72, expect 0.00034, probable 
periplasmic protein Cj0998c, C. jejuni 
11168 
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Figure 5.13:   A) MALDI-TOF analysis of OMP28 isolated from C. jejuni strain 11168 by 
acid/glycine extraction which was differentially expressed when grown in the presence of 
human and chicken bile extracts.   B) Graph representing the range of hits generated by the 
MALDI-TOF search results using the Mascot Search at www.matrixscience.com.   A score 
of > 49 is a significant match (p<0.05), the green shaded area denotes matches that are not 
significant. 
Significant match: 
Accession no. A48518, mass 28.2 kDa, Score 
130, expect 4.8e-10, probable ABC-type amino-
acid transporter periplasmic solute-binding protein 
Cj0921c (PEB1) precursor, C. jejuni 11168 
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Figure 5.14:   A) MALDI-TOF analysis of OMP64 isolated from C. jejuni strain 11168 by 
acid/glycine extraction which was differentially expressed when grown in the presence of 
human and chicken bile extracts.   B) Graph representing the range of hits generated by the 
MALDI-TOF search results using the Mascot Search at www.matrixscience.com.   A score 
of > 49 is a significant match (p<0.05), the green shaded area denotes matches that are not 
significant. 
A 
Significant match: 
Accession no. H81277, mass 58.9 kDa, Score 203, 
expect 2.4e-17, Flagellin A C. jejuni sp. 
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The PMF data generated from OMP28 when analysed by MALDI-TOF yielded a significant 
match to PEB1 which is also ~ 28 kDa (Pei et al., 1991).   The third 11168 protein 
differentially expressed and analysed by MALDI-TOF was OMP64.   The highest scoring 
significant PMF match was the flagellin A protein, FlaA.   OMP64 also matched 
significantly with flagellin B, FlaB (Figure 5.14).    
 
The GBS-associated strain displayed two differentially expressed proteins, the largest being 
the ~ 64 kDa protein discussed above and the other being ~ 10 kDa which was down-
regulated in the presence of chicken bile or up-regulated in the presence of porcine bile and 
expressed at higher levels in the absence of bile (Figure 5.10c).   The chicken isolate also 
exhibited two differentially expressed proteins, though of different molecular weights 
(Figure 5.11a).   Both the ~ 33 and 22 kDa proteins were up-regulated in the absence of bile 
or down-regulated in the presence of bile.   The human isolate behaved unlike the other 
strains tested in that all the proteins within the approximate size range of 55 – 22 kDa were 
down-regulated in the presence of chicken bile or up-regulated in the absence of bile or in 
the presence of porcine bile (Figure 5.11b).   MP0401 also expressed a ~ 10 kDa protein 
which was down-regulated in the presence of chicken bile or up-regulated in the presence of 
porcine bile or without bile (Figure 5.11b). 
 
The effect of the presence of host cells, both human (INT407, human epithelial cells) and 
chicken (CEF-DF1, chicken embryo fibroblasts), on the expression of surface proteins was 
investigated.   The larger eukaryotic cells were separated from the smaller prokaryotic cells 
by either filtration or a combination of filtration and centrifugation.   This separation method 
was validated by observing the change in the cell suspension from a mixed culture of 
bacteria and INT407 cells through each step to a purified bacterial culture.   This change was  
 208 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15:   Validation of the filtration method used to separate tissue culture cells from 
bacterial cells.   A) A flow diagram outlining the procedure used to validate the separation of 
bacteria from tissue culture cells by gentle centrifugation and filtration.   The suspension was 
also examined visually by dark field microscopy at each step.   B) At each step of the 
separation process 200 µL was transferred to a microtitre plate and the absorbance was 
measured at 600 nm. 
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observed by dark field microscopy and spectrophotometrically by the change in absorbance 
at 600 nm (Figure 5.15).   Prior to combining the mammalian cells with the bacteria to 
validate the separation method, the tissue culture was visually determined to be free of 
bacterial contamination by inverted and dark field microscopy.   Bacterial yield and quality 
of purification using filtration or centrifugation and filtration/centrifugation combined was 
determined.   The % recovery was calculated as shown below: 
 pre filtration OD600 – post filtration OD600  100 
     pre filtration OD600        1 
The recovery of bacteria passed through the 5 µm filter was on average 94.7%.   The average 
recovery of bacteria separated from a mixed culture of bacteria and tissue culture cells was 
72%.   The finalised protocol employed filtration through a 5 µm pore membrane except 
when excessive amounts of the mammalian cell monolayer had dissociated from the flask 
surface as it clogged the filter.   To avoid filter clogging, a combination of centrifugation 
followed by filtration was required.   The C. jejuni strains were exposed to either INT407 or 
CEF-DF1 cells and each cell line was grown without C. jejuni strains as a negative control.   
The positive control consisted of the C. jejuni strains grown in the absence of either 
eukaryotic cell line.   The C. jejuni strains were exposed to the test or control conditions (see 
Section 2.2.3.4).   The bacteria were separated from the eukaryotic cells and the bacterial 
surface proteins were isolated by acid/glycine extraction (see Section 2.6.2.1), then analysed 
electrophoretically (Figure 5.16-5.17).   The protein concentration was determined by a 
Lowry assay and 10 µg of protein was loaded per lane.    
 
In contrast to the previous three trials investigating the effects of temperature, blood and bile, 
the host cell trial detected only 3 differentially expressed proteins in total.   Both strains 
11168 and 990922 did not exhibit any obvious differentially expressed proteins.   Strain  
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Figure 5.16:   SDS-PAGE analysis of acid/glycine extractions from the C. jejuni strains A) 
81116 and B) 11168 grown in close association to human (INT407) and chicken (CEF-DF1) 
tissue culture cell lines.   Each sample was run in duplicate from experiments performed as 
simultaneous repeats.   Lane M, SeeBlue® protein marker (Invitrogen); Lanes 1-2, protein 
fractions from strains without tissue culture cells; Lanes 3-4, protein fractions from strains 
grown in the presence of CEF-DF1 cells; Lanes 5-6, protein fractions from strains grown in 
the presence of INT407 cells; Lanes 7-8, protein fractions from CEF-DF1 cells without 
bacteria added; Lanes 9-10, protein fractions from INT407 cells without bacteria added.   
The red arrows indicate a potential differentially expressed protein.  
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Figure 5.17:   SDS-PAGE analysis of acid/glycine extractions from C. jejuni recent isolates 
of A) chicken (990922) and B) human clinical (MP0401) origin, grown in close association 
to human (INT407) and chicken (CEF-DF1) tissue culture cell lines.   Each sample was run 
in duplicate from experiments performed as simultaneous repeats.   Lane M, SeeBlue® 
protein marker (Invitrogen); Lanes 1-2, protein fractions from strains without tissue culture 
cells; Lanes 3-4, protein fractions from strains grown in the presence of CEF-DF1 cells; 
Lanes 5-6, protein fractions from strains grown in the presence of INT407 cells; Lanes 7-8, 
protein fractions from CEF-DF1 cells without bacteria added; Lanes 9-10, protein fractions 
from INT407 cells without bacteria added.   The red arrows indicate a potential differentially 
expressed protein.   The red box indicates the band that was excised and sent to APAF for 
MALDI-TOF analysis. 
M       1       2      3       4       5       6                           M      7        8      9     10 
98 kDa 
22 kDa 
36 kDa 
50 kDa 
64 kDa 
6 kDa 
98 kDa 
22 kDa 
36 kDa 
50 kDa 
64 kDa 
16 kDa 
OMP49 
M       1      2       3        4      5       6                           M    7       8      9      10 
16 kDa 
A 
B 
 212 
81116 exhibited two putative host cell regulated proteins of ~ 64 kDa and ~ 26 kDa in size 
(Figure 5.16a).   The 64 kDa protein was up-regulated in the positive control containing 
bacteria in tissue culture media in the absence of either tissue culture cell line.   This protein 
seemed to be down-regulated to approximately the same degree in the presence of either 
human or chicken cell line.   There was no protein of this size present in the protein 
extraction collected from the negative control containing only CEF-DF1 cells, however a 
band was visible at this size in the “INT407 cells only” control sample, and was therefore 
disregarded.   The other protein of ~ 26 kDa seemed to be absent from the C. jejuni surface 
when grown in the presence of either cell line and present in the “bacteria only” positive 
control.   Neither of the negative controls contained a protein of this size.  
 
The human clinical isolate, MP0401, exhibited one differentially expressed band of ~ 49 kDa 
(Figure 5.17b), designated OMP49, which was further analysed by MALDI-TOF at APAF 
(Figure 5.18).   The presence of either host cell line, down-regulated the expression of this 
protein when compared to the positive control containing bacteria only.   There was no 49 
kDa band visible in either of the negative control samples.   The highest scoring significant 
match to the PMF of OMP49 was the C. jejuni major outer membrane protein (MOMP) 
which acts as a porin (Figure 5.18). 
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Figure 5.18:   A) MALDI-TOF analysis of OMP49 isolated from C. jejuni strain MP0401 by 
acid/glycine extraction which was differentially expressed when grown in close association 
with human and chicken tissue culture cell lines.   B) Graph representing the range of hits 
generated by the MALDI-TOF search results using the Mascot Search at 
www.matrixscience.com.   A score of > 49 is a significant match (p<0.05), the green shaded 
area denotes matches that are not significant. 
Significant match: 
Most similar match to an individual protein: Accession no. 
T12047, mass 45.7 kDa, Score 115, expect 1.5e-08, 
major outer membrane porin - C. jejuni sp.   Indicated by 
the black arrow 
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5.3 Discussion 
As more C. jejuni DNA sequence information becomes available, it appears that C. jejuni 
strains exhibit a high degree of genomic diversity (Ahmed et al., 2002; Fouts et al., 2005; 
Gaynor et al., 2004; Parker et al., 2006; Pawelec et al., 2000; Poly et al., 2005; Suerbaum et 
al., 2001).   In view of the variation between C. jejuni strains, five different strains were 
selected for this study of potential virulence determinants by investigating differential 
surface protein expression after exposure to a range of environments.   The recent human 
clinical (MP0401) and chicken (990922) isolates were included in recognition of evidence 
that the pathogenicity of C. jejuni is altered by the environment in which it is cultured 
(Newell et al., 1985b).   Passage of C. jejuni through susceptible hosts increases the 
virulence and colonisation ability of the pathogen (Cawthraw et al., 1996; Field et al., 1993; 
Newell et al., 1985b; Saha et al., 1991; Sang et al., 1989).   It is not surprising then that the 
reverse is also true, where a once virulent strain decreases in its degree of virulence 
following passage in laboratory culture conditions (Gaynor et al., 2004).    
 
The two recent isolates, 990922 and MP0401, were genotyped by PCR-RFLP targeting the 
variable general protein glycosylation gene cluster (Figure 5.1; Shi et al., 2002).   The results 
place MP0401 within the Penner serotypes of either HS:15, HS:33 or HS:44 and 990922 was 
confirmed as HS:31.   In the majority of studies, these serotypes are not among the most 
commonly isolated, unlike the predominant serotypes of HS:1/44, HS:41, HS:19, HS:4 or 
HS:2 (Albert et al., 1992; Lastovica et al., 1986; Saito et al., 2005), though it should be 
noted that the determination of predominant serotypes is dependent upon geographical 
location and host type.   An association of serotype HS:31 with poultry was observed in 
Japan, though the occurrence of this serotype was comparatively scarce (Saito et al., 2005).   
In Trinidad, a study investigating the distribution of C. jejuni serotypes among broilers 
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showed that HS:31 was the most often isolated accounting for 19.2% of isolates tested 
(Rodrigo et al., 2006).   In contrast, the HS:31 serotype was also among the most uncommon 
human isolates in a study performed in Finland (Vierikko et al., 2004).   A comparative 
genomics study investigating the LOS biosynthesis cluster of C. jejuni from a variety of 
sources includes a HS:31 chicken isolate  ( strain RM1170; Parker et al., 2005).   None of the 
human isolates in this extensive study were of the HS:31 serotype (Parker et al., 2005). 
 
The effect of different environmental conditions on the expression of C. jejuni surface 
proteins was investigated.   Surface proteins were the target of this study because they 
interact directly with the external environment, including components of the host immune 
system, and may have potential as vaccine candidates or targets for drug therapy.   However, 
it should be noted, that the acid/glycine extraction method used to isolate surface proteins 
(see Section 2.6.2.1; Logan & Trust, 1983) is limited in that it does not specifically 
differentiate OMPs from periplasmic proteins (Penn, 2001).   Therefore, caution must be 
exercised when speculating about the location of proteins isolated with this method. 
 
The environments of interest were modelled on typical human and chicken conditions, 
including temperature, blood type, bile extract and host cells.   The first parameter 
investigated was temperature due to the difference in body temperature between humans and 
chickens.   A total of 18 surface proteins from the 5 strains tested appeared to be temperature 
regulated (Figures 5.2 – 5.3).   For each of the strains 81116, 11168, HB9313, 990922 and 
MP0401 the number of differentially expressed proteins were 6, 4, 2, 2 and 4, respectively.   
The surface protein profile of each strain tested was unique.   All of the putative temperature 
regulated proteins from 81116, 11168 and HB9313 were up-regulated at 37°C or down-
regulated at 42°C.   The recent isolates produced proteins which were up and down-regulated 
at 37°C.    
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A peptide mass fingerprint (PMF) was obtained from two potential temperature regulated 
proteins of 43 kDa (OMP43) and 12 kDa (OMP12) from strains 11168 and MP0401, 
respectively.   No significant matches were found to the PMF of OMP43 (Figure 5.4).   Two 
known surface proteins of ~ 43 kDa include the adhesin, JlpA and the porin, MOMP.   
However, given that the protein analysed was expressed by C. jejuni 11168 for which the 
genome project is complete, it is surprising that there was no significant match and may 
reflect a problem with the sample itself, e.g., more than one protein present in the excised 
band making the data difficult to interpret.   The most similar match to OMP12 was Cj0715 
from C. jejuni 11168 (Figure 5.5), which based on sequence similarity is thought to encode a 
transthyretin-like protein (TLP; www.sanger.ac.uk).   The C. jejuni TLP is 15.92 kDa (Lee et 
al., 2005), which is larger than OMP12 observed in this study.   This size discrepancy can be 
accounted for by the post translational cleavage of the signal peptide thought to be 
responsible for targeting the protein to the periplasm, leaving the mature protein at ~13 kDa 
(Lee et al., 2005).    
 
TLP is the evolutionary ancestor of transthyretin (TTR), a vertebrate thyroxin transport 
protein (Eneqvist et al., 2003).   Despite some sequence and structural similarities, TLP and 
TTR have different functions.   TLPs are a highly conserved protein family present in 
animals, plants and bacteria with varying function.   A cytoplasmic TLP present in Bacillus 
subtilis (PucM) functions as a 5-hydroxyisourate (5-HIU) hydrolase (5-HIUHase) thought to 
be involved in the purine catabolic pathway enabling the bacteria to utilise purines as an 
alternative nitrogen source (Lee et al., 2005).   However, in enterobacteria such as E. coli, 
Salmonella spp. and C. jejuni, the TLP is located in the periplasm and despite it also showing 
5-HIUHase activity it seems to have a different role (Eneqvist et al., 2003; Hennebry et al., 
2006).   The TLP of enterobacteria is thought to defend against oxidative damage, as it does 
in birds (Hennebry et al., 2006).   This role is supported by the absence of two purine 
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catabolic pathway enzymes, uricase and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline 
(OHCU) decarboxylase from the enterobacteria investigated to date and also from birds 
(Hennebry et al., 2006; Simoyi et al., 2003).    
 
Oxidative (non-enzymatic) degradation of uric acid also leads to the production of 5-HIU 
and eventually allantoin (Hennebry et al., 2006; Santos et al., 1999).   Therefore, the 
presence of allantoin does not confirm the enzymatic catabolism of purines.   It has been 
demonstrated that despite lacking uricase, birds carry allantoin in their plasma and it was 
postulated that birds use uric acid as an antioxidant (Simoyi et al., 2003).   Recently it has 
been shown that E. coli is also able to generate allantoin.   However, the rate at which E. coli 
catabolises purines is not sufficient to support aerobic growth (Xi et al., 2000).   It seems 
likely that the function of the periplasmic enterobacterial TLP is one of oxidative stress 
defence rather than purine catabolism (Hennebry et al., 2006; Xi et al., 2000).   It has been 
suggested by Hennebry and colleagues that the enzymatic removal of 5-HIU by invading 
bacteria combats the accumulation of toxic free radical species such as those released during 
respiratory burst, e.g., peroxynitrite (Hennebry et al., 2006).   Thus allowing the bacteria to 
persist within the host and cause infection.    
 
The over expression of Cj0715 at 42°C was initially unexpected because C. jejuni are 
commensal in chickens and therefore are less likely to cross the intestinal epithelial mucosa 
and encounter host immune cells.   Only an invaded C. jejuni cell will encounter the effects 
of respiratory burst (Henderson et al., 1999).   Perhaps the up-regulation of Cj0715 at 42°C 
observed in strain MP0401 was not reflective of defence against respiratory burst, but may 
instead reflect the formation of a biofilm.   Two DNA microarray studies investigating C. 
jejuni (strain 11168) biofilm formation have been conducted, one identified Cj0715 as being 
over expressed in biofilm-grown cells (Kalmokoff et al., 2006) while the other did not 
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(Sampathkumar et al., 2006).   In both of these studies the bacteria were incubated at 37°C 
for 24 h under microaerobic conditions.   A ~ 12 kDa protein, which may be Cj0715, was 
also over expressed at 42°C by C. jejuni strain 11168 in this study (Figure 5.2).   Perhaps the 
increased temperature of 42°C induced the formation of a biofilm more rapidly than at 37°C, 
which in turn up-regulated Cj0715.   Immobilised bacteria have been observed to undergo a 
reprioritisation of cellular activities away from metabolic, motility and protein synthesis 
capabilities towards iron uptake, oxidative stress defence and membrane transport 
(Sampathkumar et al., 2006).   This pattern of expression shares some similarities with that 
observed for C. jejuni during host colonisation (Wang et al., 2004).   Previous studies which 
-were designed to investigate C. jejuni survival and biofilm formation have been performed 
at temperatures of 37°C or lower (Dykes et al., 2003; Joshua et al., 2006; Kalmokoff et al., 
2006; Sampathkumar et al., 2006).   Little is know about the biofilm formation of C. jejuni at 
temperatures greater than 37°C.   Earlier in this study (Chapter 4) C. jejuni strain 81116 was 
observed to be significantly more adherent to chicken cells than human cells and 
significantly more invasive of human cells than chicken cells.   It may be that immobilised 
adherent C. jejuni cells are more likely to form a biofilm than mobile invasive cells, which 
raises the question - is C. jejuni less pathogenic when growing as a biofilm?   Further 
investigation is required to fully characterise the function and regulation of Cj0715 and to 
understand the importance of biofilm formation in relation to colonisation and pathogenesis.    
 
The second environmental parameter investigated was the presence or absence of whole 
blood from a variety of sources.   A total of 18 proteins from all of the 5 strains tested 
appeared to be differentially expressed when grown on different blood agar or in the absence 
of blood (Figures 5.6-5.7).   The expression profile differed between each strain.   One of the 
18 proteins, OMP19a from strain HB9313, was analysed by MALDI-TOF to generate a 
PMF.   OMP19a was up-regulated in the presence of chicken and horse blood or was down-
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regulated in the presence of human blood or the absence of blood.   The PMF obtained from 
OMP19a was most similar to Cj0998c (20.5 kDa) and Cj1659 (19.642 kDa, which encodes 
p19 a known periplasmic protein) from C. jejuni 11168 (Figure 5.8).    
 
The protein sequence of p19 contains the Tpd conserved domain suggesting a role of high-
affinity iron (Fe2+) transport (www.ncbi.nlm.nih.gov).   P19 is conserved in both C. jejuni 
and C. coli and was not found to be immunogenic during natural infection in humans 
(Janvier et al., 1998).   More recently, p19 was identified as being a putative iron-transport 
protein (Holmes et al., 2005).   It was expressed at higher levels in C. jejuni 11168 under 
iron limitation and in a 11168 ferric uptake regulator (fur) mutant grown in an iron-rich 
environment (Holmes et al., 2005).   P19 is thought to be regulated by the Fur protein based 
on the results of the fur mutant studies and the observation of Fur binding to a promoter 
upstream of p19   (Holmes et al., 2005).   In C. jejuni, Fur is thought to regulate several of 
the proposed iron-uptake systems which includes p19, however it is not solely responsible 
for this function (van Vliet et al., 1998).    
 
The mean serum iron concentration of healthy chickens, humans or horses has been 
measured at 104, 81.5 and  130 µg iron/ 100 mL serum respectively (Króliczewska & 
Zawadzki, 2005; Osbaldiston & Griffith, 1972; Seamonds & Anderson, 1981).   Therefore, 
the iron provided by adding 5% blood to prepare CBA, HuBA or HBA is 5.2, 4.1 and 6.5 
µg/100ml respectively.   Comparatively, the average iron composition of prepared MHA is 
0.912 µg/100 mL (Oxoid Technical Support, Julie Elston personal communication).   Based 
on the relative iron concentrations estimated from the literature for each blood type used, it is 
unlikely that OMP19a is p19 as the expression observed in this study is the opposite to what 
has been previously reported.   Previous studies have found that p19 regulation was iron 
repressed and that it was up-regulated in conditions of iron limitation (Holmes et al., 2005; 
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Palyada et al., 2004).   These differences could be attributable to several variables, including 
natural variation of serum iron between individual animals or humans, as well as 
experimental differences such as growth conditions, incubation times and methods of 
analysis used.   The normal human serum iron concentrations can range from 60 to 170 
µg/100 mL with different average levels observed for males and females (Seamonds & 
Anderson, 1981).   Differences are also seen between breeds and gender of horse 
(Osbaldiston & Griffith, 1972).   Little information is available about the effect of feed type, 
gender and breed of chicken on serum iron concentration.   Without knowing the specific 
iron concentration of each blood sample used for preparing each media type, it is not 
possible to speculate beyond the average levels as they appear in the literature.   Moreover, 
previous studies investigating iron regulated expression were both performed using 
microarray technology (Holmes et al., 2005; Palyada et al., 2004).   These studies used 
shorter incubation times as less biomass is required to obtain sufficient quantities of RNA as 
opposed to protein.   As gene expression is a transient and dynamic process, the difference in 
incubation time will have an enormous impact on the resulting expression data generated 
(Palyada et al., 2004; Stintzi, 2003).    
 
On the other hand, OMP19a may be Cj0998c.   Cj0998c is a putative periplasmic protein 
which is 20.5 kDa in C. jejuni strain 11168 and at this stage is yet to be characterised.   The 
little information that we do have about this putative protein includes that its regulation is 
influenced by the presence of bile (Fox et al., 2007) and iron (Palyada et al., 2004), it may be 
glycosylated (Young et al., 2002) and it may be involved in the efflux of bile.   Further 
characterisation of the protein encoded by Cj0998c in C. jejuni and its homologues in other 
strains is required.   In the absence of confirmation about the identity of OMP19a, further 
investigation is required to determine whether it is p19, Cj0998c or a protein that has not yet 
been characterised and is therefore not in the PMF database.   Identification of the specific 
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factors contributing to the differential expression of OMP19a may shed some light on its 
function.   Moreover, additional studies are needed to confirm the identity of the 19 kDa 
protein.   Future studies should include an iron-limited environment as a negative control by 
adding an iron chelating supplement, e.g., deferoxamine mesylate, to the MHA culture media 
as previously described (Smith et al., 2001).    
 
The third environmental parameter investigated was the presence or absence of porcine or 
chicken bile extract.   The bile tolerance of C. jejuni was confirmed during this study were 
each of the five strains tested successfully grew in concentrations of up to 1% bile extract 
(Figure 5.9).   The concentration of bile extract used in test conditions was determined by a 
range finding experiment (Figure 5.9).   The results showed that the growth of each of the 5 
strains in the presence of 0.5% bile extract was reduced but not halted and no cell lysis was 
observed.   At 0.5% bile extract the bacterial growth was sufficient to produce biomass to 
facilitate surface proteins analysis.    
 
The 5 C. jejuni strains exhibited a total of 11 potentially bile regulated proteins (Figures 
5.10-5.11).   Strain 11168 exhibited the most differentially expressed proteins, of sizes ~ 64, 
28, 19 and 10 kDa (Figure 5.10).   The three proteins selected for further analysis were the 
64, 28 and 19 kDa proteins designated OMP64, OMP28 and OMP19b respectively.   OMP28 
was down-regulated in the presence of chicken bile or up-regulated in the presence of human 
or no bile.   Both OMP64 and OMP19b behaved in the opposite way to OMP28 by being up-
regulated in the presence of chicken bile or down-regulated in the presence of porcine or no 
bile.   PMF data was generated for each OMP19b, OMP28 and OMP64 with the most similar 
matches being Cj0998c, PEB1 and FlaA respectively (Figures 5.12-5.14). 
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The Cj0998c protein which is 20.6 kDa in C. jejuni 11168 has previously been shown to be 
up-regulated in the presence of bovine bile extract at a concentration of 2.5% (w/v; Fox et 
al., 2007).   As previously mentioned, its expression levels are also affected by iron levels 
(Palyada et al., 2004).   As the expression of this protein seems to be affected by 
environmental stimuli, it may be important in pathogenesis and should be the focus of future 
work.   Unfortunately, at this stage its function is unknown although it has been postulated 
that it may be involved in enhancing efflux of bile from C. jejuni (Fox et al., 2007).    
 
Multidrug efflux pumps of gram-negative bacteria can provide elevated levels of resistance 
to a particular toxin when over expressed (Li & Nikaido, 2004).   However, Cj0998c shares 
no sequence similarity with any known multidrug efflux pump sequences.   Although the 
regulation of Cj0998c appears to respond to the presence of bile, which is in keeping with 
the observations made by Fox and colleagues, it is premature to suggest that this protein is 
specifically involved in enhancing bile efflux as Fox and colleagues have suggested without 
further characterisation (Fox et al., 2007).   It is clear that the regulation of this protein 
responds to the presence of bile from various origins, however the specific function of this 
protein and its association to bile is yet to be determined.   It would be interesting to further 
investigate C. jejuni protein and gene expression in the presence of individual bile salts with 
emphasis on the typical bile salt profile of chicken and human bile. 
 
The most significant match to the PMF data obtained for OMP28 was PEB1 (Figure 5.13)   
OMP28 was up-regulated in the absence of bile and the presence of pig bile or was down-
regulated in the presence of chicken bile (Figure 5.10).   As previously discussed, PEB1 is an 
immunogenic 28 kDa periplasmic protein important for C. jejuni adhesion and contains the 
conserved domain common to ABC-type amino acid transporters (Pei & Blaser, 1993; Pei et 
al., 1998; Pei et al., 1991).   The expression of this protein being down-regulated in the 
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presence of chicken bile is not surprising as C. jejuni is only minimally invasive in the 
chicken host when compared to the relatively high levels of invasion observed in humans.   
Repression of peb1A expression would decrease its ability to adhere and therefore invade.   
It has been suggested that PEB1 is the adhesin developed specifically for the human host, 
while ompH1 which is apparently encoded by the same gene, is a variant specifically used 
for adherence within the chicken host (Meinersmann et al., 1997).   The results obtained in 
this study support the notion of host specificity of PEB1.   Perhaps this suggests that bacteria 
are chemotactically able to differentiate host type by the chemical composition of the bile it 
senses.    
 
Further investigation of the effect of bile from different origins on the pathogenicity of C. 
jejuni would improve our understanding of the importance of specific environmental signals.   
Invasion and adhesion assays incorporating chicken bile and human bile together with 
human and chicken cell lines at different temperatures would shed some light on which 
combination of environments enables C. jejuni to be most invasive thus providing clues to 
factors important to successful pathogenesis.   Identifying these factors and developing 
strategies to exploit their role in C. jejuni pathogenesis could provide much needed vaccine 
or drug therapies. 
 
OMP64 was up-regulated in the presence of chicken bile or down-regulated when grown 
with pig bile or without bile (Figure 5.10).   The highest scoring significant PMF match was 
the flagellin A protein (FlaA; Figure 5.14) which, together with FlaB, polymerises to form 
the bacterial flagellum.   A significant match was also found with FlaB which is not 
surprising given that the two proteins share >90 % sequence identity (Guerry et al., 1991).   
Motility is widely accepted as being an important trait in C. jejuni colonisation of the GI 
tract and FlaA is regarded as an important virulence factor (Carrillo et al., 2004; Morooka et 
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al., 1985; Newell et al., 1985a; Nuijten et al., 2000; Wassenaar et al., 1993; Wösten et al., 
2004).   The FlaA protein is required for invasion but FlaB is not (Wassenaar et al., 1991). 
 
The transcription of flaA is under the control of the σ28 promoter unlike flaB which is 
controlled by σ54 (Allen & Griffiths, 2001).   A previous study was performed to investigate 
environmental regulation of the σ28 promoter in the presence of intestinally relevant stimuli 
and found that bovine bile up-regulated flaA promoter activity (Allen & Griffiths, 2001).   
Other researchers have investigated the transcription of flaA and have shown it to be 
influenced by autoinducer-2 quorum sensing (Jeon et al., 2003), up-regulated by the 
chemoattractant L-fucose and down-regulated by sodium desoxycholate (Kelana & Griffiths, 
2003).   It has also been established that the expression of flaA is phase variable which 
causes the flagellum to be switched on or off (Nuijten et al., 1995).   Furthermore, nonmotile 
flaA mutants underwent DNA rearrangements which generated motile revertants after 
exposure to the chicken intestine and liquid culture, though the nature of these 
rearrangements was different in each case (Nuijten et al., 2000).    
 
The over expression of flaA in the presence of chicken bile may be attributable to the protein 
itself, rather than motility as previously observed with colonisation studies of the chicken 
caeca (Wassenaar et al., 1993).   Perhaps the up regulation of flaA is representative of C. 
jejuni’s preference for the chicken intestine, which has been suggested as its natural 
environment (Wassenaar et al., 1993).   Further investigation is required to fully elucidate 
the chemical components of bile that appear to be important in the regulation of key 
virulence factors. 
 
The fourth trial investigated the effect of host cells, human (INT407) and chicken (CEF-
DF1) cell lines, on C. jejuni surface protein expression.   For this investigation to be possible 
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it was necessary to develop a method to separate the bacteria from the host cells in the mixed 
culture.   A filtration method was developed and validated for the purpose of this study 
(Figure 5.15).   The 5 µm filter used exploited the size difference between the prokaryotic (< 
~ 5 µm) and intact eukaryotic cells (~ 10 µm).   If the eukaryotic cells dissociated from the 
flask surface, an additional separation step of gentle centrifugation prior to filtration was 
required to prevent clogging of the filter.   A clogged filter led to a low bacterial yield which, 
in turn, resulted in the extraction of an amount of protein too low to analyse.   The recovery 
of bacteria was monitored and validated by OD600 measurements and confirmed visually by 
phase contrast microscopy.   The negative controls containing either the human or chicken 
cell lines alone ensured that any secreted eukaryotic protein which carried over into the 
protein fraction would be detected and consequently not be considered for further analysis.   
Unfortunately, the isolation of invaded bacteria in large enough quantities was not possible at 
this scale and further optimisation is required. 
 
A total of 3 potentially host cell regulated proteins were identified from the profiles of the 
five C. jejuni strains tested (Figures 5.16-5.17).   The recent human clinical isolate, MP0401 
exhibited one differentially expressed band of ~ 49 kDa, OMP49.   The presence of either 
host cell line down-regulated the expression of this protein when compared to the positive 
control containing bacteria only.   There was no 49 kDa band visible in either of the negative 
control samples.   The highest scoring significant match to the PMF of this protein was the 
C. jejuni MOMP which acts as a porin (Figure 5.18).   In C. jejuni 11168 MOMP is 45.7 kDa 
and is widely distributed between C. jejuni strains, however it can vary structurally (Newell 
et al., 1984; Pumbwe et al., 2004).   The momp promoter controls the regulation of porA 
which encodes MOMP and responds to changes in pH and temperature (Dedieu et al., 2002).    
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Initially, the down regulation of MOMP in the presence of INT407 cells was surprising 
given that there is evidence of it playing a role in adherence to this cell line (Moser et al., 
1997; Schroder & Moser, 1997).   However, it is important to note that it was not possible to 
extract proteins from adhered or invaded bacteria therefore the protein profile was obtained 
from the unattached bacteria in solution.   Even though the bacteria in solution had settled 
onto the host cell monolayer and were therefore in relatively close association, they were not 
physically attached.   In this situation, the adherent bacteria would be able to “communicate” 
with the non-adherent bacteria via quorum sensing.   C. jejuni possesses a type 2 quorum 
sensing system and a link between the LuxS protein, an autoinducer synthase, and regulation 
of cytolethal distending toxin genes and flaA has been observed (Jeon et al., 2003; Jeon et 
al., 2005).   Presumably, the surface protein profile which would provide the most valuable 
information with respect to proteins involved in virulence, would be extracted from the 
bacteria that have actually interacted physically with the host cells.   Again, modification and 
further optimisation is necessary for this to be possible.   
 
A previous investigation of environmental regulation of MOMP identified that it was down-
regulated at lower pH conditions (Dedieu et al., 2002).   The expression profile of MOMP in 
C. jejuni MP0401 in different conditions is most likely attributable to the change in media 
pH.   The flasks containing both bacteria and host cell required more nutrients and produced 
more by-products than the control samples where only one cell type was present.   The 
phenol red pH indicator present in the DMEM of the test flasks was noticeably more yellow 
than the control flask which confirmed that the test flask pH decreased to create a more 
acidic environment.   Therefore, as one of the main roles of a porin is to regulate membrane 
permeability, it is not surprising that the largest and most abundant porin would be down-
regulated in a more toxic environment in an attempt to protect the bacteria from the acidic 
conditions.   Other parameters which may reduce the impact of toxic by-product build up 
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include a reduced incubation period and/or an increase in media volume.   Further 
optimisation of this experimental approach is required. 
 
In summary, it has been shown that several C. jejuni surface proteins undergo differential 
expression when exposed to modelled human and chicken environments in vitro.   The 
surface protein profile produced by each of the five C. jejuni strains tested was unique to 
each strain.   So too was the change in surface protein expression when exposed to each test 
condition.   Each modelled environment led to the detection of more than one differentially 
expressed surface protein.   The PMF data obtained from the analysis of the 7 differentially 
expressed proteins, all showed matches to C. jejuni surface proteins.   These results confirm 
that the acid/glycine extraction method used reliably isolates surface proteins without 
contamination from cytoplasmic proteins.   In this study it was concluded that the growth of 
C. jejuni at human body temperature resulted in a general increase in surface protein 
expression when compared to the avian body temperature for the three laboratory strains 
tested.   The temperature trial also highlighted the differences between the response of 
laboratory strains and recent isolates.   This was also seen in both the blood and bile trials 
where the human clinical isolate exhibited a greater number of differentially expressed 
surface proteins than any of the laboratory strains tested.   The recent chicken isolate 
consistently varied its surface expression the least across the four trials.   In vitro modelling 
of “pathogenic” versus “non-pathogenic” environments is a useful tool in identifying 
potentially important virulence factors.   However, observations made as a result of in vitro 
investigations are at best only an indication of what may or may not occur in an in vivo 
setting and should not be taken as directly representative of a natural infection.   Despite this, 
the environmentally regulated surface proteins identified in this study could potentially be 
involved in pathogenesis and provide a good starting point for further investigation. 
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CHAPTER 6: Investigation of C. jejuni gene 
expression when exposed to modelled host 
environments  
 
6.1 Introduction 
C. jejuni can successfully adapt to and protect itself from a wide range of environmental 
conditions and stresses making it ubiquitous and persistent, despite having a relatively small 
genome, an elevated optimal temperature, sensitivity to atmospheric oxygen levels and a 
requirement for rich growth media (Park, 2000).   It is essential for C. jejuni to have the 
capacity to respond rapidly to changes in environmental conditions through a range of 
regulatory systems.   These systems function to recognise specific stimuli indicative of 
environmental change and facilitate a response which translates into physical modification.   
C. jejuni possess a number of different gene regulation systems which allow a rapid response 
to changes in environment through adjustment of the transcriptome.   Some expression 
regulation mechanisms employed by C. jejuni include slippage synthesis, alternative sigma 
factors, gene organisation into operons and regulons, activator/repressor proteins, two-
component regulation systems and possibly global regulatory proteins (Finlay & Falkow, 
1997; Helmann, 2002; Nuijten et al., 1995; Park, 2000; Parkhill et al., 2000).    
 
In order for C. jejuni to mount an appropriate response to changes in its environment, it first 
needs to sense the nature of the change through the detection of relevant stimuli.   Early work 
investigating environmental gene regulation of C. jejuni focused on response to heat shock 
(Konkel et al., 1998), oxidative stress (Wai et al., 1996) and iron limitation (Field et al., 
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1986) though more recent studies have incorporated bile (Doig et al., 1996), quorum sensing 
(Elvers & Park, 2002), nitrosative stress (Elvers et al., 2004) and biofilm formation (Dykes 
et al., 2003) as factors important to environmental regulation.   One of many examples of the 
relationship between a stimulatory signal and the regulation of virulence factors can be seen 
in the work conducted by Rivera-Amill and others (2001), which detected the induction of 
Campylobacter invasion antigens in response to bile salts and various eukaryotic host cell 
components. 
 
The response of C. jejuni to changes in temperature is perhaps the most thoroughly 
investigated regulatory system.   Campylobacters can encounter a wide range of 
environmental temperatures from refrigerated food (4°C) to the avian gastrointestinal tract 
(42°C) and live C. jejuni can be isolated from both of those environments.   It is therefore 
reasonable to assume that C. jejuni possess both cold and heat shock defence mechanisms.   
Many C. jejuni heat shock proteins have been identified, though interestingly no genes 
homologous to cold shock proteins of other bacteria, e.g., CspA from  E. coli (Rath & Jawali, 
2006), have been found in C. jejuni (Hazeleger et al., 1998).    
 
Heat stress can affect bacteria by causing proteins to be folded incorrectly which can 
interfere with their function.   It is common for bacteria to respond to heat shock by over 
expressing a group of ATP-dependent proteases which are involved in the degradation of 
deformed or denatured proteins and are referred to as heat shock proteins (HSPs; Thies et al., 
1998).   Temperature is potentially a key environmental factor in the difference between C. 
jejuni as a commensal organism or C. jejuni as a pathogen, given that it is not generally 
accepted as a chicken pathogen (body temperature = 42°C) but is considered a serious 
human pathogen (Stintzi, 2003).   Some chaperones and heat shock proteins have been 
identified in C. jejuni, like GroEL, GroES, DnaJ, DnaK, GrpE, HrcA and Lon (Park, 2000).   
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Both GroEL and GroES have been observed as immunogenic in rabbits (Wu et al., 1994).   
In addition, the HSP DnaJ is important in chicken colonisation and growth at > 46°C as 
determined by analysis of a DnaJ- mutant (Konkel et al., 1998).   HrcA is thought to act as a 
repressor protein which controls the regulation of other HSPs in the same operon, those 
being grpE, dnaK and dnaJ based on studies conducted with Bacillus subtilis (Park, 2000; 
Schulz & Schumann, 1996).   In C. jejuni the organisation of a similar operon is slightly 
different in as far as dnaJ (Cj1260c) is located elsewhere on the chromosome, while 
homologues of hrcA (Cj0757), grpE (Cj0758) and dnaK (Cj0759) are located together (Park, 
2000). 
 
Enterically relevant substances, like bile, are important environmental stimuli for C. jejuni as 
the presence of which indicates entry to a host intestinal environment.   Bile consists of 
detergent-like amphiapathic molecules, cholesterol, phospholipids, bilirubin and possesses 
potent antimicrobial activity (Lin et al., 2003).   Bile is produced in the liver, stored in the 
gall bladder and secreted into the small intestine where it plays a digestive, excretory and 
protective role (Hofmann, 1999).   Bacteria that inhabit the enteric environment develop 
strategies to avoid the antimicrobial activity of bile.   Some mechanisms of bile resistance 
include porins, transport proteins, efflux pumps and LPS/LOS (Prouty et al., 2004b).   Many 
bacteria, including C. jejuni, also use bile as a stimulus for gene regulation (Allen & 
Griffiths, 2001; Lin et al., 2005; Prouty et al., 2004a).   Bile has been reported as being 
involved in the regulation of the C. jejuni efflux pump, CmeABC (Lin et al., 2005) and FlaA 
(Allen & Griffiths, 2001).    
 
C. jejuni is a human pathogen and in almost all cases, exists as a commensal in chickens 
(Byrne et al., 2007).   Investigating the regulation of C. jejuni genes when the bacteria is 
exposed to conditions which are based on pathogenic or non-pathogenic environments could 
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lead to the identification of genes important to C. jejuni virulence.   Genes which are 
expressed or up-regulated when C. jejuni enters an environment where it can be pathogenic 
could be important in the process of how the bacterium causes disease.   The identification of 
such virulence genes and an understanding of factors which are important to their regulation 
can provide valuable insights into pathogenesis mechanisms at a molecular level.   This 
knowledge could potentially highlight useful targets for treatment or prevention strategies in 
the form of drug therapies or vaccines respectively.   Many investigations focussing on 
global and gene-specific environmental regulation of C. jejuni have been conducted (Allen & 
Griffiths, 2001; Dedieu et al., 2002; Dorrell et al., 2001; Klancnik et al., 2006; Palyada et 
al., 2004; Stintzi, 2003; Stintzi et al., 2005).   Despite the wealth of knowledge in this area, 
we do not fully understand the environmental regulation of genes encoding C. jejuni 
virulence factors at a molecular level.   Furthermore, we cannot explain why C. jejuni is a 
pathogen to humans, but a commensal to chickens. 
 
The aim of this study was to investigate and identify environmentally regulated genes from 5 
different C. jejuni strains.   Those strains include two enteritis strains (C. jejuni 11168 and C. 
jejuni 81116), an enteritis strain associated with GBS (C. jejuni HB9313), a recent chicken 
isolate (C. jejuni 990922) and a recent human clinical isolate (C. jejuni MP0401).   The 
environments that the bacteria were exposed to were modelled on “human” (pathogenic) and 
“chicken” (non pathogenic) conditions.   The four environmental stimuli investigated were 
temperature (humans 37°C and birds 42°C), whole blood (human and chicken), bile extracts 
(pig and chicken) and host cells (human, INT407 and chicken, CEF-DF1).    
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6.2 Methods and Results 
The impact of environmental stimuli on global gene regulation was investigated.   Random 
arbitrarily primed (RAP) differential display (DD) reverse transcription (RT) PCR was used 
in an attempt to detect differentially expressed genes in each of the 5 C. jejuni strains, 81116, 
11168, HB9313, 990922 and MP0401.   Each of the 5 strains were subjected to the same 
environments used in the previous chapter, i.e., temperature (37°C and 42°C), blood type 
(chicken, human, horse and MH agar without blood added as a negative control), bile 
(chicken and porcine bile extracts, with PBS as a negative control) and host cells (chicken 
and human).   The duration of the incubations where the bacteria were exposed to the 
environmental conditions of interest were shorter in this chapter than the previous chapter.   
At the transcriptome level, changes can be detected within 5 min (Stintzi, 2003).   The 
detection of a change in surface protein profile requires a longer incubation time.   In 
addition, comparatively less mRNA is required for downstream analysis (pg level) than 
protein (µg level).   The cells were incubated for 15 min for the temperature trial and for 1 h 
in each of the other environments of interest.    
 
The RNAgents kit (Promega) was used to isolate total RNA from each of the 5 C. jejuni 
strains in each of the conditions tested (see Section 2.4.2.1).   An example of the RNA 
isolated was visualised by ethidium bromide stained formaldehyde agarose gel 
electrophoresis (see Section 2.4.2.3; Figure 6.1).   The number of rRNA fragments present 
differed between C. jejuni strains.   Strains 81116, HB9313 and MP0401 all produced 4 
fragments, while strains 11168 and 990922 produced the 3 expected 23S, 16S and 5S 
fragments.   No contaminating genomic DNA was visible for any strain and the A260/A280 
ratio was consistently between 1.8 and 2.1 when measured in 10 mM Tris.HCl (pH 7.5) 
suggesting a high level of purity (results not shown).   Despite this, all RNA samples  
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Figure 6.1:   RNA isolated from C. jejuni strains using RNAgents (Promega), separated by 
formaldehyde gel electrophoresis and stained with ethidium bromide.   Lane 1, Lambda 
DNA MW marker digested with PstI; Lane 2, C. jejuni 81116 total RNA isolation; Lane 3, 
C. jejuni 11168 total RNA isolation; Lane 4, C. jejuni HB9313 total RNA isolation; Lane 5, 
C. jejuni 990922 total RNA isolation; Lane 6, C. jejuni MP0401 total RNA isolation. 
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were treated with DNase (see Section 2.4.2.4).   The RT reaction was performed as described 
in Section 2.4.2.5.1.   The protocol used for the PCR step of the RT PCR was described 
previously (see Section 2.4.2.5.2).   The initial cycle containing a non stringent annealing 
temperature of 40°C, was used to encourage the production of a high number of random 
amplicons essentially as described previously (Liang & Pardee, 1992; Welsh & McClelland, 
1990).    
 
Random primers designed for the Enterobacteriaceae were used to reverse transcribe and 
amplify regions of the transcriptome from each of the 5 strains (Fislage et al., 1997).   
Optimisation of random primer combinations used for RAP DD RT PCR was performed, 
including multiplex RT PCRs (Figure 6.2).   The more complex the primer mixture became, 
the less clear and less defined were the resulting amplicons.   As a result, a single random 
primer pair was used in the optimised protocol instead of a multiplex priming system.   In 
addition, different quality Taq polymerases were compared to identify the optimal RAP DD 
RT PCR conditions.   The high quality Platinum® Taq High Fidelity DNA Polymerase 
(Invitrogen) produced stronger and more clearly defined bands than the standard Platinum® 
Taq DNA Polymerase (Invitrogen; Figure 6.3).   AmpliTaq Gold® (Applied Biosystems) 
produced very few bands (results not shown) and was therefore not used any further in this 
study. 
 
Ethidium bromide agarose gel electrophoresis was attempted as a method to resolve the RAP 
DD RT PCR profile as it would make the downstream analysis of any differentially 
expressed amplicons technically easier.   However the resolution achieved by this method of 
analysis was insufficient (results not shown) and was abandoned in favour of a more 
sensitive method.   Due to the short lengths of the individual fragments in the transcription  
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Figure 6.2:   Comparison of different random primer combinations used to amplify RAP DD 
RT PCR products.   Silver stained denaturing polyacrylamide gel of RAP DD RT PCR 
products using different combinations of random primers designed for the 
Enterobacteriaceae (Fislage et al., 1997).   Lanes 1 and 7, GeneRuler™ 100 bp DNA ladder 
(Fermentas); Lanes 2 and 8, RTase- negative control using template RNA from strain 81116 
grown at 42°C; Lanes 3-4 and 9-10, template RNA from 81116 grown at 37°C performed in 
duplicate; Lanes 5-6 and 11-12, template RNA from 81116 grown at 42°C performed in 
duplicate.   The products present in lanes 2-6 were generated using the RT primers Ea2 and 
Ea6 in combination with the multiplex PCR primer sets Ea2/Es3, Ea6/Es8 and Ea8/Es13.   
The products present in lanes 8-12 were generated using the RT primers Ea2, Ea6 and Ea8 in 
combination with the multiplex PCR primer sets Ea2/Es3, Ea6/Es8 and Ea8/Es13.    
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Figure 6.3:   Comparison of different Taq polymerase enzymes using template RNA isolated 
from C. jejuni 11168 grown at 37°C and 42°C.   Each RNA isolation and RT PCR was 
performed in duplicate.   The template RNA used for the RTase- negative controls is a 
combination of each duplicate subjected to identical treatments in equal volumes.   Lanes 1 
and 8, 100 bp DNA ladder (Promega); Lanes 2-3 and 9-10, duplicate samples grown at 37°C; 
Lanes 4-5 and 11-12, duplicate samples grown at 42°C; Lane 6 and 13, RTase- negative 
control at 37°C; Lane 7 and 14, RTase- negative control at 42°C.   The RT PCR products 
present in lanes 2-7 were generated with Platinum High Fidelity Taq polymerase 
(Invitrogen), while lanes 9-14 were generated by standard Taq polymerase (Invitrogen). 
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profile and the small amounts of product present, silver stained denaturing polyacrylamide 
gels were used to improve the resolution (see Section 2.3.2.3.2).  
 
Each of the 5 C. jejuni stains were exposed to either 37°C or 42°C for 15 minutes based on 
the method of Stinzi and co-workers (2003) as described in Section 2.2.3.   The RAP DD RT 
PCR products from each of the 5 strains exposed to the different temperatures were separated 
by denaturing polyacrylamide gels and visualised by silver staining (Figure 6.4). Strains 
81116 and 11168 exhibited 1 and 3 clear differentially expressed amplicons respectively.   
None of these potential temperature regulated bands appeared in the RTase- samples which 
were designed to detect contaminating genomic DNA should it be present.   The remaining 3 
strains showed no obvious differentially expressed genes.   However, the general clarity of 
individual bands making up the expression profiles of strains HB9313, 990922 and MP0401 
was low.   For the purpose of optimisation and to verify reproducibility each reaction was 
repeated multiple times.   Repeats of RAP DD RT PCR using the same equipment, reagents, 
conditions and RNA samples highlighted a problem with reproducibility (Figure 6.5).   The 
majority of the stronger bands were reproducible.   However, the more faint bands varied 
between repeats.   No two repeats were identical in profile.    
 
Possible differentially expressed amplicons were excised from polyacrylamide gels for down 
stream analysis to identify the target gene by DNA sequence characterisation.   Four 
different methods to recover silver stained DNA from polyacrylamide gels were attempted 
(see Section 2.3.2.1.5), including passive diffusion (Caetano-Anolles & Trigiano, 1997), 
boiling in elution buffer (Sanguinetti et al., 1994), recovery by PCR and recovery by 
multiple PCR cycles (Cho et al., 1996; Weaver et al., 1994). Despite attempting a range of 
experimental approaches, efforts to optimise each method were unsuccessful.   RAP DD  
 238 
 
Figure 6.4:   RAP DD RT PCR of each of the 5 C. jejuni strains exposed to either 37°C or 
42°C in a silver stained denaturing polyacrylamide gel.   Each RNA isolation and RT PCR 
was performed in duplicate using primers Ea2/Es3.   Lane 1, GeneRuler™ 100 bp DNA 
Ladder (Fermentas); Lanes 2-3, 81116 (37°C); Lanes 4-5, 81116 (42°C); Lane 6, RTase- 
negative control 81116 (37°C); Lane 7, RTase- negative control 81116 (42°C); Lanes 8, 15, 
22 and 29, 100 bp DNA Ladder (Promega); Lanes 9-10, 11168 (37°C); Lanes 11-12, 11168 
(42°C); Lane 13, RTase- negative control 11168 (37°C); Lane 14, RTase- negative control 
11168 (42°C); Lanes 16-17, HB9313 (37°C); Lanes 18-19, HB9313 (42°C); Lane 20, 
RTase- negative control HB9313 (37°C); Lane 21, RTase- negative control HB9313 (42°C); 
Lanes 23-24, 990922 (37°C); Lanes 25-26, 990922 (42°C); Lane 27, RTase- negative control 
990922 (37°C); Lane 28, RTase- negative control 990922 (42°C); Lanes 30-31, MP0401 
(37°C); Lanes 32-33, MP0401 (42°C); Lane 34, RTase- negative control MP0401 (37°C); 
Lane 35, RTase- negative control MP0401 (42°C).   Blue triangles highlight differentially 
expressed bands.    
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Figure 6.5:   Demonstration of lack of reproducibility of RAP DD RT PCR.   The RT PCR 
profiles present in both A and B silver stained denatured polyacrylamide gels were generated 
using the same C. jejuni 81116 RNA samples, primer sets, Taq polymerase, PCR cycling 
conditions and PCR machine.   A) Lane 1, GeneRuler™ 100 bp DNA ladder Plus 
(Fermentas).   B) Lane 1, 100 bp DNA Ladder (Promega).   A and B) Lanes 2-3, Amplicons 
generated using template RNA from strain 81116 grown at 37°C and primer set Ea2/Es3 
performed in duplicate (a and b); Lanes 4-5, Amplicons generated using template RNA from 
strain 81116 grown at 42°C and primer set Ea2/Es3 performed in duplicate (a and b).   A) 
Lane 6, RTase- negative control using template RNA from strain 81116 grown at 42°C 
duplicate a.   B) Lane 6, RTase- negative control using template RNA from strain 81116 
grown at 37°C; Lane 7, RTase- negative control using template RNA from strain 81116 
grown at 42°C. 
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RT PCR was abandoned due to the difficulties associated with reproducibility and the failure 
to recover silver stained DNA from polyacrylamide gels.    
 
Quantitative real time (rt) RT PCR using SYBR Green Supermix (Biorad) was the next 
experimental approach attempted.   Specific genes, which encoded the surface proteins that 
were identified as being environmentally regulated in the previous chapter, were targeted.   
Primers were designed which were specific to the genes of interest based on the sequence of 
the C. jejuni strain 11168.   In addition, primers were designed to amplify genes which have 
previously been demonstrated to be regulated by the environmental stimuli or important to 
the bacterial response to the environmental conditions of interest to this study, like 
temperature, iron limitation or excess, bile and the presence of host cells (Table 6.1).    
 
The heat shock protein, GrpE, was selected as the positive control for temperature regulation 
based on the expression analysis conducted previously (Stintzi, 2003). Fur, a repressor 
protein which responds to increases in intracellular Fe2+ concentration was used as the 
positive control for the blood trial as it is involved in the regulation of iron-uptake proteins 
(van Vliet et al., 1998).   FlaA was used as the positive control for the bile trial as Allen and 
Griffiths identified flaA as being up-regulated by the presence of bovine bile (Allen & 
Griffiths, 2001).   Specific experiments designed to quantitatively investigate the expression 
of the adhesin CadF have not yet been performed.   Despite the availability of specific 
expression data, the role of CadF as an important adhesin involved in attachment and 
internalisation of C. jejuni to the surface of and into host cells is well documented (Konkel et 
al., 1997; Monteville et al., 2003; Ziprin et al., 1999).   The control gene which represents a 
constitutively expressed gene whose regulation is not altered by environmental stimuli was 
rpoA.   Other investigators have also used rpoA, the alpha chain of DNA-directed RNA 
polymerase, as a transcription level control for quantitative RT PCR  
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Table 6.1:   Table of proteins observed to be differentially expressed in this study and from the literature 
Environmental 
condition of 
interest 
Name Most similar 
match 
Differential expression observed in 
chapter 5 (strain observation was made 
in) 
Function 
(* putative) 
Reference 
Temperature OMP12 Cj0715 ↑ at 42°C, ↓ at 37°C (MP0401) Oxidative stress defence* This study 
 GrpE n n Heat shock protein (Stintzi, 2003) 
Blood/Iron OMP19a p19, Cj0998c ↑C, ↓Hu, ↑H, ↓MH (HB9313) Iron regulation*, unkown This study 
 Fur n n Ferric uptake regulator (van Vliet et al., 1998) 
Bile OMP19b Cj0998c ↓PBS, ↑C, ↓P (11168) unknown This study 
 OMP28 PEB1A ↑PBS, ↓C, ↑P (11168) Adhesin This study 
 OMP64 FlaA ↓PBS, ↑C, ↓P (11168) Flagellin A, component of flagella 
filament 
This study 
Host Cells OMP49 MOMP ↑+, ↓CEF+, ↓INT+, -CEF-, -INT- 
(MP0401) 
Porin This study 
 CadF n n Fibronectin binding protein 
involved in adhesion 
(Müller et al., 2006) 
Expression 
control 
RpoA n n α subunit or DNA-directed RNA 
polymerase 
(Lemeille et al., 2005) 
n not applicable, ↑ increased expression, ↓ decreased expression, - not expressed, C chicken, H horse, Hu human, MH Mueller-Hinton agar, P pig, + 
bacteria only, CEF+ bacteria with chicken cell line, INT+ bacteria with human cell line, CEF- chicken cells only, INT- human cells only. 
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Figure 6.6:   Ethidium bromide stained agarose gel electrophoresis of PCR products 
generated from template DNA of each of the 5 C. jejuni strains using gene specific primers 
targeting both genes encoding the differentially expressed proteins which were detected in the 
previous chapter and genes encoding known environmentally regulated proteins positive 
controls.   The template DNA is denoted by the corresponding coloured lane numbers 81116, 
11168, HB9313, 990922 and MP0401.   Lanes 1, 9 and 24, Lambda DNA marker digested 
with PstI; Lanes 2, 10, 17, 25 and 32, Amplicon of Cj0715; Lanes 3, 11, 18, 26 and 33, 
Amplicon of grpE; Lanes 4, 12, 19, 27 and 34, Amplicon of Cj0998c; Lanes 5, 13, 20, 28 and 
35, Amplicon of p19; Lanes 6, 14, 21, 29 and 36, Amplicon of fur; Lanes 7, 15, 22, 30 and 
37, Amplicon of flaA; Lanes 8, 16, 23, 31 and 38, Amplicon of peb1A. 
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(Lemeille et al., 2005).   The PCR conditions using the gene specific primers were optimised 
with genomic DNA from each of the 5 C. jejuni strains of interest using the following cycling 
conditions; 94°C x 1 min, 35 x (94°C x 15 s, 58°C x 30 s, 72°C x 30 s),72°C x 1 min (Figure 
6.6).   Not all primer sets generated PCR products in all strains.   Each set of primers tested 
generated a product using DNA isolated from C. jejuni strains 11168 and 99092 generated a 
product with each set of primers tested.   The target of the optimisation was the strain that was 
used to design the primers (11168) and the strain from which the OMP data was obtained in 
Chapter 5 (Table 6.1).    
 
For the purpose of creating a standard RT PCR template to be used to generate standard curve 
data to facilitate quantification by rt RT PCR, the amplicon containing C. jejuni 11168 rpoA 
(Figure 6.7) was cloned into PCR-Script™ Amp SK+ (Stratagene) and confirmed by RFLP.   
Each of the four clones screened produced the expected RFLP pattern.   The resulting plasmid 
(prpoA; Figure 6.8) was used as the serially diluted standard for quantitative rt RT PCR.  
 
RT PCR reactions were performed prior to running quantitative rt RT PCR to confirm the 
successful removal of contaminating DNA, primer specificity and amplification of the target 
genes.   Extensive optimisation of the PCR cycling conditions was unable to completely avoid 
non-specific products (results not shown).   The denaturing agent, formamide, was added to 
each PCR to a final concentration of 1.25% to improve specificity and efficiency of the 
reaction as previously described (Figure 6.9; Sarkar et al., 1990).   The cycling parameters for 
the PCR were adjusted to 94°C x 5 min, 35 x (94°C x 45 s, 60°C x 30 s, 72°C x 5 s) 72°C x 5 
s.   No RT PCR products were generated for any of the RTase- control samples.   Therefore, 
any DNA which contaminated the original RNA sample was successfully removed during the 
DNase treatment step. 
 
 244 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7   Cloning of C. jejuni 11168 rpoA into PCR-Script™ Amp SK+ (Stratagene) 
which was used as the serially diluted standard for quantitative rt RT PCR.   A) Ethidium 
bromide stain agarose gel.   Lane 1, Lambda DNA marker digested with PstI; Lane 2,  
Amplicon of rpoA from C. jejuni 11168 using primers rpoAF1 and rpoAR1, 321 bp.   B) 
Schematic diagram depicting the genetic map of the gene amplified and the location of the 
primer set constructed using SECentral Clone Manager version 6. 
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Figure 6.8:   A) Ethidium bromide stained agarose gel electrophoresis to confirm clones of 
prpoA by RFLP.   Lanes 1-4, plasmids isolated from positive transformants (clones #1-4); 
Lane 5, PCR-Script™ amp SK + without insert (2.961 kb); Lanes 6-7, Lambda DNA marker 
digested with PstI; Lanes 8-11, prpoA digested with BglI (clones #1-4); Lane 12, PCR-
Script™ Amp SK+ digested with BglI; Lanes 13-16, prpoA digested with KpnI/SacI (clones 
#1-4); Lane 12, PCR-Script™ Amp SK+ digested with KpnI/SacI.   B) Schematic diagram of 
positive clone prpoA constructed using SECentral Clone Manager version 6. 
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Figure 6.9:   RT PCR of temperature trial to confirm the successful removal of DNA from all 
RNA isolations and optimisation of PCR conditions with 1.25% formamide.   Lanes 1 and 14, 
Lambda DNA marker digested with PstI; Lanes 2-3, Cj0715 amplified from strain 11168 
exposed to 37°C in duplicate; Lanes 4-5, Cj0715 amplified from strain 11168 exposed to 
42°C in duplicate; Lanes 6-7, grpE amplified from strain 11168 exposed to 37°C in duplicate; 
Lanes 8-9, grpE amplified from strain 11168 exposed to 42°C in duplicate; Lane 10, RTase- 
negative control of Cj0715 from 11168 at 37°C; Lane 11, RTase- negative control of Cj0715 
from 11168 at 42°C; Lane 12, genomic DNA positive control of Cj0715 from 11168; Lane 
13, genomic DNA positive control of grpE from 11168; Lanes 15-16, Cj0715 amplified from 
strain MP0401 exposed to 37°C in duplicate; Lanes 17-18, Cj0715 amplified from strain 
MP0401 exposed to 42°C in duplicate; Lane 19, RTase- negative control of Cj0715 from 
MP0401 at 37°C; Lane 20, RTase- negative control of Cj0715 from MP0401 at 42°C; Lane 
21, genomic DNA positive control of Cj0715 from MP0401; Lane 22, rpoA expression 
control for 11168 at 37°C; Lane 23, rpoA expression control for 11168 at 42°C; Lane 24, 
rpoA expression control for MP0401 at 37°C; Lane 25, rpoA expression control for MP0401 
at 42°C; Lane 26, rpoA amplified from prpoA diluted 10-6.  
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The impact of the presence of formamide and using half the recommended total reaction 
volume on the fluorescence of SYBR Green was investigated using prpoA as a template in 
four separate reactions; 1) 50 µL without formamide (50F-), 2) 25 µL without formamide 
(25F-), 3) 50 µL with formamide (50F+) and 4) 25 µL with formamide (25F+; Figure 6.10).   
For the samples 50F-, 25F-, 50F+ and 25F+ the ∆Rn values were ~ 230, 150, 145 and 110 
respectively.   The Ct values/melting temperatures of the samples 50F-, 25F-, 50F+ and 25F+ 
were 14.66/81.5°C, 15.03/81°C, 14.55/80°C and 16.78/79.5°C respectively.   The quantitative 
rt RT PCR protocol used was 94°C x 5 min, 35 x (94°C x 45 s, 60°C x 30 s, 72°C x 5 s), data 
was collected after each elongation step and the melt curve data was collected at 0.5°C 
decrements from 95°C – 45°C for 10 s at each temperature. 
 
However, despite the successful removal of non-specific amplicons with the addition of 
1.25% formamide to each RT PCR performed with the temperature trial samples, non-specific 
primer binding was a persistent problem during quantitative rt RT PCR (results not shown).   
Non-specific amplicons were present even after the increase of formamide concentration to 
2.5% (results not shown).   In addition, primer dimers were unavoidable despite using the “hot 
start” technique and keeping the reactions on ice at all times prior to loading the samples into 
the rt PCR machine (results not shown).   Despite repeated optimisation, non-specific 
products and primer dimers could not be avoided.   Further extensive optimisation would be 
required to allow the accurate and reliable quantification of expression levels using SYBR 
Green quantitative rt RT PCR. 
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Figure 6.10:   Comparison of quantitative rt RT PCR using SYBR Green (Biorad) amplifying 
rpoA from prpoA diluted 10-2 with and without formamide at different total reaction volumes.   
A) DNA product amplification curve generated by MyiQ™ software (Biorad). B) Melt curve 
graph generated by MyiQ™ software (Biorad). C) Ethidium bromide stained agarose gel 
electrophoresis. Lane 1, Lambda DNA marker digested with PstI; Lane 2, total volume = 25 
µL, no formamide (25F-); Lane 3, total volume = 50 µL, no formamide (50F-); Lane 4, total 
volume = 25 µL, with 1.25% formamide (25F+); Lane 5, total volume = 50 µL, with 1.25% 
formamide (50F+).   The colour of the lane number corresponds to the sample shown in the 
graphs above. 
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6.3 Discussion 
The 5 C. jejuni strains of interest, 81116, 11168, HB9313, 990922 and MP0401, were 
subjected to the four different environmental conditions used in the previous chapter which 
focussed on the differential expression of surface proteins.   The four environments 
investigated were temperature (37°C and 42°C), blood (chicken, human, horse and MH agar 
without blood added), bile extract (0.5%; chicken, pig and PBS without bile added) and host 
cells (human INT407 cells and chicken CEF-DF1 cells).   RAP DD RT PCR (Liang & Pardee, 
1992; Welsh et al., 1992) was selected as the experimental approach for investigating global 
regulation in response to specific environmental stimuli due to its ability to identify novel 
genes and its low cost relative to other commonly used methods, such as microarray 
technology.   If the genome sequence of C. jejuni strain 11168 had been used in conjunction 
with microarray analysis, it would not be possible to detect any genes unique to other strains 
of interest, like C. jejuni strains 81116, HB9313, 990922 and MP0401.   Given the genetic 
diversity among C. jejuni strains, microarray analysis would not sufficiently address the 
research aim of investigating differentially expressed genes in strains other than the few 
strains for which the genome projects are complete. 
 
Total RNA was isolated from each of the 5 C. jejuni strains after being exposed to modelled 
human and chicken environments (Figure 6.1).   Interestingly, the rRNA fragments isolated 
from each of the strains varied.   Strains 11168 and 990922 both produced the expected 23S, 
16S and 5S rRNA fragments.   The remaining three strains produced four fragments, two of 
which were the same sizes as the 16S and 5S rRNA fragments.   Four rRNA fragments similar 
in size to those observed in this study have been observed in several C. jejuni species 
previously (Phongsisay et al., 2007).   It has been suggested that the four fragments are due to 
cleavage of the 23S fragment resulting in two smaller molecules (Phongsisay et al., 2007).    
 
 250 
Various random primers were trialled, including random hexamers and random 10-mer and 
11-mers which were designed specifically for the Enterobacteriaceae (Fislage et al., 1997) 
and had been used for DD PCR analysis of Helicobacter pylori with success (Dong et al., 
2001).   Potential primers were trialled individually in many different combinations and as a 
multiplex system (Figure 6.2).   Multiplex priming was attempted to increase the number of 
amplicons generated however the fragments of the resulting profile were less clearly defined 
than when a primer pair was used.   The original designers of the 10-mer and 11-mer primers 
used the primers as pairs only (Fislage et al., 1997).   Another group investigating 
environmental gene regulation in Helicobacter pylori also used the 10-mer and 11-mer 
primers designed by Fislage and others as pairs only (Dong et al., 2001; Fislage et al., 1997).   
It is likely that the addition of extra primers increased the chance of primer dimer formation 
particularly in the low stringency PCR cycling conditions used for RAP DD RT PCR.   
Another parameter which impacted on the depth and breadth of the expression profile 
generated was the quality of the Taq polymerase used (Figure 6.3).   As expected, the higher 
quality Taq polymerase produced a higher quality profile than the standard Taq polymerse.   
The higher quality Taq polymerase generated more amplicons and the profile was clearer. 
 
The resolution of the RAP DD RT PCR profiles when analysed by ethidium bromide agarose 
gel electrophoresis or silver stained denaturing polyacrylamide gel electrophoresis were 
compared.   The use of ethidium bromide agarose gel electrophoresis would make 
downstream analysis of any potentially differentially expressed amplicons less complicated.   
The purification of silver stained DNA for the purpose of DNA sequence characterisation or 
cloning is a more difficult process.   The purification of ethidium bromide stained DNA from 
agarose is easy, rapid and reproducible.   Unfortunately the resolution required, to clearly 
identify differentially expressed amplicons, could not be achieved with ethidium bromide gel 
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electrophoresis, therefore silver stained denaturing polyacrylamide gel electrophoresis was 
used (results not shown). 
 
Each of the 5 C. jejuni strains were exposed to 37°C and 42°C.   Potential temperature 
regulated genes were detected in the RAP DD RT PCR profiles of strains 81116 and 11168 
only (Figure 6.4).   The profiles of the remaining 3 profiles contained fewer amplicons and the 
general clarity and definition of the PCR products was insufficient for the detection of 
differential expression.   In a similar study, where the global expression of C. jejuni strain 
11168 was investigated at both 37°C and 42°C by DNA microarray analysis, 336 genes were 
identified as being differentially expressed (Stintzi, 2003).   Comparatively, RAP DD RT 
PCR detected 3 possible temperature regulated genes in strain 11168.   It would appear that 
RAP DD RT PCR is not the method of choice if the research objective is to detect all 
differentially expressed genes present in two cell populations.   In contrast, if the research 
objective is to detect novel genes which undergo a major change in expression levels, then the 
RAP DD RT PCR method could be a powerful tool.   However, optimisation to improve the 
clarity of the resulting PCR profiles is essential. 
 
During the process of optimising the clarity of the expression profile it became apparent that 
the results achieved by RAP DD RT PCR were not reproducible and all attempts to overcome 
this problem failed.   The lack of reproducibility became apparent when the PCR was repeated 
using the same template sample, reagents, PCR machine and cycling conditions (Figure 6.5).   
An inability to reproduce results leads to an absence of confidence in the validity of the 
differentially expressed bands observed with each repeat.   Lack of reproducibility has been 
described previously as a limitation of this method (Sambrook & Russell, 2001).     
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The other major difficulty experienced with RAP DD RT PCR was the failure to re-amplify 
bands of interest from the silver-stained polyacrylamide gel.   Despite following various 
published methods, all attempts to re-amplify or identify the differentially expressed bands 
failed.   Both the passive diffusion (Caetano-Anolles & Trigiano, 1997) and boiling in elution 
buffer (Sanguinetti et al., 1994) methods failed to recover DNA from the gel as any 
subsequent PCR resulted in no products, even when performed at low stringency.   In 
addition, the presence of the silver stained DNA band within the excised gel slice was visible 
even after attempts to recover it.   The methods involving single or multiple rounds of PCR to 
recover silver stained DNA from the polyacrylamide gel slice failed to produce a single clear 
band at the expected size.   The PCR produced a smear of non-specific amplicons ranging in 
size from greater than to smaller than the size of the template band (results not shown).   
Encountering both the lack of reproducibility and failure to recover bands of interest with the 
RAP DD RT PCR method resulted in this experimental approach consequently being 
abandoned.    
 
Difficulties with this method have been recognised by other researchers (Sambrook & 
Russell, 2001).   Other limitations of this method include an inability to detect the entire 
mRNA profile, the amplified profile will be a subset of the total mRNA present within the 
cells of interest (Matz & Lukyanov, 1998).   Following on from the mRNA subset, only a 
subset of cDNA will be transcribed.   Furthermore, some cDNA fragments may amplify more 
efficiently than others which may lead to a PCR profile which is not reflective of the mRNA 
profile from which it was derived.   There is much debate over the possibility of under-
representation of less abundant mRNA fragments using differential display (Bertioli et al., 
1995; Mathieu-Daude et al., 1996; Matz & Lukyanov, 1998).   False positives are common 
and all suspected differentially expressed transcripts (DETs) must be confirmed by either 
northern, slot or dot blotting (Sambrook & Russell, 2001).   Moreover, this method can be 
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labour intensive and expensive depending on the number of samples and test conditions of 
interest and the number of repeats required to achieve a reproducible and optimised protocol.    
 
Despite these pitfalls, RAP DD RT PCR has been used successfully by many researchers and 
valuable information has resulted, including the identification of several genes involved in 
cancer (Liang et al., 1992; Sager et al., 1993), heart disease (Utans et al., 1994) and 
potentially the pathogenesis of Mycoplasma hyorhinis (Taxman & Ting, 2001), Streptococcus 
mutans (Chia et al., 2001), Helicobacter pylori (Dong et al., 2001), Vibrio cholerae 
(Chakrabortty et al., 2000) and S. typhimurium (Wong & McClelland, 1994).    
 
Some important modifications of the original RAP DD RT PCR protocol have been 
developed in an attempt to address the problems outlined above.   It has been suggested that 
the use of cDNAs generated by different reverse transcriptases can eliminate false-positives 
arising from small differences between template RNA samples by doubling the total number 
of reactions making it easy to distinguish between false positives and “true” DETs (Sung & 
Denman, 1997).   Prescreening with 16S and 23S rDNA probes to differentiate between 
differentially expressed mRNA and the more abundant rRNA addresses the problem of rRNA 
false positives (Nagel et al., 2001).   A combination of RAP DD RT PCR and a pre-screening 
method such as subtractive hybridisation, would further enhance the selection of differentially 
expressed transcripts improving the chance of their detection.   This would be useful when 
working with extensive expression profiles with high numbers of cDNAs.   The use of 
ethidium bromide stained agarose gels have proved useful and economical for the excision 
and further analysis of prominent differentially expressed bands which were confirmed as 
differentially expressed by silver stained denaturing polyacrylamide gels (Ahmed et al., 
2000).   Ethidium bromide stained agarose gels were attempted in this study, however the 
differentially expressed bands detected by silver stained denaturing polyacrylamide gel 
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analysis were not clearly visible with ethidium bromide stained agarose gels (results not 
shown).    
 
Other experimental approaches for investigating the differences in the global gene expression 
of an organism subjected to a range of environmental conditions include subtractive 
hybridisation (SH; Straus & Ausubel, 1990), suppression subtractive hybridisation (SSH; 
Diatchenko et al., 1996), northern blotting (Alwine et al., 1977), serial analysis of gene 
expression (SAGE; Velculescu et al., 1995) and microarray technologies (Schena et al., 
1995).   Each approach has its advantages and limitations.   Both SH and SSH are based on 
the comparison of two similar but not identical cDNA profiles where over expressed genes 
can be detected in one of the two profiles (Winstanley, 2002).   The limitation is that it is only 
useful when no more than two profiles are being investigated and the detection of over and 
under expressed genes requires two separate experiments.   Northern blotting requires 
comparatively large quantities of mRNA starting material and is therefore not as sensitive as 
detection methods involving an amplification step.   The detection of less abundant 
differentially expressed transcripts is difficult with northern blotting.     SAGE detects all 
transcripts in a given sample and therefore can provide more data than, for example, 
microarray which is limited by the number of known sequences (Li et al., 2006).   Its 
disadvantages are that the technique is expensive, time and labour intensive and prone to 
sequencing errors (Li et al., 2006; van Ruissen et al., 2005).   Microarray analysis is highly 
sensitive, specific and the glass microchips allow sufficient miniaturisation, compared with 
membrane-bound probes, which facilitates the arrangement of thousands of individual probes 
onto one glass slide (Chizhikov et al., 2001).   The limitation of microarray analysis is that it 
is unable to detect novel genes or genes of unknown sequence. 
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The next expression analysis approach employed during this study was gene specific 
quantitative real-time (rt) RT PCR.   Specific primers were designed based on the genome 
sequence of C. jejuni strain 11168 to amplify genes coding for differentially expressed surface 
proteins detected in the previous chapter (Table 6.1).   Control genes were selected from the 
literature as there is evidence to suggest that they are environmentally regulated in conditions 
comparable to those being tested in this study (Table 6.1).   The PCRs were optimised using 
genomic DNA (Figure 6.8).   As described previously, rpoA was used as an expression 
control as environmental changes do not impact on its regulation (Lemeille et al., 2005).   
This gene was also cloned into PCR-Script amp SK+ to generate the cloning construct 
prpoA (Figure 6.9 – 6.10), which was serially diluted and used as standards for quantitative rt 
RT PCR to facilitate the quantification of template in the test samples.    
 
As SYBR Green (Biorad) is a costly reagent, optimisation was first carried out using RT 
PCR.   A major difficulty encountered at this stage was the production of non-specific 
amplicons and primer dimers which would interfere with results obtained from quantitative rt 
RT PCR by producing fluorescence that was not representative of the target sequence.   At the 
RT PCR stage of optimisation, non-specific primer binding was overcome by the addition of 
1.25% formamide, a denaturing agent (Sarkar et al., 1990).   Although quantification was not 
possible with RT PCR alone, this optimisation stage did confirm the successful removal of 
any contaminating genomic DNA which may have been co-isolated during RNA extraction 
(Figure 6.9).   The presence of 1.25% overcame the problem of non-specific primer binding 
and also improved the efficiency of the PCR (Figure 6.9).    
 
It was confirmed that the presence of 1.25% formamide and a 50% reduction in the suggested 
reaction volume did not prevent the fluorescence of SYBR Green during quantitative rt RT 
PCR at detectable levels.   These conditions were tested using prpoA as template (Figure 
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6.10).   As expected the 50 µL total reaction volume produced approximately twice the 
fluorescence of the 25 µL reaction.   In keeping with results obtained from other researchers, 
the addition of formamide did not adversely affect the fluorescence of SYBR Green (Grassi et 
al., 2006).   Unfortunately, the presence of formamide at either 1.25% or 2.5% did not prevent 
the generation of non-specific amplicons as it had done with RT PCR (results not shown).   In 
addition, the presence of primer dimers was a constant problem and as a result, quantification 
of the template cDNA was not possible due to the non-specific background fluorescence.   A 
“hot start” PCR protocol was attempted, but did not resolve the primer dimer issues (results 
not shown).   The reason for formamide improving specificity during RT PCR but not during 
quantitative rt RT PCR is unknown.   The main variables between the two systems are the 
presence of fluorescein and stabilisers in the iQ SYBR Green supermix used for quantitative 
rt RT PCR and the difference in PCR cycling conditions.   Further optimisation of the 
quantitative rt RT PCR conditions is required and would include redesigning and lengthening 
of the primers to improve specificity.   The utilisation of more sophisticated rt PCR 
chemistries, such as TaqMan Probes or Molecular Beacons would also increase specificity 
and prevent the interference of fluorescence being produced by primer dimers which can be a 
problem when using the non specific fluorescein of SYBR Green.    
 
Other parameters which would be included in further work would be analysis of different time 
points.   As demonstrated by Stinzi and colleagues, the majority of temperature regulated gene 
expression occurs within 10 – 20 min of exposure to the test environment (Stintzi, 2003).   
Although, environmentally regulated expression could still be detected after 50 min, only a 
small subset of differentially expressed genes were represented.   Shorter incubation times for 
the blood, bile and host cell trials would be investigated.   The protocol for the exposure of the 
bacteria to host cell lines would have to be modified as the bacteria took ~ 1 h to settle onto 
the eukaryotic cell monolayer.   The experiment would therefore need to be performed in a 
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tissue culture plate that would enable centrifugation to bring the bacteria into close association 
with the eukaryotic cells more rapidly.    
 
Unfortunately, time did not permit further optimisation necessary to enable the efficient 
analysis of the mRNA profiles isolated from the 5 different C. jejuni strains exposed to each 
environmental condition of interest in this study.   RAP DD RT PCR has the potential to be a 
powerful molecular tool if all of its limitations can be overcome.   Quantitative rt RT PCR 
could also be a useful method for confirming and quantifying the increase or decrease of any 
differentially expressed genes highlighted by RAP DD RT PCR.    
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CHAPTER 7: General Discussion 
Arguably, the central question facing researchers of bacterial pathogenicity is – why are some 
strains more pathogenic than others?   This question can be expanded to – why is a particular 
strain more pathogenic in a certain environment than it is in others?   This study was 
undertaken to identify molecular factors involved in the pathogenesis of C. jejuni via a variety 
of experimental approaches.   Particular attention was paid to LOS, a known virulence factor, 
and surface proteins.   Due to their physical location, they interact directly with the external 
environment and consequently the hosts whom they infect.   A major focus of this work was 
investigating the difference in behaviour of C. jejuni when grown in conditions which 
modelled “human” or “chicken” environments as they reflect pathogenic and non-pathogenic 
situations respectively.   This is important as little is known about why C. jejuni is pathogenic 
to humans but exists as a commensal in chickens.   A comparison of the genes and/or proteins 
expressed in different environments has identified many molecules which may be involved in 
pathogenesis both in this study and in studies performed by other research groups (Allen & 
Griffiths, 2001; Holmes et al., 2005; Moen et al., 2005; On et al., 2006; Palyada et al., 2004; 
Sampathkumar et al., 2006; Stintzi, 2003; Stintzi et al., 2005).   Identifying and characterising 
molecular factors important in pathogenesis contributes to knowledge required for the design 
of treatment and preventative measures to combat the diseases caused by this serious human 
pathogen. 
 
C. jejuni LOS is a known virulence determinant and is implicated in enabling the bacteria to 
adhere to host cells, avoid the host immune response and cause serious complications like the 
Guillain-Barré syndrome (McSweegan & Walker, 1986; van Vliet & Ketley, 2001; Yuki et 
al., 2004).   Six genes located within the LOS biosynthesis gene cluster, wlaRE, wlaRF, 
wlaTA, wlaTB, wlaTC and waaV, were investigated during this study.   Four separate C. jejuni 
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81116 knock-out mutants, wlaRF::KanR, wlaTB::KanR, wlaTC::KanR and waaV::KanR were 
analysed in vitro for phenotypic changes relevant to pathogenesis.   In addition the 
mutagenesis of wlaRE and wlaTA from C. jejuni 81116 was attempted.    
 
Attempts to insertionally inactivate wlaRE and wlaTA did not result in the production of a 
mutant.   Despite several different strategies to overcome the difficulties encountered with the 
cloning of wlaRE, all attempts to generate an insertionally inactivated mutant failed and other 
cloning strategies need to be investigated.    The mutagenesis of wlaTA also failed.   However, 
we believe that this failure was due to wlaTA being essential for the survival of C. jejuni strain 
81116.   Due to the lethality of this mutation, investigation of this gene by inactivation was no 
longer an option.   Further studies could be targeted toward expression, purification and 
characterisation of the protein encoded by wlaTA with a view to determine its specific 
function.    
 
The amino acid sequence of each of the six putative LOS biosynthesis proteins were analysed 
in silico.   Proteins which displayed significant sequence similarity to each putative LOS 
biosynthesis protein sequence analysed were involved in glycosylation.   WlaRE and WlaTB 
showed greatest sequence similarity to putative CPS biosynthesis proteins, WlaRF appeared 
to be a putative sugar aminotransferase and WlaTA, WlaTC and WaaV were most similar to  
LOS biosynthesis proteins.   
 
It is not surprising that proteins encoded by genes located within the LOS biosynthesis gene 
cluster would show sequence similarity to CPS biosynthesis proteins as C. jejuni is known to 
produce both LOS and CPS molecules (Karlyshev et al., 2000; Karlyshev et al., 2001).   
Further, both the LOS and CPS molecules contain some of the same carbohydrate residues 
(Bernatchez et al., 2005; St Michael et al., 2002; Szymanski et al., 2003b).   In addition, it is 
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known that glycosyltransferases produced by C. jejuni can be involved in more than one 
function (Bernatchez et al., 2005).   It is likely therefore that the putative LOS biosynthesis 
proteins, particularly those which showed sequence similarity to CPS biosynthesis proteins, 
are involved in the glycosylation of more than one substrate, i.e., LOS and CPS.   The 
multiple functionality of WlaRF and WlaTC is implied by the mutation resulting in a loss of 
motility in addition to the truncation of the LOS molecule.   It would appear that failure to 
properly glycosylate flagellar proteins prevents the functionality and correct assembly of the 
flagellum.   C. jejuni flagellins are heavily glycosylated and previous work conducted by 
Goon and co-workers (2003) determined that the inactivation of a gene involved in flagella 
glycosylation (Cj1293) in strain 81-176 led to the creation of a non-motile and non-flagellated 
mutant which accumulated unglycosylated flagellin intracellularly (Goon et al., 2003).   The 
observations made in this study as a result of motility and TEM analysis of the WlaRF and 
WlaTC mutants are in keeping with the results described by Goon and co-workers, in that the 
mutation of both of these genes (wlaRF and wlaTC) resulted in non-motile and non-
flagellated mutants (Goon et al., 2003).   A recent speculative model for O- and N- linked 
flagellar glycosylation in bacteria proposes that O-linked flagellin glycosylation occurs at the 
cytoplasmic face of the inner membrane in the vicinity of the basal body/type III secretion 
complex (Logan, 2006).   Confirming the location of the flagellin proteins that were not 
correctly assembled into the flagellar filament in the C. jejuni strain 81116 WlaRF and 
WlaTC mutants and whether or not they were successfully glycosylated would perhaps 
provide more evidence of the requirement of glycosylation in flagella function and assembly. 
 
Characterisation of the impact caused by the mutation of each of the C. jejuni strain 81116 
genes, wlaRF, wlaTB, wlaTC and waaV, revealed that the product of each gene played a role 
in the biosynthesis of the LOS molecule.   Further analysis of each mutant would involve 
elucidation of the specific function of WlaRF, WlaTB, WlaTC and WaaV.   This could be 
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achieved by more detailed biochemical characterisation of the truncated LOS molecules with 
a view to identify the specific glycans absent in the LOS molecules produced by each mutant, 
but present in the parent strain LOS.   In addition, the function of the individual enzymes 
could be confirmed by enzymatic assays performed with the purified protein designed to 
determine the substrate specificity of each individual enzyme.    
 
The next step in the analysis of the phenotypic changes brought about by the mutation of 
individual putative LOS biosynthesis genes could include in vivo analysis.   In vivo analysis 
could include chicken colonisation studies and pathogenesis studies involving the use of 
animal models for human campylobacteriosis.   However, at this stage there is a lack of 
animal models that mimic the disease as seen in humans (Friis et al., 2005).   This approach 
would provide perhaps more clinically relevant information regarding the impact of each 
mutation on the ability of C. jejuni strain 81116 to persist within different hosts and cause 
disease.  
 
This study was designed to investigate virulence factors in addition to LOS biosynthesis 
proteins in recognition of the fact that bacterial pathogenesis is a complicated combination of 
factors that we are yet to fully understand.   Other approaches included the investigation of 
environmentally regulated C. jejuni genes and surface proteins with a focus on modelled 
“chicken” and “human” environments.   Observing the differences in behaviour of a pathogen 
in a pathogenic or non-pathogenic environment at a molecular level can lead to the 
identification of novel virulence factors.    
 
Of the many environmentally regulated surface proteins detected in Chapter 5, six were 
further characterised.   The temperature regulated OMP12 which is thought to be a 
transthyretin-like protein was over-expressed when grown at chicken body temperature.   
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OMP19 appears to be iron regulated as determined by the blood trial where it was over-
expressed in the presence of chicken blood.   The most similar matches to the three bile 
regulated proteins were Cj0988c, PEB1 and FlaA.   Both Cj0998c and FlaA were over-
expressed in the presence of chicken bile, while PEB1 was over-expressed in the presence of 
human bile.   The most similar match to OMP49 whose regulation was reduced by the 
presence of either chicken or human host cell was MOMP, a known C. jejuni porin.   Many 
other differentially expressed proteins across each environmental condition were detected 
during this study and the MALDI-TOF analysis of all of them needs to be completed.  In 
addition, it would be useful to quantify the differential expression of each protein to avoid 
false positives and confirm the degree of differential protein expression.   At the gene level, 
this could be achieved by quantitative real time RT PCR or at the protein level by ELISA 
incorporating antibodies specific for the target protein.    
 
Investigation of the specific function of each differentially expressed protein is also important 
as this information may indicate how each protein enables the bacteria to survive, persist, 
adapt and/or infect.   Each of these abilities contributes to the success of the pathogen and 
requires further attention.   Knowledge regarding the molecular mechanisms important in 
these processes can potentially be exploited for the purpose of treatment or preventative 
strategies. 
 
Not all environmentally regulated proteins behaved differently when exposed to modelled 
“chicken” or “human” environments.   They may have behaved the same in both test 
conditions, but differently in the control.   However, those proteins which were over-
expressed under “human” conditions in vitro, like PEB1, may represent possible vaccine 
candidates.   Like PEB1, such proteins should be assessed for the efficacy as vaccine antigens.   
Currently a study is underway to assess PEB1, minus its signal sequence, as a vaccine antigen 
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delivered using live attenuated S. typhimurium as a vector (Sizemore et al., 2006).   At this 
stage no protection after oral challenge has been observed.   However, this may be reflective 
of the delivery system and not of the efficacy of PEB1 as a vaccine antigen (Holden, 2006).   
This is particularly likely with a protein that undergoes post translational modification 
(Holden, 2006).   PEB1 is glycosylated and if S. typhimurium failed to generate the mature 
protein as seen in C. jejuni then the protein would be antigenically different and may explain 
the lack of protection after oral challenge.   Such proteins should be the focus of further 
characterisation as their expression appears to be stimulated when the bacteria enter an 
environment in which they are likely to be pathogenic.   Further confirmation of the role of 
such environmentally regulated proteins in the process of pathogenesis is required.   
Mutagenesis studies involving the analysis of phenotypic changes in both in vitro and in vivo 
settings targeting the differentially expressed proteins would improve our understanding of 
their potential role in pathogenesis.    
 
Investigation of changes in global gene expression when different strains of C. jejuni were 
exposed to a range of environmental conditions was unsuccessful due to technical issues 
arising from the experimental approach.   Random arbitrarily primed differential display 
(RAP DD) RT PCR is potentially a powerful tool to identify differentially expressed genes in 
pathogenically relevant environments.   As it stands, this method requires considerable 
attention to resolve the reproducibility issues and further optimisation of methods to identify 
the sequence of the differentially expressed genes is needed.   Perhaps the consideration of an 
alternative experimental approach, e.g., Southern hybridisation, cDNA library screening 
(Henics et al., 2003) or microarray(Dorrell et al., 2001; Moen et al., 2005; Stintzi et al., 2005; 
Woodall et al., 2005), is needed as each of these methods has been applied successfully to 
campylobacters.   There are no reports of RAP DD RT PCR having been successfully applied 
to campylobacters.   However, each method has its advantages and limitations. 
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The purpose of this study was to investigate the pathogenesis of C. jejuni at a molecular level.   
Expanding on the current body of knowledge regarding molecular mechanisms important for 
pathogenesis will make the task of developing successful antimicrobial therapies or vaccines 
to control or prevent infection easier.   C. jejuni is one of, if not the leading bacterial cause of 
gastroenteritis world wide.   Our understanding of this human pathogen is rapidly increasing.   
Despite these advances, it remains a significant health burden in both socioeconomically 
developing and developed nations.   Continued efforts are required to reduce the impact of 
this major human pathogen.    
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Appendices 
 
Appendix I:   Cloning vector pBluescript (Stratagene).   The red arrows indicate open reading 
frames including the ampicillin resistance gene (amp) and the gene encoding the β 
galactosidase α subunit (lacZ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pBluescript
2961 bps
500
1000
1500
2000
2500
NaeI
DraIII
KpnI
ApaI
EcoO109I
XhoI
AccI
HincII
SalI
ClaI
HindIII
EcoRV
EcoRI
PstI
SmaI
XmaI
BamHI
SpeI
XbaI
NotI
XmaIII
BstXI
DsaI
SacII
SacI
BsaI
ScaI
XmnI
LacZ
Amp
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Appendix II:   Cloning vector pCR2.1 (Invitrogen).   The red arrows indicate open reading 
frames including the ampicillin (amp) and kanamycin (kan) resistance genes and the gene 
encoding the β galactosidase α subunit (lacZ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR2.1
3929 bps
500
1000
1500
2000
2500
3000
3500
HindIII
Acc65I
KpnI
Ecl136II
SacI
BamHI
SpeI
AflII
EcoRV
NotI
AvaI
XhoI
NsiI
Ppu10I
XbaI
EcoO109I
ApaI
PspOMI
DraIII
PsiI
BstAPI
XcmI
BglII
BclI
MscI
Tth111I
BssHII
BtgI
NcoI
RsrII
XmnI
ScaI
TatI
BpmI
BsaI
AhdI
BspHI
PciI
LacZ
Kan
Amp
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Appendix III:   Cloning vector PCR-Script Amp SK+ (Stratagene).   The red arrows indicate 
open reading frames including the ampicillin resistance gene (amp) and the gene encoding the 
β galactosidase α subunit (lacZ).   The blue box indicates the multiple cloning site (MCS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR-Script AmpR SK +
2961 bps
500
1000
1500
2000
2500
BglI
KpnI
XhoI
SalI
ClaI
HindIII
EcoRV
BamHI
SrfI
DdeI
DdeI
DdeI
BglI
DdeI
LacZ
MCS
AmpR
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Appendix IV:   Cloning construct containing wlaTA and wlaTB used for mutagenesis of 
wlaTA (Lodge, 2000).   The red arrows indicate genes and the blue boxes indicate primers orf 
9.2 and orf9.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
pKL1314 
5088 bps 
HindIII 
DdeI 
DdeI 
BglII 
BglII 
ClaI 
HincII 
SalI 
XhoI 
KpnI 
DdeI 
DdeI 
DdeI 
DdeI 
XbaI 
BamHI 
wlaTA 
orf9.2 
orf9.3 
wlaTB 
‘lacZ 
Amp 
lacZ' 
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Appendix V:   Cloning construct containing wlaTA and wlaTB used for mutagenesis of 
wlaTA (Ying, 2001).   The red arrows indicate genes and the blue boxes indicate primers 
orf9.2 and orf9.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pTY9 
4207 bps 
HindIII 
DdeI 
DdeI 
XhoI 
KpnI 
DdeI 
DdeI 
DdeI 
DdeI 
XbaI 
BamHI 
wlaTA 
orf9.2 
orf9.3 
wlaTB' 
‘lacZ 
Amp 
lacZ' 
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Appendix VI:   Cloning construct containing the Kanamycin resistance gene used to 
insertionally inactivate target genes of interest to generate a knock-out mutant (Wösten, 
1997).   The red arrows indicate genes and a promoter (pr). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pMW2 
4452 bps 
HindIII 
BamHI 
XbaI 
KpnI 
XhoI 
HincII 
SalI 
ClaI 
HindIII 
BamHI 
ClaI 
Kan 
lacZ’ 
Amp 
'lacZ 
pr 
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Appendix VII:   DNA Sequence alignment of data derived post transformation by DNA 
sequence analysis and the fragment excised from pMW2 containing the kanamycin resistance 
gene to confirm wlaTA as a lethal mutation.   Sequence 2 = sequence of the region excised 
from pMW2 containing KanR, Sequence 3 = DNA sequence experimentally derived from the 
transformation of pKLko13 into C. jejuni 81116 using primer wlaSB. 
 
 
 
M13 seq data    635 gatccccgggaattctcatgtttgacagcttatcatcgataaacccagcg 
kanaR             1 gatccccgggaattctcatgtttgacagcttatcatcgataaacccagcg 
 
M13 seq data    685 aaccatttgaggtgataggtaagattataccgaggtatgaaaacgagaat 
kanaR            51 aaccatttgaggtgataggtaagattataccgaggtatgaaaacgagaat 
 
M13 seq data    735 tggacctttacagaattactctatgaagcgccatatttaaaaagctacca 
kanaR           101 tggacctttacagaattactctatgaagcgccatatttaaaaagctacca 
 
M13 seq data    785 agacga 
kanaR           151 agacga 
 
 
 
Sequence 2
Sequence 2 
Sequence 2
Sequence 2
Sequence 3 
Sequence 3 
Sequence 3 
Sequence 3 
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Appendix VIII:   Blastp analysis of the protein encoded by wlaRE using Biomanager 
(WebANGIS). 
 
Matching 
Entry (in 
SwissProt + 
SpTrEMBL) 
Position 
Beginning 
– End (bp) 
Description Score E 
Value 
Q9ALS8_CAMJE [20-369] Hypothetical protein. 660.0 0.0 
Q93TI5_STRAG [22-301] Putative glycosyltransferase CpsIVJ. 113.0 1e-23 
Q7N2R1_PHOLL [20-360] Similar to putative glycosyltransferase. 109.0 2e-22 
Q9RG46_STRSU [23-293] Cps1I. 105.0 3e-21 
Q8XN34_CLOPE [22-293] Spore coat polysaccharide biosynthesis protein. 103.0 1e-20 
Q67AY0_STRAG [25-246] Cps8J. 103.0 1e-20 
Q9ALX0_STRAG [25-245] Beta-1,3-glucosyltransferase CpsVII. 101.0 4e-20 
Q8Y828_LISMO [24-139] Lmo1090 protein. 101.0 4e-20 
Q7N0X9_PHOLL [26-282] Similar to putative glycosyl transferase. 101.0 4e-20 
Q9X4V5_STRSU [26-245] Cps2K (Fragment). 101.0 7e-20 
Q8A779_BACTN [26-138] Putative glycosyltransferase. 100.0 9e-20 
Q97P78_STRPN [25-247] Glycosyl transferase, family 2. 100.0 1e-19 
Q9RG44_STRSU [26-253] Cps1K (Fragment). 99.8 1e-19 
Q74BU3_GEOSL [22-238] Glycosyl transferase, group 2 family protein. 99.5 2e-19 
Q9S4F8_LEPIN [23-139] Hypothetical protein. 97.5 8e-19 
O07339_STRPN [26-248] Ss-1,3-N-acetylglucosaminyltransferase. 97.1 1e-18 
Q9ZGK2_LEPBO [23-139] Hypothetical protein. 96.7 1e-18 
Q9RG45_STRSU [26-295] Cps1J. 96.7 1e-18 
Q7VJN9_HELHP [19-277] Conserved hypothetical glycosyl transferase. 96.7 1e-18 
Q9K6R6_BACHD [24-134] Teichuronic acid biosynthesis. 96.3 2e-18 
Q5NGN8_FRATT [25-136] Glycosyl transferase family protein. 96.0 2e-18 
Q8VLB0_STRAG [20-240] CpsIaI (CpsI). 96.0 2e-18 
Q8VL99_STRAG [20-240] CpsI (CpsIaI) (Fragment). 96.0 2e-18 
O87182_STRAG [20-240] N-acetylglucosaminyltransferase (CpsIaI). 96.0 2e-18 
Q8F5N2_LEPIN [23-297] Putative glycosyl transferase. 95.6 3e-18 
Q72QG5_LEPIC [23-297] Glycosyltransferase. 95.6 3e-18 
Q5LZN9_STRTR [25-266] Exopolysaccharide biosynthesis protein, sugar 
transferase. 
95.2 4e-18 
Q56046_STRTR [25-266] Putative glycosyltransferase EpsI (Putative 
glycosyltransferaseCpsI). 
95.2 4e-18 
Q8XN57_CLOPE [24-290] Beta-1,4-galactosyltransferase. 94.4 7e-18 
Q9RPC2_STRAG [19-245] CpsJ (Cps2J). 94.0 9e-18 
Q9AQJ0_STRAG [20-240] CpsIbI. 94.0 9e-18 
Q8VTW7_LEPIN [20-146] Hypothetical protein. 93.6 1e-17 
Q64W33_BACFR [19-247] Glycosyltransferase. 93.6 1e-17 
Q6HAL0_BACHK [20-132] Beta-1,3-N-acetylglucosaminyltransferase (EC 
2.4.1.-). 
93.6 1e-17 
Q72XI9_BACC1 [22-142] Glycosyl transferase, group 2 family protein. 93.6 1e-17 
Q7P737_FUSNV [20-236] Glycosyltransferase involved in cell wall 
biogenesis (EC 2.4.-). 
93.2 1e-17 
Y868_HAEIN [24-132] Putative glycosyl transferase HI0868 (EC 2.-.-.-). 92.8 2e-17 
Q9S4I0_LEPIN [22-141] Hypothetical protein. 92.8 2e-17 
Q8VLC3_LEPIN [20-139] Hypothetical protein. 92.8 2e-17 
Q9AEE3_LEPIN [20-139] Hypothetical protein (Putative glycosyl 
transferase). 
92.8 2e-17 
Q72QI5_LEPIC [20-139] Glycosyl transferase. 92.8 2e-17 
Q93CQ9_SHIBO [22-133] Putative glycosyl transferase. 92.4 3e-17 
Q8VTW6_LEPIN [20-139] Hypothetical protein. 92.4 3e-17 
Q8VLK4_LEPIN [20-139] Hypothetical protein. 92.4 3e-17 
Q9AFH3_STRAG [26-245] CpsVJ. 92.1 3e-17 
O87183_STRAG [19-245] Galactosyltransferase (CpsIaJ). 92.1 3e-17 
Q8E4Z8_STRA3 [19-245] Hypothetical protein CpsIaJ. 92.1 3e-17 
Q8DZE0_STRA5 [26-245] Glycosyl transferase CpsJ(V). 92.1 3e-17 
Q6ASC1_DESPS [24-297] Related to glycosyltransferase involved capsular 
polysaccharidebiosynthesis. 
92.1 3e-17 
Q65EK7_BACLD [22-248] YveR (Polysaccharide biosynthesis protein, 
Glycosyl transferase Family2,YveR). 
91.7 4e-17 
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Appendix IX:   Blastp analysis of the protein encoded by wlaTA using Biomanager 
(WebANGIS). 
 
Matching 
Entry (in 
SwissProt + 
SpTrEMBL) 
Position 
Beginnin
g – End 
(bp) 
Description Score E Value 
Q9ALT2_CAMJE [1-257] Hypothetical protein. 473.0 1e-132 
Q6EB17_CAMJE [1-257] Tgh001. 472.0 1e-132 
Q7N2Q7_PHOLL [1-212] Similarities with glycosyltransferase. 90.1 8e-17 
Q6DAU8_ERWCT [1-187] Putative beta1,4-galactosyltransferase. 90.1 8e-17 
Q9X6Q5_ACTPL [1-211] Putative LPS biosynthesis protein. 78.4 3e-13 
Q8YIM5_BRUME [1-204] LIPOOLIGOSACCHARIDE BIOSYNTHESIS PROTEIN LIC2B. 77.3 6e-13 
Q6T357_AERHY [4-190] Putative LPS biosynthesis protein. 75.3 2e-12 
Q47960_HAEDU [4-203] LOS biosynthesis enzyme LBGA 
(Lipooligosaccharidegalactosyltransferase I) 
(LosA). 
75.3 2e-12 
Q8FZ87_BRUSU [1-204] Glycosyl transferase, family 25. 74.1 5e-12 
Q8IYK4_HUMAN [2-124] Glycosyltransferase 25 domain containing 2 
(C1orf17). 
73.7 7e-12 
Q5SXQ3_HUMAN [2-124] Glycosyltransferase 25 domain containing 2. 73.7 7e-12 
O60327_HUMAN [2-124] KIAA0584 protein (Fragment). 73.7 7e-12 
Q6NVG7_MOUSE [2-124] Glycosyltransferase 25 domain containing 2. 73.0 1e-11 
Q8BWD4_MOUSE [2-124] Mus musculus 10 days lactation, adult female 
mammary gland cDNA, RIKENfull-length enriched 
library, clone:D730045O08 
product:hypotheticalGlycosyltransferase family 25 
containing protein, full insertsequence. 
71.4 4e-11 
Q5U483_XENLA [4-175] Hypothetical protein. 68.3 3e-10 
Q8GF12_EDWTA [1-172] Putative beta1,4-galactosyltransferase. 67.9 4e-10 
Q8IPK4_DROME [2-183] CG31915-PA. 67.5 5e-10 
Q18989_CAEEL [2-220] Hypothetical protein D2045.9. 66.7 9e-10 
Q8K297_MOUSE [4-124] Glycosyltransferase 25 domain containing 1. 66.3 1e-09 
Q6PGL1_MOUSE [4-124] Glycosyltransferase 25 domain containing 1. 66.3 1e-09 
Q65VF7_MANSM [2-203] Hypothetical protein. 66.3 1e-09 
Q9RHG8_HELPY [21-210] Beta-1,4-galactosyltransferase. 66.0 2e-09 
Q937Y0_EDWIC [1-175] Putative glycosyltransferase. 66.0 2e-09 
O25500_HELPY [21-210] Lipooligosaccharide 5G8 epitope biosynthesis-
associated protein(Lex2B). 
65.6 2e-09 
Q9ALY2_CAMJE [1-211] Hypothetical protein. 64.4 5e-09 
Q9ZL17_HELPJ [21-210] Putative lipopolysaccharide biosynthesis protein. 63.2 1e-08 
Q8NC64_HUMAN [4-124] Hypothetical protein FLJ90460. 62.5 2e-08 
Q8NBJ5_HUMAN [4-124] Hypothetical protein PSEC0241. 62.5 2e-08 
Q6IPW8_HUMAN [4-124] GLT25D1 protein (Fragment). 62.5 2e-08 
Q60Y49_CAEBR [2-220] Hypothetical protein CBG18383. 61.7 3e-08 
Q6UJ92_SHIBO [1-188] Glycosyltransferase. 61.7 3e-08 
Q7Q021_ANOGA [4-98] ENSANGP00000014001 (Fragment). 61.3 4e-08 
Q5TY19_ANOGA [4-98] ENSANGP00000026032 (Fragment). 61.3 4e-08 
Q5HTW3_CAMJE [1-198] Lipooligosaccharide biosynthesis 
glycosyltransferase, putative. 
60.9 5e-08 
Q9ALZ3_CAMJE [1-198] Hypothetical protein. 60.9 5e-08 
Q6JAB2_ECOLI [14-210] Hypothetical protein. 60.9 5e-08 
Q6LVL9_PHOPR [4-187] Putative Lex2B protein (Lipooligosaccharide 5G8 
epitope biosynthesis-associated protein). 
60.9 5e-08 
Q8N107_HUMAN [4-98] Hypothetical protein FLJ90038 (OTTHUMP00000022269) 
(Hypotheticalprotein FLJ90042). 
60.5 7e-08 
Q5T4B2_HUMAN [4-98] OTTHUMP00000022267. 60.5 7e-08 
Q9P226_HUMAN [4-98] KIAA1502 protein (Fragment). 60.5 7e-08 
Q96EZ5_HUMAN [4-98] CEECAM1 protein (Fragment). 60.5 7e-08 
Q9CLR6_PASMU [4-122] LosA. 58.9 2e-07 
Q8YFC0_BRUME [1-137] GLYCOSYLTRANSFERASE (EC 2.4.1.-). 58.9 2e-07 
Q8G2J8_BRUSU [1-137] Glycosyl transferase, family 25. 58.9 2e-07 
Q5U309_RAT [4-99] Hypothetical protein. 58.6 3e-07 
Q9UMW5_HUMAN [4-98] Cerebral cell adhesion molecule. 58.2 3e-07 
Q65U48_MANSM [1-121] Hypothetical protein. 57.8 4e-07 
Q48023_HAEIN [4-209] Lex2B. 55.8 2e-06 
Q9ZIS2_ECOLI [1-121] Putative beta1,4-galactosyltransferase WaaX. 55.4 2e-06 
Q8L2H6_HAEIN [4-209] Lex2B (Fragment). 55.4 2e-06 
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Appendix X:   Blastp analysis of the protein encoded by wlaRF using Biomanager 
(WebANGIS). 
 
Matching 
Entry (in 
SwissProt + 
SpTrEMBL) 
Position 
Beginning 
– End (bp) 
Description Score E Value 
Q9ALS9_CAMJE [1-360] Putative aminotransferase. 730.0 0.0 
Q6EB20_CAMJE [3-360] Tgh42. 717.0 0.0 
Q7VK21_HELHP [3-359] Hypothetical protein. 463.0 1e-129 
Q6T1W6_ANETH [3-358] DTDP-6-deoxy-D-xylo-hex-3-ulose aminase. 460.0 1e-128 
Q7MY75_PHOLL [3-359] WblQ protein. 413.0 1e-114 
Q6TFC4_CLOTS [3-359] QdtB. 401.0 1e-110 
Q6QNC6_ECOLI [3-359] Putative aminotransferase. 400.0 1e-110 
O31015_VIBAN [3-358] Putative amino transferase. 399.0 1e-110 
Q64Q29_BACFR [3-358] Putative aminotransferase. 397.0 1e-109 
Q73MT1_TREDE [3-359] Aminotransferase, DegT/DnrJ/EryC1/StrS family. 393.0 1e-108 
Q697E2_ECOLI [3-359] FdtB. 393.0 1e-108 
Q9RGJ4_BACFR [3-359] Putative aminotransferase. 389.0 1e-106 
Q8GMJ8_ECOLI [3-359] Putative aminotransferase. 380.0 1e-104 
Q8VTX8_LEPIN [5-358] Hypothetical protein. 357.0 3e-97 
Q9S4G0_LEPIN [5-358] Hypothetical protein (Probable 
DegT/DnrJ/EryC1/StrS familyprotein). 
357.0 3e-97 
Q72QI3_LEPIC [5-358] Aminotransferase. 357.0 3e-97 
Q9ZGK4_LEPBO [5-358] Hypothetical protein. 356.0 8e-97 
Q8PA22_XANCP [3-351] Aminotransferase. 351.0 3e-95 
Q8PLU8_XANAC [3-345] Aminotransferase. 346.0 9e-94 
Q8DJ84_SYNEL [3-357] Tlr1344 protein. 335.0 1e-90 
Q8KRX4_9ACTO [3-358] NbmG. 281.0 3e-74 
Q9ZGH4_9ACTO [3-358] Transaminase. 279.0 1e-73 
Q8RC02_THETN [4-357] Predicted pyridoxal phosphate-dependent enzyme 
apparently involved inregulation of cell wall 
biogenesis. 
279.0 1e-73 
Q83WE5_MICGR [3-358] Transaminase. 277.0 4e-73 
ERBS_SACER [3-341] Erythromycin biosynthesis sensory transduction 
protein eryC1. 
267.0 5e-70 
Q9L6B9_STRAT [3-353] Aminotransferase-like protein. 264.0 5e-69 
O68842_STRAT [3-353] Aminotransferase. 261.0 3e-68 
Q60BR6_METCA [4-357] Aminotransferase, DegT/DnrJ/EryC1/StrS family. 254.0 5e-66 
Q72KY1_THET2 [21-357] Pleiotropic regulatory protein. 252.0 1e-65 
Q7V311_PROMP [15-357] Putative pleiotropic regulatory protein. 250.0 6e-65 
Q65MH1_BACLD [4-357] SpsC (Spore ciat biosynthesis protein). 248.0 3e-64 
Q5Y9I3_9ACTO [3-355] Transaminase. 245.0 2e-63 
Q888F4_PSESM [16-353] Aminotransferase, DegT/DnrJ/EryC1/StrS family. 245.0 3e-63 
Q74AT8_GEOSL [23-355] Pleiotropic regulatory protein. 244.0 3e-63 
DEGT_BACST [4-353] Pleiotropic regulatory protein. 243.0 1e-62 
Q5KV33_GEOKA [4-353] Pleiotropic regulatory protein. 242.0 2e-62 
Q8PCT6_XANCP [23-358] Aminotransferase. 241.0 4e-62 
Q93S94_XANCP [23-358] Putative aminotransferase. 240.0 9e-62 
Q54142_STRFR [28-345] Hypothetical protein. 239.0 1e-61 
Q7UXR4_RHOBA [4-353] Pleiotropic regulatory protein. 236.0 1e-60 
Q8YZG2_ANASP [3-357] DegT/DnrJ/EryC1/StrS family. 236.0 1e-60 
Q894B1_CLOTE [2-358] Pleiotropic regulatory protein. 235.0 2e-60 
Q8U2R5_PYRFU [16-357] Pleiotropic regulatory protein degT. 235.0 2e-60 
Q8KN86_PSEAE [3-355] Similar to DegT/DnrJ/EryC1/StrS family. 229.0 2e-58 
Q9HZ76_PSEAE [3-355] Probable aminotransferase WbpE. 229.0 2e-58 
Q6QHI5_THIFE [16-357] Pyridoxal phosphate-dependent UDP 2-acetamido-2-
deoxy-alpha-D-ribo-hexopyranos-3-ulose 3-
aminotransferase. 
228.0 2e-58 
P74668_SYNY3 [4-357] Pleiotropic regulatory protein. 228.0 2e-58 
Q5N247_SYNP6 [5-355] Pleiotropic regulatory protein homolog. 228.0 3e-58 
Q7VDQ2_PROMA [24-348] DegT/DnrJ/EryC1/StrS aminotransferase family 
enzyme. 
228.0 3e-58 
Q5HVQ8_CAMJE [1-351] DegT/DnrJ/EryC1/StrS aminotransferase family. 228.0 4e-58 
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Appendix XI:   Blastp analysis of the protein encoded by wlaTB using Biomanager 
(WebANGIS).   Significant hits are above the dotted line. 
 
Matching 
Entry (in 
SwissProt + 
SpTrEMBL) 
Position 
Beginning
-End (bp) 
Description Score E 
Value 
Q9ALT3_CAMJE [1-318] Hypothetical protein. 642.0 0.0 
Q6EB16_CAMJE [1-318] Tgh002. 640.0 0.0 
Q7BC54_CAMJE [2-315] Hypothetical protein (Hypothetcal protein 
Cj1137c). 
270.0 7e-71 
Q8A3T2_BACTN [47-300] Putative capsular polysaccharide synthesis 
protein. 
173.0 1e-41 
Q9F0B9_LACDE [31-303] Alpha(1,2)galactosyltransferase EpsI. 122.0 3e-26 
Q9AH90_STRPN [25-307] WciW. 108.0 4e-22 
O07341_STRPN [35-297] Capsular polysaccharide synthesis protein. 106.0 1e-21 
Q88XM3_LACPL [72-316] Polysaccharide biosynthesis protein. 105.0 3e-21 
Q6X853_STRPN [48-297] Putative alpha-1,2-galactosyltransferase. 102.0 1e-20 
O86892_STRPN [31-294] Capp33fI protein. 93.2 1e-17 
Q9RIN8_STRPN [31-294] Cap37I protein. 92.1 3e-17 
Q8GIC8_9PROT [65-245] EpsC. 87.8 5e-16 
Q8VW69_PASPI [44-190] Capsular polysaccharide. 74.5 5e-12 
Q7WTN0_HAEIN [49-318] Bcs4. 73.0 2e-11 
Q48233_HAEIN [49-318] DNA for serotype b capsulation locus (Bcs4) 
(Bcs4'). 
72.2 3e-11 
Q40712_ORYSA [71-156] Polyprotein. 49.2 0.0002 
Q9X9A7_STRPN [70-175] Cap8J protein. 46.9 0.001 
Q9AHA0_STRPN [70-175] WciT. 46.5 0.001 
Q8R5W3_FUSNN [87-176] Polysaccharide biosynthesis protein. 45.3 0.003 
Q88418_9VIRU [36-217] , complete genome. 43.0 0.017 
Q93UA7_CARRU [1-63] ATP synthase gamma subunit. 43.0 0.017 
Q967M4_PLAFA [6-227] Myosin D. 42.6 0.022 
Q8I5C2_PLAF7 [6-227] Myosin d. 42.6 0.022 
Q7RNC3_PLAYO [26-218] Hypothetical protein (Fragment). 42.2 0.029 
VG1_SPV1R [36-217] Capsid protein (VP1). 41.8 0.038 
Q25802_PLAFA [24-245] RpoD protein. 41.4 0.049 
Q5UQW4_MIMIV [71-234] Putative glycosyltransferase. 41.0 0.064 
Q7R9N3_PLAYO [18-315] Hypothetical protein (Fragment). 41.0 0.064 
Q81GN3_BACCR [80-209] Transcriptional regulator, XRE family. 41.0 0.064 
Q93UC2_CARRU [1-63] ATP synthase gamma subunit. 40.6 0.084 
Q7MY70_PHOLL [137-241] WblS protein. 40.6 0.084 
Q7RPE5_PLAYO [5-233] Outer arm dynein beta heavy chain (Fragment). 40.2 0.11 
Q7RI77_PLAYO [26-222] Bromodomain, putative. 40.2 0.11 
Q8IM41_PLAF7 [1-67] Hypothetical protein. 39.1 0.25 
Q8ILM9_PLAF7 [2-244] Hypothetical protein. 39.1 0.25 
O97331_PLAF7 [115-246] PFC0075c, MAL3P8.13 protein. 37.9 0.56 
Q5M499_STRTR [87-161] Exopolysaccharide biosynthesis protein, 
glycosyltransferase. 
37.9 0.56 
Q8VM03_STRTR [87-161] Eps10 protein. 37.9 0.56 
Q98S55_GUITH [9-247] Hypothetical protein orf1613. 37.5 0.73 
Q93TI6_STRAG [70-175] Putative glycosyltransferase CpsIVN. 37.5 0.73 
Q8A190_BACTN [70-293] Hypothetical protein. 37.5 0.73 
Q8ILZ8_PLAF7 [15-310] Hypothetical protein. 37.1 0.96 
Q8IJM1_PLAF7 [10-219] Hypothetical protein. 37.1 0.96 
Q8IC09_PLAF7 [2-207] Hypothetical protein MAL7P1.25. 37.1 0.96 
Q7RTC3_PLAYO [3-251] Hypothetical protein. 37.1 0.96 
Q7RG76_PLAYO [30-237] Peptide chain release factor 1. 36.7 1.3 
Q8RTG8_VIBCH [139-250] Putative glycosyl transferase. 36.7 1.3 
Q83VE5_LACLC [70-241] EpsQ. 36.7 1.3 
Q8IBD4_PLAF7 [40-238] Hypothetical protein PF08_0002. 36.4 1.6 
Q8I577_PLAF7 [2-195] Hypothetical protein. 36.4 1.6 
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Appendix XII:   Blastp analysis of  the protein encoded by wlaTC using Biomanager 
(WebANGIS).   Significant hits are above the dotted line. 
 
Matching 
Entry (in 
SwissProt + 
SpTrEMBL) 
Begin-
End 
Description Score E 
Value 
Q9ALT4_CAMJE [1-319] Hypothetical protein. 608.0 1e-173 
Q6EB15_CAMJE [1-210] Tgh003. 397.0 1e-109 
HTRL_ECOLI [1-271] Protein htrL. 100.0 1e-19 
Q83PP3_SHIFL [7-271] Involved in lipopolysaccharide biosynthesis. 99.5 2e-19 
Q8XDD7_ECO57 [1-271] Involved in lipopolysaccharide biosynthesis. 97.1 8e-19 
Q22402_CAEEL [2-261] Hypothetical protein T11F9.12. 78.8 3e-13 
Q60MB4_CAEBR [2-261] Hypothetical protein CBG23225. 74.1 7e-12 
Q8I552_PLAF7 [1-263] Hypothetical protein. 45.3 0.003 
Q7RDC9_PLAYO [14-217] Hypothetical protein. 41.0 0.065 
Q8IBG3_PLAF7 [42-275] Hypothetical protein PF07_0124. 40.6 0.085 
Q8IE74_PLAF7 [13-173] Hypothetical protein MAL13P1.133. 39.5 0.19 
Q8IDL9_PLAF7 [13-120] Hypothetical protein MAL13P1.240. 38.7 0.33 
Q7RB17_PLAYO [2-192] CCAAT-box DNA binding protein subunit B (Fragment). 38.7 0.33 
Q7RAB1_PLAYO [12-253] Asparagine-rich protein. 38.7 0.33 
POLG_ZYMVC [75-193] Genome polyprotein [Contains: P1 proteinase (N-
terminal protein);Helper component proteinase (EC 
3.4.22.45) (HC-pro); Protein P3; 6 kDaprotein 1 
(6K1); Cytoplasmic inclusion protein (EC 3.6.1.-) 
(CI); 6kDa protein 2 (6K2); Viral genome-linked 
protein (VPg); Nuclearinclusion protein A (EC 
3.4.22.44) (NI-a) (NIa) (NIa-pro) (49 kDaproteinase) 
(49 kDa-Pro); Nuclear inclusion protein B (EC 
2.7.7.48)(NI-b) (NIb) (RNA-directed RNA polymerase); 
Coat protein (CP)]. 
38.3 0.43 
Q8B6A8_9POTV [75-193] Polyprotein (Fragment). 38.3 0.43 
Q8I1P7_PLAF7 [20-172] Hypothetical protein PFD0920w. 37.9 0.57 
Q6BFB8_PARTE [2-107] Hypothetical protein. 37.9 0.57 
Q7RMT1_PLAYO [86-273] Hypothetical protein. 37.5 0.74 
Q98PW2_MYCPU [22-256] LIPOPROTEIN. 37.5 0.74 
Q8I565_PLAF7 [16-189] Hypothetical protein. 37.1 0.97 
Q6LFL8_PLAF7 [4-188] Hypothetical protein. 37.1 0.97 
EAF6_CANAL [14-97] Chromatin modification-related protein EAF6. 36.7 1.3 
Q7T917_9POTV [75-185] Polyprotein. 36.7 1.3 
Q9ZNQ3_ARATH [72-211] Hypothetical protein At2g27520. 36.4 1.7 
Q7R8Y5_PLAYO [2-268] Hypothetical protein. 36.4 1.7 
Q5HUC9_CAMJE [29-101] Hypothetical protein. 36.4 1.7 
Q9XMS2_TETPY [9-220] Orf1386. 36.0 2.2 
Q8IKU6_PLAF7 [22-216] Hypothetical protein. 36.0 2.2 
Q8IJQ0_PLAF7 [40-120] Hypothetical protein. 36.0 2.2 
Q8I5L0_PLAF7 [24-105] Hypothetical protein. 36.0 2.2 
Q89331_9POTV [75-193] P1 protease, helper component, and P3 protease; 5' 
end.(Fragment). 
35.6 2.9 
Q89327_9POTV [75-193] Helper component (Fragment). 35.6 2.9 
Q7T909_9POTV [75-193] Polyprotein (Fragment). 35.6 2.9 
Q6WN48_9POTV [75-193] Polyprotein. 35.6 2.9 
Q6WN47_9POTV [75-193] Polyprotein. 35.6 2.9 
Q8IEG9_PLAF7 [35-110] Lipoate-protein ligase a, putative (EC 6.-.-.-) (EC 
6.3.4.-). 
35.6 2.9 
Q8IC40_PLAF7 [3-275] Hypothetical protein PF07_0010. 35.6 2.9 
Q6BX37_DEBHA [3-185] Similarities with CA0999 IPF12368 Candida albicans 
IPF12368 unknownfunction. 
35.6 2.9 
Q6MUH9_MYCMS [18-149] Hypothetical protein. 35.6 2.9 
UBC3_MIMIV [18-110] Probable ubiquitin-conjugating enzyme E2 R521 (EC 
6.3.2.19)(Ubiquitin-protein ligase) (Ubiquitin 
carrier protein). 
35.2 3.7 
UBC3_MIMIV [18-110] Probable ubiquitin-conjugating enzyme E2 R521 (EC 
6.3.2.19)(Ubiquitin-protein ligase) (Ubiquitin 
carrier protein). 
35.2 3.7 
Q8ID69_PLAF7 [40-182] Hypothetical protein MAL13P1.319. 35.2 3.7 
Q8I5C0_PLAF7 [18-218] Hypothetical protein. 35.2 3.7 
Q7RIN2_PLAYO [10-65] Hypothetical protein. 35.2 3.7 
Q7RGY4_PLAYO [14-191] Hypothetical protein (Fragment). 35.2 3.7 
Q68XY9_RICTY [5-96] Polynucleotide adenylyltransferase (EC 2.7.7.19). 35.2 3.7 
RCO1_YEAST [12-125] Transcriptional regulatory protein RCO1. 34.8 4.9 
RCO1_YEAST [12-125] Transcriptional regulatory protein RCO1. 34.8 4.9 
Q7T908_9POTV [75-193] Polyprotein. 34.8 4.9 
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Appendix XIII:   Blastp analysis of the protein encoded by waaV using Biomanager 
(WebANGIS). 
 
 
Matching 
Entry (in 
SwissProt + 
SpTrEMBL) 
Begin-
End 
Description Score E 
Value 
Q9ALT5_CAMJE [1-272] WaaV. 530.0 1e-149 
Q6EB14_CAMJE [1-272] Tgh003. 508.0 1e-143 
Q93MP5_CAMJE [1-262] Putative glycosyltransferase. 496.0 1e-139 
Q9K375_CAMJE [1-262] Glycosyltransferase. 488.0 1e-137 
Q938X1_CAMJE [1-262] Putative glycosyltransferase. 482.0 1e-135 
Q6TDC7_CAMJE [1-262] WaaV. 481.0 1e-134 
Q93D01_CAMJE [1-262] Putative glycosyltransferase. 481.0 1e-134 
Q9F0M4_CAMJE [1-262] Glycosyltransferase. 480.0 1e-134 
Q5HTW5_CAMJE [1-265] Lipooligosaccharide biosynthesis 
glycosyltransferase. 
478.0 1e-133 
Q8KWQ8_CAMJE [1-265] Putative glycosyltransferase. 478.0 1e-133 
Q5WQY8_CAMJE [1-265] Putative glycosyltransferase. 478.0 1e-133 
Q6T616_CAMJE [1-265] Putative glycosyltransferase. 475.0 1e-133 
Q6T5A5_CAMJE [1-265] Putative glycosyltransferase. 473.0 1e-132 
Q7BC48_CAMJE [1-271] Putative glycosyltransferase (Putative 
glucosyltransferase). 
466.0 1e-130 
Q93CZ1_CAMJE [1-251] Putative glycosyltransferase. 460.0 1e-128 
Q5RLK4_CAMJE [21-271] WaaV. 438.0 1e-121 
Q6T5A8_CAMJE [1-208] Putative glycosyltransferase. 147.0 4e-34 
Q9F0N0_CAMJE [1-259] Beta-1,3-galactosyltransferase. 140.0 7e-32 
Q9K2V8_CAMJE [1-259] Glycosyltransferase (Beta-1,3-
galactosyltransferase). 
139.0 2e-31 
Q938X7_CAMJE [1-259] Putative beta-1,3-galactosyltransferase. 138.0 2e-31 
Q93MQ1_CAMJE [1-270] Beta-1,3-galactosyltransferase. 136.0 8e-31 
Q9PNF5_CAMJE [1-244] Putative galactosyltransferase. 134.0 3e-30 
Q5HTW7_CAMJE [1-232] Lipooligosaccharide biosynthesis 
galactosyltransferase, putative. 
122.0 2e-26 
Q8KWR0_CAMJE [1-232] Putative galactosyltransferase. 122.0 2e-26 
Q6T620_CAMJE [1-246] Putative glycosyltransferase. 119.0 1e-25 
Q5WQZ2_CAMJE [1-246] Putative galactosyltransferase. 119.0 1e-25 
Q5RLK6_CAMJE [1-246] Putative glycosyltransferase. 119.0 1e-25 
Q5HTW9_CAMJE [1-246] Lipooligosaccharide biosynthesis 
galactosyltransferase, putative. 
118.0 2e-25 
Q8KWR2_CAMJE [1-246] Putative galctosyltransferase. 118.0 2e-25 
Q933S0_CAMJE [1-110] Beta-1,3-galactosyltransferase. 85.8 2e-15 
Q64ZU9_BACFR [1-226] Putative glycosyltransferase. 85.4 2e-15 
Q64Q34_BACFR [1-211] Putative glycosyltransferase. 84.7 4e-15 
Q9X4V5_STRSU [1-208] Cps2K (Fragment). 83.1 1e-14 
Q7P738_FUSNV [4-224] Glycosyltransferase (EC 2.4.1.-). 81.9 3e-14 
Q8XN37_CLOPE [1-186] Capsular polysaccharide biosynthsis protein. 81.1 4e-14 
Q8A779_BACTN [4-242] Putative glycosyltransferase. 80.4 8e-14 
P71057_BACSU [2-219] Hypothetical protein yveR. 79.2 2e-13 
Q9AQJ0_STRAG [4-213] CpsIbI. 78.4 3e-13 
O86893_STRPN [4-232] Glycosyl transferase (Putative galactosyl 
transferase). 
78.4 3e-13 
Q8A821_BACTN [1-220] Glycosyltransferase. 78.4 3e-13 
Q65EK7_BACLD [2-208] YveR (Polysaccharide biosynthesis protein, Glycosyl 
transferase Family2,YveR). 
78.0 4e-13 
Q8XN34_CLOPE [3-267] Spore coat polysaccharide biosynthesis protein. 77.6 5e-13 
Q9RG44_STRSU [3-208] Cps1K (Fragment). 77.3 7e-13 
P71059_BACSU [1-231] Hypothetical protein yveT. 76.9 9e-13 
Q9ALX0_STRAG [4-268] Beta-1,3-glucosyltransferase CpsVII. 76.5 1e-12 
Q8VLB0_STRAG [4-187] CpsIaI (CpsI). 75.3 3e-12 
Q8VL99_STRAG [4-187] CpsI (CpsIaI) (Fragment). 75.3 3e-12 
O87182_STRAG [4-187] N-acetylglucosaminyltransferase (CpsIaI). 75.3 3e-12 
Q6HAL0_BACHK [4-259] Beta-1,3-N-acetylglucosaminyltransferase (EC 2.4.1.-
). 
75.3 3e-12 
Q9RPC3_STRAG [3-213] CpsI (Cps2I). 74.9 3e-12 
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Appendix XIV:   GCMS analysis LOS isolated from parent strain C. jejuni 81116. 
 
 
 
 
 
 324 
Appendix XV:   GCMS analysis of LOS isolated from the C. jejuni 81116 wlaRF- mutant. 
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Appendix XVI:   GCMS analysis of LOS isolated from the C. jejuni 81116 wlaTB- mutant. 
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Appendix XVII:   GCMS analysis of LOS isolated from the C. jejuni 81116 wlaTC- mutant. 
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Appendix XVIII:   GCMS analysis of LOS isolated from the C. jejuni 81116 waaV- mutant. 
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Appendix XIX:   Lambda DNA digested with PstI used as a molecular weight marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.5 kb 
5.1, 4.7, 4.5 kb 
2.8 kb 
2.6, 2.5, 2.4 kb 
2.14 kb 
1.99 kb 
1.70 kb 
1.16 kb 
1.09 kb 
0.8 kb 
0.51 kb 
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Appendix XX:   General chemicals and equipment. 
 
Reagent Supplier 
Acetic Acid, Glacial BDH Chemicals, Australia 
Acrylamide-Bis-Acrylamide (40%) Amresco, USA 
Acrylease Stratagene, USA 
Agarose (DNA grade) Amresco, USA 
Alcian Blue Dye Sigma-Aldrich Pty Ltd, USA 
Ammonium Hydroxide Sigma-Aldrich Pty Ltd, USA 
Ammonium Persulfate (10%, APS) Sigma-Aldrich Pty Ltd, USA 
Ampicillin CSL, Australia 
Bacteriological Agar No1 Oxoid, Australia 
Balances:  
 - Analytical balance Sartorius, Germany 
 - Balance (0.1 – 300 g) U-Lab, Australia 
Bind Silane Amersham Pharmacia,  
Boric Acid BDH Chemicals, Australia 
Bromophenol Blue Sigma-Aldrich Pty Ltd, USA  
Brucella Broth Becton Dickinson, USA 
Camera, digital Panasonic NV-DS50A 
Campygen Gas Pack Oxoid, Australia 
Cell Counting Chamber Propper MFG Co., USA 
Concentration Devices  
 - Amicon Centricon YM-3 Millipore Corporation, USA 
 - Amicon Ultra-4 Millipore Corporation, USA 
Centrifuges:  
 - EBA 12 Microfuge Hettich, Germany 
 - Eppendorf 5415D Eppendorf, Germany 
 - Bench Top Centrifuge Beckman, USA 
 - High Speed Centrifuge Beckman, USA 
Centrifuge Tubes:  
 - 1.5 mL Microfuge Tubes Sarstedt, Germany 
 - 10, 15 and 50 mL Polycarbonate Greiner Labortechnik, Germany 
Chloroform Sigma-Aldrich Pty Ltd., USA 
4-Chloro-1-Napthol Sigma-Aldrich Pty Ltd., USA 
Citric Acid BDH Chemicals, Australia 
Columbia Agar Base Oxoid, Australia 
Coomassie Brilliant Blue R-250 Sigma-Aldrich Pty Ltd., USA 
Coomassie Brilliant Blue G-250 Sigma-Aldrich Pty Ltd., USA 
Cover Slips Mediglass, Australia 
Cryovials (1.8 mL) Iwaki, Canada 
Deoxynucleotide Triphophates (dNTPs) Roche Diagnostics, Germany 
Dialysis Membrane Millipore Corporation, USA 
Diethyl Pyrocarbonate (DEPC) Sigma-Aldrich Pty Ltd, USA 
Dimethylsulfoxide (DMSO) Sigma-Aldrich Pty Ltd, USA 
DNA Ligase, T4 Promega, USA 
DNase I Sigma-Aldrich Pty Ltd, USA 
DNA Polymerase:   
 - AmpliTaq Roche Diagnostics, Germany 
 - Platinum high fidelity Invitrogen, USA 
 - Platinum Invitrogen, USA 
 - Taq polymerase Invitrogen, USA 
 - Gold Taq Roche Diagnostics, Germany 
 - Pfu polymerase Promega, USA 
 - Expand long template system Roche Diagnostics, Germany 
Dulbecco’s Modified Eagle’s Medium ThermoTrace, Australia 
Dye-Terminator Sequencing Mix V3.1 Monash University, Australia 
Electrophoresis Power Supply:  
 - EPS 1000/500 Bio-Rad Laboratories, USA 
 - EPS 3000xi Bio-Rad Laboratories, USA 
 - EPS 300 Bio-Rad Laboratories, USA 
 - EPS 600 Pharmacia Biotech,  
 - EPS 500/400 Pharmacia Fine Chemicals,  
Electrophoresis Units:  
 Horizontal  
 - Mini gel Bio-Rad Laboratories, USA 
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 - Midi gel Bio-Rad Laboratories, USA 
 Vertical  
 - Mini gel Bio-Rad Laboratories, USA 
 - Maxi gel Bio-Rad Laboratories, USA 
Electroporation Cuvette (0.2 cm) Molecular Bio Products, USA 
ELISA Plate Reader (model MR7000) Dynatech  
Ethanol BDH Chemicals, Australia 
Ethidium Bromide Sigma-Aldrich Pty Ltd, USA 
Ethylenediamine Tetra Acetic Acid (EDTA) BDH Chemicals, Australia 
Ficoll-400 BDH Chemicals, Australia 
Filter Discs (Acrodisc, 0.2, 0.45 and 5 µm) PALL Life Sciences, USA 
Folin-Ciocalteus’ Reagent Ajax Chemicals Ltd., Australia 
Formaldehyde Sigma-Aldrich Pty Ltd, USA 
Gel Doc System Bio-Rad Laboratories, USA 
Geneclean Kit Q-Biogene, USA 
Gentamicin Sulfate Sigma-Aldrich Pty Ltd, USA 
D-Glucose BDH Chemicals, Australia 
L-Glutamine ThermoTrace, Australia 
Glycerol BDH Chemicals, Australia 
Glycine Amresco, USA 
Goat-anti-mouse IgG Antibodies Bio-Rad Laboratories, USA 
HEPES Buffer (1 M) ThermoTrace, Australia 
Horse Blood, Defibrinated Oxoid, Australia 
Hydrochloric Acid (32%) Equicell Products, Australia 
Hydrogen Peroxide (30%) BDH Chemicals, Australia 
Incubator, for tissue culture (5 % CO2) Forma Scientific, USA 
Isopropylthio-β-D-Galacrosidase (IPTG) Sigma-Aldrich Pty Ltd., USA 
Isoamyl Alcohol BDH Chemicals, Australia 
Isopropanol BDH Chemicals, Australia 
Kanamycin Sigma-Aldrich Pty Ltd, USA 
Klenow Enzyme Roche Diagnostics, Germany 
Kim Wipes Kimberley Clarke 
Lambda DNA Promega, USA 
Ligase Buffer (10x) Promega, USA 
Lysozyme Roche Diagnostics, Germany 
Magnesium Chloride Roche Diagnostics, Germany 
β-Mercaptoethanol Bio-Rad Laboratories, USA 
Methanol BDH Chemicals, Australia 
Microaerobic Gas (CO2 9.9%, O2 5 %, N2 84.1 %) Linde Gas, Australia 
Microscopes:  
 - Light Microscope Olympus Optical, Australia 
 - Inverted Light Microscope Olympus Optical, Australia 
 - Transmission Electron Microscope JEOL EM100SX-1 
Microscope Slides Sail Brand, China 
Microtitre Plate (flat bottom: 6, 24, 96 well) NUNC, Denmark 
Microtitre Immuno Modules (flat bottom16 well) NUNC, Denmark 
Mueller-Hinton Agar Oxoid, Australia 
Mueller-Hinton Broth Oxoid, Australia 
Needle (21g) Terumo Pty Ltd, Australia 
Newborn Calf Serum (NCS) ThermoTrace, Australia 
Nitrocellulose Membrane (Hybond-C) PALL Life Sciences, USA 
Orange G Dye Sigma-Aldrich, Pty Ltd., USA 
Parafilm Pechiney Packaging, USA 
Penicillin/Streptomycin ThermoTrace, Australia 
Petri Dish LabServ Biolab,  
pH Meter Radiometer, Denmark 
Phenol, Saturated Research Organics, USA 
Phenol/Chloroform/Isoamyl Alcohol (PCI) Research Organics, USA 
Phosphate Buffered Saline (PBS) Oxoid, Australia 
Potassium Acetate BDH Chemicals, Australia 
Potassium Hydroxide BDH Chemicals, Australia 
Proteinase K Roche Diagnostics, Germany 
Restriction Enzymes Promega, USA 
RNAgents (RNA Isolation Kit) Promega, USA 
RNase Sigma-Aldrich Pty Ltd, USA 
RNase-free DNase Sigma-Aldrich Pty Ltd, USA 
RNasin® Promega, USA 
SeeBlue Protein Standard Invitrogen, USA 
Silver Nitrate Sigma-Aldrich Pty Ltd, USA 
 331 
Skirrow Campylobacter Selective Supplement Oxoid, Australia 
Sodium Bicarbonate (7.5 %) ThermoTrace, Australia 
Sodium Chloride BDH Chemicals, Australia 
Sodium Citrate BDH Chemicals, Australia 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich Pty Ltd, USA 
Sodium Hydroxide (NaOH) BDH Chemicals, Australia 
Sonicator Branson Sonic Power Co., USA 
Syringe (1, 3, 5, 10, 20 and 60 mL) Terumo Pty Ltd, Australia 
TEMED Bio-Rad Laboratories, USA 
Thioglycolate broth Oxoid, Australia 
Tissue culture flask (Cellstar; 25 cm2, 75 cm2) Greiner-Bio One, Germany 
Trans blot electrophoretic transfer cell Bio-Rad Laboratories, USA 
Transilluminator (UV) Bio-Rad Laboratories, USA 
Tris-base Amresco, USA 
Triton-X-114 Sigma-Aldrich Pty Ltd., USA 
Trypan blue Sigma-Aldrich Pty Ltd., USA 
Trypsin/EDTA ThermoTrace, Australia 
Urea BDH Chemicals, Australia 
Whattman blotting paper Whattman, England 
X-gal (5-bromo-4chloro-3-indolyl-β-D-galactoside) Sigma-Aldrich Pty Ltd, USA 
 
 
